[{"article_id":439,"discovery_date":"2021-03-09T06:56:46","title":"Barriers and facilitators to employment: A comparison of participants with multiple sclerosis and spinal cord injury","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arch Phys Med Rehabil. 2021 Mar 5:S0003-9993(21)00222-7. doi: 10.1016&#x2F;j.apmr.2021.02.015. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To compare self-reported barriers and facilitators to employment among employed and unemployed participants with multiple sclerosis (MS) and spinal cord injury (SCI).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: Cross-sectional using self-report assessment obtained by mail or online.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: Medical university in the Southeastern USA.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS: There was a total of 2,624 participants, including 1,234 with MS and 1,390 with SCI, identified from either a specialty hospital or a state-based surveillance system in the Southeastern USA. All were under the age of 65 at the time of assessment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERVENTIONS: N&#x2F;A MAIN OUTCOME MEASURES: Self-reported barriers and facilitators to employment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Overall, the MS participants reported more barriers, particularly stress, cognition, and fatigue, whereas those with SCI were more likely to report not having the proper education and training, resources, transportation, and attendant care. Follow-up analyses broken down by employment status indicated several barriers and facilitators were significantly related to diagnosis for either employed or unemployed participants, but not both. Among those employed, those with SCI were more likely to report they could not do the same types of jobs as they could pre-SCI and those with MS were more likely to state that they did not know much about jobs for people with disabilities (no differences were noted for these variables among those unemployed). Unemployed individuals with SCI were more likely to report the jobs for which they were trained were not accessible.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The primary barriers for people with MS revolve around the condition itself, whereas those for SCI appear more related to modifiable factors. Vocational rehabilitation specialists need to identify diagnostic specific barriers to promote employment outcomes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684369&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684369&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.apmr.2021.02.015&gt;10.1016&#x2F;j.apmr.2021.02.015&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684369&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":438,"discovery_date":"2021-03-09T06:56:46","title":"Oxysterols and Multiple Sclerosis: physiopathology, evolutive biomarkers and therapeutic strategy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Steroid Biochem Mol Biol. 2021 Mar 5:105870. doi: 10.1016&#x2F;j.jsbmb.2021.105870. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis is an autoimmune disease that affects the central nervous system. Dysfunction of the immune system leads to lesions that cause motor, sensory, cognitive, visual and&#x2F;or sphincter disturbances. In the long term, these disorders can progress towards an irreversible handicap. The diagnosis takes time because there are no specific criteria to diagnose multiple sclerosis. To realize the diagnosis, a combination of clinical, biological, and radiological arguments is therefore required. Hence, there is a need to identify multiple sclerosis biomarkers. Some biomarkers target immunity through the detection of oligoclonal bands, the measurement of the IgG index and cytokines. During the physiopathological process, the blood-brain barrier can be broken, and this event can be identified by measuring metalloproteinase activity and diffusion of gadolinium in the brain by magnetic resonance imaging. Markers of demyelination and of astrocyte and microglial activity may also be of interest as well as markers of neuronal damage and mitochondrial status. The measurement of different lipids in the plasma and cerebrospinal fluid can also provide suitable information. These different lipids include fatty acids, fatty acid peroxidation products, phospholipids as well as oxidized derivatives of cholesterol (oxysterols). Oxysterols could constitute new biomarkers providing information on the form of multiple sclerosis, the outcome of the disease and the answer to treatment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684483&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684483&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jsbmb.2021.105870&gt;10.1016&#x2F;j.jsbmb.2021.105870&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684483&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":437,"discovery_date":"2021-03-09T06:56:46","title":"The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 27;354:577520. doi: 10.1016&#x2F;j.jneuroim.2021.577520. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Regulatory B cells are a rare B-cell subset widely known to exert their immunosuppressive function via the production of interleukin-10 (IL-10) and other mechanisms. B10 cells are a special subset of regulatory B cells with immunoregulatory function that is fully attributed to IL-10. Their unique roles in the animal model of multiple sclerosis (MS) have been described, as well as their relevance in MS patients. This review specifically focuses on the identification and development of B10 cells, the signals that promote IL-10 production in B cells, the roles of B10 cells in MS, and the potential and major challenges of the application of B10-based therapies for MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684831&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684831&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577520&gt;10.1016&#x2F;j.jneuroim.2021.577520&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684831&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":436,"discovery_date":"2021-03-09T00:16:46","title":"Regulation of the expression of human endogenous retroviruses (HERVs): elements in fetal development and a possible role in the development of cancer and neurological diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;APMIS. 2021 Mar 8. doi: 10.1111&#x2F;apm.13130. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Human endogenous retroviruses (HERVs) are remnants of ancient retroviral germline infections. Most HERV sequences are silenced in somatic cells, but interest is emerging on the involvement of HERV derived transcripts and proteins in human physiology and disease. A HERV-W encoded protein, syncytin-1, has been co-opted into fetal physiology, where it plays a role in trophoblast formation. Altered HERV transcription and expression of HERV derived proteins are associated with various cancer types and neurological diseases such as multiple sclerosis (MS). The implication of HERVs as potential mediators of both health and disease suggests important roles of regulatory mechanisms and alterations of these in physiological and pathological processes. The regulation of HERV sequences is mediated by a wide variety of mechanisms, and the focus of this review is on selected aspects of these, including epigenetic mechanisms such as CpG methylation and histone modifications of the HP1-H3K9me axis, viral transactivation events, and regulatory perspectives of transient stimuli in the microenvironment. Increasing knowledge of the regulation of HERV sequences will not only contribute to the understanding of complex pathogeneses, but may pinpoint potential targets for better diagnosis and treatment in complex diseases as MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683784&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308191644&amp;v&#x3D;2.14.2&quot;&gt;33683784&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;apm.13130&gt;10.1111&#x2F;apm.13130&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683784&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308191644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":435,"discovery_date":"2021-03-08T21:43:30","title":"Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease","summary":"Emerging evidence indicates that impaired mitophagy-mediated clearance of defective mitochondria is a critical event in Alzheimer’s disease (AD) pathogenesis. Amyloid-beta (Aβ) metabolism and the microtubule-a...","link":"https:&#x2F;&#x2F;molecularneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13024-021-00435-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":434,"discovery_date":"2021-03-08T21:43:30","title":"Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes","summary":"Alexander disease (AxD) is a rare neurodegenerative disorder that is caused by dominant mutations in the gene encoding glial fibrillary acidic protein (GFAP), an intermediate filament that is primarily express...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02118-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":433,"discovery_date":"2021-03-08T21:43:30","title":"Correction to: Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial","summary":"An amendment to this paper has been published and can be accessed via the original article.","link":"https:&#x2F;&#x2F;trialsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13063-021-05152-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":432,"discovery_date":"2021-03-08T18:56:46","title":"Synergic use of botulinum toxin injection and radial extracorporeal shockwave therapy in Multiple Sclerosis spasticity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Biomed. 2021 Jan 28;92(1):e2021076. doi: 10.23750&#x2F;abm.v92i1.11101.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND AIM: In Multiple Sclerosis (MS) spasticity worsen patient&#39;s quality of life. Botulinum NeuroToxin TypeA (BoNT-A) is extensively used in focal spasticity, frequently combined with physical therapies. Radial extracorporeal shock waves (rESW) were already used in association with BoNT-A. Considering that loss of efficacy and adverse events are determinants of BoNT-A treatment interruption, this study aimed to evaluate the possibility to prolong BoNT-A&#39;s effect by using rESW in MS focal spasticity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Sixteen MS patients with spasticity of triceps surae muscles were first subjected to BoNT-A therapy and, four months later, to 4 sections of rESWT. Patients were evaluated before, 30, 90 days after the end of the treatments, by using Modified Ashworth Scale (MAS), Modified Tardieu Scale (MTS) and kinematic analysis of passive and active ankle ROM. Results: BoNT-A determined a significant reduction of spasticity evaluated by MAS with a reduction of positive effects after 4months (p&amp;lt;0.05); MTS highlighted the efficacy only 90 days after injection (p&amp;lt;0.05). rESWT decreased MAS values at the end and 30 days later the treatment (p&amp;lt;0.01); MTS values showed instead a prolonged effect (p&amp;lt;0.01). BoNT-A determined a gain of passive and active ankle ROM, persisting along with treatment and peaking the maximum value after rESWT (p&amp;lt;0.05). Conclusions: rESWT can prolong BoNT-A effect inducing significant reduction of spasticity and improvement in passive and active ankle ROM in MS patients. The use of rESWT following BoNT-A injection is useful to avoid some limitations and to prolong the therapeutic effects of BoNT-A therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682833&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33682833&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.23750&#x2F;abm.v92i1.11101&gt;10.23750&#x2F;abm.v92i1.11101&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682833&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":431,"discovery_date":"2021-03-08T18:56:46","title":"Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Vis Exp. 2021 Feb 19;(168). doi: 10.3791&#x2F;62142.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The overall goal of this article is to demonstrate a state-of-the-art ultrahigh field (UHF) magnetic resonance (MR) protocol of the brain at 7.0 Tesla in multiple sclerosis (MS) patients. MS is a chronic inflammatory, demyelinating, neurodegenerative disease that is characterized by white and gray matter lesions. Detection of spatially and temporally disseminated T2-hyperintense lesions by the use of MRI at 1.5 T and 3 T represents a crucial diagnostic tool in clinical practice to establish accurate diagnosis of MS based on the current version of the 2017 McDonald criteria. However, the differentiation of MS lesions from brain white matter lesions of other origins can sometimes be challenging due to their resembling morphology at lower magnetic field strengths (typically 3 T). Ultrahigh field MR (UHF-MR) benefits from increased signal-to-noise ratio and enhanced spatial resolution, both key to superior imaging for more accurate and definitive diagnoses of subtle lesions. Hence, MRI at 7.0 T has shown encouraging results to overcome the challenges of MS differential diagnosis by providing MS-specific neuroimaging markers (e.g., central vein sign, hypointense rim structures and differentiation of MS grey matter lesions). These markers and others can be identified by other MR contrasts other than T1 and T2 (T2*, phase, diffusion) and substantially improve the differentiation of MS lesions from those occurring in other neuroinflammatory conditions such as neuromyelitis optica and Susac syndrome. In this article, we describe our current technical approach to study cerebral white and grey matter lesions in MS patients at 7.0 T using different MR acquisition methods. The up-to-date protocol includes the preparation of the MR setup including the radio-frequency coils customized for UHF-MR, standardized screening, safety and interview procedures with MS patients, patient positioning in the MR scanner and acquisition of dedicated brain scans tailored for examining MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682856&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33682856&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3791&#x2F;62142&gt;10.3791&#x2F;62142&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682856&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":430,"discovery_date":"2021-03-08T18:56:46","title":"The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177&#x2F;1352458521999274. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The impact of cerebellar damage and (dys)function on cognition remains understudied in multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess the cognitive relevance of cerebellar structural damage and functional connectivity (FC) in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This study included 149 patients with early RRMS, 81 late RRMS, 48 SPMS and 82 controls. Cerebellar cortical imaging included fractional anisotropy, grey matter volume and resting-state functional magnetic resonance imaging (MRI). Cerebellar FC was assessed with literature-based resting-state networks, using static connectivity (that is, conventional correlations), and dynamic connectivity (that is, fluctuations in FC strength). Measures were compared between groups and related to disability and cognition.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Cognitive impairment (CI) and cerebellar damage were worst in SPMS. Only SPMS showed cerebellar connectivity changes, compared to early RRMS and controls. Lower static FC was seen in fronto-parietal and default-mode networks. Higher dynamic FC was seen in dorsal and ventral attention, default-mode and deep grey matter networks. Cerebellar atrophy and higher dynamic FC together explained 32% of disability and 24% of cognitive variance. Higher dynamic FC was related to working and verbal memory and to information processing speed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Cerebellar damage and cerebellar connectivity changes were most prominent in SPMS and related to worse CI.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683158&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33683158&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521999274&gt;10.1177&#x2F;1352458521999274&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683158&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":429,"discovery_date":"2021-03-08T18:43:30","title":"A pilot study of the impact of an exercise intervention on brain structure, cognition, and psychosocial symptoms in individuals with relapsing-remitting multiple sclerosis","summary":"Despite pharmacological treatment, many individuals with multiple sclerosis (MS) continue to experience symptoms and medication side effects. Exercise holds promise for MS, but changes in brain structure follo...","link":"https:&#x2F;&#x2F;pilotfeasibilitystudies.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40814-021-00806-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":428,"discovery_date":"2021-03-08T18:43:30","title":"An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases","summary":"PIWI-interacting RNAs (piRNAs) are small non-coding transcripts that are highly conserved across species and regulate gene expression through pre- and post-transcriptional processes. piRNAs were originally dis...","link":"https:&#x2F;&#x2F;translationalneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40035-021-00233-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":427,"discovery_date":"2021-03-08T18:43:30","title":"Thyroid hormone: sex-dependent role in nervous system regulation and disease","summary":"Thyroid hormone (TH) regulates many functions including metabolism, cell differentiation, and nervous system development. Alteration of thyroid hormone level in the body can lead to nervous system-related prob...","link":"https:&#x2F;&#x2F;bsd.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13293-021-00367-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":426,"discovery_date":"2021-03-08T18:43:30","title":"The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): translation, adaptation and validation of the Polish version for patients with multiple sclerosis and spinal cord injury","summary":"Polish physicians and researchers lack an extensive and precise instrument in their native language for evaluating sexual dysfunction in individuals with neurogenic disorders. The aim of this study was to crea...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02132-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":425,"discovery_date":"2021-03-08T12:36:46","title":"Constructing and validating a diagnostic nomogram for multiple sclerosis via bioinformatic analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;3 Biotech. 2021 Mar;11(3):127. doi: 10.1007&#x2F;s13205-021-02675-1. Epub 2021 Feb 16.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The purpose of this study was to identify biomarkers and construct a diagnostic prediction model for multiple sclerosis (MS). Microarray datasets in the Gene Expression Omnibus (GEO) were downloaded. Weighted gene coexpression analysis (WGCNA) was used to search for hub modules and biomarkers related to MS. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to roughly define their biological functions and pathways. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analysis were used to identify the diagnostic biomarkers and construct a nomogram. The calibration curve and receiver operating characteristic (ROC) curve were used to judge the diagnostic predictive ability. In addition, cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm was used to calculate the proportion of 22 kinds of immune cells. GSE41850 was used as the training set, and GSE17048 was used as the test set. WGCNA revealed one hub module containing 165 hub genes. Most of their biological functions and pathways are related to cell metabolism and immune cell activation. The diagnostic nomogram contained &lt;i&gt;ARPC5&lt;&#x2F;i&gt;, &lt;i&gt;ROD1&lt;&#x2F;i&gt;, &lt;i&gt;UBQLN2&lt;&#x2F;i&gt;, &lt;i&gt;ZNF281&lt;&#x2F;i&gt;, &lt;i&gt;ABCA1&lt;&#x2F;i&gt; and &lt;i&gt;FAS&lt;&#x2F;i&gt;. The ROC curve and the calibration curve of the training set and test set confirmed that the nomogram had great prediction ability. In addition, monocytes and M0 macrophages were significantly different between MS patients and healthy people. The expression of &lt;i&gt;ARPC5, ZNF281&lt;&#x2F;i&gt; and &lt;i&gt;ABCA1&lt;&#x2F;i&gt; is correlated with M0 macrophages. The nomogram provides new insights and contributes to the accurate diagnosis of MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007&#x2F;s13205-021-02675-1.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680693&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7886954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7886954&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13205-021-02675-1&gt;10.1007&#x2F;s13205-021-02675-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":424,"discovery_date":"2021-03-08T12:36:46","title":"Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Mar 23;2(1):e000022. doi: 10.1136&#x2F;bmjno-2019-000022. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: This study aimed to assess the effect of RIPC on walking in people with multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a double-blind randomised controlled clinical trial. We used three cycles of RIPC delivered by occluding the upper arm with a blood pressure (BP) cuff inflated to a pressure of 30 mm Hg above the systolic BP. In patients in the sham intervention group, the BP cuff was inflated only to 30 mm Hg below diastolic BP. Outcome measures included the Six-Minute Walk Test (6MWT), gait speed, the Borg rate of perceived exertion (RPE) scale, the tolerability of the RIPC using a Numerical Rating Scale for discomfort from 0 to 10, and adverse events. We identified responders meeting the minimal clinically important difference (MCID) established in the literature in each group.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Seventy-five participants completed the study (RIPC: 38 and Sham: 37). The distance walked during the 6MWT improved by 1.9% in the sham group and 5.7% in the RIPC group (p&#x3D;0.012). The number of responders meeting MCID criteria in the RIPC group was significantly greater compared with the sham intervention group. No serious adverse events occurred.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Single cycle of RIPC resulted in immediate improvement in walking distances during 6MWT in people with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION NUMBERS: NCT03153553.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681776&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681776&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2019-000022&gt;10.1136&#x2F;bmjno-2019-000022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681776&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":423,"discovery_date":"2021-03-08T12:36:46","title":"Development of a Multi-Study Repository to Support Research on Veteran Health: The VA Cooperative Studies Program Epidemiology Center-Durham (CSPEC-Durham) Data and Specimen Repository","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Public Health. 2021 Feb 17;9:612806. doi: 10.3389&#x2F;fpubh.2021.612806. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Federal agencies, including the Department of Veterans Affairs (VA), have prioritized improved access to scientific data and results collected through federally funded research. Our VA Cooperative Studies Program Epidemiology Center in Durham, North Carolina (CSPEC-Durham) assembled a repository of data and specimens collected through multiple studies on Veteran health issues to facilitate future research in these areas. We developed a single protocol, request process that includes scientific and ethical review of all applications, and a database architecture using metadata (common variable descriptors) to securely store and share data across diverse studies. In addition, we created a mechanism to allow data and specimens collected through older studies in which re-use was not addressed in the study protocol or consent forms to be shared if the future research is within the scope of the original consent. Our CSPEC-Durham Data and Specimen Repository currently includes research data, genomic data, and study specimens (e.g., DNA, blood) for three content areas: colorectal cancer, amyotrophic lateral sclerosis, and Gulf War research. The linking of the study specimens and research data can support additional genetic analyses and related research to improve Veterans&#39; health.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681131&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681131&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7925406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7925406&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fpubh.2021.612806&gt;10.3389&#x2F;fpubh.2021.612806&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681131&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":422,"discovery_date":"2021-03-08T12:36:46","title":"Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer&#39;s Disease","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:639369. doi: 10.3389&#x2F;fimmu.2021.639369. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases are closely related to inflammatory and autoimmune events, suggesting that the dysregulation of the immune system is a key pathological factor. Both multiple sclerosis (MS) and Alzheimer&#39;s disease (AD) are characterized by infiltrating immune cells, activated microglia, astrocyte proliferation, and neuronal damage. Moreover, MS and AD share a common pro-inflammatory signature, characterized by peripheral leukocyte activation and transmigration to the central nervous system (CNS). MS and AD are both characterized by the accumulation of activated neutrophils in the blood, leading to progressive impairment of the blood-brain barrier. Having migrated to the CNS during the early phases of MS and AD, neutrophils promote local inflammation that contributes to pathogenesis and clinical progression. The role of circulating T cells in MS is well-established, whereas the contribution of adaptive immunity to AD pathogenesis and progression is a more recent discovery. Even so, blocking the transmigration of T cells to the CNS can benefit both MS and AD patients, suggesting that common adaptive immunity mechanisms play a detrimental role in each disease. There is also growing evidence that regulatory T cells are beneficial during the initial stages of MS and AD, supporting the link between the modulatory immune compartments and these neurodegenerative disorders. The number of resting regulatory T cells declines in both diseases, indicating a common pathogenic mechanism involving the dysregulation of these cells, although their precise role in the control of neuroinflammation remains unclear. The modulation of leukocyte functions can benefit MS patients, so more insight into the role of peripheral immune cells may reveal new targets for pharmacological intervention in other neuroinflammatory and neurodegenerative diseases, including AD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679799&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933037&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933037&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.639369&gt;10.3389&#x2F;fimmu.2021.639369&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":421,"discovery_date":"2021-03-08T12:36:46","title":"Protective Effects of a Nano-Formulation of Curcumin against Cuprizone-Induced Demyelination in the Mouse Corpus Callosum","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Iran J Pharm Res. 2020 Summer;19(3):310-320. doi: 10.22037&#x2F;ijpr.2020.112952.14033.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), characterized by neuroinflammation, oligodendrocytes (OLs) loss, and demyelination Curcumin, a natural phenolic substance, has been shown to have significant therapeutic properties in various neurodegenerative diseases, including MS. In our laboratory by loading curcumin in dendrosome nanoparticles we improved its solubility and bioavailability. Our previous study showed anti-inflammatory and anti-oxidative effects of dendrosomal nano-curcumin (DNC) in experimental autoimmune encephalomyelitis (EAE) model of MS. Here, by using a toxic demyelination model, induced by cuprizone (CPZ), we investigated the protective effect of DNC on oligodendroglial lineage cells (OLLC) and myelin preservation in context of acute demyelination. CPZ is a copper chelator, thus its intake reduces the mitochondrial activity, activates oxidative stress response, leading to specific OLs death, due to their high-energy consumption. We also evaluated DNC effect on activation of astrocytes and microglia, which are enriched in both MS and CPZ demyelinated lesions. Our results demonstrated that DNC treatment protected Oligodendrocyte lineage cells (OLLCs) against CPZ toxin. Besides DNC treatment suppressed accumulation of astrocytes and microglia in CC of CPZ-fed mice, compared to PBS treated onse. Moreover, DNC treatment lead to higher index of luxol fast bluefast blue (LFB) and myelin-specific proteins, myelin basic protein (MBP) intensity in the corpus callosum (CC), as indicators of myelin content. These results suggest a potent pleiotropic therapeutic efficiency for DNC for protection of myelinating cells, possibly via suppression of astrocytes and microglia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680032&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7758014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7758014&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22037&#x2F;ijpr.2020.112952.14033&gt;10.22037&#x2F;ijpr.2020.112952.14033&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":420,"discovery_date":"2021-03-08T12:36:46","title":"Delayed phases of contrast MRI, can it be valuable in multiple sclerosis active phase diagnosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Caspian J Intern Med. 2020 Fall;11(4):432-436. doi: 10.22088&#x2F;cjim.11.4.432.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Observing the enhancing plaques in magnetic resonance imaging (MRI) is one of the most valuable diagnostic modalities in confirming the diagnosis of multiple sclerosis (MS), its recurrence and for better detection of active disease. Since active lesions discovery can improve designating diffusion in time diagnosis of MS and controlling disease activity, and there is not any definite time for delay image acquisition, therefore, the aim of the current study was to evaluate the enhancement of MS plaques in different delayed phases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this interventional study, after receiving written consent, 40 MS patients with at least one enhancing plaque in a previous MRI were evaluated in Babol Ayatollah Rouhani Hospital. Gadolinium was injected to all patients at the dose of 0.1 mg&#x2F;kg, and MRI was taken at 5 and 15 minutes. The results were analyzed using SPSS 23. A p&amp;lt;0.05 was considered as significant level.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean of plaque signal intensity was 1190.20 and 1349.60 at 5 and 15 min, respectively, and this difference was significant (p&amp;lt;0.001). Moreover, the mean of plaque total size was 5.16 cm and 7.04 cm at 5 and 15 min with significant difference, respectively (p&amp;lt;0.001). The mean of plaque number was 1.92 and 2.58 at 5 and 15 min, respectively, which was significantly different (P&amp;lt;0.001).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The results indicated improvement in detection of MS plaques in images taken in the delayed phase compared to those in the early phase. The plaque intensity, size and number were significantly higher in the delayed phase (15 min), than early phase (5 min).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680386&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680386&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7911766&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7911766&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22088&#x2F;cjim.11.4.432&gt;10.22088&#x2F;cjim.11.4.432&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680386&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":419,"discovery_date":"2021-03-08T12:36:46","title":"Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:620963. doi: 10.3389&#x2F;fimmu.2021.620963. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Platelets are clearly central to thrombosis and hemostasis. In addition, more recently, evidence has emerged for non-hemostatic roles of platelets including inflammatory and immune reactions&#x2F;responses. Platelets express immunologically relevant ligands and receptors, demonstrate adhesive interactions with endothelial cells, monocytes and neutrophils, and toll-like receptor (TLR) mediated responses. These properties make platelets central to innate and adaptive immunity and potential candidate key mediators of autoimmune disorders. Multiple sclerosis (MS) is the most common chronic autoimmune central nervous system (CNS) disease. An association between platelets and MS was first indicated by the increased adhesion of platelets to endothelial cells. This was followed by reports identifying structural and functional changes of platelets, their chronic activation in the peripheral blood of MS patients, platelet presence in MS lesions and the more recent revelation that these structural and functional abnormalities are associated with all MS forms and stages. Investigations based on the murine experimental autoimmune encephalomyelitis (EAE) MS model first revealed a contribution to EAE pathogenesis by exacerbation of CNS inflammation and an early role for platelets in EAE development via platelet-neuron and platelet-astrocyte associations, through sialated gangliosides in lipid rafts. Our own studies refined and extended these findings by identifying the critical timing of platelet accumulation in pre-clinical EAE and establishing an initiating and central rather than merely exacerbating role for platelets in disease development. Furthermore, we demonstrated platelet-neuron associations in EAE, coincident with behavioral changes, but preceding the earliest detectable autoreactive T cell accumulation. In combination, these findings establish a new paradigm by asserting that platelets play a neurodegenerative as well as a neuroinflammatory role in MS and therefore, that these two pathological processes are causally linked. This review will discuss the implications of these findings for our understanding of MS, for future applications for imaging toward early detection of MS, and for novel strategies for platelet-targeted treatment of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679764&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679764&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933211&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933211&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.620963&gt;10.3389&#x2F;fimmu.2021.620963&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679764&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":418,"discovery_date":"2021-03-08T12:36:46","title":"Lactobacillus acidipiscis Induced Regulatory Gamma Delta T Cells and Attenuated Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:623451. doi: 10.3389&#x2F;fimmu.2021.623451. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis is a chronic autoimmune disease involving the central nervous system, and shows a high disability rate. Its pathogenesis is complicated, and there is no good treatment. In recent years, with in-depth studies on the regulation of gastrointestinal flora, the relationship between the mammalian immune system and the intestinal flora has been extensively explored. Changes in the composition and structure of the gastrointestinal flora can affect the characteristics and development of the host immune system and even induce a series of central nervous system inflammation events. The occurrence and development of multiple sclerosis are closely related to the continuous destruction of the intestinal barrier caused by intestinal dysbacteriosis. In this study, we analyzed &lt;i&gt;Lactobacillus acidipiscis&lt;&#x2F;i&gt; in a mouse model of experimental autoimmune encephalomyelitis (EAE). We found that the amount of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; in the intestinal tract was inversely proportional to the progress of EAE development. In addition, the number of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; FOXP3&lt;sup&gt;+&lt;&#x2F;sup&gt; regulatory T cells in the mesenteric lymph nodes of mice increased significantly after the mice were fed with &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt;, and the differentiation of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells to Th1 and Th17 cells was inhibited. However, the protective effect of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; was lost in γδ T cell-deficient mice and hence was concluded to depend on the presence of regulatory γδ T cells in the intestinal epithelium. Moreover, including &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; enhanced the development of Vγ1&lt;sup&gt;+&lt;&#x2F;sup&gt;γδ T cells but suppressed that of Vγ4&lt;sup&gt;+&lt;&#x2F;sup&gt;γδ T cells. In summary, our results demonstrated the ability of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; to induce generation of regulatory γδ T cells that suppress the development of the encephalomyelitic Th1 and Th17 cells and the progress of EAE.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679767&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933195&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933195&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.623451&gt;10.3389&#x2F;fimmu.2021.623451&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":417,"discovery_date":"2021-03-08T12:36:46","title":"Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:624685. doi: 10.3389&#x2F;fimmu.2021.624685. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Antigen-specific therapy for multiple sclerosis may lead to a more effective therapy by induction of tolerance to a wide range of myelin-derived antigens without hampering the normal surveillance and effector function of the immune system. Numerous attempts to restore tolerance toward myelin-derived antigens have been made over the past decades, both in animal models of multiple sclerosis and in clinical trials for multiple sclerosis patients. In this review, we will give an overview of the current approaches for antigen-specific therapy that are in clinical development for multiple sclerosis as well provide an insight into the challenges for future antigen-specific treatment strategies for multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679769&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679769&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933447&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933447&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.624685&gt;10.3389&#x2F;fimmu.2021.624685&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679769&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":416,"discovery_date":"2021-03-08T12:36:46","title":"Asymptomatic Herpes Simplex Virus Type 1 Infection Causes an Earlier Onset and More Severe Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 15;12:635257. doi: 10.3389&#x2F;fimmu.2021.635257. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is an increasingly prevalent progressive autoimmune and debilitating chronic disease that involves the detrimental recognition of central nervous system (CNS) antigens by the immune system. Although significant progress has been made in the last decades on the biology of MS and the identification of novel therapies to treat its symptoms, the etiology of this disease remains unknown. However, recent studies have suggested that viral infections may contribute to disease onset. Interestingly, a potential association between herpes simplex virus type 1 (HSV-1) infection and MS has been reported, yet a direct relationship among both has not been conclusively demonstrated. Experimental autoimmune encephalomyelitis (EAE) recapitulates several aspects of MS in humans and is widely used to study this disease. Here, we evaluated the effect of asymptomatic brain infection by HSV-1 on the onset and severity of EAE in C57BL&#x2F;6 mice. We also evaluated the effect of infection with an HSV-1-mutant that is attenuated in neurovirulence and does not cause encephalitis. Importantly, we observed more severe EAE in mice previously infected either, with the wild-type (WT) or the mutant HSV-1, as compared to uninfected control mice. Also, earlier EAE onset was seen after WT virus inoculation. These findings support the notion that a previous exposure to HSV-1 can accelerate and enhance EAE, which suggests a potential contribution of asymptomatic HSV-1 to the onset and severity of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679788&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7928309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7928309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.635257&gt;10.3389&#x2F;fimmu.2021.635257&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":415,"discovery_date":"2021-03-08T12:36:46","title":"Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Jul 9;2(1):e000060. doi: 10.1136&#x2F;bmjno-2020-000060. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the Clozapine and Risperidone in Progressive Multiple Sclerosis (CRISP) trial was conducted to determine whether clozapine and risperidone are suitable for progressive multiple sclerosis (pMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The CRISP trial (ACTRN12616000178448) was a blinded, randomised, placebo-controlled trial with three parallel arms (n&#x3D;12&#x2F;arm). Participants with pMS were randomised to clozapine (100-150 mg&#x2F;day), risperidone (2.0-3.5 mg&#x2F;day) or placebo for 6 months. The primary outcome measures were safety (adverse events (AEs)&#x2F;serious adverse events (SAE)) and acceptability (Treatment Satisfaction Questionnaire for Medication-9).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: An interim analysis (n&#x3D;9) revealed significant differences in the time-on-trial between treatment groups and placebo (p&#x3D;0.030 and 0.025, clozapine and risperidone, respectively) with all participants receiving clozapine being withdrawn during the titration period (mean dose&#x3D;35±15 mg&#x2F;day). Participants receiving clozapine or risperidone reported a significantly higher rate of AEs than placebo (p&#x3D;0.00001) but not SAEs. Specifically, low doses of clozapine appeared to cause an acute and dose-related intoxicant effect in patients with pMS who had fairly severe chronic spastic ataxic gait and worsening over all mobility, which resolved on drug cessation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: The CRISP trial results suggest that patients with pMS may experience increased sensitivity to clozapine and risperidone and indicate that the dose and&#x2F;or titration schedule developed for schizophrenia may not be suitable for pMS. While these findings do not negate the potential of these drugs to reduce multiple sclerosis-associated neuroinflammation, they highlight the need for further research to understand the pharmacodynamic profile and effect of clozapine and risperidone in patients with pMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION NUMBER: ACTRN12616000178448.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681788&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903182&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903182&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000060&gt;10.1136&#x2F;bmjno-2020-000060&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":414,"discovery_date":"2021-03-08T12:36:46","title":"Comparison of neurofilament light chain results between two independent facilities","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Oct 19;2(2):e000063. doi: 10.1136&#x2F;bmjno-2020-000063. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To examine levels of neurofilament light chain (NFL) in identical cerebrospinal fluid (CSF) and blood samples at two different facilities, and how differences affect interpretation of levels within and above the normal range.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: CSF and plasma from patients with multiple sclerosis (MS) and healthy controls (HCs) were analysed by Simoa (Quanterix) for levels of NFL providing a total of 165 CSF samples (119 from MS) and 225 plasma samples (180 from MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: CSF and plasma concentrations highly correlated between NFL laboratory facilities (R: 0.92 and 0.84, &amp;lt;0.0001, respectively), and there were no differences between facilities. A bias between the two sites for plasma was -0.95 pg&#x2F;mL and for CSF -73.53 pg&#x2F;mL. The cut-offs for CSF were 807.5 and 571.0 pg&#x2F;mL at site 1 and site 2, respectively; the cut-offs for plasma were 13.0 and 11.8 pg&#x2F;mL, respectively. Seven out of 180 plasma samples (3.9%) and 3 out of 119 CSF samples (2.5%) from MS patients could be reclassified as normal&#x2F;abnormal, that is, below&#x2F;above cut-off, when measured at different facilities.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our study demonstrates that results of NFL in CSF and blood measured with SIMOA are comparable between facilities. Nevertheless, healthcare practitioners should consider reference values at different laboratories, since different sensitivity&#x2F;specificity can affect interpretation when low values are adjacent to cut-offs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681796&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7871722&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7871722&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000063&gt;10.1136&#x2F;bmjno-2020-000063&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":413,"discovery_date":"2021-03-08T12:36:46","title":"Hospital diagnosed pneumonia before age 20 years and multiple sclerosis risk","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Jun 16;2(1):e000044. doi: 10.1136&#x2F;bmjno-2020-000044. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Respiratory inflammation has been proposed as a risk factor for MS. This study aims to determine if hospital-diagnosed pneumonia in adolescence (before age 20 years) is associated with subsequent multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This case-control study included incident MS cases after age 20 years identified using the Swedish national registers. Cases were matched with 10 general population controls by age, sex and region. Pneumonia diagnoses were identified between 0-5, 6-10, 11-15 and 16-20 years of age. Conditional logistic regression models adjusted for infectious mononucleosis (IM) and education calculated ORs with 95% CIs. Urinary tract infections (UTIs), a common complication of MS, before age 20 years were included as a control diagnosis for reverse causation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were 6109 cases and 49 479 controls included. Pneumonia diagnosed between age 11-15 years was associated with subsequent MS (adj OR 2.00, 95% CI 1.22 to 3.27). Although not statistically significant, sensitivity analyses showed similar magnitude associations of pneumonia between age 11-15 years and MS. No statistically significant associations with MS for pneumonia at other age groups were observed. Adjustment for IM had no notable effect on associations, but was statistically significantly associated with MS. UTIs were not associated with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Pneumonia at 11-15 years of age was associated with MS, suggesting a possible role for inflammation of the respiratory system in the aetiology of MS during a period of susceptibility in adolescence. Further research on respiratory infections prior to MS onset should be conducted to replicate this finding and determine explanatory causal mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681783&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681783&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903180&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903180&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000044&gt;10.1136&#x2F;bmjno-2020-000044&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681783&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":412,"discovery_date":"2021-03-08T12:36:46","title":"Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2021 Jan 18;3(1):e000095. doi: 10.1136&#x2F;bmjno-2020-000095. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe the case histories of two patients who developed acquired haemophilia A following treatment with alemtuzumab for multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Two patients, a 48-year-old woman and a 31-year-old woman, developed acquired haemophilia A 21 months after their second doses of alemtuzumab. Both presented with spontaneous bruising, and the second case reported menorrhagia. One patient required treatment to control bleeding. Both patients responded to treatment with prednisolone and cyclophosphamide to eliminate the inhibitor.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Acquired haemophilia A is a rare complication following treatment with alemtuzumab. Activated partial thromboplastin time and prothrombin time should be performed in cases of abnormal bleeding in which the platelet count is normal, to facilitate timely diagnosis and prevention of major bleeding complications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681807&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7871705&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7871705&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000095&gt;10.1136&#x2F;bmjno-2020-000095&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":411,"discovery_date":"2021-03-08T12:36:46","title":"Serum vasohibin-1 levels: a potential marker of dermal and pulmonary fibrosis in systemic sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Exp Dermatol. 2021 Mar 8. doi: 10.1111&#x2F;exd.14321. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Vasohibin-1 (VASH-1) is a potent anti-angiogenic factor mainly produced by endothelial cells. In addition, VASH-1 prevents TGF-β-dependent activation of renal fibroblasts. Since systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy and fibrosis of multiple organs, VASH-1 may be involved in the development of this disease. In this study, we investigated the potential role of VASH-1 in SSc by evaluating the clinical correlation of serum VASH-1 levels and the expression of VASH-1 in SSc-involved skin. Serum VASH-1 levels were higher in SSc patients, especially those with diffuse cutaneous involvement, than in healthy controls and positively correlated with skin score. Furthermore, SSc patients with interstitial lung disease had significantly elevated levels of serum VASH-1 as compared to those without. Importantly, serum VASH-1 levels correlated inversely with both the percentage of predicted vital capacity and the percentage of predicted diffusion lung capacity for carbon monoxide and positively with serum KL-6 levels, but not serum surfactant protein-D levels. In SSc-involved skin, VASH1 mRNA was remarkably upregulated compared with healthy control skin, but the major source of VASH-1 was not clear. Fli1 deficiency, a predisposing factor inducing SSc-like endothelial properties, did not affect VASH-1 expression in human dermal microvascular endothelial cells. Collectively, these results suggest that VASH-1 upregulation in the skin and sera is linked to dermal and pulmonary fibrotic changes in SSc, while the contribution of VASH-1 to SSc vasculopathy seems to be limited.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682189&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33682189&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;exd.14321&gt;10.1111&#x2F;exd.14321&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682189&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":410,"discovery_date":"2021-03-08T09:56:46","title":"Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Semin Arthritis Rheum. 2021 Feb 19;51(2):425-429. doi: 10.1016&#x2F;j.semarthrit.2021.02.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION&#x2F;BACKGROUND: Skin ulcers are a complex array of clinical manifestations of systemic sclerosis (SSc) and are often difficult to treat. However, the definition of SSc-skin ulcers has to date not been promising, demonstrating poor reliability and accuracy. There are emerging data that ultrasound has significant potential to evaluate SSc-skin ulcers.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To perform a systematic literature review (SLR) to understand the degree to which ultrasound of SSc skin ulcers has been validated according to OMERACT criteria.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In a SLR, we investigated the Cochrane Library, Web of Science and Pubmed databases for manuscripts from inception to 1st April 2020. Inclusion and exclusion criteria included manuscripts on SSc patients aged over 16 years, performing SSc-related skin ulcer evaluation with ultrasound machines. Papers on animal model, diseases other than SSc, venous ulcers were excluded. Data extraction used a uniform case report form which collected data on patient demographics, disease activity, description of the ultrasound machine and procedures and the degree to which domains of validity were fulfilled. Manuscript evaluation and extraction was performed by two independent assessors, with a third author being consulted in case of disagreement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: amongst 308 manuscripts that were identified, 6 published manuscripts&#x2F; posters fulfilled the inclusion&#x2F;exclusion criteria and were extracted. Face validity was found. Three studies developed an US definition of SSc-ulcers across patients (content validity); one study evaluated the concordance between US image and clinical assessment. Criterion validity was shown by one study and ultrasound detected improvement (sensitivity to change) of SSc-skin ulcer in response to therapy. Feasibility was demonstrated by US use for skin ulcers in multiple settings (the 6 manuuscripts&#x2F;posters).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This systematic literature review shows that ultrasound for skin ulcers in SSc has been partially validated. It has face, content, criterion validity, responsiveness and reasonable feasibility. Further validation for construct validity, reliability and discrimination is required.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.semarthrit.2021.02.008&gt;10.1016&#x2F;j.semarthrit.2021.02.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":409,"discovery_date":"2021-03-08T09:56:46","title":"Developing a clinical pathway to identify and manage cognitive problems in Multiple Sclerosis: Qualitative findings from patients, family members, charity volunteers, clinicians and healthcare commissioners","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Oct 4;49:102563. doi: 10.1016&#x2F;j.msard.2020.102563. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Cognitive problems are a common and debilitating symptom of multiple sclerosis (MS). Screening and treatment for cognitive problems are recommended, however these are not routinely delivered in UK clinics. We collected and synthesised stakeholder perspectives to develop a care pathway for cognitive problems in MS and produce a logic model, illustrating how this pathway might operate.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Forty-nine stakeholders, including people with MS and care providers, participated in semi-structured interviews and focus groups. Participants viewed information that illustrated how the pathway might work and provided feedback. Data, transcribed verbatim and analysed using Framework Analysis, were mapped onto a preliminary logic model and accompanying thematic framework.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The proposed pathway was perceived as helpful in providing standardised support for a neglected MS symptom. Training packages, online cognitive screening, and triaging decisions were viewed as crucial activities. Shared responsibility, a person-centred approach, and addressing the complexity of cognitive problems were important engagement mechanisms. Allocating time during clinic appointments and within staff workloads were essential resources for implementation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our co-constructed MS cognitive screening and management pathway will be evaluated for clinical and cost-effectiveness in a trial. However, in the interim, clinicians can adapt and implement this pathway in their own services and evaluate it locally.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677366&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677366&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2020.102563&gt;10.1016&#x2F;j.msard.2020.102563&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677366&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":408,"discovery_date":"2021-03-08T09:56:46","title":"beta-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 27;50:102868. doi: 10.1016&#x2F;j.msard.2021.102868. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an autoimmune-mediated degenerative disorder with increased peripheral inflammation disrupting the blood brain barrier. With increasing MS-related healthcare costs, the requirement to validate minimally invasive biomarkers has become imperative.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Relapsing-remitting MS patients on disease modifying therapies were consented at the Penn State Health MS Clinic to provide blood samples for analyses of serum cytokines and endogenous opioid peptides, as well as to complete the MSQOL-54 survey.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Serum OGF levels in MS patients on glatiramer acetate (mean &#x3D; 326 pg&#x2F;ml), dimethyl fumarate (mean &#x3D; 193.3 pg&#x2F;ml) and natalizumab (mean &#x3D; 393.4 pg&#x2F;ml) were significantly elevated (p &amp;lt; 0.01) compared to healthy controls (mean &#x3D; 98.46 pg&#x2F;ml). Individuals with elevated OGF levels also had increased levels of TNFα (r &#x3D; 0.78) and IL-17A (r &#x3D; 0.81). Only patients treated with glatiramer acetate had significant (p &amp;lt; 0.01) elevations in serum β-endorphin levels. Analyses of MS-QoL 54 data showed no significant differences in physical or mental composite scores between treatment groups. However, serum levels of β-endorphin had a direct correlation with physical health composite score (r &#x3D; 0.70) in all treatments. Serum vitamin D levels had an indirect relationship with 25-foot walk test times (r &#x3D; 0.47).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Both regression and cohort data suggest that serum levels of OGF, β-endorphin, and vitamin D are potential biomarkers for physical disease status in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677409&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102868&gt;10.1016&#x2F;j.msard.2021.102868&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":407,"discovery_date":"2021-03-08T09:56:46","title":"A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;50:102867. doi: 10.1016&#x2F;j.msard.2021.102867. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We performed a pilot trial investigating the effect of a steroid taper on adrenal function and safety measures after acute MS relapses. Twenty-five patients were randomized to either prednisone taper (n&#x3D;12) or placebo (n&#x3D;13) after 3 days of intravenous methylprednisolone. No patient showed signs of adrenal insufficiency at any time by cortisol response to ACTH. This significantly increased between baseline and 6 months in both groups. Patients remained clinically and radiologically stable, but those under prednisone taper experienced more frequently mood disorders, hyperglycaemia and weight increase. If confirmed by sufficiently powered studies, these results would question the need of a steroid taper following short-term intravenous methylprednisolone.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677411&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102867&gt;10.1016&#x2F;j.msard.2021.102867&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":406,"discovery_date":"2021-03-08T09:56:46","title":"The cholesterol autoxidation products, 7-ketocholesterol and 7beta-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 26;50:102864. doi: 10.1016&#x2F;j.msard.2021.102864. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Serum neurofilament light chain (sNfL) is an established marker of neuroaxonal injury in multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To investigate if oxysterols produced from non-enzymatic and enzymatic cholesterol oxidation are differentially associated with sNfL measurements in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This longitudinal study included 62 relapsing-remitting (RR-MS) and 36 progressive MS (PMS) patients with baseline and 5-year follow-up measures of serum levels of 6 oxysterols, sNfL and lipids. The oxysterols, 24-hydroxycholesterol (24HC), 25HC, 27HC, 7αHC, 7βHC and 7-ketocholesterol (7KC), were measured using liquid chromatography-mass spectrometry. sNfL was measured using single molecular array assay. Serum high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were obtained from a lipid profile.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The enzymatically produced oxysterols 24HC, 25HC, 27HC and 7αHC were not associated with sNfL. However, baseline levels of reactive oxygen species (ROS) produced oxysterols, 7KC (p &#x3D; 0.032) and 7βHC (p &#x3D; 0.0025), were positively associated with sNfL levels at follow-up. Follow-up 7KC (p &#x3D; 0.038) levels were also associated with follow-up sNfL levels. The associations of 7KC or 7βHC with sNfL remained significant after adjusting for LDL-C or HDL-C.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: 7KC and 7βHC, produced by ROS-mediated cholesterol oxidation are associated with neuroaxonal injury as assessed by sNfL in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677412&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677412&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102864&gt;10.1016&#x2F;j.msard.2021.102864&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677412&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":405,"discovery_date":"2021-03-08T09:56:46","title":"Synergistic neuroprotective effects of Fingolimod and Mesenchymal Stem Cells (MSC) in Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Lett. 2021 Mar 4:S0165-2478(21)00033-X. doi: 10.1016&#x2F;j.imlet.2021.03.003. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Fingolimod (Gilenya™) is an effective oral medication approved for relapsing-remitting multiple sclerosis (MS), albeit less effective in chronic disease. Its main mechanism of action is through peripheral immunomodulation but neuroprotective effects may also be involved. Mesenchymal stem cells (MSC) were shown to exert immunomodulatory and neurotrophic effects in the model of multiple sclerosis (experimental autoimmune encephalomyelitis-EAE). The use of combination treatments in chronic diseases such as MS, has long been advocated and may result in improvement of the beneficial effects of each one of them. We tested the in vitro effects of Fingolimod on MSC and the in vivo effect of such combination treatment in the model of EAE. Fingolimod did not affect in any detrimental way the basic features of MSCs and it promoted their migration ability and neurotrophic factors&#39; secretion and suppressed the production of pro-inflammatory cytokines from astrocytes, in vitro. In vivo, the combined treatment of FTY720 and MSC (either by the intravenous or the intra-cerebroventricular route of administration) resulted in synergistic clinical beneficial effects compared to FTY720 or MSC alone, paralleled by a significant reduction of inflammatory CNS infiltrations and of axonal loss. These data may indicate a synergism of fingolimod with MSC and may support future combinations of immunomodulatory drugs with cellular therapies for the improvement of the benefits in progressive forms of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33676976&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.imlet.2021.03.003&gt;10.1016&#x2F;j.imlet.2021.03.003&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":404,"discovery_date":"2021-03-08T09:56:46","title":"Late-onset MS is associated with an increased rate of reaching disability milestones","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Mar 7. doi: 10.1007&#x2F;s00415-021-10490-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe patient characteristics and assess the risk of disability worsening in patients of different age groups with focus on late-onset multiple sclerosis (LOMS) defined as disease onset after the age of 50 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The nationwide population-based Danish Multiple Sclerosis Registry served as data source. We described baseline characteristics and analyzed rates of reaching Expanded Disability Status Scale (EDSS) milestones.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified 28,232 patients with MS with a known year of clinical onset, of which 2661 had LOMS. The LOMS group had a higher proportion of males and patients with primary progressive disease course, and they were less likely to receive disease-modifying therapy. The initial rate of reaching EDSS milestone 6 after diagnosis was higher in LOMS [hazard ratio (HR) 1.53; 95% confidence interval (CI) 1.14-2.06]; however, when assessing the risk of reaching EDSS 6 according to age, the HR was significantly lower for the LOMS group (HR 0.307; 95% CI 0.221-0.426).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The clinical characteristics and treatment approaches for patients with LOMS differ from their younger counterparts. Following diagnosis, patients with LOMS initially have an increased rate of reaching EDSS score 6; however, the risk of reaching EDSS score 6 at any given age is higher in patients with non-LOMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677675&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10490-0&gt;10.1007&#x2F;s00415-021-10490-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":403,"discovery_date":"2021-03-08T09:56:46","title":"Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 6. doi: 10.1007&#x2F;s10072-021-05127-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Comparative effectiveness of natalizumab and fingolimod over a follow-up longer than 2 years has been not addressed yet.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To compare the effect on no evidence of disease activity (NEDA-3) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab or fingolimod for at least 4 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We included RRMS patients switched from first-line agents to natalizumab or fingolimod. Patients were propensity score (PS)-matched on a 1-to-1 basis. Percentages of patients reaching NEDA-3 status at 2 and 4 years of follow-up were compared using the chi-square test. The risk of not achieving NEDA-3 at 4 years was explored in matched samples by Cox regression models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We evaluated 174 PS-matched patients. Patients receiving natalizumab reached a NEDA-3 status at 2 and 4 years more frequently than those exposed to fingolimod (63% vs 44%, p&#x3D;0.037; 45.7% vs 25.8%, p&#x3D;0.015, respectively). Patients receiving natalizumab were at a significant lower risk of not achieving the NEDA-3 status at 4 years compared to those exposed to fingolimod (hazard ratio (95% confidence interval): 0.54 (0.36-0.80), p&#x3D;0.002).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Although both medications were effective in patients non-responding to first-line agents, natalizumab seems to be superior to fingolimod in RRMS in obtaining NEDA-3 status at 4 years.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677753&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05127-z&gt;10.1007&#x2F;s10072-021-05127-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":402,"discovery_date":"2021-03-08T06:43:30","title":"Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension","summary":"In pulmonary arterial hypertension (PAH), progressive right ventricular (RV) dysfunction is believed to be largely secondary to RV ischaemia. A recent pilot study has demonstrated the feasibility of Oxygen-sen...","link":"https:&#x2F;&#x2F;jcmr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12968-020-00694-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":401,"discovery_date":"2021-03-07T18:43:30","title":"Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury","summary":"Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide....","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00793-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":400,"discovery_date":"2021-03-07T15:43:30","title":"Effect of fecal microbiota transplantation on neurological restoration in a spinal cord injury mouse model: involvement of brain-gut axis","summary":"Spinal cord injury (SCI) patients display disruption of gut microbiome, and gut dysbiosis exacerbate neurological impairment in SCI models. Cumulative data support an important role of gut microbiome in SCI. H...","link":"https:&#x2F;&#x2F;microbiomejournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40168-021-01007-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":399,"discovery_date":"2021-03-07T12:16:46","title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 20;50:102849. doi: 10.1016&#x2F;j.msard.2021.102849. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Background Eculizumab, a terminal complement inhibitor, significantly reduced the risk of relapse compared with placebo in patients with anti-aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the PREVENT trial. We report efficacy and safety analyses in Asian patients in PREVENT and its open-label extension (OLE). Methods PREVENT was a double-blind, randomized, phase 3 trial. Patients with AQP4+ NMOSD were randomly assigned (2:1) to receive intravenous eculizumab (maintenance dose, 1200 mg&#x2F;2 weeks) or placebo. Patients who completed PREVENT could receive eculizumab in an OLE. Analyses were performed in a prespecified subgroup of Asian patients. Results Of 143 patients enrolled, 52 (36.4%) were included in the Asian subgroup (eculizumab, n &#x3D; 37; placebo, n &#x3D; 15); 45 Asian patients received eculizumab in the OLE. Most Asian patients (86.5%) received concomitant immunosuppressive therapy. During PREVENT, one adjudicated relapse occurred in patients receiving eculizumab and six occurred in patients receiving placebo in the Asian subgroup (hazard ratio, 0.05; 95% confidence interval: 0.01-0.35; p &#x3D; 0.0002). An estimated 95.2% of Asian patients remained relapse-free after 144 weeks of eculizumab treatment. Upper respiratory tract infections, headache, and nasopharyngitis were the most common adverse events with eculizumab in the Asian subgroup. Conclusion Eculizumab reduces the risk of relapse in Asian patients with AQP4+ NMOSD, with a benefit-risk profile similar to the overall PREVENT population. The benefits of eculizumab were maintained during long-term therapy. Clinical trial registration ClinicalTrials.gov identifiers: NCT01892345 (PREVENT); NCT02003144 (open-label extension).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210307071644&amp;v&#x3D;2.14.2&quot;&gt;33676197&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102849&gt;10.1016&#x2F;j.msard.2021.102849&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210307071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":398,"discovery_date":"2021-03-07T04:16:45","title":"Whole Brain Adiabatic T(1rho) and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Magn Reson Imaging. 2021 Mar 6. doi: 10.1002&#x2F;jmri.27586. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: In preclinical models of multiple sclerosis (MS), both adiabatic T&lt;sub&gt;1rho&lt;&#x2F;sub&gt; (T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; ) and relaxation along a fictitious field (RAFF) imaging have demonstrated potential to noninvasively characterize MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: To evaluate the feasibility of whole brain T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and RAFF imaging in healthy volunteers and patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STUDY TYPE: Single institutional clinical trial.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUBJECTS: About 38 healthy volunteers (24-69 years) and 21 patients (26-59 years) with MS. Five healthy volunteers underwent a second MR examination performed within 8 days. Clinical disease severity (The Expanded Disability Status Scale [EDSS] and The Multiple Sclerosis Severity Score [MSSS]) was evaluated at baseline and 1-year follow-up (FU).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FIELD STRENGTH&#x2F;SEQUENCE: RAFF in second rotating frame of reference (RAFF2) was performed at 3 T using 3D-fast-field echo with magnetization preparation, RF amplitude of 11.74 μT while the corresponding value for T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; was 13.50 μT. T&lt;sub&gt;1&lt;&#x2F;sub&gt; -, T&lt;sub&gt;2&lt;&#x2F;sub&gt; -, and FLAIR-weighted images were acquired with reconstruction voxel size 1.0 × 1.0 × 1.0 mm&lt;sup&gt;3&lt;&#x2F;sup&gt; .&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;ASSESSMENT: The parametric maps of T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and RAFF2 (T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; ) were calculated using a monoexponential model. Semi-automatic segmentation of MS lesions, white matter (WM), and gray matter (GM), and WM tracks was performed using T&lt;sub&gt;1&lt;&#x2F;sub&gt; -, T&lt;sub&gt;2&lt;&#x2F;sub&gt; -, and FLAIR-weighted images.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STATISTICAL TESTS: Regression analysis was used to evaluated correlation of T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; with age and disease severity while a Friedman test followed by Wilcoxon Signed Rank test for differences between tissue types. Short-term repeatability was evaluated on voxel level.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Both T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; demonstrated good short-term repeatability with relative differences on voxel level in the range of 6.1%-11.9%. Differences in T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; between the tissue types in MS patients were significant (P &amp;lt; 0.05). T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; correlated (P &amp;lt; 0.001) with baseline EDSS&#x2F;MSSM and disease progression at FU (P &amp;lt; 0.001).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DATA CONCLUSION: Whole brain T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; at 3 T was feasible with significant differences in T&lt;sub&gt;1ρadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; values between tissues time and correlation with disease severity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 1.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306231644&amp;v&#x3D;2.14.2&quot;&gt;33675564&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;jmri.27586&gt;10.1002&#x2F;jmri.27586&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306231644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":397,"discovery_date":"2021-03-07T00:43:30","title":"Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease","summary":"Regenerative therapies to mitigate Alzheimer’s disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells h...","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00791-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":396,"discovery_date":"2021-03-06T21:43:30","title":"Blockage of NLRP3 inflammasome activation ameliorates acute inflammatory injury and long-term cognitive impairment induced by necrotizing enterocolitis in mice","summary":"Necrotizing enterocolitis (NEC) is an inflammatory gastrointestinal disease in premature neonates with high mortality and morbidity, while the underlining mechanism of intestinal injury and profound neurologic...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02111-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":395,"discovery_date":"2021-03-06T14:16:46","title":"The Role of the Inflammasome in Neurodegenerative Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Molecules. 2021 Feb 11;26(4):953. doi: 10.3390&#x2F;molecules26040953.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases are chronic, progressive disorders that occur in the central nervous system (CNS). They are characterized by the loss of neuronal structure and function and are associated with inflammation. Inflammation of the CNS is called neuroinflammation, which has been implicated in most neurodegenerative diseases, including Alzheimer&#39;s disease (AD), Parkinson&#39;s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Much evidence indicates that these different conditions share a common inflammatory mechanism: the activation of the inflammasome complex in peripheral monocytes and in microglia, with the consequent production of high quantities of the pro-inflammatory cytokines IL-1β and IL-18. Inflammasomes are a group of multimeric signaling complexes that include a sensor Nod-like receptor (NLR) molecule, the adaptor protein ASC, and caspase-1. The NLRP3 inflammasome is currently the best-characterized inflammasome. Multiple signals, which are potentially provided in combination and include endogenous danger signals and pathogens, trigger the formation of an active inflammasome, which, in turn, will stimulate the cleavage and the release of bioactive cytokines including IL-1β and IL-18. In this review, we will summarize results implicating the inflammasome as a pivotal player in the pathogenesis of neurodegenerative diseases and discuss how compounds that hamper the activation of the NLRP3 inflammasome could offer novel therapeutic avenues for these diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33670164&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;molecules26040953&gt;10.3390&#x2F;molecules26040953&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":394,"discovery_date":"2021-03-06T14:16:46","title":"Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Aging Cell. 2021 Mar 5:e13335. doi: 10.1111&#x2F;acel.13335. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Brain ageing is characterised by a decline in neuronal function and associated cognitive deficits. There is increasing evidence that myelin disruption is an important factor that contributes to the age-related loss of brain plasticity and repair responses. In the brain, myelin is produced by oligodendrocytes, which are generated throughout life by oligodendrocyte progenitor cells (OPCs). Currently, a leading hypothesis points to ageing as a major reason for the ultimate breakdown of remyelination in Multiple Sclerosis (MS). However, an incomplete understanding of the cellular and molecular processes underlying brain ageing hinders the development of regenerative strategies. Here, our combined systems biology and neurobiological approach demonstrate that oligodendroglial and myelin genes are amongst the most altered in the ageing mouse cerebrum. This was underscored by the identification of causal links between signalling pathways and their downstream transcriptional networks that define oligodendroglial disruption in ageing. The results highlighted that the G-protein coupled receptor Gpr17 is central to the disruption of OPCs in ageing and this was confirmed by genetic fate-mapping and cellular analyses. Finally, we used systems biology strategies to identify therapeutic agents that rejuvenate OPCs and restore myelination in age-related neuropathological contexts.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33675110&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;acel.13335&gt;10.1111&#x2F;acel.13335&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":393,"discovery_date":"2021-03-06T14:16:46","title":"Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Agonist","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Drug Metab Dispos. 2021 Mar 4:DMD-AR-2020-000220. doi: 10.1124&#x2F;dmd.120.000220. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Ozanimod is approved for the treatment of relapsing forms of multiple sclerosis. Absorption, metabolism and excretion of ozanimod was investigated following a single oral dose of 1.0 mg &lt;sup&gt;14&lt;&#x2F;sup&gt;C-ozanimod hydrochloride to six healthy subjects. In vitro experiments were conducted to understand the metabolic pathways and enzyme involved in the metabolism of ozanimod and its active metabolites. The total mean recovery of the administered radioactivity was ~63%, with ~26% and ~37% recovered from urine and feces, respectively. Based on exposure, the major circulating components were active metabolite CC112273 and inactive metabolite RP101124 and together accounted for 50% of the circulating total radioactivity exposure while ozanimod accounted for 6.7% of the total radioactive exposure. Ozanimod was extensively metabolized, with 13 metabolites identified including 2 major active metabolites (CC112273 and CC1084037) and 1 major inactive metabolite (RP101124) in circulation. Ozanimod is metabolized by three primary pathways including aldehyde dehydrogenase and alcohol dehydrogenase, cytochrome P450 (CYP) isoforms 3A4, 1A1, and reductive metabolism by gut microflora. The primary metabolite RP101075 is further metabolized to form major active metabolite CC112273 by monoamine oxidase B which further undergoes reduction by carbonyl reductases (CBR) to form CC1084037 or CYP2C8 mediated oxidation to form RP101509. CC1084037 is oxidized rapidly to form CC112273 by aldo-keto reductase (AKR) 1C1&#x2F;1C2, and&#x2F;or 3β- and 11β-hydroxysteroid dehydrogenase (HSD) and this reversible oxido-reduction between two active metabolites favors CC112273. Ozanimod example illustrates the need for conducting timely radiolabeled human ADME studies for characterization of disproportionate metabolites and assessment of exposure coverage during drug development. &lt;b&gt;Significance Statement&lt;&#x2F;b&gt; Absorption, metabolism, and excretion of ozanimod was characterized in humans and the enzymes involved in complex metabolism were elucidated. Disproportionate metabolites were identified, and the activity of these metabolites were determined.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33674268&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33674268&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1124&#x2F;dmd.120.000220&gt;10.1124&#x2F;dmd.120.000220&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33674268&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":392,"discovery_date":"2021-03-06T14:16:46","title":"Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Med. 2021 Feb 19;10(4):868. doi: 10.3390&#x2F;jcm10040868.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing&#x2F;remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33669799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33669799&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;jcm10040868&gt;10.3390&#x2F;jcm10040868&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33669799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":391,"discovery_date":"2021-03-06T14:16:46","title":"Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 22;22(4):2182. doi: 10.3390&#x2F;ijms22042182.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The effect of the inflammatory response on regenerative processes in the brain is complex. This complexity is even greater when the cause of the tissue damage is an autoimmune response. Multiple sclerosis (MS) is an immune-mediated disease in which demyelination foci are formed in the central nervous system. The degree of repair through oligodendrocyte regeneration and remyelination is insufficient. Ephrins are membrane-bound ligands activating tyrosine kinase signaling proteins that are known to have an inhibitory effect on oligodendrocyte regeneration. In this study, we examined the expression of ephrins on immune cells of 43 patients with relapsing-remitting (RR) MS compared to 27 matched healthy controls (HC). We found an increased expression of ephrin-A2, -A3 and -B3, especially on T cell subpopulations. We also showed overexpression of ephrins on immune cells of patients with RR-MS that increases the forward signaling pathway and that expression of ephrins on immune cells has an inhibitory effect on the differentiation of oligodendrocyte precursor cells (OPCs) in vitro. Our study findings support the concept that the immune activity of T cells in patients with RR-MS has an inhibitory effect on the differentiation capacity of OPCs through the expression and forward signaling of ephrins.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671716&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671716&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22042182&gt;10.3390&#x2F;ijms22042182&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671716&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":390,"discovery_date":"2021-03-06T14:16:46","title":"The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 11;22(4):1804. doi: 10.3390&#x2F;ijms22041804.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Currently, there is some information on the consequences of COVID-19 infection in multiple sclerosis (MS) patients, as it is a newly discovered coronavirus, but its far-reaching effects on participation in neurodegenerative diseases seem to be significant. Recent cases reports showed that SARS-CoV-2 may be responsible for initiating the demyelination process in people who previously had no symptoms associated with any nervous system disorders. It is presently known that infection of SARS-CoV-2 evokes cytokine storm syndrome, which may be one of the factors leading to the acute cerebrovascular disease. One of the substantial problems is the coexistence of cerebrovascular disease and MS in an individual&#39;s life span. Epidemiological studies showed an enhanced risk of death rate from vascular disabilities in MS patients of approximately 30%. It has been demonstrated that patients with severe SARS-CoV-2 infection usually show increased levels of D-dimer, fibrinogen, C-reactive protein (CRP), and overactivation of blood platelets, which are essential elements of prothrombotic events. In this review, the latest knowledge gathered during an ongoing pandemic of SARS-CoV-2 infection on the neurodegeneration processes in MS is discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670394&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33670394&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22041804&gt;10.3390&#x2F;ijms22041804&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670394&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":389,"discovery_date":"2021-03-06T14:16:46","title":"Pharmacological Management of Neurogenic Bowel Dysfunction after Spinal Cord Injury and Multiple Sclerosis: A Systematic Review and Clinical Implications","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Med. 2021 Feb 22;10(4):882. doi: 10.3390&#x2F;jcm10040882.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurogenic bowel dysfunction (NBD) is a common problem for people with spinal cord injury (SCI) and multiple sclerosis (MS), which seriously impacts quality of life. Pharmacological management is an important component of conservative bowel management. The objective of this study was to first assemble a list of pharmacological agents (medications and medicated suppositories) used in current practice. Second, we systematically examined the current literature on pharmacological agents to manage neurogenic bowel dysfunction of individuals specifically with SCI or MS. We searched Medline, EMBASE and CINAHL databases up to June 2020. We used the GRADE System to provide a systematic approach for evaluating the evidence. Twenty-eight studies were included in the review. We found a stark discrepancy between the large number of agents currently prescribed and a very limited amount of literature. While there was a small amount of literature in SCI, there was little to no literature available for MS. There was low-quality evidence supporting rectal medications, which are a key component of conservative bowel care in SCI. Based on the findings of the literature and the clinical experience of the authors, we have provided clinical insights on proposed treatments and medications in the form of three case study examples on patients with SCI or MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671492&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671492&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;jcm10040882&gt;10.3390&#x2F;jcm10040882&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671492&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":388,"discovery_date":"2021-03-06T14:16:46","title":"Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 28;22(5):2440. doi: 10.3390&#x2F;ijms22052440.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The need for remyelinating drugs is essential for healing disabling diseases such as multiple sclerosis (MS). One of the reasons for the lack of this class of therapies is the impossibility to monitor remyelination in vivo, which is of utmost importance to perform effective clinical trials. Here, we show how optical coherence tomography (OCT), a cheap and non-invasive technique commonly used in ophthalmology, may be used to assess remyelination in vivo in MS patients. Our pioneer approach validates OCT as a technique to study remyelination of the optic nerve and reflects what is occurring in non-accessible central nervous system (CNS) structures, like the spinal cord. In this study we used the orally bioavailable small molecule VP3.15, confirming its therapeutical potential as a neuroprotective, anti-inflammatory, and probably remyelinating drug for MS. Altogether, our results confirm the usefulness of OCT to monitor the efficacy of remyelinating therapies in vivo and underscore the relevance of VP3.15 as a potential disease modifying drug for MS therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671012&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671012&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22052440&gt;10.3390&#x2F;ijms22052440&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671012&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":387,"discovery_date":"2021-03-06T14:16:46","title":"Methylxanthines and Neurodegenerative Diseases: An Update","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nutrients. 2021 Feb 28;13(3):803. doi: 10.3390&#x2F;nu13030803.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Methylxanthines (MTX) are purine derived xanthine derivatives. Whereas naturally occurring methylxanthines like caffeine, theophylline or theobromine are widely consumed in food, several synthetic but also non-synthetic methylxanthines are used as pharmaceuticals, in particular in treating airway constrictions. Besides the well-established bronchoprotective effects, methylxanthines are also known to have anti-inflammatory and anti-oxidative properties, mediate changes in lipid homeostasis and have neuroprotective effects. Known molecular mechanisms include adenosine receptor antagonism, phosphodiesterase inhibition, effects on the cholinergic system, wnt signaling, histone deacetylase activation and gene regulation. By affecting several pathways associated with neurodegenerative diseases via different pleiotropic mechanisms and due to its moderate side effects, intake of methylxanthines have been suggested to be an interesting approach in dealing with neurodegeneration. Especially in the past years, the impact of methylxanthines in neurodegenerative diseases has been extensively studied and several new aspects have been elucidated. In this review we summarize the findings of methylxanthines linked to Alzheimer´s disease, Parkinson&#39;s disease and Multiple Sclerosis since 2017, focusing on epidemiological and clinical studies and addressing the underlying molecular mechanisms in cell culture experiments and animal studies in order to assess the neuroprotective potential of methylxanthines in these diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671099&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;nu13030803&gt;10.3390&#x2F;nu13030803&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":386,"discovery_date":"2021-03-06T14:16:46","title":"Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Diagnostics (Basel). 2021 Feb 17;11(2):325. doi: 10.3390&#x2F;diagnostics11020325.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Aqueduct of Sylvius (AoS) cerebrospinal fluid flow can be quantified using phase-contrast (PC) Magnetic Resonance Imaging. The software used for AoS segmentation might affect the PC-derived measures. We analyzed AoS PC data of 30 people with multiple sclerosis and 19 normal controls using three software packages, and estimated cross-sectional area (CSA), average and highest AoS velocity (Vmean and Vmax), flow rate and volume. Our aims were to assess the repeatability and reproducibility of each PC-derived measure obtained with the various software packages, including in terms of group differentiation. All the variables had good repeatability, except the average Vmean, flow rate and volume obtained with one software package. Substantial to perfect agreement was seen when evaluating the overlap between the AoS segmentations obtained with different software packages. No variable was significantly different between software packages, with the exception of Vmean diastolic peak and CSA. Vmax diastolic peak differentiated groups, regardless of the software package. In conclusion, a clinical study should preliminarily evaluate the repeatability in order to interpret its findings. Vmax seemed to be a repeatable and reproducible measure, since the pixel with its value is usually located in the center of the AoS, and is thus unlikely be affected by ROI size.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671219&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671219&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;diagnostics11020325&gt;10.3390&#x2F;diagnostics11020325&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671219&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":385,"discovery_date":"2021-03-06T14:16:46","title":"Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Molecules. 2021 Feb 23;26(4):1188. doi: 10.3390&#x2F;molecules26041188.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Alzheimer&#39;s, Parkinson&#39;s, and multiple sclerosis are neurodegenerative diseases related by neuronal degeneration and death in specific areas of the central nervous system. These pathologies are associated with neuroinflammation, which is involved in disease progression, and halting this process represents a potential therapeutic strategy. Evidence suggests that microglia function is regulated by A&lt;sub&gt;1&lt;&#x2F;sub&gt; and A&lt;sub&gt;2A&lt;&#x2F;sub&gt; adenosine receptors (AR), which are considered as neuroprotective and neurodegenerative receptors, respectively. The manuscript&#39;s aim is to elucidate the role of these receptors in neuroinflammation modulation through potent and selective A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists (N&lt;sup&gt;6&lt;&#x2F;sup&gt;-cyclopentyl-2&#39;- or 3&#39;-deoxyadenosine substituted or unsubstituted in 2 position) and A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists (9-ethyl-adenine substituted in 8 and&#x2F;or in 2 position), synthesized in house, using N13 microglial cells. In addition, the combined therapy of A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists and A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists to modulate neuroinflammation was evaluated. Results showed that A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists were able, to varying degrees, to prevent the inflammatory effect induced by cytokine cocktail (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and interferon (IFN)-γ), while A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists showed a good ability to counteract neuroinflammation. Moreover, the effect achieved by combining the two most effective compounds (&lt;b&gt;1&lt;&#x2F;b&gt; and &lt;b&gt;6&lt;&#x2F;b&gt;) in doses previously found to be non-effective was greater than the treatment effect of each of the two compounds used separately at maximal dose.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33672225&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33672225&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;molecules26041188&gt;10.3390&#x2F;molecules26041188&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33672225&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":384,"discovery_date":"2021-03-06T14:16:46","title":"Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 22;11(2):272. doi: 10.3390&#x2F;brainsci11020272.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Suitable in vivo and in vitro models are instrumental for the development of new drugs aimed at improving symptoms or progression of multiple sclerosis (MS). The cuprizone (CPZ)-induced murine model has gained momentum in recent decades, aiming to address the demyelination component of the disease. This work aims at assessing the differential cytotoxicity of CPZ in cells of different types and from different species: human oligodendroglial (HOG), human neuroblastoma (SH-SY5Y), human glioblastoma (T-98), and mouse microglial (N-9) cell lines. Moreover, the effect of CPZ was investigated in primary rat brain cells. Cell viability was assayed by oxygen rate consumption and by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based (MTT) method. Our results demonstrated that CPZ did not cause death in any of the assayed cell models but affected mitochondrial function and aerobic cell respiration, thus compromising cell metabolism in neural cells and neuron-glia co-cultures. In this sense, we found differential vulnerability between glial cells and neurons as is the case of the CPZ-induced mouse model of MS. In addition, our findings demonstrated that reduced viability was spontaneous reverted in a time-dependent manner by treatment discontinuation. This reversible cell-based model may help to further investigate the role of mitochondria in the disease, and study the molecular intricacies underlying the pathophysiology of the MS and other demyelinating diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671675&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11020272&gt;10.3390&#x2F;brainsci11020272&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":383,"discovery_date":"2021-03-06T14:16:46","title":"The Dying Forward Hypothesis of ALS: Tracing Its History","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 27;11(3):300. doi: 10.3390&#x2F;brainsci11030300.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The site of origin of amyotrophic lateral sclerosis (ALS), although unsettled, is increasingly recognized as being cortico-fugal, which is a dying-forward process primarily starting in the corticomotoneuronal system. A variety of iterations of this concept date back to over 150 years. Recently, the hallmark TAR DNA-binding protein 43 (TDP-43) pathology, seen in &amp;gt;95% of patients with ALS, has been shown to be largely restricted to corticofugal projecting neurons (&quot;dying forward&quot;). Possibly, soluble but toxic cytoplasmic TDP-43 could enter the axoplasm of Betz cells, subsequently causing dysregulation of nuclear protein in the lower brainstem and spinal cord anterior horn cells. As the disease progresses, cortical involvement in ALS becomes widespread, including or starting with frontotemporal dementia, implying a broader view of ALS as a brain disease. The onset at the motor and premotor cortices should be considered a nidus at the edge of multiple cortical networks which eventually become disrupted, causing failure of a widespread cortical connectome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33673524&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33673524&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11030300&gt;10.3390&#x2F;brainsci11030300&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33673524&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":382,"discovery_date":"2021-03-06T14:16:46","title":"Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 15;22(4):1914. doi: 10.3390&#x2F;ijms22041914.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). MS and its animal model called experimental autoimmune encephalomyelitis (EAE) immunopathogenesis involve a plethora of immune cells whose activation releases a variety of proinflammatory mediators and free radicals. Vitamin D3 (VitD) is endowed with immunomodulatory and antioxidant properties that we demonstrated to control EAE development. However, this protective effect triggered hypercalcemia. As such, we compared the therapeutic potential of VitD and paricalcitol (Pari), which is a non-hypercalcemic vitamin D analog, to control EAE. From the seventh day on after EAE induction, mice were injected with VitD or Pari every other day. VitD, but not Pari, displayed downmodulatory ability being able to reduce the recruitment of inflammatory cells, the mRNA expression of inflammatory parameters, and demyelination at the CNS. Lower production of proinflammatory cytokines by lymph node-derived cells and IL-17 by gut explants, and reduced intestinal inflammation were detected in the EAE&#x2F;VitD group compared to the EAE untreated or Pari groups. Dendritic cells (DCs) differentiated in the presence of VitD developed a more tolerogenic phenotype than in the presence of Pari. These findings suggest that VitD, but not Pari, has the potential to be used as a preventive therapy to control MS severity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671896&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671896&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22041914&gt;10.3390&#x2F;ijms22041914&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671896&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":381,"discovery_date":"2021-03-06T14:16:46","title":"A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 6. doi: 10.1002&#x2F;acn3.51325. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess feasibility, tolerability, and safety of N-acetyl cysteine (NAC) for fatigue in progressive MS. Secondary objectives evaluated changes in fatigue and oxidative pathway biomarkers on NAC versus placebo.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Individuals with progressive MS with Modified Fatigue Impact Scale (MFIS) &amp;gt; t38 were randomized 2:1 to NAC 1250mg TID or placebo for 4 weeks. The primary outcome was tolerability and safety. The secondary outcome to evaluate efficacy was MFIS change from baseline to week 4 between groups. Exploratory biomarker outcomes included change in blood GSH&#x2F;GSSG ratio (reduced-to-oxidized glutathione (GSH)) and in vivo relative GSH using 7T MR spectroscopy (MRS) between groups. Fisher exact test was used for categorical and rank sum for continuous outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Fifiteen were randomized (10 NAC, 5 placebo; mean age 56.1 years, 80% female, median EDSS 6.0). At least one adverse event (AE) occurred in 60% on NAC versus 80% on placebo (p &#x3D; 0.75). There were two AEs attributed to NAC in one patient (abdominal pain and constipation), with 94% adherence to NAC. MFIS decreased in both groups at week 4, with the mean improvement of 11-points on NAC versus 18-points on placebo (p &#x3D; 0.33). GSH&#x2F;GSSG ratio decreased on placebo (-0.6) and NAC (-0.1) (p &#x3D; 0.18). Change in GSH levels to total creatine in anterior and posterior cingulate cortex, insula, caudate, putamen, and thalamus did not differ between groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: NAC was well-tolerated in progressive MS, although reduction in fatigue on NAC was similar to placebo. Antioxidant blood and MRS biomarkers were not significantly altered by NAC, which could be due to dose, route of administration, time of sample collection, short half-life, or lack of effect. REGISTERED: clinicaltrials.gov NCT02804594.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675156&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33675156&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51325&gt;10.1002&#x2F;acn3.51325&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675156&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":380,"discovery_date":"2021-03-06T12:35:19","title":"Dorsal Hippocampal Actin Polymerization Is Necessary for Activation of G-Protein-Coupled Estrogen Receptor (GPER) to Increase CA1 Dendritic Spine Density and Enhance Memory Consolidation","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9598","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":379,"discovery_date":"2021-03-06T12:35:19","title":"White Matter Stroke Induces a Unique Oligo-Astrocyte Niche That Inhibits Recovery","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;47&#x2F;9343","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":378,"discovery_date":"2021-03-06T12:35:19","title":"Autophagy in Myelinating Glia","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2019&#x2F;11&#x2F;19&#x2F;JNEUROSCI.1066-19.2019","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":377,"discovery_date":"2021-03-06T12:35:19","title":"NeuroEVs: Characterizing Extracellular Vesicles Generated in the Neural Domain","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;47&#x2F;9262","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":376,"discovery_date":"2021-03-06T12:35:19","title":"Blocking the Thrombin Receptor Promotes Repair of Demyelinated Lesions in the Adult Brain","summary":"","link":"https://www.jneurosci.org//content/40/7/1483","published_date":"","source":"JNeuroSci","relevant":1,"table_constraints":null},{"article_id":375,"discovery_date":"2021-03-06T12:35:19","title":"Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer&#39;s Disease","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9645","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":374,"discovery_date":"2021-03-06T12:35:19","title":"Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;6&#x2F;1176","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":373,"discovery_date":"2021-03-06T12:35:19","title":"Distinct P2Y Receptors Mediate Extension and Retraction of Microglial Processes in Epileptic and Peritumoral Human Tissue","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;7&#x2F;1373","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":372,"discovery_date":"2021-03-06T12:35:19","title":"Meningeal Lymphangiogenesis and Enhanced Glymphatic Activity in Mice with Chronically Implanted EEG Electrodes","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2371","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":371,"discovery_date":"2021-03-06T12:35:19","title":"p75NTR and DR6 Regulate Distinct Phases of Axon Degeneration Demarcated by Spheroid Rupture","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9503","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":370,"discovery_date":"2021-03-06T12:35:19","title":"Activated CX3CL1&#x2F;Smad2 signals prevent neuronal loss and Alzheimer&#39;s tau pathology-mediated cognitive dysfunction","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2019&#x2F;12&#x2F;10&#x2F;JNEUROSCI.1333-19.2019","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":369,"discovery_date":"2021-03-06T12:35:19","title":"The Next 50 Years of Neuroscience","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;1&#x2F;101","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":368,"discovery_date":"2021-03-06T12:35:19","title":"Aberrant ER Stress Induced Neuronal-IFNβ Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;424","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":367,"discovery_date":"2021-03-06T12:35:19","title":"Attenuating Neurogenic Sympathetic Hyperreflexia Robustly Improves Antibacterial Immunity After Chronic Spinal Cord Injury","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;478","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":366,"discovery_date":"2021-03-06T12:35:19","title":"Hippocampal Neurogenesis and Neural Circuit Formation in a Cuprizone-Induced Multiple Sclerosis Mouse Model","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;447","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":365,"discovery_date":"2021-03-06T12:35:19","title":"Convergence between Microglia and Peripheral Macrophages Phenotype during Development and Neuroinflammation","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;4&#x2F;784","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":364,"discovery_date":"2021-03-06T12:35:19","title":"Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological Mechanisms","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;5&#x2F;1162","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":363,"discovery_date":"2021-03-06T12:35:19","title":"Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;26&#x2F;5105","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":362,"discovery_date":"2021-03-06T12:35:19","title":"Idebenone Has Distinct Effects on Mitochondrial Respiration in Cortical Astrocytes Compared to Cortical Neurons Due to Differential NQO1 Activity","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;23&#x2F;4609","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":361,"discovery_date":"2021-03-06T12:35:19","title":"Actin-Binding Protein Cortactin Promotes Pathogenesis of Experimental Autoimmune Encephalomyelitis by Supporting Leukocyte Infiltration into the Central Nervous System","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;7&#x2F;1389","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":360,"discovery_date":"2021-03-06T12:35:19","title":"Nonionotropic Action of Endothelial NMDA Receptors on Blood–Brain Barrier Permeability via Rho&#x2F;ROCK-Mediated Phosphorylation of Myosin","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;8&#x2F;1778","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":359,"discovery_date":"2021-03-06T12:35:19","title":"Fingolimod rescues demyelination in a mouse model of Krabbe&#39;s disease","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2020&#x2F;02&#x2F;27&#x2F;JNEUROSCI.2346-19.2020","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":358,"discovery_date":"2021-03-06T12:35:19","title":"Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2189","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":357,"discovery_date":"2021-03-06T12:35:19","title":"Behavioral and Neural Signatures of Working Memory in Childhood","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;26&#x2F;5090","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":356,"discovery_date":"2021-03-06T12:35:19","title":"Interferon-β Plays a Detrimental Role in Experimental Traumatic Brain Injury by Enhancing Neuroinflammation That Drives Chronic Neurodegeneration","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2357","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":355,"discovery_date":"2021-03-06T12:35:19","title":"Colocalized White Matter Plasticity and Increased Cerebral Blood Flow Mediate the Beneficial Effect of Cardiovascular Exercise on Long-Term Motor Learning","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;12&#x2F;2416","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":354,"discovery_date":"2021-03-06T12:35:19","title":"Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;14&#x2F;2960","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":353,"discovery_date":"2021-03-06T12:35:19","title":"Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during Myelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;15&#x2F;2993","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":352,"discovery_date":"2021-03-06T12:35:19","title":"Deletion of Voltage-Gated Calcium Channels in Astrocytes during Demyelination Reduces Brain Inflammation and Promotes Myelin Regeneration in Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;17&#x2F;3332","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":351,"discovery_date":"2021-03-06T12:35:19","title":"Neonatal Stroke and TLR1&#x2F;2 Ligand Recruit Myeloid Cells through the Choroid Plexus in a CX3CR1-CCR2- and Context-Specific Manner","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;19&#x2F;3849","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":350,"discovery_date":"2021-03-06T12:35:19","title":"Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;20&#x2F;3896","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":349,"discovery_date":"2021-03-06T12:35:19","title":"Dendritic Spine Dynamics after Peripheral Nerve Injury: An Intravital Structural Study","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;22&#x2F;4297","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":348,"discovery_date":"2021-03-06T12:35:19","title":"Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;23&#x2F;4596","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":347,"discovery_date":"2021-03-06T12:35:19","title":"N-Wasp Regulates Oligodendrocyte Myelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;32&#x2F;6103","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":346,"discovery_date":"2021-03-06T12:35:19","title":"Differential Contribution of Cadm1–Cadm3 Cell Adhesion Molecules to Peripheral Myelinated Axons","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;7&#x2F;1393","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":345,"discovery_date":"2021-03-06T12:35:19","title":"The Neuroimmunology of Chronic Pain: From Rodents to Humans","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;5&#x2F;855","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":344,"discovery_date":"2021-03-06T12:35:19","title":"How to Interpret Resting-State fMRI: Ask Your Participants","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;6&#x2F;1130","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":343,"discovery_date":"2021-03-06T12:35:19","title":"NF-κB Activation Accounts for the Cytoprotective Effects of PERK Activation on Oligodendrocytes during EAE","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;33&#x2F;6444","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":342,"discovery_date":"2021-03-06T12:35:19","title":"A Developmental Analysis of Juxtavascular Microglia Dynamics and Interactions with the Vasculature","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;34&#x2F;6503","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":341,"discovery_date":"2021-03-06T12:35:19","title":"Spinal Wnt5a Plays a Key Role in Spinal Dendritic Spine Remodeling in Neuropathic and Inflammatory Pain Models and in the Proalgesic Effects of Peripheral Wnt3a","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;35&#x2F;6664","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":340,"discovery_date":"2021-03-06T12:35:19","title":"The Secreted Glycoprotein Reelin Suppresses the Proliferation and Regulates the Distribution of Oligodendrocyte Progenitor Cells in the Embryonic Neocortex","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;40&#x2F;7625","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":339,"discovery_date":"2021-03-06T12:35:19","title":"Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;40&#x2F;7609","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":338,"discovery_date":"2021-03-06T12:35:19","title":"Corticocortical and Thalamocortical Changes in Functional Connectivity and White Matter Structural Integrity after Reward-Guided Learning of Visuospatial Discriminations in Rhesus Monkeys","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;41&#x2F;7887","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":337,"discovery_date":"2021-03-06T12:35:19","title":"Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;44&#x2F;8587","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":336,"discovery_date":"2021-03-06T12:35:19","title":"Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;48&#x2F;9327","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":335,"discovery_date":"2021-03-06T12:35:19","title":"CREB Coactivator CRTC2 Plays a Crucial Role in Endothelial Function","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;49&#x2F;9533","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":334,"discovery_date":"2021-03-06T12:35:19","title":"Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;2&#x2F;376","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":333,"discovery_date":"2021-03-06T12:35:19","title":"Heparanome-mediated rescue of oligodendrocyte progenitor quiescence following inflammatory demyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2021&#x2F;01&#x2F;14&#x2F;JNEUROSCI.0580-20.2021","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":332,"discovery_date":"2021-03-06T12:35:19","title":"Disruption of Conscious Access in Psychosis Is Associated with Altered Structural Brain Connectivity","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;3&#x2F;513","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":331,"discovery_date":"2021-03-06T12:35:19","title":"The Wnt Effector TCF7l2 Promotes Oligodendroglial Differentiation by Repressing Autocrine BMP4-Mediated Signaling","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;8&#x2F;1650","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":330,"discovery_date":"2021-03-06T12:14:20","title":"CXCL13&#x2F;CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis","summary":"","link":"https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;ebiom&#x2F;article&#x2F;PIIS2352-3964(20)30473-4&#x2F;fulltext","published_date":"","source":"The Lancet","relevant":null,"table_constraints":null},{"article_id":329,"discovery_date":"2021-03-06T11:22:22","title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30342-2/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":328,"discovery_date":"2021-03-06T11:22:22","title":"Incidence of multiple sclerosis in China: A nationwide hospital-based study","summary":"","link":"https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(20)30010-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":327,"discovery_date":"2021-03-06T11:22:22","title":"Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30247-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":326,"discovery_date":"2021-03-06T11:22:22","title":"Catherine Lubetzki—expert on remyelination in multiple sclerosis","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30241-6/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":325,"discovery_date":"2021-03-06T11:22:21","title":"hESC-derived immune suppressive dendritic cells induce immune tolerance of parental hESC-derived allografts","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30496-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":324,"discovery_date":"2021-03-06T11:22:21","title":"CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30473-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":323,"discovery_date":"2021-03-06T11:22:21","title":"Remyelination in multiple sclerosis: from basic science to clinical translation","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30140-X/fulltext","published_date":"","source":"The Lancet","relevant":1,"table_constraints":null},{"article_id":322,"discovery_date":"2021-03-06T11:22:21","title":"Tolerance-inducing medicines in autoimmunity: rheumatology and beyond","summary":"","link":"https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30100-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":321,"discovery_date":"2021-03-06T11:22:21","title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30432-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":320,"discovery_date":"2021-03-06T11:22:21","title":"Regional and global perspectives on the incidence of multiple sclerosis and neuromyelitis optica and its spectrum disorders from Asia with emphasis on China","summary":"","link":"https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(20)30039-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":319,"discovery_date":"2021-03-06T11:22:21","title":"The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017","summary":"","link":"https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30190-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":318,"discovery_date":"2021-03-06T11:22:21","title":"Cognition in multiple sclerosis: Charcot was right","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30306-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":317,"discovery_date":"2021-03-06T11:22:21","title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30277-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":316,"discovery_date":"2021-03-06T11:22:21","title":"Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?","summary":"","link":"https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30340-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":315,"discovery_date":"2021-03-06T11:22:21","title":"High-dose biotin in multiple sclerosis: the end of the road","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30353-7/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":314,"discovery_date":"2021-03-06T11:22:21","title":"Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30347-1/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":313,"discovery_date":"2021-03-06T11:22:21","title":"Long-term ocrelizumab in progressive multiple sclerosis","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30399-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":312,"discovery_date":"2021-03-06T11:22:21","title":"Are drugs for multiple sclerosis fatigue just placebos?","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30415-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":311,"discovery_date":"2021-03-06T11:22:21","title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30354-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":310,"discovery_date":"2021-03-06T11:22:21","title":"Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study","summary":"","link":"https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30362-X/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":309,"discovery_date":"2021-03-06T11:22:21","title":"Multiple sclerosis in 2020: un bon cru","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30441-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":308,"discovery_date":"2021-03-06T11:22:21","title":"Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00004-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":307,"discovery_date":"2021-03-06T11:22:21","title":"Serum markers of multiple sclerosis - a new approach","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00022-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":306,"discovery_date":"2021-03-06T11:22:21","title":"Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00020-7/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":305,"discovery_date":"2021-03-06T11:22:21","title":"Established and novel therapeutic options for autoimmune hepatitis","summary":"","link":"https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30328-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":304,"discovery_date":"2021-03-06T11:06:13","title":"Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S1677-55382020000600891&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":303,"discovery_date":"2021-03-06T11:06:13","title":"Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001100741&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":302,"discovery_date":"2021-03-06T11:06:13","title":"Telemedicine in neurology: current evidence","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200818&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":301,"discovery_date":"2021-03-06T11:06:13","title":"Neurobiology of COVID-19: how can the virus affect the brain?","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S1516-44462021005003203&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":300,"discovery_date":"2021-03-06T11:06:13","title":"Decreased levels of interleukin 27 in the serum of vitiligo patients,","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0365-05962020000500570&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":299,"discovery_date":"2021-03-06T11:06:13","title":"Qualitative and Quantitative Ultrastructural Analysis of the Mitochondria from Adrenal Gland Cortex Under the Action of Viperidae family Snake Venoms","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000501271&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":298,"discovery_date":"2021-03-06T11:06:13","title":"The Modified Method of Luxol Fast Blue for Paraffin-Embedded Myelin Sheath Staining","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000501197&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":297,"discovery_date":"2021-03-06T11:06:13","title":"Altered Oligodendrocytes in Spinal Enlargements of Streptozotocin Diabetic Rats","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000601606&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":296,"discovery_date":"2021-03-06T11:06:13","title":"Cobalt deficiency in cattle and its impact on production","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0100-736X2020001100837&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":295,"discovery_date":"2021-03-06T11:06:13","title":"Restless legs syndrome&#x2F;Willis-Ekbom disease in multiple sclerosis: a contributing factor for anxiety, disability, sleep disorder, and quality of life","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001100708&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":294,"discovery_date":"2021-03-06T11:06:13","title":"Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200789&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":293,"discovery_date":"2021-03-06T11:06:13","title":"Acute Disseminated Encephalomyelitis in COVID-19: presentation of two cases and review of the literature","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200805&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":292,"discovery_date":"2021-03-06T11:06:13","title":"Probabilistic Multiple Sclerosis Lesion Detection using Superpixels and Markov Random Fields","summary":"","link":"http:&#x2F;&#x2F;www.scielo.org.mx&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0188-95322020000300102&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":291,"discovery_date":"2021-03-06T11:06:13","title":"Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0100-879X2021000300602&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":290,"discovery_date":"2021-03-06T11:06:13","title":"Ultrastructural Clarification of the Peripherally Located Actin Network in the Myelinated Axons","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022021000100179&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":289,"discovery_date":"2021-03-06T10:52:00","title":"Exercise therapy for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;14622","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":288,"discovery_date":"2021-03-06T10:52:00","title":"Identification and management of depression in multiple sclerosisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;46271","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":287,"discovery_date":"2021-03-06T10:52:00","title":"Multiple sclerosis: management of multiple sclerosis in primary and secondary care: full guideline (CG186)Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;42404","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":286,"discovery_date":"2021-03-06T10:52:00","title":"Effectiveness of physical therapy interventions in reducing fear of falling among individuals with neurological diseases: a systematic review and meta-analysisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;61919","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":285,"discovery_date":"2021-03-06T10:52:00","title":"Which behavioural and exercise interventions targeting fatigue show the most promise in multiple sclerosis? A systematic review with narrative synthesis and meta-analysis [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;59262","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":284,"discovery_date":"2021-03-06T10:52:00","title":"Occupational therapy for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;9626","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":283,"discovery_date":"2021-03-06T10:52:00","title":"Treatment for ataxia in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;17698","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":282,"discovery_date":"2021-03-06T10:52:00","title":"Multidisciplinary rehabilitation for adults with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;18223","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":281,"discovery_date":"2021-03-06T10:52:00","title":"Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;22189","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":280,"discovery_date":"2021-03-06T10:52:00","title":"Whole-body vibration training for patients with neurodegenerative disease (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;30992","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":279,"discovery_date":"2021-03-06T10:52:00","title":"Non pharmacological interventions for spasticity in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;34946","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":278,"discovery_date":"2021-03-06T10:52:00","title":"Exercise therapy for fatigue in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;43790","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":277,"discovery_date":"2021-03-06T10:52:00","title":"Telerehabilitation for persons with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;42483","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":276,"discovery_date":"2021-03-06T10:52:00","title":"Respiratory muscle training for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;52008","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":275,"discovery_date":"2021-03-06T10:52:00","title":"Non-pharmacological interventions for chronic pain in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;55880","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":274,"discovery_date":"2021-03-06T10:52:00","title":"Interventions for preventing falls in people with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;59246","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":273,"discovery_date":"2021-03-06T10:52:00","title":"Palliative care interventions for people with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;58944","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":272,"discovery_date":"2021-03-06T10:52:00","title":"Rehabilitation for people with multiple sclerosis: an overview of Cochrane reviews (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;56062","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":271,"discovery_date":"2021-03-06T10:52:00","title":"EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;25074","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":270,"discovery_date":"2021-03-06T10:52:00","title":"Nursing management of the patient with multiple sclerosisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;33859","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":269,"discovery_date":"2021-03-06T10:36:00","title":"18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study","summary":"Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting tha...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02460-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":268,"discovery_date":"2021-03-06T10:36:00","title":"Zygomatic implant penetration to the central portion of orbit: a case report","summary":"Zygomatic implants have been proposed in literature for atrophic maxillary fixed oral rehabilitations. The aim of the present research was to evaluate, by a clinical and tomography assessment, a surgical compl...","link":"https:&#x2F;&#x2F;bmcophthalmol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12886-021-01846-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":267,"discovery_date":"2021-03-06T10:18:24","title":"Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020","summary":"Little attention has been paid to customising fatigue questionnaires for patients with Substance Use Disorders (SUDs). The present study aims to validate and shorten the nine-item Fatigue Severity Scale (FSS-9...","link":"https:&#x2F;&#x2F;hqlo.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12955-021-01708-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":266,"discovery_date":"2021-03-06T10:18:24","title":"","summary":"","link":"https:","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":265,"discovery_date":"2021-03-06T10:18:24","title":"Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis","summary":"Juvenile primary fibromyalgia syndrome (JPFS) is a chronic, musculoskeletal pain syndrome affecting children and adolescents, most commonly adolescent girls. The syndrome has a multifactorial etiology, with al...","link":"https:&#x2F;&#x2F;ped-rheum.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12969-021-00493-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":264,"discovery_date":"2021-03-06T10:18:24","title":"Consistency and applicability of different brief screen instrument of cognitive function in elderly population","summary":"Screening for cognitive impairment (CI) is often hampered by lack of consensus as to which screening instrument to use. The aim is to assess the consistence and applicability of different CI screening tools.","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02048-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":263,"discovery_date":"2021-03-06T10:18:24","title":"Outcomes of intra-articular calcaneal fractures: surgical treatment of 114 consecutive cases at a maximum care trauma center","summary":"The aim of this retrospective monocentric study was to investigate the outcomes of surgically treated intra-articular calcaneus fractures in a maximum care trauma center.","link":"https:&#x2F;&#x2F;bmcmusculoskeletdisord.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12891-021-04088-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":262,"discovery_date":"2021-03-06T10:18:24","title":"Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds","summary":"Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be ab...","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00789-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":261,"discovery_date":"2021-03-06T10:18:24","title":"Knockdown of Circ_SLC39A8 protects against the progression of osteoarthritis by regulating miR-591&#x2F;IRAK3 axis","summary":"The dysregulation of circular RNAs (circRNAs) has been identified in various human diseases, including osteoarthritis (OA). The purpose of this study was to identify the role and mechanism of circ_SLC39A8 in r...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02323-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":260,"discovery_date":"2021-03-06T10:18:24","title":"Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction","summary":"Physiological disturbances in cortical network excitability and plasticity are established and widespread in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those harb...","link":"https:&#x2F;&#x2F;molecularneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13024-021-00433-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":259,"discovery_date":"2021-03-06T10:18:24","title":"An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer","summary":"Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1&#x2F;2 (gBRCA1&#x2F;2) mutations, and efforts to expand the utility of PARPi beyond BRCA1&#x2F;2 are ongoing. In preclin...","link":"https:&#x2F;&#x2F;breast-cancer-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13058-021-01408-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":258,"discovery_date":"2021-03-06T10:18:24","title":"Case report: exome sequencing achieved a definite diagnosis in a Chinese family with muscle atrophy","summary":"Due to large genetic and phenotypic heterogeneity, the conventional workup for Charcot-Marie-Tooth (CMT) diagnosis is often underpowered, leading to diagnostic delay or even lack of diagnosis. In the present s...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02093-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":257,"discovery_date":"2021-03-06T10:18:24","title":"The effects of vitamin D3 supplementation on TGF-β and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial","summary":"Although the exact mechanism involved in migraine pathogenesis remained uncertain, and different researches have been developed to address the role of neuroinflammation and immune dysfunction. Therefore, consi...","link":"https:&#x2F;&#x2F;jphcs.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40780-021-00192-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":256,"discovery_date":"2021-03-06T10:18:24","title":"Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)","summary":"Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a sho...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02454-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":255,"discovery_date":"2021-03-06T10:18:24","title":"Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms","summary":"Pien Tze Huang (PZH) is a well-known Traditional Chinese Medicine (TCM), characterized by a multitude of pharmacological effects, such as hepatoprotection and inhibition of inflammation and cell proliferative ...","link":"https:&#x2F;&#x2F;cancerci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12935-021-01785-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":254,"discovery_date":"2021-03-06T10:18:24","title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","summary":"Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, ...","link":"https:&#x2F;&#x2F;ojrd.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13023-021-01758-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":253,"discovery_date":"2021-03-06T10:18:23","title":"seqQscorer: automated quality control of next-generation sequencing data using machine learning","summary":"Controlling quality of next-generation sequencing (NGS) data files is a necessary but complex task. To address this problem, we statistically characterize common NGS quality features and develop a novel qualit...","link":"https:&#x2F;&#x2F;genomebiology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13059-021-02294-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":252,"discovery_date":"2021-03-06T10:18:23","title":"Pre-implantation exogenous progesterone and pregnancy in sheep: I. polyamines, nutrient transport, and progestamedins","summary":"Administration of exogenous progesterone (P4) to ewes during the pre-implantation period advances conceptus development and implantation. This study determined effects of exogenous P4 on transport of select nu...","link":"https:&#x2F;&#x2F;jasbsci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40104-021-00554-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":251,"discovery_date":"2021-03-06T10:18:23","title":"Eye Movement Desensitization (EMD) to reduce posttraumatic stress disorder-related stress reactivity in Indonesia PTSD patients: a study protocol for a randomized controlled trial","summary":"Posttraumatic stress disorder (PTSD) may develop after exposure to a traumatic event. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based psychological treatment for PTSD. It is yet uncle...","link":"https:&#x2F;&#x2F;trialsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13063-021-05100-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":250,"discovery_date":"2021-03-06T10:18:23","title":"Clinical utility of cerebrospinal fluid vitamin D-binding protein as a novel biomarker for the diagnosis of viral and bacterial CNS infections","summary":"Rapid and accurate diagnosis of central nervous system (CNS) infections is important, and laboratory tests help diagnose CNS infections. Even when the patient has symptoms, laboratory tests often do not reveal...","link":"https:&#x2F;&#x2F;bmcinfectdis.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12879-021-05924-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":249,"discovery_date":"2021-03-06T10:18:23","title":"Renal transplantation outcomes in obese patients: a French cohort-based study","summary":"Whilst there are a number of publications comparing the relationship between body mass index (BMI) of kidney transplant recipients and graft&#x2F;patient survival, no study has assessed this for a French patient co...","link":"https:&#x2F;&#x2F;bmcnephrol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12882-021-02278-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":248,"discovery_date":"2021-03-06T10:16:45","title":"The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biomed Pharmacother. 2021 Mar 2;138:111428. doi: 10.1016&#x2F;j.biopha.2021.111428. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In an ageing society, neurodegenerative diseases have attracted attention because of their high incidence worldwide. Despite extensive research, there is a lack of conclusive insights into the pathogenesis of neurodegenerative diseases, which limit the strategies for symptomatic treatment. Therefore, better elucidation of the molecular mechanisms involved in neurodegenerative diseases can provide an important theoretical basis for the discovery of new and effective prevention and treatment methods. The innate immune system is activated during the ageing process and in response to neurodegenerative diseases. Inflammasomes are multiprotein complexes that play an important role in the activation of the innate immune system. They mediate inflammatory reactions and pyroptosis, which are closely involved in neurodegeneration. There are different types of inflammasomes, although the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is the most common inflammasome; NLRP3 plays an important role in the pathogenesis of neurodegenerative diseases. In this review, we will discuss the mechanisms that are involved in the activation of the NLRP3 inflammasome and its crucial role in the pathology of neurodegenerative disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis and multiple sclerosis. We will also review various treatments that target the NLRP3 inflammasome pathway and alleviate neuroinflammation. Finally, we will summarize the novel treatment strategies for neurodegenerative disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33667787&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306051644&amp;v&#x3D;2.14.2&quot;&gt;33667787&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.biopha.2021.111428&gt;10.1016&#x2F;j.biopha.2021.111428&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33667787&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306051644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":247,"discovery_date":"2021-03-06T00:56:45","title":"Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurovirol. 2021 Mar 5. doi: 10.1007&#x2F;s13365-021-00951-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Given the complexity of immune complex diseases including multiple sclerosis (MS) and the plausible interactions between different risk factors, delineating the interplay between them would be imperative. The current study aimed to evaluate the in vitro effects of Epstein-Barr virus (EBV) and vitamin D on immune response in MS patients and healthy controls. The status of vitamin D and EBV load was evaluated using multiple techniques. In vitro EBV-infected peripheral blood mononuclear cells (PBMCs), in the presence or absence of vitamin D, were checked for IL-10, IFN-γ, and vitamin D receptor. MS patients showed significantly higher plasma levels of 1,25-(OH)2D but not 25-OHD, increased EBV load, and lower levels of vitamin D receptor (VDR) expression compared with healthy controls. Interestingly, an inverse correlation was observed between VDR expression and EBV load in PBMCs. Indeed, the levels of IFN-γ and IL-10 production were significantly higher in supernatant collected from in vitro EBV-infected PBMCs in MS patients compared with controls. While all vitamin D-treated PBMCs showed reduced levels of IFN-γ production, in vitro treatment of vitamin D showed no influence in IL-10 production. EBV and vitamin D were found to exert opposite in vitro effects on immune dysregulation in these patients. Our results highlight the complex interactions of different risk factors with immune system.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2&quot;&gt;33666884&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13365-021-00951-7&gt;10.1007&#x2F;s13365-021-00951-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":246,"discovery_date":"2021-03-06T00:56:45","title":"Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Drug Saf. 2021 Mar 5. doi: 10.1007&#x2F;s40264-021-01057-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective of this systematic review was to investigate the safety profile of S1P modulators in patients with multiple sclerosis, ulcerative colitis, Crohn&#39;s disease, psoriasis, and systemic lupus erythematosus.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1 January, 1990 through 1 April, 2020. We also performed a manual review of conference databases from 2017 through 2020. The primary outcome was the occurrence of adverse events and serious adverse events. We also estimated the occurrence of serious infections, herpes zoster infection, malignancy, bradycardia, atrio-ventricular block, and macular edema. We performed a meta-analysis of controlled studies to assess the risks of such events.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified 3843 citations; of these, 26 studies were finally included, comprising 9604 patients who were exposed to a sphingosine-1-phosphate modulator. A meta-analysis of randomized controlled trials showed an increased risk in herpes zoster infection [risk ratio, 1.75 (95% confidence interval 1.09-2.80)], bradycardia [2.64 (1.77-3.96)], and atrio-ventricular block [1.73 (1.03-2.91)] among subjects exposed to sphingosine-1-phosphate modulators as compared with a placebo or an active comparator.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLINICAL TRIAL REGISTRATION: PROSPERO CRD42020172575.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2&quot;&gt;33666900&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40264-021-01057-z&gt;10.1007&#x2F;s40264-021-01057-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":245,"discovery_date":"2021-03-05T23:50:03","title":"Berg Balance Scale (BBS) for Multiple Sclerosis (MS)","summary":"Berg Balance Scale for Multiple Sclerosis","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/berg-balance-scale-bbs-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":244,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis (MS) Functional Composite (MSFC) ","summary":"Measures limitations and unidimensionality of prior existing functional status outcomes such as the Expanded Disability Status Scale (EDSS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-functional-composite-msfc-","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":243,"discovery_date":"2021-03-05T23:50:03","title":"Expanded Disability Status Scale (EDSS) for Multiple Sclerosis (MS)","summary":"Measures neurologic evaluation of multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/expanded-disability-status-scale-edss-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":242,"discovery_date":"2021-03-05T23:50:03","title":"Rivermead Mobility Index for Multiple Sclerosis (MS)","summary":"Target population: People with multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/rivermead-mobility-index-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":241,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis (MS) Quality of Life Inventory ","summary":"Measures fatigue, pain, gait, quality of life, role function, social function.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-quality-of-life-inventory-","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":240,"discovery_date":"2021-03-05T23:50:03","title":"Hauser Ambulation Index for Multiple Sclerosis","summary":"Target population: People with multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/hauser-ambulation-index-for-multiple-sclerosis","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":239,"discovery_date":"2021-03-05T23:50:03","title":"Functional Reach Test for Multiple Sclerosis (MS)","summary":"Functional Reach Test for Multiple Sclerosis (MS)","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/functional-reach-test-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":238,"discovery_date":"2021-03-05T23:50:03","title":"Activities-specific Balance Confidence (ABC) Scale for Multiple Sclerosis (MS) ","summary":"A 16-item self-report measure in which patients rate their balance confidence in performing several activities.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/activities-specific-balance-confidence-abc-scale-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":237,"discovery_date":"2021-03-05T23:50:03","title":"Four Square Step Test (FSST) for Multiple Sclerosis (MS)","summary":"Four Square Step Test (FSST) for Multiple Sclerosis (MS)","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/four-square-step-test-fsst-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":236,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis in Adults: Management [NICE CG186]","summary":"This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over and aims to improve the quality of life for adults with multiple sclerosis.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/cpgs/multiple-sclerosis-in-adults-management-nice-cg186","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":235,"discovery_date":"2021-03-05T18:56:46","title":"What is the evidence that mycobacteria are associated with the pathogenesis of Sjogren&#39;s syndrome?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Transl Autoimmun. 2021 Feb 5;4:100085. doi: 10.1016&#x2F;j.jtauto.2021.100085. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Sjogren&#39;s syndrome (SS) is a common, systemic autoimmune disorder primarily affecting the exocrine glands resulting in xerostomia and xerophthalmia. SS may also manifest with polyarthralgia, polyarthritis, polymyalgia, cutaneous&#x2F;other organ vasculitis, interstitial lung disease, and&#x2F;or various other disorders. The primary autoantibodies associated with SS and used as adjuncts to diagnosis are anti-Ro (SSA) and anti-La (SSB). The pathogenesis of SS is considered to involve genetic susceptibility and environmental triggers. An identified genetic susceptibility for SS lies in variants of the tumor necrosis factor alpha inducible protein 3 (&lt;i&gt;TNFAIP3&lt;&#x2F;i&gt;) gene, the product of which is known as A20. Deficiency or dysfunction of A20 is known to induce macrophage inflammatory response to mycobacteria, potentially increasing the repertoire of mycobacterial antigens available and predisposing to autoimmunity &lt;i&gt;via&lt;&#x2F;i&gt; the paradigm of molecular mimicry; &lt;i&gt;i.e.&lt;&#x2F;i&gt;, providing a mechanistic link between genetic susceptibility to SS and exposure to environmental non-tuberculous mycobacteria (NTM). &lt;i&gt;Mycobacterium avium&lt;&#x2F;i&gt; ss. &lt;i&gt;paratuberculosis&lt;&#x2F;i&gt; (&lt;i&gt;MAP&lt;&#x2F;i&gt;) is an NTM that causes Johne&#39;s disease, an enteritis of ruminant animals. Humans are broadly exposed to &lt;i&gt;MAP&lt;&#x2F;i&gt; or its antigens in the environment and in food products from infected animals. &lt;i&gt;MAP&lt;&#x2F;i&gt; has also been implicated as an environmental trigger for a number of autoimmune diseases &lt;i&gt;via&lt;&#x2F;i&gt; cross reactivity of its heat shock protein 65 (hsp65) with host-specific proteins. In the context of SS, mycobacterial hsp65 shares epitope homology with the Ro and La proteins. A recent study showed a strong association between SS and antibodies to mycobacterial hsp65. If and when this association is validated, it would be important to determine whether bacillus Calmette-Guerin (BCG) vaccination (known to be protective against NTM likely through epigenetic alteration of innate and adaptive immunity) and anti-mycobacterial drugs (to decrease mycobacterial antigenic load) may have a preventive or therapeutic role against SS. Evidence to support this concept is that BCG has shown benefit in type 1 diabetes mellitus and multiple sclerosis, autoimmune diseases that have been linked to &lt;i&gt;MAP via&lt;&#x2F;i&gt; hsp65 and disease-specific autoantibodies. In conclusion, a number of factors lend credence to the notion of a pathogenic link between environmental mycobacteria and SS, including the presence of antibodies to mycobacterial hsp65 in SS, the homology of hsp65 with SS autoantigens, and the beneficial effects seen with BCG vaccination against certain autoimmune diseases. Furthermore, given that BCG may protect against NTM, has immune modifying effects, and has a strong safety record of billions of doses given, BCG and&#x2F;or anti-mycobacterial therapeutics should be studied in SS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665595&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33665595&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7902540&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;PMC7902540&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jtauto.2021.100085&gt;10.1016&#x2F;j.jtauto.2021.100085&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665595&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":234,"discovery_date":"2021-03-05T18:56:46","title":"Cardiac autonomic function in patients with early multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Auton Res. 2021 Mar 4. doi: 10.1007&#x2F;s10286-021-00790-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Cardiac autonomic dysfunction has been reported in patients with long-standing multiple sclerosis (MS); however, data in early disease are limited. The present study was aimed at evaluating cardiac autonomic function in patients with early MS in the context of white matter metabolic status, which could potentially affect functions of the autonomic brain centers.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Cardiac sympathetic and baroreflex cardiovagal responses to the Valsalva maneuver, orthostatic test, and the Stroop test were evaluated in 16 early, treatment-naïve patients with relapsing-remitting MS, and in 14 healthy participants. Proton magnetic resonance spectroscopic imaging (MRSI) of the brain was performed in eight of these MS patients and in eight controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Valsalva maneuver outcomes were comparable between patients and controls. At baseline, norepinephrine levels were lower (p &#x3D; 0.027) in MS patients compared to controls. The patients had higher heart rate (p &#x3D; 0.034) and lower stroke volume (p &#x3D; 0.008), but similar blood pressure, cardiac output and norepinephrine increments from baseline to 2 min of the orthostatic test compared to controls. MS patients and controls did not differ in responses to the Stroop test. MRSI showed lower total N-acetylaspartate&#x2F;total creatine (p &#x3D; 0.038) and higher myo-inositol&#x2F;total creatine (p &#x3D; 0.013) in MS lesions compared to non-lesional white matter.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results show normal cardiac sympathetic and baroreflex cardiovagal function in MS patients with relapsing-remitting MS with lesions at the post-acute&#x2F;early resolving stage.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov under the Identifier: NCT03052595 and complies with the STROBE checklist for cohort, case-control, and cross-sectional studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665745&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33665745&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10286-021-00790-w&gt;10.1007&#x2F;s10286-021-00790-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665745&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":233,"discovery_date":"2021-03-05T18:56:46","title":"Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177&#x2F;1352458521993070. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rarely recognized hyperinflammatory condition of high death risk.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective was to describe a case of HLH in a patient with multiple sclerosis (MS) treated with ocrelizumab.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Clinical observation, laboratory testing, and use of HLH-2004 criteria for HLH diagnosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A 32-year-old Caucasian female developed HLH during ocrelizumab treatment. She met six of the eight HLH criteria including fever, splenomegaly, cytopenia, hypertriglyceridemia and hypofibrinogenemia, high serum ferritin level, and low natural killer (NK) cells.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: HLH should be considered in the differential diagnosis in MS patients displaying a fever and malaise syndrome following administration of ocrelizumab.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33666121&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521993070&gt;10.1177&#x2F;1352458521993070&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":232,"discovery_date":"2021-03-05T18:56:46","title":"Functional correlates of motor control impairments in multiple sclerosis: A 7 Tesla task functional MRI study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Hum Brain Mapp. 2021 Mar 5. doi: 10.1002&#x2F;hbm.25389. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Upper and lower limb impairments are common in people with multiple sclerosis (pwMS), yet difficult to clinically identify in early stages of disease progression. Tasks involving complex motor control can potentially reveal more subtle deficits in early stages, and can be performed during functional MRI (fMRI) acquisition, to investigate underlying neural mechanisms, providing markers for early motor progression. We investigated brain activation during visually guided force matching of hand or foot in 28 minimally disabled pwMS (Expanded Disability Status Scale (EDSS) &amp;lt; 4 and pyramidal and cerebellar Kurtzke Functional Systems Scores ≤ 2) and 17 healthy controls (HC) using ultra-high field 7-Tesla fMRI, allowing us to visualise sensorimotor network activity in high detail. Task activations and performance (tracking lag and error) were compared between groups, and correlations were performed. PwMS showed delayed (+124 s, p &#x3D; .002) and more erroneous (+0.15 N, p &#x3D; .001) lower limb tracking, together with lower cerebellar, occipital and superior parietal cortical activation compared to HC. Lower activity within these regions correlated with worse EDSS (p &#x3D; .034), lower force error (p &#x3D; .006) and higher lesion load (p &amp;lt; .05). Despite no differences in upper limb task performance, pwMS displayed lower inferior occipital cortical activation. These results demonstrate that ultra-high field fMRI during complex hand and foot tracking can identify subtle impairments in lower limb movements and upper and lower limb brain activity, and differentiates upper and lower limb impairments in minimally disabled pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33666314&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;hbm.25389&gt;10.1002&#x2F;hbm.25389&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":231,"discovery_date":"2021-03-05T13:36:45","title":"Multiple sclerosis, B cell therapy, and the COVID-19 vaccine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;eNeurologicalSci. 2021 Mar;22:100319. doi: 10.1016&#x2F;j.ensci.2021.100319. Epub 2021 Jan 21.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33521339&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2&quot;&gt;33521339&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7826102&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2&quot;&gt;PMC7826102&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.ensci.2021.100319&gt;10.1016&#x2F;j.ensci.2021.100319&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33521339&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":230,"discovery_date":"2021-03-05T12:16:45","title":"Imperative role of glycosylation in human MOG-HLA interaction: molecular insights of MOG-Ab associated demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Biomol Struct Dyn. 2021 Mar 4:1-11. doi: 10.1080&#x2F;07391102.2021.1893816. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Myelin oligodendrocyte glycoprotein is a transmembrane protein found on the outer lamella of the myelin sheath. The autoimmune attack on the MOG leads to demyelination which differs from normal multiple sclerosis. MOG has three epitope regions MOG&lt;sub&gt;1-22&lt;&#x2F;sub&gt;, MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt;, and MOG&lt;sub&gt;92-106&lt;&#x2F;sub&gt; in the extracellular region, and the crucial MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt; epitope and Human Leukocyte Antigen (HLA) interaction is the initial step for autoantibody generation. To study the effective role of glycosylation in MOG-HLA interaction, we performed molecular dynamics simulations of the complex where HLA interacts with three MOG epitopes both in the absence and presence of glycan. The results projected that the epitope MOG&lt;sub&gt;1-22&lt;&#x2F;sub&gt; is decisive for the HLA interaction in the absence of glycan and HLA interacts with the epitope MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt; irrespective of glycan existence. The residues Arg9, Arg46, and Arg66 were found to interact strongly with HLA even in the presence of glycan. The glycan increased the flexibility of hMOG and enhanced the interaction of MOG with water molecules.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33663341&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2&quot;&gt;33663341&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;07391102.2021.1893816&gt;10.1080&#x2F;07391102.2021.1893816&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33663341&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":229,"discovery_date":"2021-03-05T12:16:45","title":"Associations of serum short-chain fatty acids with circulating immune cells and serum biomarkers in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Mar 4;11(1):5244. doi: 10.1038&#x2F;s41598-021-84881-8.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Altered composition of gut bacteria and changes to the production of their bioactive metabolites, the short-chain fatty acids (SCFAs), have been implicated in the development of multiple sclerosis (MS). However, the immunomodulatory actions of SCFAs and intermediaries in their ability to influence MS pathogenesis are uncertain. In this study, levels of serum SCFAs were correlated with immune cell abundance and phenotype as well as with other relevant serum factors in blood samples taken at first presentation of Clinically Isolated Syndrome (CIS; an early form of MS) or MS and compared to healthy controls. There was a small but significant reduction in propionate levels in the serum of patients with CIS or MS compared with healthy controls. The frequencies of circulating T follicular regulatory cells and T follicular helper cells were significantly positively correlated with serum levels of propionate. Levels of butyrate associated positively with frequencies of IL-10-producing B-cells and negatively with frequencies of class-switched memory B-cells. TNF production by polyclonally-activated B-cells correlated negatively with acetate levels. Levels of serum SCFAs associated with changes in circulating immune cells and biomarkers implicated in the development of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33664396&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2&quot;&gt;33664396&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-84881-8&gt;10.1038&#x2F;s41598-021-84881-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33664396&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":228,"discovery_date":"2021-03-05T06:56:45","title":"The distinct roles of monoamines in multiple sclerosis: a bridge between the immune and nervous systems?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Behav Immun. 2021 Mar 1:S0889-1591(21)00095-7. doi: 10.1016&#x2F;j.bbi.2021.02.030. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The monoaminergic neurotransmitters dopamine, noradrenaline, and serotonin are pivotal actors of the interplay between the nervous and the immune system due to their ability of binding to cell-receptors of both systems, crucially regulating their function within the central nervous system and the periphery. As monoamines are dysfunctional in many neurological and psychiatric diseases, they have been successfully used as pharmacological targets. Multiple sclerosis (MS) is one of the best examples of neurological disease caused by an altered interaction between the nervous and immune system and emerging evidence supports a dysregulation of monoaminergic systems in the pathogenesis of MS, secondary to both inflammation-induced reduction of monoamines&#39; synthesis and structural damage to monoaminergic pathways within the brain. Here we review the evidence for monoamines being key mediators of neuroimmune interaction, affecting MS pathogenesis and course. Moreover, we discuss how the reduction&#x2F;dysfunction of monoamines in MS may contribute to some clinical features typical of the disease, particularly fatigue and depression. Finally, we summarize different drugs targeting monoamines that are currently under evaluation for their potential efficacy to treat MS, as well as to alleviate fatigue and depression in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662501&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.bbi.2021.02.030&gt;10.1016&#x2F;j.bbi.2021.02.030&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":227,"discovery_date":"2021-03-05T06:56:45","title":"Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102856. doi: 10.1016&#x2F;j.msard.2021.102856. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The COVID-19 pandemic has raised concerns for increased risk of infection in patients with multiple sclerosis (MS) and disrupted their routine MS care. The aim of this study is to characterize the extent of MS patients&#39; perceptions of risk and adherence to care during the pandemic.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A survey was emailed to patients from a large MS center in New York City during the local peak of the pandemic to assess perceptions of infection risk and adherence to MS care including appointments, laboratory studies, MRIs, and taking disease-modifying therapies (DMT).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 529 patients from the MS center responded to the survey during two weeks in April 2020. Patients collectively showed concern about becoming infected with COVID-19 (88%) and perceived a higher infection risk due of having MS (70%) and taking DMTs (68%). Patients frequently postponed appointments (41%), laboratory studies (46%), and MRIs (41%). Noncompliance with DMTs was less common (13%). Decisions to alter usual recommendations for care were made by the patient more often than by the provider regarding adherence to appointments (68%), laboratory studies (70%), MRI (67%), and DMT (65%). Degree of concern for infection was associated with adherence to appointments (p&#x3D;0.020) and laboratory studies (p&#x3D;0.016) but not with adherence to MRI and DMTs. Thirty-five patients reported being tested for COVID-19, of whom fourteen reported a positive test.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with MS were highly concerned about becoming infected during the local peak of the COVID-19 pandemic. Behaviors that deviated from originally recommended MS care were common and often self-initiated, but patients were overall compliant with continuing DMTs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662858&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662858&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102856&gt;10.1016&#x2F;j.msard.2021.102856&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662858&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":226,"discovery_date":"2021-03-05T06:56:45","title":"COVID-19 in a temporal relation to the onset of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;50:102863. doi: 10.1016&#x2F;j.msard.2021.102863. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurological complications of COVID-19 have been described. We present the case of a 27-year-old woman who developed COVID-19 in April 2020. She continued to present anosmia and ageusia eight months later. Six months after contracting COVID-19, she developed dysesthesia, hypoesthesia and hyperreflexia. Her magnetic resonance imaging showed demyelinating lesions, of which two were enhanced by gadolinium. She was positive for oligoclonal bands in her spinal fluid. This patient developed multiple sclerosis with a temporal relationship to COVID-19. We believe that SARS-CoV-2 led to her autoimmune disease through a virus-induced neuroimmunopathological condition.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662859&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102863&gt;10.1016&#x2F;j.msard.2021.102863&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":225,"discovery_date":"2021-03-05T06:56:45","title":"Multiple Sclerosis and Incidence of Urinary and Fecal Incontinence in Almost 9,000 Patients Followed Up for up to 10 Years in Germany","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroepidemiology. 2021 Mar 4:1-8. doi: 10.1159&#x2F;000513234. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: There is a lack of large studies on urinary (UI) and fecal incontinence (FI) following multiple sclerosis (MS) diagnosis. Thus, our goal was to investigate the association between MS and the incidence of UI and FI in patients followed up for up to 10 years in Germany.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This study included patients who received an initial documentation of MS diagnosis in general practices in Germany during 2005-2018 (index date). Patients without MS were matched (1:1) to those with MS using propensity scores based on sex, age, index year, follow-up time (in years), general practice, and the Charlson Comorbidity Index score (index date: a randomly selected visit date).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: This retrospective study included 4,461 patients with MS and 4,461 patients without MS (69.9% women; mean [SD] age 44.2 [12.7] years). Within 10 years of index date, a higher proportion of patients with MS were diagnosed with UI (11.7 vs. 3.2%) and FI (2.3 vs. 0.5%; p values &amp;lt;0.001) than those without MS. MS was further found to be associated with both UI (hazard ratio [HR] &#x3D; 3.85) and FI (HR &#x3D; 5.38; p values &amp;lt;0.001) in the Cox regressions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: UI and FI are frequent complications of MS, and the presence of these complications should be regularly assessed in primary care practices.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662954&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000513234&gt;10.1159&#x2F;000513234&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":224,"discovery_date":"2021-03-05T02:56:45","title":"Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Opin Neurol. 2021 Mar 1. doi: 10.1097&#x2F;WCO.0000000000000921. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: With the introduction of new diagnostic criteria, the sensibility for multiple sclerosis (MS) diagnosis increased and the number of cases with the clinically isolated syndrome (CIS) decreased. Nevertheless, a misdiagnosis might always be around the corner, and the exclusion of a &#39;better explanation&#39; is mandatory.There is a pressing need to provide an update on the main prognostic factors that increase the risk of conversion from CIS or from radiologically isolated syndrome (RIS) to MS, and on the potential &#39;red flags&#39; to consider during the diagnostic workup.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: We discuss diagnostic challenges when facing patients presenting with a first demyelinating attack or with a RIS, with a focus on recently revised diagnostic criteria, on other neuroinflammatory conditions to be considered in the differential diagnosis and on factors distinguishing patients at risk of developing MS.A correct definition of a &#39;typical&#39; demyelinating attack, as well as a correct interpretation of MRI findings, remains crucial in the diagnostic process. The cerebrospinal fluid examination is warmly recommended to confirm the dissemination in time of the demyelinating process and to increase the diagnostic accuracy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: An early and accurate diagnosis of MS requires careful consideration of all clinical, paraclinical and radiological data, as well the reliable exclusion of other mimicking pathological conditions. This is advocated to promptly initiate an appropriate disease-modifying therapy, which can impact positively on the long-term outcome of the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661162&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;WCO.0000000000000921&gt;10.1097&#x2F;WCO.0000000000000921&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":223,"discovery_date":"2021-03-05T02:56:45","title":"Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Exp Med. 2021 May 3;218(5):e20201290. doi: 10.1084&#x2F;jem.20201290.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with continuous neuronal loss. Treatment of clinical progression remains challenging due to lack of insights into inflammation-induced neurodegenerative pathways. Here, we show that an imbalance in the neuronal receptor interactome is driving glutamate excitotoxicity in neurons of MS patients and identify the MS risk-associated metabotropic glutamate receptor 8 (GRM8) as a decisive modulator. Mechanistically, GRM8 activation counteracted neuronal cAMP accumulation, thereby directly desensitizing the inositol 1,4,5-trisphosphate receptor (IP3R). This profoundly limited glutamate-induced calcium release from the endoplasmic reticulum and subsequent cell death. Notably, we found Grm8-deficient neurons to be more prone to glutamate excitotoxicity, whereas pharmacological activation of GRM8 augmented neuroprotection in mouse and human neurons as well as in a preclinical mouse model of MS. Thus, we demonstrate that GRM8 conveys neuronal resilience to CNS inflammation and is a promising neuroprotective target with broad therapeutic implications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661276&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661276&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1084&#x2F;jem.20201290&gt;10.1084&#x2F;jem.20201290&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661276&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":222,"discovery_date":"2021-03-05T02:56:45","title":"Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Cell Biochem. 2021 Mar 4. doi: 10.1007&#x2F;s11010-021-04103-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), can be clinically heterogeneous which may be explained by the co-inheritance of multiple genetic variants that modify the clinical course. In this study we examine variants in three genes in a family with one individual presenting with ALS and lipodystrophy. Sequencing revealed a p.Gly602Ser variant in LMNA, and two additional variants, one each in SETX (g.intron10-13delCTT) and FUS (p.Gly167_Gly168del). These latter genes have been linked to ALS. All family members were genotyped and each variant, and each combination of variants detected, were functionally evaluated in vitro regarding effects on cell survival, expression patterns and cellular phenotype. Muscle biopsy retrieved from the individual with ALS showed leakage of chromatin from the nucleus, a phenotype that was recapitulated in vitro with expression of all three variants simultaneously. Individually expressed variants gave cellular phenotypes there were unremarkable. Interestingly the FUS variant appears to be protective against the effects of the SETX and the LMNA variants on cell viability and may indicate loss of interaction of FUS with SETX and&#x2F;or R-loops. We conclude that these findings support genetic modifications as an explanation of the clinical heterogeneity observed in human disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661429&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661429&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11010-021-04103-7&gt;10.1007&#x2F;s11010-021-04103-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661429&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":221,"discovery_date":"2021-03-05T02:56:45","title":"Prevalence of pain in amyotrophic lateral sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Amyotroph Lateral Scler Frontotemporal Degener. 2021 Mar 4:1-10. doi: 10.1080&#x2F;21678421.2021.1892765. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;i&gt;Objectives:&lt;&#x2F;i&gt; Physical pain is a known symptom in amyotrophic lateral sclerosis (ALS), but no systematically derived prevalence estimate is available. The aim of this study was to determine the pooled prevalence of pain in ALS, relative to its method of measurement and pain characteristics. &lt;i&gt;Methods&lt;&#x2F;i&gt;: A systematic search across multiple databases was conducted on January 16, 2020. Random-effects meta-analyses of single proportions were performed on prevalence data. Heterogeneity was determined using the &lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; statistic. Where available, pain location, intensity, and type or source were compared. &lt;i&gt;Results:&lt;&#x2F;i&gt; 2552 articles were identified. Twenty-one eligible studies were included. All studies used observational designs (14 cross-sectional, 6 cohort, 1 case-control). Pooled prevalence of pain in ALS across all studies was 60% (95% CI &#x3D; 50-69%), with a high degree of heterogeneity (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 94%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; .001). Studies that used only validated measures had lower heterogeneity (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 82%, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.002), compared to those that used tailored measures, or tailored supplemented with validated measures (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 90%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001 and &lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 83%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001, respectively). In a subset of studies (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 9), the most commonly reported pain location was the upper limbs including shoulders&#x2F;extremities (41.5%). A further study subset (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 7) showed moderate-severe intensity pain was most frequently reported. Type of pain was commonly related to cramp or spasm. &lt;i&gt;Conclusions:&lt;&#x2F;i&gt; Experiencing physical pain in ALS occurs with high prevalence. Deriving consensus on which specific tools should be used to assess, monitor and compare symptoms of pain in this population will reduce current heterogeneity in approaches and increase the likelihood of ameliorating distressing experiences more effectively.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661072&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;21678421.2021.1892765&gt;10.1080&#x2F;21678421.2021.1892765&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":220,"discovery_date":"2021-03-05T02:56:45","title":"The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Mar 4. doi: 10.1007&#x2F;s00415-021-10489-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: High Temperature Requirement Serine Protease A1 (HTRA1) degrades extracellular matrix molecules (ECMs) and growth factors. It interacts with several proteins implicated in multiple sclerosis (MS), but has not previously been linked to the disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Investigate the levels of HTRA1 in cerebrospinal fluid (CSF) in different subtypes of MS and brain tissue.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Using ELISA, HTRA1 levels were compared in CSF from untreated patients with relapsing-remitting MS (RRMS, n &#x3D; 23), secondary progressive MS (SPMS, n &#x3D; 26) and healthy controls (HCs, n &#x3D; 26). The effect of disease modifying therapies (DMTs) were examined in both patient groups. Cellular distribution in human brain was studied using immunochemistry and the oligointernode database, based on a single-nuclei RNA expression map.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: HTRA1 increased in RRMS and SPMS compared to HCs. DMT decreased HTRA1 levels in both types of MS. Using ROC analysis, HTRA1 cut-offs could discriminate HCs from RRMS patients with 100% specificity and 82.6% sensitivity. In the brain, HTRA1 was expressed in glia and neurons.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: HTRA1 is a promising CSF biomarker for MS correlating with disease- and disability progression. Most cell species of the normal and diseased CNS express HTRA1 and the expression pattern could reflect pathological processes involved in MS pathogenesis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661357&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661357&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10489-7&gt;10.1007&#x2F;s00415-021-10489-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661357&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":219,"discovery_date":"2021-03-05T02:56:45","title":"The role of prolactin in central nervous system inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Jan 1. doi: 10.1515&#x2F;revneuro-2020-0082. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Prolactin has been shown to favor both the activation and suppression of the microglia and astrocytes, as well as the release of inflammatory and anti-inflammatory cytokines. Prolactin has also been associated with neuronal damage in diseases such as multiple sclerosis, epilepsy, and in experimental models of these diseases. However, studies show that prolactin has neuroprotective effects in conditions of neuronal damage and inflammation and may be used as neuroprotector factor. In this review, we first discuss general information about prolactin, then we summarize recent findings of prolactin function in inflammatory and anti-inflammatory processes and factors involved in the possible dual role of prolactin are described. Finally, we review the function of prolactin specifically in the central nervous system and how it promotes a neuroprotective effect, or that of neuronal damage, particularly in experimental autoimmune encephalomyelitis and during excitotoxicity. The overall studies indicated that prolactin may be a promising molecule for the treatment of some neurological diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661585&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661585&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1515&#x2F;revneuro-2020-0082&gt;10.1515&#x2F;revneuro-2020-0082&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661585&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":218,"discovery_date":"2021-03-04T18:56:45","title":"The relationship between vitamin D levels and cognitive impairment in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2021-2030. doi: 10.26355&#x2F;eurrev_202102_25105.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Neurocognitive impairment is one of the most common manifestations of multiple sclerosis (MS). However, the pathophysiology of this issue is still poorly understood. The objective of this study is to investigate the relationship between vitamin D levels and cognitive function in patients with MS as assessed by the Cambridge Neuropsychological Test Automated Battery (CANTAB).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: This was a cross-sectional, case-control study; the subjects were 39 Saudi patients diagnosed with MS. For all participants, demographic information, including age, sex, and educational level, was collected. Participants were also evaluated using the disease steps scale and the PHQ-9 scale. Their vitamin D levels were assessed, and the participants completed a computerized cognitive assessment using the CANTAB.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: From the total sample of 39 patients with MS, 31 (79.5%) were female. Physical disability due to MS was insignificant in 25 (64.1%) of the subjects and significant in 14 (35.9%). Seventeen (43.6%) of the participants had normal vitamin D levels; 22 (56.4%) had low vitamin D levels. The MS patients had lower MOT mean errors than the control group, and this difference was statistically significant (t &#x3D; -4.313, p &amp;lt; 0.01). Moreover, the scores of the two groups for all subcategories of the memory domain were different at statistically significant levels. Furthermore, the control group had higher PAL total errors (adjusted), PAL total errors (6 shapes, adjusted), and PRM percent correct than the MS patients (p &amp;lt; 0.01). The control group also achieved lower scores on SWM between errors and SWM strategy than the MS patients (p &amp;lt; 0.01). The MOT mean error was found to correlate with the disease steps score (r &#x3D; 0.394, p &amp;lt; 0.05) and with significant physical disability (r &#x3D; 0.457, p&amp;lt; 0.01). In the memory domain, PAL total errors (adjusted) correlated with age (r &#x3D; 0.381, p &amp;lt; 0.05), SWM between errors correlated with age at onset of disease (r &#x3D; 0.345, p &amp;lt; 0.05), and vitamin D level (r &#x3D; 0.335, p &amp;lt; 0.05) and SWM strategy correlated with the number of relapses in the past 12 months (r &#x3D; -0.355, p &amp;lt; 0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Cognitive performance was impaired in patients with MS. Vitamin D deficiency, a potentially modifiable risk factor, independently predicted cognitive impairment in MS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660814&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660814&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.26355&#x2F;eurrev_202102_25105&gt;10.26355&#x2F;eurrev_202102_25105&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660814&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":217,"discovery_date":"2021-03-04T18:56:45","title":"Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Invest. 2021 Mar 4:1-16. doi: 10.1080&#x2F;08820139.2021.1887888. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;This systematic review and meta-analysis aimed to identify deferentially expressed serum miRNAs in multiple sclerosis patients and to evaluate their diagnostic value in multiple sclerosis diagnosis. Studies were identified on PubMed, Google scholar and Saudi digital library up to 30 September 2019. Articles that examined miRNA expression level in MS patients compared to healthy control group were included in the review and the data were extracted by three independent author. The comprehensive Meta-Analysis version 3 software was used for meta-analysis and heterogeneity of studies was identified according to I2 value. Our literatures search identified 9 eligible articles concerning the serum miRNA as a diagnostic biomarker for multiple sclerosis in comparison to healthy control group. 19 serum miRNAs differentially expressed in MS patients were identified (8 downregulated, 11 upregulated and 1 with discordant result). In publications that provided information on specific miRNA diagnostic value, the pooled AUC was 72% (95% CI 0.65-0.78, &lt;i&gt;p&lt;&#x2F;i&gt;-value 0.00) for the overall multiple sclerosis patients and primary progressive MS (PPMS) (95% CI 0.66-0.78 &lt;i&gt;p&lt;&#x2F;i&gt;-value 0.00). A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups. When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%. The available data from the literature and this meta-analysis suggests the potential use of serum miRNA as biomarkers for early diagnosis of MS with high sensitivity and specificity in distinguishing multiple sclerosis subtypes from healthy controls.&lt;b&gt;Abbreviation&lt;&#x2F;b&gt;: MS: Multiple sclerosis; IDD: inflammatory demyelinating diseases; RRMS: relapsing-remitting Multiple sclerosis; PPMS: primary progressive Multiple sclerosis; SPMS: secondary progressive Multiple sclerosis; NMO: Neuromyelitis optica; miRNA: microRNA; ECmiRNA: extracellular microRNA; AUC: Area Under the Curve; ROC: Receiver Operator Characteristic.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660581&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;08820139.2021.1887888&gt;10.1080&#x2F;08820139.2021.1887888&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":216,"discovery_date":"2021-03-04T18:56:45","title":"The gelsolin level in patients with primary Sjogren&#39;s syndrome","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2072-2078. doi: 10.26355&#x2F;eurrev_202102_25112.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Gelsolin (GSN) is a multifunctional protein that can regulate cell proliferation, apoptosis, inflammation and infection. GSN has been reported to be involved in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and many other diseases. The role of GSN in primary Sjogren&#39;s syndrome (pSS) remains still unclear. The aim of this study is to investigate the changes of GSN level in serum and whole blood cells of pSS patients and evaluate the relationship between GSN and fatigue or other clinical indicators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: The cross-sectional study included 47 pSS patients (1 male and 46 females, average age: 52.83±12.63 years) and 51 healthy controls (all females, average age: 50.61±9.86 years). The patients were collected from the Second Affiliated Hospital of Harbin Medical University, China, without the age and sex differences. The levels of GSN in serum of pSS patients and the healthy controls were measured by Western blotting. The sequencing gene expression omnibus (GEO) data from National Center for Biotechnology Information (NCBI) about GSN levels in the whole blood cells of pSS patients and the healthy controls were analyzed by R language.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Compared with healthy controls, the level of GSN was significantly decreased in the serum of pSS patients (98.89 ± 28.94 vs. 131.6 ± 37.1 µg&#x2F;ml, p&amp;lt;0.001). The expression of GSN in the whole blood cells of pSS patients was significantly lower than that in the healthy controls (6.4 ± 0.19 vs. 6.6 ± 0.17, p&amp;lt;0.01). Compared to non-fatigued pSS patients, the level of GSN was down-regulated in serum (85.69 ± 27.08 vs. 111.52 ± 24.71 µg&#x2F;ml, p&amp;lt;0.01) and whole blood cells (6.43 ± 0.18 vs. 6.58 ± 0.21, p&amp;lt;0.001) in fatigue pSS patients. However, there was no significant correlation between the level of GSN and EULAR Sjogrens syndrome disease activity index (ESSDAI) in pSS patients (p&#x3D;0.73).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: GSN is decreased in serum and whole blood cells of pSS patients, and it is much lower in fatigue patients than that in non-fatigue patients. The correlation between the level of GSN and ESSDAI was not significant in pSS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660820&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660820&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.26355&#x2F;eurrev_202102_25112&gt;10.26355&#x2F;eurrev_202102_25112&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660820&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":215,"discovery_date":"2021-03-04T12:16:45","title":"New methods of posturographic data analysis may improve the diagnostic value of static posturography in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Heliyon. 2021 Feb 11;7(2):e06190. doi: 10.1016&#x2F;j.heliyon.2021.e06190. eCollection 2021 Feb.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Early and accurate diagnosis of multiple sclerosis (MS) is crucial for its effective treatment. In MS diagnostic, neuronal networks that control posture and movement are of particular importance, which performance can be assessed using static posturography. Unfortunately, most of the commercially available posturographic platforms are not equipped with the appropriate procedures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: To solve this problem, the postural sway trajectories have been recorded in 55 MS patients while standing quiet with eyes open (EO), and then with eyes closed (EC). The trajectories were analyzed using our novel methods of postural sway parametrization, including sway stability vector (SV), anteroposterior and mediolateral sway indices (DIAP and DIML).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The results exhibited unique postural sway patterns that may be attributed to MS. Our novel parametrization methods of postural sway showed pathology specific increase of the postural sway velocity in EC tests. Additionally, we documented the abnormal alterations of the anteroposterior (AP) and the mediolateral (ML) sway indices that were also uniquely dependent on visual input. In EC tests, patients exhibited a characteristic pattern of sway increase in both AP and ML directions that correlated with the advance of the disease as measured by the EDSS Kurtzke scale and Functional System Scores.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The applied in the present study our novel posturographic metrics give the assessment a diagnostic value. It allows us to recommend the static posturography test as a simple and safe supplementary clinical tool in the diagnosis of MS. In the assessment of MS pathology or the effects of its treatment, the impact of vision on the sway stability vector seems the most important factor.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659736&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659736&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7892908&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7892908&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.heliyon.2021.e06190&gt;10.1016&#x2F;j.heliyon.2021.e06190&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659736&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":214,"discovery_date":"2021-03-04T12:16:45","title":"Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 15;12:625465. doi: 10.3389&#x2F;fimmu.2021.625465. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659007&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659007&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7917254&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7917254&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.625465&gt;10.3389&#x2F;fimmu.2021.625465&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659007&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":213,"discovery_date":"2021-03-04T12:16:45","title":"Poster Abstracts from the 10th International Symposium on Gait and Balance in Multiple Sclerosis: The Role of Fatigue and Fatigability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):45-46. doi: 10.7224&#x2F;1537-2073-23.1.45. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658906&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658906&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906032&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073-23.1.45&gt;10.7224&#x2F;1537-2073-23.1.45&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658906&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":212,"discovery_date":"2021-03-04T12:16:45","title":"Editorial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):iv. doi: 10.7224&#x2F;1537-2073-23.1.iv. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658907&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906026&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906026&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073-23.1.iv&gt;10.7224&#x2F;1537-2073-23.1.iv&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":211,"discovery_date":"2021-03-04T12:16:45","title":"Safety, Feasibility, and Efficacy of an Eccentric Exercise Intervention in People with Multiple Sclerosis with Ankle Contractures","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):31-36. doi: 10.7224&#x2F;1537-2073.2019-022. Epub 2020 Mar 6.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The primary aim of this study was to investigate the safety and feasibility of an eccentric exercise program for people with multiple sclerosis (MS) who have ankle contractures, ie, reduced ankle range of motion (ROM). Secondary aims were to explore the efficacy of this eccentric exercise on ankle joint ROM and functional mobility.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Five adults with MS with ankle contractures (three women and two men; mean ± SD age, 50.8 ± 9.4; MS duration, 7.6 ± 5.6 years) completed two eccentric exercise training sessions (10-45 minutes) per week for 12 weeks. The training involved walking backward downhill on an inclined treadmill (gradient, 10°-14°) at a self-selected pace. The intervention was assessed for safety (adverse events), feasibility (recruitment rates, adherence rates, enjoyment levels, difficulty, and discomfort), and clinical outcomes, including passive&#x2F;active ankle ROM and distance walked in 6 minutes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were no adverse events during or after the eccentric exercise training. There was a 100% adherence rate. All participants enjoyed the training and experienced low levels of muscle soreness&#x2F;discomfort. The training program improved passive&#x2F;active ankle ROM in all participants; however, improvements did not translate to improvements in walking for all participants.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Walking backward and downhill is a safe and feasible training modality for people with MS with ankle contractures. Clinical outcomes (greater passive&#x2F;active ankle ROM) after this eccentric exercise training were evident. However, translation to clinically meaningful changes in walking function requires further examination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658904&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906030&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906030&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-022&gt;10.7224&#x2F;1537-2073.2019-022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":210,"discovery_date":"2021-03-04T12:16:45","title":"Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):37-44. doi: 10.7224&#x2F;1537-2073.2020-026. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services. The purpose of this scoping review was to identify the barriers people with MS encounter when attempting to access multidisciplinary health services and the reported facilitators for better access to health services.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The MEDLINE, Embase, and CINAHL databases were searched, without date or geographic restrictions, using the following terms: &lt;i&gt;multiple sclerosis, health services accessibility, health care access, health care delivery,&lt;&#x2F;i&gt; and &lt;i&gt;delivery of health care&lt;&#x2F;i&gt;. After screening based on exclusion criteria, 23 articles were included in the final review.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Five main themes were identified as barriers and facilitators to accessing health services: 1) information (information available to people with MS, health care provider knowledge of and familiarity with MS), 2) interactions (interactions between health care providers and people with MS, social networks and support of people with MS, collaboration among health care providers), 3) beliefs and skills (personal values and beliefs, perceived time to travel to and attend appointments, and self-assessment of symptoms and needs of people with MS), 4) practical considerations (wait times, physical barriers, affordability of services), and 5) nature of MS (complexity and unpredictability of disease symptoms).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: People with MS and their health care providers may benefit from structured and comprehensive MS-specific education to address barriers to accessing health care services. The education can ultimately facilitate the process of addressing unmet health care needs and contribute to a greater quality of life for people with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658905&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658905&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906029&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2020-026&gt;10.7224&#x2F;1537-2073.2020-026&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658905&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":209,"discovery_date":"2021-03-04T12:16:45","title":"Modeling the Multiple Sclerosis Specialist Nurse Workforce by Determination of Optimum Caseloads in the United Kingdom","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):1-7. doi: 10.7224&#x2F;1537-2073.2019-058. Epub 2020 Jan 13.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: It is estimated that there are more than 100,000 people in the United Kingdom who have multiple sclerosis (MS). Patient experience and outcome are improved by access to a specialist nursing service. The aim of this study was to perform demand modeling to understand the need for MS nursing interventions, and thus inform modeling of the future UK MS nursing workforce.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Existing national data and specific workload and service data were collected from 163 MS specialist nurses who completed a questionnaire on activity and complexity of work both done and left undone.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Data were received from across all of the United Kingdom. Twenty-nine percent of respondents were specialist nurses in the field for 3 years or less. Unpaid overtime was regularly performed by 83.4% of respondents. The MS specialist nurse was part of all areas of the patient journey. Areas of work left undone were psychological interventions, physical assessments, social interventions&#x2F;benefits, and recommending or prescribing medications.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The current recommended caseload of 358 people with MS per full-time equivalent seems to be too high, with a considerable amount of work left undone, particularly psychosocial care. Factors such as travel time, complexity of caseload, changing drug therapies, and societal issues such as the benefits system contributed to driving demand&#x2F;workload.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658899&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906027&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906027&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-058&gt;10.7224&#x2F;1537-2073.2019-058&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":208,"discovery_date":"2021-03-04T12:16:45","title":"Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):8-15. doi: 10.7224&#x2F;1537-2073.2019-051. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Fatigue is the most disabling symptom in patients with multiple sclerosis (MS). Although there is no standard tool to evaluate fatigue in clinical settings, the Fatigue Impact Scale (FIS), Fatigue Severity Scale (FSS), and Multidimensional Assessment of Fatigue (MAF) scale are popular instruments for this purpose. The aim of this study was to compare the psychometric properties of the Persian versions of these scales.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: One hundred thirty adult patients with MS and 60 controls participated in this study. They completed the scales on two occasions 3 days apart. Reproducibility and internal consistency were evaluated as intraclass correlation coefficients (ICCs) and Cronbach α. Convergent validity was assessed by evaluating the association of the fatigue scales with age, sex, Expanded Disability Status Scale (EDSS) score, disease duration, and sleep quality. Dimensionality was evaluated using confirmatory factor analysis. Acceptability and known-group validity were investigated. The effect size of each scale was computed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The ICC of all instruments was 0.99. Internal consistency was 0.97 for the MAF scale, 0.93 for FSS, and 0.83 for FIS. The instruments showed moderate-to-good correlations with Pittsburgh Sleep Quality Index, EDSS score, and disease duration. Acceptability was acceptable. The FIS had three dimensions, and the FSS and MAF scale were unidimensional. All scales were able to discriminate patients with MS from controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The Persian version of the MAF scale seems to be the most suitable instrument to evaluate fatigue in patients with MS based on its time efficiency, effect size, and detailed data about various aspects of fatigue.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658900&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906033&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906033&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-051&gt;10.7224&#x2F;1537-2073.2019-051&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":207,"discovery_date":"2021-03-04T12:16:45","title":"Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):16-20. doi: 10.7224&#x2F;1537-2073.2019-032. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis (MS). The objective was to describe clinical pharmacy services provided, as well as provider satisfaction with and perceived impact of incorporating a clinical pharmacist in MS patient care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The study consisted of a retrospective medical record review and a provider survey conducted in an outpatient neurology clinic at an academic medical center. Between April 2017 and June 2018, electronic medical records of patients with documented interventions by a pharmacist were reviewed to describe clinical pharmacy services provided to patients with MS. A voluntary, anonymous survey was distributed to neurology providers to evaluate provider satisfaction with and perceived impact of clinical pharmacist involvement in MS patient care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were 64 patients identified with 378 documented interventions made by clinical pharmacists. Pharmacist interventions were mostly related to facilitating medication access (n &#x3D; 208), pretreatment screening (n &#x3D; 57), patient counseling (n &#x3D; 51), and providing drug information (n &#x3D; 43). All nine providers surveyed indicated that facilitating medication access, counseling patients, and managing drug interactions were moderately or very important clinical pharmacy services. Furthermore, all providers surveyed strongly agreed that pharmacist involvement decreased time to therapy initiation and provider time spent on medication management.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Clinical pharmacists play an integral role in MS patient care, particularly with facilitating medication access. Prospective studies are needed to further evaluate the contribution of clinical pharmacists in MS patient care.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658901&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906034&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906034&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-032&gt;10.7224&#x2F;1537-2073.2019-032&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":206,"discovery_date":"2021-03-04T12:16:45","title":"Social Cognitive Theory and Physical Activity in Older Adults with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):21-25. doi: 10.7224&#x2F;1537-2073.2019-071. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The expanding population of older adults with multiple sclerosis (MS) likely experiences many of the same benefits of physical activity (PA) as younger and middle-aged adults with MS. However, participation in PA is exceedingly low in this segment of the MS population. This study examined variables from social cognitive theory (SCT) as correlates of PA in older adults with MS to inform the subsequent development of behavioral interventions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Older adults with MS (≥60 years of age, N &#x3D; 180) completed an online survey including demographic and clinical characteristics, SCT variables (exercise self-efficacy, exercise goal setting, social support, and outcome expectations), and PA (total PA [TPA] and moderate-to-vigorous PA [MVPA]).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Bivariate correlation analyses indicated that all SCT variables were significantly associated with TPA and MVPA (all &lt;i&gt;P&lt;&#x2F;i&gt; ≤ .001). Hierarchical linear regression analyses indicated that disability status was a significant correlate of TPA (&lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.48, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.23) and MVPA (&lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.44, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.19) in step 1; disability and self-efficacy were significant correlates of TPA (disability &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.20, self-efficacy &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.59, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.50) and MVPA (disability &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.16, self-efficacy &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.60, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.47) in step 2; and disability, self-efficacy, and exercise goal setting were significant correlates of TPA (disability &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.21, self-efficacy &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.50, exercise goal setting &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.14, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.55) and MVPA (disability &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; -0.17, self-efficacy &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.51, exercise goal setting &lt;i&gt;β&lt;&#x2F;i&gt; &#x3D; 0.15, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.51) in step 3.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results suggest that behavioral interventions focusing on self-efficacy and exercise goal setting as targets from SCT may be appropriate for increasing PA in older adults with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658902&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658902&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906028&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906028&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-071&gt;10.7224&#x2F;1537-2073.2019-071&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658902&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":205,"discovery_date":"2021-03-04T12:16:45","title":"Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):26-30. doi: 10.7224&#x2F;1537-2073.2019-015. Epub 2020 Apr 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients at the Beth Israel Deaconess Medical Center MS Clinic were screened for TB as part of routine testing with the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Ltd) from 2013 to 2017. Patients were tested either before or during immunomodulatory therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Four of 222 patients (1.8%; 95% CI, 0.1%-3.6%) had positive QFT-GIT results; three patients had risk factors for TB, having emigrated from TB-endemic countries or worked in the health care industry. Twenty-eight of 222 patients (12.6%) had an indeterminate assay result, and 75.0% of these occurred in patients taking dimethyl fumarate. Fingolimod, natalizumab, or anti-CD20 treatments showed 0% to 7.7% indeterminate results.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The prevalence of LTBI was 1.8% in the Beth Israel Deaconess Medical Center MS Clinic. Not all LTBI cases were associated with known risk factors for TB. Screening for LTBI before starting immunosuppressive agents for MS could help prevent activation of TB. Dimethyl fumarate use is associated with indeterminate QFT-GIT results, possibly due to functional effects on lymphocytes and levels of cytokines, such as interferon gamma. In contrast, fingolimod use was rarely associated with indeterminate QFT-GIT results despite a high rate of lymphopenia in virtually all patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658903&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906031&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906031&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-015&gt;10.7224&#x2F;1537-2073.2019-015&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":204,"discovery_date":"2021-03-04T12:16:45","title":"Minimally Invasive Oral Surgery Induction of the FRICT-ION Chronic Neuropathic Pain Model","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Bio Protoc. 2020 Apr 20;10(8):e3591. doi: 10.21769&#x2F;BioProtoc.3591. eCollection 2020 Apr 20.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;An easily induced preclinical trigeminal neuropathic nerve injury model is described here for the study of chronic pain, the model acronym &lt;b&gt;FRICT-ION (F&lt;&#x2F;b&gt;oramen &lt;b&gt;R&lt;&#x2F;b&gt;otundum &lt;b&gt;I&lt;&#x2F;b&gt;nflammatory &lt;b&gt;C&lt;&#x2F;b&gt;onstriction &lt;b&gt;T&lt;&#x2F;b&gt;rigeminal &lt;b&gt;I&lt;&#x2F;b&gt;nfra&lt;b&gt;O&lt;&#x2F;b&gt;rbital &lt;b&gt;N&lt;&#x2F;b&gt;erve). In patients, neuropathic pain is thought to be related to vascular alignment or multiple sclerosis along this small trigeminal nerve branch (V2) innervating the maxillary teeth and middle third of the face. With no detectable outward physical signs, the FRICT-ION model is ideal for blinded studies. The acronym FRICT-ION applied relates to the persistence of the trigeminal neuropathic pain model likely due to sliding irritation with normal chewing in the mice. A step-by-step method to induce the mild chronic rodent neuropathic pain model is described here. The surgery is performed orally through a tiny surgical slit inside the cheek crease to align a chromic gut suture irritant along the nerve as it passes into the skull. The model allows testing of non-evoked subjective measures and evoked quantitative mechanical hypersensitivity (allodynia) testing with von Frey filaments through at least 10-14 weeks (100 days). Anxiety and depression behaviors develop within 3-6 weeks relevant to the affective component of chronic pain. While many pain drugs have failed based on testing performed in the acute animal models available, the more stable and easily replicated trigeminal inflammatory compression model is the better suited for understanding both mechanistic and affective components of nerve injury-induced chronic neuropathic pain states as well as the more ideal for preclinical trials of novel non-opioid pain relief therapies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659557&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659557&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7842532&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7842532&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.21769&#x2F;BioProtoc.3591&gt;10.21769&#x2F;BioProtoc.3591&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659557&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":203,"discovery_date":"2021-03-04T12:16:45","title":"Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Pharmacol. 2020 Nov 20;11:589146. doi: 10.3389&#x2F;fphar.2020.589146. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P&lt;sub&gt;3&lt;&#x2F;sub&gt; receptor activation. &lt;b&gt;Methods:&lt;&#x2F;b&gt; e systematically searched PUBMED, EMBASE database, and Cochrane Library database to identify randomized controlled trials (RCTs) from inception to June 28, 2020. Trials were considered eligible if they 1) were randomized clinical trials (RCTs); 2) enrolled adult participants diagnosed with Relapsing-remitting MS; 3) compared ozanimod with placebo or any other approved DMDs that evaluated in phase III or phase II clinical trials; 4) enrolled over 100 participants; 5) provided any available information for predefined primary or secondary outcomes. &lt;b&gt;Results:&lt;&#x2F;b&gt; 2917 participants from three high-quality, multi-centered randomized clinical trials were pooled in our analysis. We found that using ozanimod was significantly associated with the reduction of the annualized relapse rate during the treatment period (RR, -0.10 [95% CI, -0.15, -0.06]). Also, the decreased number of gadolinium-enhancing lesions at the end of the trial was relative to the treatment of ozanimod (ozanimod, 0.29; control, 0.65; RR, -0.20 [95% CI, -0.34, -0.06]). Compared with patients in the control group, the number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod (ozanimod, 1.82; control, 3.55; RR, -1.12 [95% CI, -1.52, -0.71]). As to the safety endpoints, patients in the ozanimod group reported a lower rate of adverse events (ozanimod, 66.03%; control, 77.07%; RR, 0.64 [95% CI, 0.43, 0.95]). Similar incidence of infection-related TEAEs was found across treatment groups (nasopharyngitis: ozanimod, 11.19%; control, 9.83%; RR, 1.10 [95% CI, 0.77-1.57]; urinary-tract infection: ozanimod, 3.81%; control, 2.97%; RR, 1.29 [95% CI, 0.83-2.00]). No case of macular edema was noted as well as second-degree, type 2, or third-degree atrioventricular block. As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). No significant difference in causing adverse events between 1 and 0.5 mg was found. &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Our meta-analysis found that, with favorable safety performance, the use of ozanimod as a treatment of relapsing-remitting multiple sclerosis in adults was associated with a significant reduction of the annualized relapse rate during the treatment period, decreased number of gadolinium-enhancing lesions at the end of the trial, and lowered number of new or enlarging T2 lesions over the treatment period. Ozanimod 1 mg outperformed 0.5 mg dose in efficacy without increasing the risk of adverse events.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658933&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7919188&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7919188&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fphar.2020.589146&gt;10.3389&#x2F;fphar.2020.589146&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":202,"discovery_date":"2021-03-04T12:16:45","title":"Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 15;11:574748. doi: 10.3389&#x2F;fneur.2020.574748. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Multiple sclerosis (MS), a disabling demyelinating disease of the central nervous system, is associated with cognitive impairment, spasticity, and fatigue. There are still no established guidelines on the management of MS-related sequela. Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue. &lt;b&gt;Objectives:&lt;&#x2F;b&gt; This study aims to determine the efficacy and safety of memantine in preventing cognitive impairment, reducing spasticity and fatigue, and controlling disability in MS patients through a review of relevant randomized trials. &lt;b&gt;Methods:&lt;&#x2F;b&gt; MEDLINE, CENTRAL, Scopus, Embase, LILACS, ClinicalTrials.gov, and HERDIN were searched from inception to May 2020 for relevant trials. &lt;b&gt;Results:&lt;&#x2F;b&gt; The search yielded 203 articles; four studies were included in the analysis. Pooled evidence shows that memantine compared with placebo does not significantly improve PASAT, ASS, MFIS, and EDSS scores of patients with MS. Memantine is associated with mild adverse drug events such as dizziness, fatigue, and anxiety. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; There is not enough evidence to support the efficacy of memantine in preventing cognitive decline, controlling spasticity, reducing fatigue, and preventing disability. Future researches should consider the different MS subtypes, effect of co-administration of disease-modifying therapies, longer duration of administration, and more sensitive outcome measures to evaluate the potential benefit of memantine in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658967&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7917060&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7917060&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2020.574748&gt;10.3389&#x2F;fneur.2020.574748&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":201,"discovery_date":"2021-03-04T12:16:45","title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 3. doi: 10.1007&#x2F;s10072-021-05145-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safety of ALM in real-world clinical practice in two MS centers in Slovenia and Croatia.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a retrospective chart review of 71 consecutive patients with relapsing-remitting MS who were treated with ALM from 2015 till 2018. The following data were collected: gender, age at disease onset, disease duration at ALM initiation, previous disease modifying therapy, number of relapses, active MRI lesions, and EDSS in the year prior to ALM initiation and every year of follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: All patients completed the standard dosing schedule and were followed for a mean time of 3.2±1.1 years after the initiation of treatment. Complete data for the 2 years after treatment (relapses, EDSS, and MRI) were available for 48 patients, of which 14 (29.2%) achieved NEDA. Clinical NEDA was achieved in 38 out of 63 participants (60.3%). In year 1, 24 out of 57 (42.1%) patients achieved NEDA. In year 2, 26 out of 41 (63.4%) patients achieved NEDA. Lower EDSS prior to starting ALM was the only independent predictor of NEDA in a multivariable model. Adverse events occurred in 58 participants (84.1%), with no new safety signals identified.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660157&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33660157&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05145-x&gt;10.1007&#x2F;s10072-021-05145-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660157&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":200,"discovery_date":"2021-03-04T00:16:45","title":"Correction for: Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Aging (Albany NY). 2021 Mar 3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33657013&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303191644&amp;v&#x3D;2.14.2&quot;&gt;33657013&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33657013&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303191644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":199,"discovery_date":"2021-03-03T18:56:45","title":"Disease-modifying treatment of secondary progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 3. doi: 10.1007&#x2F;s00115-021-01080-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a disease continuum from a clinically isolated syndrome through relapsing remitting MS to secondary progressive MS (SPMS). There are numerous therapeutic approaches with proven efficacy on relapse and focal inflammatory disease aspects, whereas treatment of secondary progression and associated neuropathological aspects continues to be a challenge.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Overview of the current options for disease-modifying treatment of SPMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: Results of randomized clinical trials are presented and evaluated on a substance-specific basis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Randomized SPMS trials showed inconsistent results regarding disability progression for beta interferons and negative results for natalizumab. Oral cladribine and ocrelizumab reduced disability progression in relapsing MS but have not been specifically studied in an SPMS population. Positive results for mitoxantrone are only partially applicable to current SPMS patients. For siponimod, a substance that crosses the blood-brain barrier, the EXPAND trial demonstrated a significant reduction in the risk of disability progression in typical SPMS. Subgroup analyses suggest a higher efficacy of siponimod in younger patients with active SPMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: There is limited evidence for the use of previously available disease-modifying treatment in SPMS. Siponimod represents a new therapeutic option for active SPMS, defined by relapses or focal inflammatory MRI activity. To establish the therapeutic indications for siponimod, early detection of relapse-independent progression as well as differentiation of active SPMS from inactive disease are of critical importance.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656569&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656569&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01080-6&gt;10.1007&#x2F;s00115-021-01080-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656569&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":198,"discovery_date":"2021-03-03T18:56:45","title":"Blood-cerebrospinal fluid (CSF) barrier dysfunction means reduced CSF flow not barrier leakage - conclusions from CSF protein data","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arq Neuropsiquiatr. 2021 Jan;79(1):56-67. doi: 10.1590&#x2F;0004-282X-anp-2020-0094.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Increased concentrations of serum proteins in cerebrospinal fluid (CSF) are interpreted as blood-CSF barrier dysfunction. Frequently used interpretations such as barrier leakage, disruption or breakdown contradict CSF protein data, which suggest a reduced CSF flow rate as the cause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Even the severest barrier dysfunctions do not change the molecular size-dependent selectivity or the interindividual variation of the protein transfer across barriers. Serum protein concentrations in lumbar CSF increase with hyperbolic functions, but the levels of proteins that do not pass the barrier remain constant (brain proteins) or increase linearly (leptomeningal proteins). All CSF protein dynamics above and below a lumbar blockade can also be explained, independent of their barrier passage, by a reduced caudally directed flow. Local accumulation of gadolinium in multiple sclerosis (MS) is now understood as due to reduced bulk flow elimination by interstitial fluid (ISF). Nonlinear change of the steady state in barrier dysfunction and along normal rostro-caudal gradients supports the diffusion&#x2F;flow model and contradicts obstructions of diffusion pathways. Regardless of the cause of the disease, pathophysiological flow blockages are found in bacterial meningitis, leukemia, meningeal carcinomatosis, Guillain-Barré syndrome, MS and experimental allergic encephalomyelitis. In humans, the fortyfold higher albumin concentrations in early fetal development decrease later with maturation of the arachnoid villi, i.e., with beginning CSF outflow, which contradicts a relevant outflow to the lymphatic system. Respiration- and heartbeat-dependent oscillations do not disturb net direction of CSF flow.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Blood-CSF and blood-brain barrier dysfunctions are an expression of reduced CSF or ISF flow rate.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656113&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1590&#x2F;0004-282X-anp-2020-0094&gt;10.1590&#x2F;0004-282X-anp-2020-0094&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":197,"discovery_date":"2021-03-03T18:56:45","title":"Change in Learning and Memory Partially Mediates Effects of Compensatory Cognitive Training on Self-Reported Cognitive Symptoms","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Head Trauma Rehabil. 2021 Feb 22. doi: 10.1097&#x2F;HTR.0000000000000662. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine associations among compensatory cognitive training (CCT), objective cognitive functioning, and self-reported cognitive symptoms. We examined whether change in objective cognitive functioning associated with participation in CCT at 10-week follow-up mediates change in self-reported cognitive symptoms associated with CCT at 15-week follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: Three VA outpatient mental health clinics.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS: Veterans with a history of mild traumatic brain injury who reported cognitive deficits.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: Randomized controlled trial post hoc causal mediation analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MAIN MEASURES: Self-reported cognitive symptoms were measured by the Prospective-Retrospective Memory Questionnaire and the Multiple Sclerosis Neuropsychological Screening Questionnaire. Objective cognitive functioning was measured using a battery of neuropsychological tests.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Improvement on the Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall test mediated the association between participation in CCT and decrease in the Prospective-Retrospective Memory Questionnaire total score. Improvement on the HVLT-R Total Recall and HVLT-R Delayed Recall tests both meditated the association between participation in CCT and decrease in the Multiple Sclerosis Neuropsychological Screening Questionnaire total score. No other measures of objective cognitive functioning were significant mediators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients&#39; perceptions of cognitive symptom improvement due to CCT are partially mediated by learning and memory, though these subjective improvements occur regardless of other changes in objective cognitive functioning associated with CCT.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656484&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656484&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;HTR.0000000000000662&gt;10.1097&#x2F;HTR.0000000000000662&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656484&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":196,"discovery_date":"2021-03-03T18:56:45","title":"The effects of PDE inhibitors on multiple sclerosis: a review of in vitro and in vivo models","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Pharm Des. 2021 Mar 3. doi: 10.2174&#x2F;1381612827666210303142356. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and immune-mediated disease, whose current therapeutic means are mostly effective in the relapsing-remitting form of MS, where inflammation is still prominent, but fall short of preventing long term impairment. However, apart from inflammation-mediated demyelination, autoimmune mechanisms play a major role in MS pathophysiology, constituting a promising pharmacological target. Phosphodiesterase (PDE) inhibitors have been approved for clinical use in psoriasis and have undergone trials suggesting their neuroprotective effects, rendering them eligible as an option for accessory MS therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: In this review, we discuss the potential role of PDE inhibitors as a complementary MS therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We conducted a literature search through which we screened and comparatively assessed papers on the effects of PDE inhibitor use, both in vitro and in animal models of MS, taking into account a number of inclusion and exclusion criteria.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In vitro studies indicated that PDE inhibitors promote remyelination and axonal sustenance, while curbing inflammatory cell infiltration, hindering oligodendrocyte and neuronal loss and suppressing cytokine production. In vivo studies underlined that these agents alleviate symptoms and reduce disease scores in MS animal models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: PDE inhibitors proved to be effective in addressing various aspects of MS pathogenesis both in vitro and in vivo models. Given the latest clinical trials proving that the PDE4 inhibitor Ibudilast exerts neuroprotective effects in patients with progressive MS, research on this field should be intensified and selective PDE4 inhibitors with enhanced safety features should be seriously considered as prospective complementary MS therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655851&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655851&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1381612827666210303142356&gt;10.2174&#x2F;1381612827666210303142356&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655851&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":195,"discovery_date":"2021-03-03T18:56:45","title":"Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Stem Cell Res Ther. 2021 Mar 3. doi: 10.2174&#x2F;1574888X16666210303151237. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Mesenchymal stem cells (MSCs) have shown promising therapeutic effects in a wide variety of medical conditions including neurodegenerative disorders and cardiovascular diseases. Although preliminary research has emphasized the ability of MSCs to engraft at sites of injury, several studies have revealed that MSCs mediate their effects through release of various paracrine factors, and through their antioxidant, anti-inflammatory, immunomodulatory, and anti-apoptotic effects. However, the clinical implications of MSCs application are limited due to their low survival rate in conditions of inflammation, oxidative stress, and nutrient restriction in damaged areas. Furthermore, the function of isolated MSCs is usually affected by the patient&#39;s health. Therefore, it is necessary to develop new methods to enhance the therapeutic efficacy of MSCs under pathophysiological conditions. This review provides an overview of the general properties of MSCs, their therapeutic potential in neurodegenerative disorders such as Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease, as well as cardiovascular diseases such as myocardial infarction, diabetic cardiomyopathy, and dilated cardiomyopathy, and their related mechanisms. In addition, this review also discusses potential problems and side effects, as well as current and future directions for improvement of MSCs therapy and their implications and applications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655876&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1574888X16666210303151237&gt;10.2174&#x2F;1574888X16666210303151237&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":194,"discovery_date":"2021-03-03T18:56:45","title":"What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Medicine (Baltimore). 2021 Mar 5;100(9):e24931. doi: 10.1097&#x2F;MD.0000000000024931.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Although the mutual relationship between ambulation and physical activity (PA) in people with multiple sclerosis (pwMS) has been described in several studies, there is still a lack of detailed information about the way in which specific aspects of the gait cycle are associated with amount and intensity of PA. This study aimed to verify the existence of possible relationships among PA parameters and the spatio-temporal parameters of gait when both are instrumentally assessed.Thirty-one pwMS (17F, 14 M, mean age 52.5, mean Expanded Disability Status Scale (EDSS) score 3.1) were requested to wear a tri-axial accelerometer 24 hours&#x2F;day for 7 consecutive days and underwent an instrumental gait analysis, performed using an inertial sensor located on the low back, immediately before the PA assessment period. Main spatio-temporal parameters of gait (i.e., gait speed, stride length, cadence and duration of stance, swing, and double support phase) were extracted by processing trunk accelerations. PA was quantified using average number of daily steps and percentage of time spent at different PA intensity, the latter calculated using cut-point sets previously validated for MS. The existence of possible relationships between PA and gait parameters was assessed using Spearman rank correlation coefficient rho.Gait speed and stride length were the parameters with the highest number of significant correlations with PA features. In particular, they were found moderately to largely correlated with number of daily steps (rho 0.62, P&amp;lt; .001), percentage of sedentary activity (rho &#x3D; -0.44, P &amp;lt; .001) and percentage of moderate-to-vigorous activity (rho &#x3D; 0.48, P &amp;lt; .001). Small to moderate significant correlations were observed between PA intensity and duration of stance, swing and double support phases.The data obtained suggest that the most relevant determinants associated with higher and more intense levels of PA in free-living conditions are gait speed and stride length. The simultaneous quantitative assessment of gait parameters and PA levels might represent a useful support for physical therapists in tailoring optimized rehabilitative and training interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655958&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;MD.0000000000024931&gt;10.1097&#x2F;MD.0000000000024931&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":193,"discovery_date":"2021-03-03T18:56:45","title":"The impact of physical functions on depressive symptoms in people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arq Neuropsiquiatr. 2021 Jan;79(1):44-50. doi: 10.1590&#x2F;0004-282X20200099.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Cross-sectional study including 26 people with MS. Anxiety and&#x2F;or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656111&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1590&#x2F;0004-282X20200099&gt;10.1590&#x2F;0004-282X20200099&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":192,"discovery_date":"2021-03-03T18:56:45","title":"Effects on Motor Control of Personalized Neuromodulation Against Multiple Sclerosis Fatigue","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Mar 3. doi: 10.1007&#x2F;s10548-021-00820-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Fatigue is a hidden symptom of Multiple Sclerosis (MS) disease that nevertheless impacts severely on patients&#39; everyday life. Evidence indicates the involvement of the sensorimotor network and its inter-nodes communication at the basis of this symptom. Two randomized controlled trials (RCTs) showed that the personalized neuromodulation called Fatigue Relief in Multiple Sclerosis (FaReMuS) efficaciously fights multiple sclerosis (MS) fatigue. By this Proof of Concept study, we tested whether FaReMuS reverts the alteration of the brain-muscular synchronization previously observed occurring with fatigue. The cortico muscular coherence (CMC) was studied in 11 patients before and after FaReMuS, a 5-day tDCS (1.5 mA, 15 min per day) anodal over the whole body&#39;s somatosensory representation (S1) via a personalized MRI-based electrode (35 cm&lt;sup&gt;2&lt;&#x2F;sup&gt;) against the occipital cathode (70 cm&lt;sup&gt;2&lt;&#x2F;sup&gt;). Before FaReMuS, the CMC was observed at a mean frequency of 31.5 ± 1.6 Hz (gamma-band) and positively correlated with the level of fatigue (p &#x3D; .027). After FaReMuS, fatigue reduced in average of 28% ± 33% the baseline level, and the CMC frequency reduced to 26.6 ± 1.5 Hz (p &#x3D; .022), thus forthcoming the physiological beta-band as observed in healthy people. The personalized S1 neuromodulation treatment, ameliorating the central-peripheral communication that subtends simple everyday movements, supports the appropriateness of neuromodulations aiming at increasing the parietal excitability in fighting MS fatigue. The relationship between central-peripheral features and fatigue profile strengthens a central more than peripheral origin of the symptom.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656622&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656622&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10548-021-00820-w&gt;10.1007&#x2F;s10548-021-00820-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656622&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":191,"discovery_date":"2021-03-03T12:36:46","title":"The Seaweed Diet in Prevention and Treatment of the Neurodegenerative Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mar Drugs. 2021 Feb 26;19(3):128. doi: 10.3390&#x2F;md19030128.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Edible marine algae are rich in bioactive compounds and are, therefore, a source of bioavailable proteins, long chain polysaccharides that behave as low-calorie soluble fibers, metabolically necessary minerals, vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae were used primarily as gelling agents and thickeners (phycocolloids) in food and pharmaceutical industries in the last century, but recent research has revealed their potential as a source of useful compounds for the pharmaceutical, medical, and cosmetic industries. The green, red, and brown algae have been shown to have useful therapeutic properties in the prevention and treatment of neurodegenerative diseases: Parkinson, Alzheimer&#39;s, and Multiple Sclerosis, and other chronic diseases. In this review are listed and described the main components of a suitable diet for patients with these diseases. In addition, compounds derived from macroalgae and their neurophysiological activities are described.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33652930&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;md19030128&gt;10.3390&#x2F;md19030128&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":190,"discovery_date":"2021-03-03T12:36:46","title":"Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011788. doi: 10.1212&#x2F;WNL.0000000000011788. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To evaluate whether a retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS), we performed SD-OCT and Expanded Disability Status Scale (EDSS) assessments among 132 PwMS at baseline and at a median of 10 years later.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this prospective, longitudinal study, participants underwent SD-OCT, EDSS, and visual acuity (VA) assessments at baseline and at follow-up. Statistical analyses were performed using generalized linear regression models, adjusted for age, sex, race, MS subtype, and baseline disability. We defined clinically meaningful EDSS worsening as an increase of ≥2.0 if baseline EDSS score was &amp;lt;6.0, or an increase of ≥1.0 if baseline EDSS score was ≥6.0.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 132 PwMS (mean age: 43 years; n&#x3D;106 patients with relapsing remitting MS) were included in analyses. Median duration of follow-up was 10.4 years. In multivariable models excluding eyes with prior optic neuritis, relative to patients with an average baseline ganglion cell+inner plexiform layer (GCIPL) thickness ≥70µm (the mean GCIPL thickness of all eyes at baseline), an average baseline GCIPL thickness &amp;lt;70µm was associated with a 4-fold increased odds of meaningful EDSS worsening (adjusted odds ratio: 3.97; 95% CI: 1.24-12.70; p&#x3D;0.02), and an almost 3-fold increased odds of low-contrast VA worsening (adjusted odds ratio: 2.93; 95% CI: 1.40-6.13; p&#x3D;0.04).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS. Accordingly, SD-OCT at a single time-point may help to guide therapeutic decision making among individual PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653904&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011788&gt;10.1212&#x2F;WNL.0000000000011788&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":189,"discovery_date":"2021-03-03T12:36:46","title":"Brain Activation Changes While Walking in Adults with and without Neurological Disease: Systematic Review and Meta-Analysis of Functional Near-Infrared Spectroscopy Studies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 26;11(3):291. doi: 10.3390&#x2F;brainsci11030291.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;(1) Functional near-infrared spectroscopy (fNIRS) provides a useful tool for monitoring brain activation changes while walking in adults with neurological disorders. When combined with dual task walking paradigms, fNIRS allows for changes in brain activation to be monitored when individuals concurrently attend to multiple tasks. However, differences in dual task paradigms, baseline, and coverage of cortical areas, presents uncertainty in the interpretation of the overarching findings. (2) Methods: By conducting a systematic review of 35 studies and meta-analysis of 75 effect sizes from 17 studies on adults with or without neurological disorders, we show that the performance of obstacle walking, serial subtraction and letter generation tasks while walking result in significant increases in brain activation in the prefrontal cortex relative to standing or walking baselines. (3) Results: Overall, we find that letter generation tasks have the largest brain activation effect sizes relative to walking, and that significant differences between dual task and single task gait are seen in persons with multiple sclerosis and stroke. (4) Conclusions: Older adults with neurological disease generally showed increased brain activation suggesting use of more attentional resources during dual task walking, which could lead to increased fall risk and mobility impairments. PROSPERO ID: 235228.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33652706&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11030291&gt;10.3390&#x2F;brainsci11030291&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":188,"discovery_date":"2021-03-03T12:36:46","title":"Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011796. doi: 10.1212&#x2F;WNL.0000000000011796. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653899&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011796&gt;10.1212&#x2F;WNL.0000000000011796&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":187,"discovery_date":"2021-03-03T12:36:46","title":"Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011793. doi: 10.1212&#x2F;WNL.0000000000011793. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653903&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011793&gt;10.1212&#x2F;WNL.0000000000011793&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":186,"discovery_date":"2021-03-03T12:36:46","title":"Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Mar 2;8(3):e975. doi: 10.1212&#x2F;NXI.0000000000000975. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but within the unique microenvironment of the brain, type II antibodies may be more beneficial, as type II antibodies exhibit reduced complement-dependent cytotoxicity and they have an increased capacity to induce direct cell death that is independent of the host immune response.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We compared the effect of type I with type II anti-CD20 therapy in a new rodent model of secondary progressive MS (SPMS), which recapitulates the principal histopathologic features of MS including meningeal B-cell aggregates. Focal MS-like lesions were induced by injecting heat-killed &lt;i&gt;Mycobacterium tuberculosis&lt;&#x2F;i&gt; into the piriform cortex of MOG-immunized mice. Groups of mice were treated with anti-CD20 antibodies (type I [rituxumab, 10 mg&#x2F;kg] or type II [GA101, 10 mg&#x2F;kg]) 4 weeks after lesion initiation, and outcomes were evaluated by immunohistochemistry.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Anti-CD20 therapy decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes in the lesion, and resulted in disruption of the meningeal aggregates. Moreover, at the given dose, the type II anti-CD20 therapy was more efficacious than the type I and also protected against neuronal death.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results indicate that anti-CD20 may be an effective therapy for SPMS with B-cell aggregates and that the elimination of CD20&lt;sup&gt;+&lt;&#x2F;sup&gt; B cells alone is sufficient to cause disruption of aggregates in the brain.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653962&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653962&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000975&gt;10.1212&#x2F;NXI.0000000000000975&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653962&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":185,"discovery_date":"2021-03-03T12:36:46","title":"Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Rev Neurosci. 2021 Mar 2. doi: 10.1038&#x2F;s41583-021-00431-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43; also known as TARDBP or TDP-43) is a key pathological feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasm to exert its multiple functions, which include regulation of the splicing, trafficking and stabilization of RNA. Cytoplasmic mislocalization and nuclear loss of TDP43 have both been associated with ALS and FTD, suggesting that calibrated levels and correct localization of TDP43 - achieved through an autoregulatory loop and tightly controlled nucleocytoplasmic transport - safeguard its normal function. Furthermore, TDP43 can undergo phase transitions, including its dispersion into liquid droplets and its accumulation into irreversible cytoplasmic aggregates. Thus, autoregulation, nucleocytoplasmic transport and phase transition are all part of an intrinsic control system regulating the physiological levels and localization of TDP43, and together are essential for the cellular homeostasis that is affected in neurodegenerative disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654312&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33654312&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41583-021-00431-1&gt;10.1038&#x2F;s41583-021-00431-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654312&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":184,"discovery_date":"2021-03-03T12:36:46","title":"Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuropsychiatr Dis Treat. 2021 Feb 22;17:587-604. doi: 10.2147&#x2F;NDT.S268360. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a demyelinating disease that can damage neurons in the brain and spinal cord and is associated with several psychiatric disorders. However, few studies have evaluated the risk of psychiatric disorders in patients with MS by using a nationwide database. This study investigated the association between MS and the risk of psychiatric disorders.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Using data from the Taiwan National Health Insurance Research Database from 2000 to 2015, we identified 1066 patients with MS. After adjustment for confounding factors, Fine and Gray&#39;s competing risk model was used to compare the risk of psychiatric disorders during 15 years of follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of the patients with MS, 531 (4622.86 per 10&lt;sup&gt;5&lt;&#x2F;sup&gt; person years) developed psychiatric disorders; by contrast, 891 of the 3198 controls (2485.31 per 10&lt;sup&gt;5&lt;&#x2F;sup&gt; person years) developed psychiatric disorders. Fine and Gray&#39;s competing risk model revealed an adjusted hazard ratio (HR) of 5.044 (95% confidence interval &#x3D; 4.448-5.870, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001) after adjustment for all the covariates. MS was associated with depression, anxiety, bipolar disorder, sleep disorders, schizophrenia, schizophreniform disorder, and other psychotic disorders (adjusted HR: 12.464, 4.650, 6.987, 9.103, 2.552, 2.600, 2.441, and 2.574, respectively; all p &amp;lt; 0.001). Some disease-modifying drugs were associated with a lower risk of anxiety or depression.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with MS were determined to have a higher risk of developing a wide range of psychiatric disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33654401&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7910105&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7910105&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;NDT.S268360&gt;10.2147&#x2F;NDT.S268360&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":183,"discovery_date":"2021-03-03T12:36:46","title":"The emerging role of the chondroitin sulfate proteoglycan family in neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Mar 1. doi: 10.1515&#x2F;revneuro-2020-0146. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Chondroitin sulfate (CS) is a kind of linear polysaccharide that is covalently linked to proteins to form proteoglycans. Chondroitin sulfate proteoglycans (CSPGs) consist of a core protein, with one or more CS chains covalently attached. CSPGs are precisely regulated and they exert a variety of physiological functions by binding to adhesion molecules and growth factors. Widely distributed in the nervous system in human body, CSPGs contribute to the major component of extracellular matrix (ECM), where they play an important role in the development and maturation of the nervous system, as well as in the pathophysiological response to damage to the central nervous system (CNS). While there are more than 30 types of CSPGs, this review covers the roles of the most important ones, including versican, aggrecan, neurocan and NG2 in the pathogenesis of neurodegenerative diseases, including Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis and multiple sclerosis. The updated reports of the treatment of neurodegenerative diseases are involving CSPGs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655733&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33655733&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1515&#x2F;revneuro-2020-0146&gt;10.1515&#x2F;revneuro-2020-0146&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655733&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":182,"discovery_date":"2021-03-03T07:16:46","title":"Roles of leptin on the key effector cells of rheumatoid arthritis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Lett. 2021 Feb 27:S0165-2478(21)00029-8. doi: 10.1016&#x2F;j.imlet.2021.02.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Leptin, an adipokine sharing structural characteristics of the long-chain helical cytokine family with the crucial role as a regulator in energy homeostasis, has been paid more and more attention on its immunoregulatory function. Emerging evidence has indicated the roles of leptin on autoimmune diseases such as systemic lupus erythematous (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA) and psoriasis, implying that leptin might be involved in autoimmune disorders. It is very definite that there exists immunocyte dysfunction in RA patients. Growing data has manifested that leptin was increased in both serum and synovial fluid of RA patients compared to healthy controls, suggesting leptin might take part in the pathogenesis of RA. The aim of this review is to discuss about what we currently know with regard to the role of leptin in immune system and its effects on RA crucial cells. To clarify the role of leptin in the pathogenesis of RA is beneficial to both the treatment and medical study.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652029&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.imlet.2021.02.008&gt;10.1016&#x2F;j.imlet.2021.02.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":181,"discovery_date":"2021-03-03T07:16:46","title":"Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Contemp Clin Trials. 2021 Feb 27:106331. doi: 10.1016&#x2F;j.cct.2021.106331. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) causes cognitive impairment in approximately 50% of cases. Disease modifying medications and cognitive rehabilitation produce only small positive effects on cognition in MS. Converging animal and human research suggests that aerobic exercise may improve cognition in people with MS, but definitive trials are lacking. We describe the design of the GET Smart study, a randomized controlled trial comparing the effects of aerobic exercise versus stretching and toning on cognition in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The study is a single-blind, parallel group randomized (1:1) controlled trial that compares aerobic exercise training with an active control group consisting of stretching and toning exercises for improving cognition. Participants are nondepressed, ambulatory, non-exercising adults with MS aged 18-54 years who have below average cognitive processing speed. Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PROJECTED PATIENT OUTCOMES: The primary hypothesis is that the aerobic training group will demonstrate significantly greater cognitive processing speed compared with the control group at the end of the treatment phase (6 months) as measured by a composite of the Paced Auditory Serial Additon Test and the oral Symbol-Digit Modalities Test using intent-to treat analyses. Secondary outcomes are neuropsychological functioning and cardiorespiratory fitness as well as participant reported outcomes such as depression, sleep, and fatigue. Study findings will inform future research, patient education, clinical care and policymaking.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02106052.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652128&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652128&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.cct.2021.106331&gt;10.1016&#x2F;j.cct.2021.106331&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652128&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":180,"discovery_date":"2021-03-03T07:16:46","title":"Accuracy of the Brazilian version of the DYMUS questionnaire for the screening of oropharyngeal dysphagia in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 19;50:102772. doi: 10.1016&#x2F;j.msard.2021.102772. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Oropharyngeal dysphagia is a common symptom of many neurological diseases, including Multiple Sclerosis (MS). Early identification of the risk of dysphagia in neurological patients is very important for early referral for specialized evaluations of oropharyngeal swallowing and treatments. The Dysphagia in Multiple Sclerosis (DYMUS) questionnaire has been translated and validated in different countries over the last 10 years. We aimed to analyze the accuracy of the Brazilian Portuguese version of the DYMUS (DYMUS-BR) questionnaire in identifying dysphagia in patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The DYMUS questionnaire and a videofluorographic swallowing study (VFSS) were conducted in 30 patients with MS. Dysphagia was identified by at least one abnormal response and was considered alarming when the DYMUS scores were equal to or higher than 3. Patients were considered to have dysphagia in the VFSS when one or more signs of impairment in the efficiency and&#x2F;or safety of swallowing were detected.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: According to the initial self-assessment, 37% (N &#x3D; 11) of patients with MS self-reported with dysphagia. According to the DYMUS-BR scores, 53% (N &#x3D; 16) of the patients with MS were classified as having dysphagia. The sensitivity, specificity, and positive and negative predictive values of the DYMUS-BR questionnaire for the detection of dysphagia as measured by the VFSS were 50% [95% confidence interval (CI) 29-71], 78% (95% CI 61-90), 60% (95% CI 42-76), and 70% (95% CI 60-78), respectively. The area under the receiver-operating characteristic curve for detecting dysphagia was 64% (95% CI 49-79).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The accuracy of the DYMUS-BR questionnaire is poor to detect mild swallowing impairment in patients with MS. However, we suggest longitudinal follow-up in patients with low DYMUS-BR scores for early detection of oropharyngeal dysphagia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652231&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652231&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102772&gt;10.1016&#x2F;j.msard.2021.102772&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652231&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":179,"discovery_date":"2021-03-03T07:16:46","title":"Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102859. doi: 10.1016&#x2F;j.msard.2021.102859. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;HBV screening and immunization is recommended in all MS patients and is mandatory before the start of some DMT. However, studies evaluating the immune response to HBV vaccine in MS patients are scarce. We aimed to evaluate the seroprotection rate following HBV immunization in MS patients and to assess if older age and DMT-treatment influenced seroprotection. We conducted a cohort study between 2016 and 2020 and compared the immune response to HBV vaccine in MS patients under different DMTs and in patients 50 years old or younger and older than 50. We found that patients under non-injectable DMT presented lower rates of seroprotection comparing to patients under injectable DMT&#39;s or without treatment. In patients older than 50, although the seroprotection rate was similar to the remaining patients, the antibody anti-HBV surface antigen titers following HBV immunization were lower and patients were more likely to require a 4th dose of the vaccine to achieve seroprotection. Our findings highlight to need to consider HBV immunization in MS patients early in the disease course, in order to ensure a proper immune response to the vaccine.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652232&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652232&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102859&gt;10.1016&#x2F;j.msard.2021.102859&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652232&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":178,"discovery_date":"2021-03-03T07:16:46","title":"Efficacy of core stability versus task oriented trainings on balance in ataxic persons with multiple sclerosis. A single blinded randomized controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102866. doi: 10.1016&#x2F;j.msard.2021.102866. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Balance and ataxic symptoms are commonly encountered in people with multiple sclerosis (PwMS). Many intervention approaches have been proposed to address balance in PwMS. The purpose of this study was to investigate the efficacy of adding core stability versus task oriented trainings on traditional approaches on balance in ataxic PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Forty five ataxic relapsing-remitting PwMS from both sexes were randomly assigned into three identical groups. Control group (CG) treated with conventional balance exercise program; study groups I (GI) and II (GII) received respectively additional training using core stability exercises and task oriented trainings. Outcome measures recorded pre and post study period included stability index (SI), anterior posterior stability index (APSI), and mediolateral stability index (MLSI) using Biodex stability system in addition to the Berg balance scale (BBS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Post treatment, the results indicated significant improvement in (SI) and (APSI) (p&amp;lt;0.05), and non-significant improvement (p&amp;gt;0.05) in (MLSI) and BBS in CG. In GI and GII there was a significant improvement in all balance measures (p&amp;lt;0.05). Comparison of post treatment results between groups indicated a significant improvement of GII compared to CG in all study measures, GI showed non- significant difference in all balance measures compared to the CG(P&amp;gt;0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: In PwMS balance rehabilitation should be multimodal; core stability exercises and task-oriented training in addition to conventional balance training are effective to improve balance and should be considered as an essential part of the training program for balance rehabilitation in ataxic PwMS. Task-oriented training in addition to conventional balance rehabilitation seem to be a favorable approach.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652233&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652233&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102866&gt;10.1016&#x2F;j.msard.2021.102866&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652233&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":177,"discovery_date":"2021-03-03T00:36:46","title":"Validity of the Italian multiple sclerosis neuropsychological screening questionnaire","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 2. doi: 10.1007&#x2F;s10072-021-05141-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a brief questionnaire useful for screening patients with multiple sclerosis (MS) at risk for cognitive impairment. It includes a patient self-assessment (MSNQ-p) and a section for the caregiver (informant) (MSNQ-i). This study&#39;s aim was to validate the Italian version of MSNQ and to compare MSNQ scores with Symbol Digit Modality Test (SDMT), Beck Depression Inventory (BDI), and Expanded Disability Status Scale (EDSS) score, measuring cognitive skills, mood status, and physical disability respectively. We enrolled 122 MS patients (and related caregivers) at MS center of Tor Vergata University Hospital of Rome. The final study sample consisted of 122 patients with MS (90 relapsing-remitting, 24 secondary progressive, and 8 primary progressive). Our results highlighted that MSNQ has a unidimensional factor structure. Correlational analyses found a good correlation between both versions (MSNQ-p and MSNQ-i) of the questionnaire. Both MSNQ-p and MSNQ-i were correlated with clinical variables, specifically with cognitive impairment, mood disorder, and with disability. The Italian version of MSNQ is reliable and useful as screening tool to identify MS patients at high risk of cognitive impairment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651198&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2&quot;&gt;33651198&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05141-1&gt;10.1007&#x2F;s10072-021-05141-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651198&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":176,"discovery_date":"2021-03-03T00:36:46","title":"A man with erythematosquamous plaques","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ned Tijdschr Geneeskd. 2021 Feb 18;165:D5795.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;A 43-year-old male visited our dermatology department with a skin eruption diagnosed as psoriasis. It began 1 month after starting peg-interferon-α-1a therapy for multiple sclerosis. Peg-interferon is known to be able to induce psoriasis, as well as other medication, while the pathophysiology remains unclear.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651510&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2&quot;&gt;33651510&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651510&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":175,"discovery_date":"2021-03-02T23:16:45","title":"Benign monomelic amyotrophy of lower limb in a cohort of chinese patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Behav. 2021 Mar 2:e02073. doi: 10.1002&#x2F;brb3.2073. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Benign monomelic amyotrophy of lower limb (BMALL) is a neurogenic syndrome representing an unclear field. Further studies might be helpful to elucidate uncertainties regarding causation, outcome, and the risk of progression to amyotrophic lateral sclerosis (ALS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: According to the inclusion and exclusion criteria, 37 patients with BMALL were retrospectively collected in three neuromuscular centers from January 2012 to October 2018. The detailed medical data were summarized. Multiple laboratory tests were examined. Routine electrophysiological examinations, muscle MRI of lower limbs, and muscle biopsy were conducted.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The cohort included 24 male and 13 female cases with median age of onset 47 years. Muscle MRI revealed that the distribution of involved muscles matched with the extent of fat infiltration, so the pattern muscle atrophy can be divided into the following four types: six patients with thigh atrophy (type I), 14 patients with leg atrophy (type II); 10 patients with disproportionate atrophy in both thigh and leg (type III); and seven patients with well-proportionate atrophy in both thigh and leg (type IV). Electrophysiological findings showed neurogenic pattern, spontaneous activity, and abnormal H reflex, which suggested a disorder of spinal anterior horn cell in the patients with types I-III. However, no electrophysiological abnormalities were found in the patients with type IV. Muscle pathology varied from almost normal pattern to advanced neurogenic pattern in nine biopsied patients. Follow-up showed that two patients with type II developed to ALS four years later, and all patients with type IV were in stable condition without any complaints.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Muscle MRI was useful to exactly localize the distribution of involved muscles in BMALL patients. The distribution of atrophic muscles can be roughly divided into four types based on the MRI features. The classification of distributing types might be as an indicator for the prognosis of BMALL.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650811&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650811&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;brb3.2073&gt;10.1002&#x2F;brb3.2073&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650811&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":174,"discovery_date":"2021-03-02T23:16:45","title":"Untreated patients with multiple sclerosis: a study of French expert centers","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Mar 1. doi: 10.1111&#x2F;ene.14790. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Disease modifying therapies (DMTs), have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (pwMS) remain untreated. The objective of the present study was to determine the proportion of untreated patients with multiple sclerosis (pwMS) followed in expert centers in France and determine the predictive factors of non-treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on 12&#x2F;15&#x2F;2018 and pwMS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included. Results Among the 21,189 pwMS (age 47.1±13.1; EDSS 3.4±2.4), 6,631 (31.3%; 95%CI&#x3D;30.7-31.9) of the patients were not receiving any DMT. Although patients with a relapsing-remitting course (n &#x3D; 11,693) were the most likely to receive DMT, 14.8% (95%CI &#x3D; 14.2-15.4) were still untreated (6.8% never treated). After multivariate analysis among relapsing-remitting pwMS, the main factors explaining never having been treated were not having ≥9 lesions on brain MRI (OR &#x3D; 0.52 [0.44-0.61]) and lower EDSS (OR &#x3D; 0.78 [0.74-0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, 11.6% for secondary and 34.0% for primary progressive MS had never received any DMT.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: A significant proportion of pwMS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650261&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650261&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14790&gt;10.1111&#x2F;ene.14790&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650261&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":173,"discovery_date":"2021-03-02T23:16:45","title":"Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Med Internet Res. 2021 Mar 2;23(3):e19309. doi: 10.2196&#x2F;19309.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Mindfulness-based stress reduction is an efficacious treatment for people with chronic health problems; however, it is highly intensive and time-consuming, which is a barrier for service provision.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: This study aims to develop an internet-delivered adapted version of mindfulness-based stress reduction for people with multiple sclerosis to make the intervention more accessible.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We co-designed a web-based mindfulness program with end users, that is, people with multiple sclerosis (N&#x3D;19). Iterative feedback was also collected from a subsample of the initial group of end users (n&#x3D;11), and the program was reviewed by experts (n&#x3D;8).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified three main themes common to people with multiple sclerosis: dealing with uncertainty and fears for the future, grief and loss, and social isolation. These themes were incorporated into narratives throughout the program. People with multiple sclerosis who reviewed the program gave feedback that the program was relatable, feasible, and acceptable. Experts agreed that the program appropriately represented the main tenets of mindfulness. Iterative feedback was used to further refine the program.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The web-based mindfulness program that we developed was viewed positively by both experts and end users. The program reflects common concerns for people with multiple sclerosis and has the potential to meet important unmet psychological needs. A randomized controlled trial was planned to determine the efficacy of the program.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650980&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650980&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2196&#x2F;19309&gt;10.2196&#x2F;19309&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650980&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":172,"discovery_date":"2021-03-02T23:16:45","title":"Metformin Protects Myelin from Degeneration in A Mouse Model of Iysophosphatidylcholine-Induced Demyelination in The Optic Chiasm","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell J. 2021 Apr;23(1):119-128. doi: 10.22074&#x2F;cellj.2021.7174. Epub 2021 Mar 1.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. The autoimmune pathology and long-term inflammation lead to substantial demyelination. These events lead to a substantial loss of oligodendrocytes (OLs), which in a longer period, results in axonal loss and long-term disabilities. Neural cells protection approaches decelerate or inhibit the disease progress to avoid further disability. Previous studies showed that metformin has beneficial effects against neurodegenerative conditions. In this study, we examined possible protective effects of metformin on toxin-induced myelin destruction in adult mice brains.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: In this experimental study, lysophosphatidylcholine (LPC) was used to induce demyelination in mice optic chiasm. We examined the extent of demyelination at different time points post LPC injection using myelin staining and evaluated the severity of inflammation. Functional state of optic pathway was evaluated by visual evoked potential (VEP) recording.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Metformin attenuated LPC-induced demyelination (P&amp;lt;0.05) and inflammation (P&amp;lt;0.05) and protected against significant decrease (P&amp;lt;0.05) in functional conductivity of optic tract. These data indicated that metformin administration attenuates the myelin degeneration following LPC injection which led to functional enhancement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our findings suggest metformin for combination therapy for patients suffering from the myelin degenerative diseases, especially multiple sclerosis; however, additional mechanistic studies are required.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650828&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22074&#x2F;cellj.2021.7174&gt;10.22074&#x2F;cellj.2021.7174&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":171,"discovery_date":"2021-03-02T23:16:45","title":"Neuroimmunology of COVID-19","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 2. doi: 10.1007&#x2F;s00115-021-01077-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Many neuroimmunological diseases, such as encephalopathy, encephalitis, myelitis and acute disseminated encephalomyelitis (ADEM) have occurred more frequently after infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which indicates a parainfectious or postinfectious association. The most likely underlying mechanisms include virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but potentially also the development of specific autoantibodies against central nervous system (CNS) tissue. These were predominantly detected in the cerebrospinal fluid of severely ill coronavirus disease 2019 (COVID-19) patients. In contrast, direct damage after invasion of SARS-CoV‑2 into the brain and spinal cord does not seem to play a relevant role. Susceptibility to infection with SARS-CoV‑2 in patients with multiple sclerosis, myasthenia or other neuroimmunological diseases including the risk for severe disease courses, is not determined by the administered immunotherapy but by known risk factors, such as age, comorbidities and the disease-related degree of disability. Therefore, immunotherapy in these patients should not be delayed or discontinued. The contribution of neuroimmunological mechanisms to long-term sequelae after survival of a COVID-19 illness, such as fatigue, impairment of memory, sleep dysfunction or anxiety, will require long-term clinical follow-up, preferentially in COVID-19 register studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33651117&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01077-1&gt;10.1007&#x2F;s00115-021-01077-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":170,"discovery_date":"2021-03-02T13:09:11","title":"Neuronal hibernation following hippocampal demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neuropathol Commun. 2021 Mar 1;9(1):34. doi: 10.1186&#x2F;s40478-021-01130-9.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cognitive dysfunction occurs in greater than 50% of individuals with multiple sclerosis (MS). Hippocampal demyelination is a prominent feature of postmortem MS brains and hippocampal atrophy correlates with cognitive decline in MS patients. Cellular and molecular mechanisms responsible for neuronal dysfunction in demyelinated hippocampi are not fully understood. Here we investigate a mouse model of hippocampal demyelination where twelve weeks of treatment with the oligodendrocyte toxin, cuprizone, demyelinates over 90% of the hippocampus and causes decreased memory&#x2F;learning. Long-term potentiation (LTP) of hippocampal CA1 pyramidal neurons is considered to be a major cellular readout of learning and memory in the mammalian brain. In acute slices, we establish that hippocampal demyelination abolishes LTP and excitatory post-synaptic potentials of CA1 neurons, while pre-synaptic function of Schaeffer collateral fibers is preserved. Demyelination also reduced Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt;-mediated firing of hippocampal neurons in vivo. Using three-dimensional electron microscopy, we investigated the number, shape (mushroom, stubby, thin), and post-synaptic densities (PSDs) of dendritic spines that facilitate LTP. Hippocampal demyelination did not alter the number of dendritic spines. Surprisingly, dendritic spines appeared to be more mature in demyelinated hippocampi, with a significant increase in mushroom-shaped spines, more perforated PSDs, and more astrocyte participation in the tripartite synapse. RNA sequencing experiments identified 400 altered transcripts in demyelinated hippocampi. Gene transcripts that regulate myelination, synaptic signaling, astrocyte function, and innate immunity were altered in demyelinated hippocampi. Hippocampal remyelination rescued synaptic transmission, LTP, and the majority of gene transcript changes. We establish that CA1 neurons projecting demyelinated axons silence their dendritic spines and hibernate in a state that may protect the demyelinated axon and facilitates functional recovery following remyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648591&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s40478-021-01130-9&gt;10.1186&#x2F;s40478-021-01130-9&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":169,"discovery_date":"2021-03-02T13:09:11","title":"Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Genome Med. 2021 Feb 28;13(1):35. doi: 10.1186&#x2F;s13073-021-00853-7.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Immunoglobulin G4-related disease (IgG4-RD) and systemic sclerosis (SSc) are rare autoimmune diseases characterized by the presence of CD4+ cytotoxic T cells in the blood as well as inflammation and fibrosis in various organs, but they have no established etiologies. Similar to other autoimmune diseases, the gut microbiome might encode disease-triggering or disease-sustaining factors.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The gut microbiomes from IgG4-RD and SSc patients as well as healthy individuals with no recent antibiotic treatment were studied by metagenomic sequencing of stool DNA. De novo assembly-based taxonomic and functional characterization, followed by association and accessory gene set enrichment analysis, were applied to describe microbiome changes associated with both diseases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Microbiomes of IgG4-RD and SSc patients distinctly separated from those of healthy controls: numerous opportunistic pathogenic Clostridium and typically oral Streptococcus species were significantly overabundant, while Alistipes, Bacteroides, and butyrate-producing species were depleted in the two diseases compared to healthy controls. Accessory gene content analysis in these species revealed an enrichment of Th17-activating Eggerthella lenta strains in IgG4-RD and SSc and a preferential colonization of a homocysteine-producing strain of Clostridium bolteae in SSc. Overabundance of the classical mevalonate pathway, hydroxyproline dehydratase, and fibronectin-binding protein in disease microbiomes reflects potential functional differences in host immune recognition and extracellular matrix utilization associated with fibrosis. Strikingly, the majority of species that were differentially abundant in IgG4-RD and SSc compared to controls showed the same directionality in both diseases. Compared with multiple sclerosis and rheumatoid arthritis, the gut microbiomes of IgG4-RD and SSc showed similar signatures; in contrast, the most differentially abundant taxa were not the facultative anaerobes consistently identified in inflammatory bowel diseases, suggesting the microbial signatures of IgG4-RD and SSc do not result from mucosal inflammation and decreased anaerobism.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results provide an initial characterization of gut microbiome ecology in fibrosis-prone IgG4-RD and SSc and reveal microbial functions that offer insights into the pathophysiology of these rare diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648559&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s13073-021-00853-7&gt;10.1186&#x2F;s13073-021-00853-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":168,"discovery_date":"2021-03-02T13:09:11","title":"Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Immunol. 2021 Mar 1:ji1900656. doi: 10.4049&#x2F;jimmunol.1900656. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IL-17A and IL-22 derived from Th17 cells play a significant role in mucosal immunity and inflammation. TGF-β and IL-6 promote Th17 differentiation; however, these cytokines have multiple targets. The identification and screening of additional molecules that regulate IL-17A and IL-22 responses in certain inflammatory conditions is of great clinical significance. In this study, we show that CDDO-Im, a specific Nrf2 activator, promotes IL-17A and IL-22 responses in murine Th17 cells. In contrast, CDDO-Im inhibits IL-17A response in multiple sclerosis patient-derived PBMCs. However, Nrf2 specifically regulates IL-22 response in vivo. Nrf2 acts through the regulation of antioxidant response element (ARE) binding motifs in target genes to induce or repress transcription. Promoter analysis revealed that &lt;i&gt;Il17a&lt;&#x2F;i&gt;, &lt;i&gt;Rorc&lt;&#x2F;i&gt;, and &lt;i&gt;Ahr&lt;&#x2F;i&gt; genes have several ARE motifs. We showed that Nrf2 bound to ARE repressor (ARE-R2) of &lt;i&gt;Rorc&lt;&#x2F;i&gt; and inhibited &lt;i&gt;Rorc&lt;&#x2F;i&gt;-dependent IL-17A transactivation. The luciferase reporter assay data showed that CDDO-Im regulated &lt;i&gt;Ahr&lt;&#x2F;i&gt; promoter activity. Chromatin immunoprecipitation quantitative PCR data showed that Nrf2 bound to ARE of AhR. Finally, we confirmed that the CDDO-Im-mediated induction of IL-22 production in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells was abrogated in CD4-specific &lt;i&gt;Ahr&lt;&#x2F;i&gt; knockout mice (&lt;i&gt;Ahr&lt;sup&gt;CD4&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; ). CH-223191, a specific AhR antagonist, inhibits CDDO-Im-induced IL-22 production in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells, which further confirmed the AhR-dependent regulation. Collectively, our data showed that Nrf2 via AhR pathways regulated IL-22 response in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648937&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648937&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.4049&#x2F;jimmunol.1900656&gt;10.4049&#x2F;jimmunol.1900656&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648937&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":167,"discovery_date":"2021-03-02T13:09:11","title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 1:jnnp-2020-325302. doi: 10.1136&#x2F;jnnp-2020-325302. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to non-limbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33649021&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325302&gt;10.1136&#x2F;jnnp-2020-325302&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":166,"discovery_date":"2021-03-02T13:09:11","title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 1:jnnp-2020-325300. doi: 10.1136&#x2F;jnnp-2020-325300. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. Corticosteroids alone or combined with other agents (intravenous IG or plasmapheresis) were selected as a first-line therapy by 84% of responders for patients with a general presentation, 74% for patients presenting with faciobrachial dystonic seizures, 63% for NMDAR-IgG encephalitis and 48.5% for classical paraneoplastic encephalitis. Half the responders indicated they would add a second-line agent only if there was no response to more than one first-line agent, 32% indicated adding a second-line agent if there was no response to one first-line agent, while only 15% indicated using a second-line agent in all patients. As for the preferred second-line agent, 80% of responders chose rituximab while only 10% chose cyclophosphamide in a clinical scenario with unknown antibodies. Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649022&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33649022&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325300&gt;10.1136&#x2F;jnnp-2020-325300&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649022&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":165,"discovery_date":"2021-03-02T11:49:12","title":"Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102860. doi: 10.1016&#x2F;j.msard.2021.102860. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Primary progressive multiple sclerosis (PPMS) has long been defined by progressive disability accrual in the absence of initial relapses. However, its underlying neurodegenerative process seems to be accompanied by central nervous system inflammation. A new classification defined multiple sclerosis courses according to clinical&#x2F;radiological activity and progression. We provide further insight into PPMS activity according to this classification and other daily living aspects.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a multicentre, prospective, cohort study including 55 adult patients with PPMS according to 2010 McDonald criteria, within ten years from neurologic symptom onset and not receiving disease-modifying therapies during the past six months, who were followed up for 12 months. The primary study endpoint was the percentage of patients with active disease based on clinical relapses and&#x2F;or magnetic resonance activity. Disability progression, cognitive function, physical&#x2F;psychological impact, depression symptoms, stigma and employment were secondary endpoints.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Eleven (25.6%) patients exhibited multiple sclerosis activity throughout the 12-month study follow-up. Fourteen showed non-active multiple sclerosis without progression, 11 non-active multiple sclerosis with progression, 6 active multiple sclerosis without progression and 4 active multiple sclerosis with progression; one patient with disease activity was not assessable for progression. Cognitive function scores remained unchanged or increased, disease physical impact was maintained and disease psychological impact significantly decreased. The proportion of patients with depression symptoms or stigma remained without significant changes as well as employment outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This study shows that one-fourth of PPMS patients may exhibit disease activity over one year, with disability progression in approximately one-third but without worsening of cognitive function, disease impact, depression, stigma or employment outcomes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647591&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102860&gt;10.1016&#x2F;j.msard.2021.102860&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":164,"discovery_date":"2021-03-02T11:49:12","title":"Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 20;353:577525. doi: 10.1016&#x2F;j.jneuroim.2021.577525. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Tumour Necrosis Factor alpha (TNFα) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFα blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFα blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFα blockers-associated Multiple Sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647875&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577525&gt;10.1016&#x2F;j.jneuroim.2021.577525&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":163,"discovery_date":"2021-03-02T11:49:12","title":"Kidney Imaging Surveillance in Commercially Insured Patients With Tuberous Sclerosis Complex","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Pediatr Neurol. 2020 Dec 26;117:21-26. doi: 10.1016&#x2F;j.pediatrneurol.2020.12.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Kidney disease has historically been the primary source of early mortality in adults with tuberous sclerosis complex (TSC). Kidney imaging surveillance promotes early detection of lesions requiring intervention. We describe kidney imaging frequency in relationship to patient-level characteristics for commercially insured patients with TSC in the United States.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This retrospective observational study used 2003 to 2016 enrollment and claims data from a de-identified fully insured commercial health insurer. Patients with TSC less than 65 years were included. The patient-level kidney imaging rate was calculated as the number of kidney imaging procedures divided by length of continuous enrollment. A multiple linear regression model was used to determine the relationship between imaging rate and progression of TSC-associated kidney disease, number of specialists seen, and nephrologist care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At least half of the 70 patients with TSC included in the study were aged 16 years or younger. Over a follow-up period of up to 14 years, the median kidney imaging rate was 0.13 procedures per year with 43% (N &#x3D; 30) of patients lacking evidence of kidney imaging during the observation period. Imaging frequency increased with progression of TSC-associated kidney disease, more specialists, and nephrologist care (P &amp;lt; 0.05 for all three in regression model).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: A substantial percentage of patients with TSC in the United States are at risk for delayed detection of kidney manifestations due to infrequent kidney imaging surveillance. Multispecialty care, including neurologists, may positively affect kidney surveillance rates.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647778&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647778&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.pediatrneurol.2020.12.008&gt;10.1016&#x2F;j.pediatrneurol.2020.12.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647778&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":162,"discovery_date":"2021-03-02T01:29:12","title":"Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Diagn Ther. 2021 Mar 1. doi: 10.1007&#x2F;s40291-021-00513-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cerebrospinal fluid (CSF) is a clear and paucicellular fluid that circulates within the ventricular system and the subarachnoid space of the central nervous system (CNS), and diverse CNS disorders can impact its composition, volume, and flow. As conventional CSF testing suffers from suboptimal sensitivity, this review aimed to evaluate the role of next-generation sequencing (NGS) in the work-up of infectious, neoplastic, neuroimmunological, and neurodegenerative CNS diseases. Metagenomic NGS showed improved sensitivity-compared to traditional methods-to detect bacterial, viral, parasitic, and fungal infections, while the overall performance was maximized in some studies when all diagnostic modalities were used. In patients with primary CNS cancer, NGS findings in the CSF were largely concordant with the molecular signatures derived from tissue-based molecular analysis; of interest, additional mutations were identified in the CSF in some glioma studies, reflecting intratumoral heterogeneity. In patients with metastasis to the CNS, NGS facilitated diagnosis, prognosis, therapeutic management, and monitoring, exhibiting higher sensitivity than neuroimaging, cytology, and plasma-based molecular analysis. Although evidence is still rudimentary, NGS could enhance the diagnosis and pathogenetic understanding of multiple sclerosis in addition to Alzheimer and Parkinson disease. To conclude, NGS has shown potential to aid the research, facilitate the diagnostic approach, and improve the management outcomes of all the aforementioned CNS diseases. However, to establish its role in clinical practice, the clinical validity and utility of each NGS protocol should be determined. Lastly, as most evidence has been derived from small and retrospective studies, results from randomized control trials could be of significant value.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646562&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646562&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40291-021-00513-x&gt;10.1007&#x2F;s40291-021-00513-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646562&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":161,"discovery_date":"2021-03-02T01:29:12","title":"Neurologic Features Associated With SARS-CoV-2 Infection in Children: A Case Series Report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Child Neurol. 2021 Mar 1:883073821989164. doi: 10.1177&#x2F;0883073821989164. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Although multiple neurologic manifestations associated with SARS-CoV-2 infection have been described in adults, there is little information about those presented in children. Here, we described neurologic manifestations associated with COVID-19 in the pediatric population.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Retrospective case series report. We included patients younger than 18 years, admitted with confirmed SARS-CoV-2 infection and neurologic manifestations at our hospital in Santiago, Chile. Demographics, clinical presentations, laboratory results, radiologic and neurophysiological studies, treatment, and outcome features were described. Cases were described based on whether they presented with predominantly central or peripheral neurologic involvement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Thirteen of 90 (14.4%) patients admitted with confirmed infection presented with new-onset neurologic symptoms and 4 patients showed epilepsy exacerbation. Neurologic manifestations ranged from mild (headache, muscle weakness, anosmia, ageusia), to severe (status epilepticus, Guillain-Barré syndrome, encephalopathy, demyelinating events).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We found a wide range of neurologic manifestations in children with confirmed SARS-CoV-2 infection. In general, neurologic symptoms were resolved as the systemic presentation subsided. It is essential to recognize and report the main neurologic manifestations related to this new infectious disease in the pediatric population. More evidence is needed to establish the specific causality of nervous system involvement.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646895&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646895&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;0883073821989164&gt;10.1177&#x2F;0883073821989164&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646895&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":160,"discovery_date":"2021-03-02T01:29:12","title":"Impact of complement activation on clinical outcomes in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 1. doi: 10.1002&#x2F;acn3.51334. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We determined activation profiles of the classical and alternative complement pathway in 39 treatment-naïve patients with early relapse-onset MS. Plasma concentrations of complement fragments were unchanged in MS compared to 32 patients with non-inflammatory neurological diseases. Profiles in patients experiencing clinical exacerbations did not differ from patients with stable disease and did not correlate with baseline EDSS, numbers of T2 lesions and time to second relapse. Long-term EDSS outcomes 4 years after diagnosis did not significantly correlate with baseline complement levels. These data do not support the use of complement activation products as biomarkers for disease activity in early MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646629&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646629&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51334&gt;10.1002&#x2F;acn3.51334&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646629&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":159,"discovery_date":"2021-03-02T01:29:12","title":"DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Feb 26;10:e58430. doi: 10.7554&#x2F;eLife.58430. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We performed a systematic analysis of blood DNA methylation profiles from 4,483 participants from seven independent cohorts identifying differentially methylated positions (DMPs) associated with psychosis, schizophrenia and treatment-resistant schizophrenia. Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNA methylation data, with the largest differences seen in treatment-resistant schizophrenia patients. We implemented a stringent pipeline to meta-analyze epigenome-wide association study (EWAS) results across datasets, identifying 95 DMPs associated with psychosis and 1,048 DMPs associated with schizophrenia, with evidence of colocalization to regions nominated by genetic association studies of disease. Many schizophrenia-associated DNA methylation differences were only present in patients with treatment-resistant schizophrenia, potentially reflecting exposure to the atypical antipsychotic clozapine. Our results highlight how DNA methylation data can be leveraged to identify physiological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis and molecular biomarkers of treatment-resistant schizophrenia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646943&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646943&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.58430&gt;10.7554&#x2F;eLife.58430&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646943&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":158,"discovery_date":"2021-03-01T18:49:10","title":"Fingolimod-associated macular edema: A case report of late onset","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Ophthalmol. 2021 Mar 1:1120672121999632. doi: 10.1177&#x2F;1120672121999632. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: The authors present a case of a male with Multiple Sclerosis (MS) who developed unilateral Fingolimod-Associated Macular Edema (FAME) 10 years after initiating fingolimod therapy. By reporting this case study, the authors present a comprehensive review on FAME, its current incidence, and therapy options in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE DESCRIPTION: A 58-year-old Caucasian male patient was referred to the hospital with a history of MS. He was on fingolimod treatment for 10 years. The patient presented with a referring second episode of blurred vision in his left eye (OS). His best corrected visual acuity (BCVA) was 20&#x2F;20 (right eye - OD) and 20&#x2F;30 (OS). Dilated fundus examination of the OS revealed dull foveal reflex with retinal thickening. Spectral domain optical coherence tomography (SD-OCT) scan demonstrated increased central macular thickness of 459 μm, foveal cysts and subretinal fluid. Neurologists decided to discontinue fingolimod treatment based on the ophthalmological findings. Three months post fingolimod discontinuation, macular edema resolved and BCVA was 20&#x2F;20 (OD) and 20&#x2F;25 (OS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The authors report a case of late onset FAME. FAME may occur several years after starting fingolimod treatment and it should be part of differential diagnosis of blurred vision in patients receiving fingolimod. Both Microcystic Macular Edema secondary to MS and Macular Edema Associated with MS-induced Uveitis should always be excluded. Those two conditions, secondary to MS, might show the lack of drug effectiveness and the possible need for changing the existing therapy in order to prevent further disease progress.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645300&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1120672121999632&gt;10.1177&#x2F;1120672121999632&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":157,"discovery_date":"2021-03-01T18:49:10","title":"Translation, cross-cultural adaptation, and reliability and validity of the Turkish version of the SF-Qualiveen in people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurourol Urodyn. 2021 Mar 1. doi: 10.1002&#x2F;nau.24645. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: The short form Qualiveen (SF-Qualiveen) is a simple, easy to understand, and valid scale used to evaluate the effect of urologic problems on quality of life in neurological patients. The aim of this study was to translate, culturally adapt, and validate the Turkish version of the SF-Qualiveen in people with multiple sclerosis (pwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Translation and cultural adaptation of the questionnaire was carried out after obtaining the necessary permissions. To decide on the final Turkish version of SF-Qualiveen, ten pwMS with urologic problems were pre-tested. Patients included in the study were asked to complete the Turkish SF-Qualiveen and urinary distress inventory-short form (UDI-6) questionnaires. The validity and reliability of the scale were determined after the retest 2 weeks later.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Sixty-three pwMS with urologic problems were enrolled. Internal consistency (Cronbach&#39;s α &#x3D; 0.87) and reproducibility intraclass correlation coefficient [ICC] &#x3D; 0.97) were good for the total SF-Qualiveen. The Cronbach&#39;s α and ICC values ranged from 0.43 to 0.77 and 0.88-0.98 for SF-Qualiveen subscales, respectively. Content validity of the questionnaire was appropriate. A moderate correlation was founded between the SF-Qualiveen and the UDI-6 (r &#x3D; 0.62; p &amp;lt; 0.001). There were no floor or ceiling effects in our study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The Turkish version of the SF-Qualiveen is a valid and reliable questionnaire for pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645839&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;nau.24645&gt;10.1002&#x2F;nau.24645&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":156,"discovery_date":"2021-03-01T18:49:10","title":"Plasma Creatinine Level Does Not Predict Respiratory Function in Amyotrophic Lateral Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuromuscul Dis. 2021 Feb 23. doi: 10.3233&#x2F;JND-200583. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In amyotrophic lateral sclerosis (ALS) lower plasma creatinine level has been associated with shorter survival and faster functional decline. It has not been clear if creatinine is associated with respiratory outcome. We analyzed retrospectively a population of unselected ALS patients. Multiple-regression and Cox-regression analyses were performed. We included 233 patients, mean age 62.8, mean disease duration of 18.6 months. At baseline, creatinine was significantly associated with ALSFRS-R, but not with its decline rate. No predictive value was disclosed for FVC, or their decline rate, or with survival. We did not confirm that creatinine is a marker of respiratory outcome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646173&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33646173&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3233&#x2F;JND-200583&gt;10.3233&#x2F;JND-200583&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646173&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":155,"discovery_date":"2021-03-01T18:49:10","title":"Exploiting Rational Assembly to Map Distinct Roles of Regulatory Cues during Autoimmune Therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;ACS Nano. 2021 Mar 1. doi: 10.1021&#x2F;acsnano.0c07440. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Autoimmune diseases like multiple sclerosis (MS), type 1 diabetes, and lupus occur when the immune system attacks host tissue. Immunotherapies that promote selective tolerance without suppressing normal immune function are of tremendous interest. Here, nanotechnology was used for rational assembly of peptides and modulatory immune cues into immune complexes. Complexes containing self-peptides and regulatory nucleic acids reverse established paralysis in a preclinical MS model. Importantly, mice responding to immunotherapy maintain healthy, antigen-specific B and T cell responses during a foreign antigen challenge. A therapeutic library isolating specific components reveals that regulatory nucleic acids suppress inflammatory genes in innate immune cells, while disease-matched peptide sequences control specificity of tolerance. Distinct gene expression profiles in cells and animals are associated with the immune signals administered in particulate and soluble forms, highlighting the impact of biophysical presentation of signals. This work provides insight into the rational manipulation of immune signaling to drive tolerance.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645967&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1021&#x2F;acsnano.0c07440&gt;10.1021&#x2F;acsnano.0c07440&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":154,"discovery_date":"2021-03-01T18:49:10","title":"Connection between JAK&#x2F;STAT and PPARgamma signaling during the progression of multiple sclerosis: Insights into the modulation of T-cells and immune responses in the brain","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Mol Pharmacol. 2021 Mar 1. doi: 10.2174&#x2F;1874467214666210301121432. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple Sclerosis (MS) is a severe brain and spinal cord condition with a diverse autoimmune response and a wide variety of demyelination symptoms that primarily affect young adults. The primary reason for this disease is inflammation of white and grey matter caused by increased production of proinflammatory cytokines, which further damages the progenitor oligodendrocytes and appears to induce hypertrophy of the astrocytes and gliosis. Overexpression of the JAK&#x2F;STAT signaling pathway contributes directly to physiological and pathological results in motor neuron diseases. Cytokines such as IL-17, IL-6, IL-12, TNF-α, and INF-ϒ use JAK&#x2F;STAT signaling to trigger self-reactive CD4+ T-cells differentiate them into Th1 phenotypes that over-activate immune reactions in the brain. Similarly, PPARγ plays a critical role in regulating the immune response by providing an anti-inflammatory effect by inhibiting macrophage and cytokine production activation. PPARγ also mediates the intrinsic molecular process of the T-cell, which selectively regulates the differentiation of Th17. Various studies indicate the neuroprotective function of PPARγ agonists by attenuating the JAK&#x2F;STAT mediated activation of glial cells, inhibiting interleukin, and the differentiation of Th1 cells. Therefore, to maintain the brain&#39;s immune system, both PPARγ,and JAK&#x2F;STAT oppositely regulate each other. Dysregulation in JAK&#x2F;STAT and PPARγ signaling contributes to several physiological changes leading to neurological disorders, including MS. Based on the above view; we summarized the combined role of JAK&#x2F;STAT-PPARγsignaling in MS and explored potential therapeutic strategies for disease improvement by the use of pathway modulators.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645493&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645493&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1874467214666210301121432&gt;10.2174&#x2F;1874467214666210301121432&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645493&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":153,"discovery_date":"2021-03-01T18:49:10","title":"Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Invest. 2021 Mar 1;131(5):141694. doi: 10.1172&#x2F;JCI141694.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Approximately 80% of neuromyelitis optica spectrum disorder (NMOSD) patients harbor serum anti-aquaporin-4 autoantibodies targeting astrocytes in the CNS. Crucial for NMOSD lesion initiation is disruption of the blood-brain barrier (BBB), which allows the entrance of Abs and serum complement into the CNS and which is a target for new NMOSD therapies. Astrocytes have important functions in BBB maintenance; however, the influence of their loss and the role of immune cell infiltration on BBB permeability in NMOSD have not yet been investigated. Using an experimental model of targeted NMOSD lesions in rats, we demonstrate that astrocyte destruction coincides with a transient disruption of the BBB and a selective loss of occludin from tight junctions. It is noteworthy that BBB integrity is reestablished before astrocytes repopulate. Rather than persistent astrocyte loss, polymorphonuclear leukocytes (PMNs) are the main mediators of BBB disruption, and their depletion preserves BBB integrity and prevents astrocyte loss. Inhibition of PMN chemoattraction, activation, and proteolytic function reduces lesion size. In summary, our data support a crucial role for PMNs in BBB disruption and NMOSD lesion development, rendering their recruitment and activation promising therapeutic targets.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645550&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645550&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1172&#x2F;JCI141694&gt;10.1172&#x2F;JCI141694&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645550&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":152,"discovery_date":"2021-03-01T18:49:10","title":"Telehealth in Multiple Sclerosis Clinical Care and Research","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Neurol Neurosci Rep. 2021 Feb 28;21(4):14. doi: 10.1007&#x2F;s11910-021-01103-4.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: The COVID-19 pandemic has provided us with a unique opportunity to experiment with telehealth and evaluate its benefits and limitations. This review discusses the impact of telehealth on multiple sclerosis (MS) care and research in adults and children.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: Telehealth visits for MS patients have been shown to reduce missed workdays and costs for patients. Brief telephone-based counseling may be associated with better adherence to disease-modifying therapy, although results of multiple home-based tele-rehabilitation for people with MS have been equivocal. Overall, patients and providers have reported high levels of satisfactions with telehealth. Several remote disability measures and numerous other technological tools have emerged for use in remote MS research and care. Major challenges of telehealth include limitations to performing a complete neurologic exam and disparities in access to telehealth amongst vulnerable populations with limited access to virtual platforms. Following the rapid expansion of telehealth during the pandemic, it is highly likely that we will continue to embrace the benefits of this valuable tool. Future directions for improving telehealth should include more evidence-based research on the diagnostic accuracy in neuroimmunology and reducing disparities in the access to telehealth.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33646409&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11910-021-01103-4&gt;10.1007&#x2F;s11910-021-01103-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":151,"discovery_date":"2021-03-01T11:11:00","title":"Recent developments on PET radiotracers for TSPO and their applications in neuroimaging","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Pharm Sin B. 2021 Feb;11(2):373-393. doi: 10.1016/j.apsb.2020.08.006. Epub 2020 Aug 25.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, is predominately localized to the outer mitochondrial membrane in steroidogenic cells. Brain TSPO expression is relatively low under physiological conditions, but is upregulated in response to glial cell activation. As the primary index of neuroinflammation, TSPO is implicated in the pathogenesis and progression of numerous neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer&#x27;s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson&#x27;s disease (PD), multiple sclerosis (MS), major depressive disorder (MDD) and obsessive compulsive disorder (OCD). In this context, numerous TSPO-targeted positron emission tomography (PET) tracers have been developed. Among them, several radioligands have advanced to clinical research studies. In this review, we will overview the recent development of TSPO PET tracers, focusing on the radioligand design, radioisotope labeling, pharmacokinetics, and PET imaging evaluation. Additionally, we will consider current limitations, as well as translational potential for future application of TSPO radiopharmaceuticals. This review aims to not only present the challenges in current TSPO PET imaging, but to also provide a new perspective on TSPO targeted PET tracer discovery efforts. Addressing these challenges will facilitate the translation of TSPO in clinical studies of neuroinflammation associated with central nervous system diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643818/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643818&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7893127/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7893127&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.apsb.2020.08.006&gt;10.1016/j.apsb.2020.08.006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643818/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":150,"discovery_date":"2021-03-01T11:11:00","title":"Impact of Excipients on Stability of Polymer Microparticles for Autoimmune Therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Bioeng Biotechnol. 2021 Feb 11;8:609577. doi: 10.3389/fbioe.2020.609577. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Therapies for autoimmune diseases such as multiple sclerosis and diabetes are not curative and cause significant challenges for patients. These include frequent, continued treatments required throughout the lifetime of the patient, as well as increased vulnerability to infection due to the non-specific action of therapies. Biomaterials have enabled progress in antigen-specific immunotherapies as carriers and delivery vehicles for immunomodulatory cargo. However, most of this work is in the preclinical stage, where small dosing requirements allow for on-demand preparation of immunotherapies. For clinical translation of these potential immunotherapies, manufacturing, preservation, storage, and stability are critical parameters that require greater attention. Here, we tested the stabilizing effects of excipients on the lyophilization of polymeric microparticles (MPs) designed for autoimmune therapy; these MPs are loaded with peptide self-antigen and a small molecule immunomodulator. We synthesized and lyophilized particles with three clinically relevant excipients: mannitol, trehalose, and sucrose. The biophysical properties of the formulations were assessed as a function of excipient formulation and stage of addition, then formulations were evaluated in primary immune cell culture. From a manufacturing perspective, excipients improved caking of lyophilized product, enabled more complete resuspension, increased product recovery, and led to smaller changes in MP size and size distribution over time. Cocultures of antigen-presenting cells and self-reactive T cells revealed that MPs lyophilized with excipients maintained tolerance-inducing function, even after significant storage times without refrigeration. These data demonstrate that excipients can be selected to drive favorable manufacturing properties without impacting the immunologic properties of the tolerogenic MPs.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33644005/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33644005&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7906284/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7906284&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fbioe.2020.609577&gt;10.3389/fbioe.2020.609577&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33644005/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":149,"discovery_date":"2021-03-01T11:11:00","title":"Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;ERJ Open Res. 2021 Feb 22;7(1):00235-2020. doi: 10.1183/23120541.00235-2020. eCollection 2021 Jan.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;This systematic review summarises current evidence to help guide treatment decisions for patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A systematic search of the literature (January 2012 to April 2018), including grey literature (searched between 1992 and 2011), was conducted using multiple electronic databases. Guidelines, meta-analyses, randomised controlled trials and observational studies reporting on risk stratification, screening, diagnosis, treatment and management outcomes for patients with SSc-ILD were included. A quality assessment of the included evidence was undertaken. In total, 2464 publications were identified and 280 included. Multiple independent risk factors for ILD in patients with SSc were identified, including older age, male sex and baseline pulmonary function. High-resolution computed tomography (HRCT) has been used for characterising ILD in patients with SSc, and pulmonary function tests are a key adjunctive component in the diagnostic and monitoring pathway. The clinical value of biomarkers relating to SSc-ILD diagnosis or assessment for disease progression is unknown at present. Immunosuppressive therapy (monotherapy or combined therapy) is the current standard of care for SSc-ILD; long-term evidence for effective and safe treatment of SSc-ILD is limited. Identification of patients at risk for SSc-ILD remains challenging. HRCT and pulmonary function tests are key to diagnosing and monitoring for disease progression. Although immunosuppressive therapy is considered current first-line treatment, it is partly associated with adverse effects and long-term follow-up evidence is limited. Novel therapies and biomarkers should be further explored in well-controlled clinical studies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33644224/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33644224&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7897846/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7897846&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1183/23120541.00235-2020&gt;10.1183/23120541.00235-2020&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33644224/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":148,"discovery_date":"2021-03-01T11:11:00","title":"Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinsons Disease","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol India. 2021 Jan-Feb;69(1):115-118. doi: 10.4103/0028-3886.310102.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONTEXT: A host of microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, microRNA changes are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues of central nervous system diseases, including glioma, Alzheimer&#x27;s disease (AD), Parkinson&#x27;s disease (PD), multiple sclerosis, and depression. Compared with other body fluids, CSF can reflect the brain pathological processes more accurately.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIMS: To understand whether microRNA expression may be misregulated in patients with PD, and further discover potential diagnostic biomarkers and promising therapeutic targets for PD.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: Here, through real-time reverse-transcription polymerase chain reaction (RT-PCR), we compared CSF microRNA from 15 PD patients, 11 AD patients, and 16 controls with other neurologic disorders, such as encephalitis and Guillain-Barre syndrome.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Finally, we identified hsa-miR-626 changes in the CSF of PD patients. The mean expression level of hsa-miR-626 was significantly reduced in the CSF of PD patients compared with AD patients and controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our approach provides a preliminary research for identifying biomarkers in the CSF that could be used for the detection, diagnosis, and monitoring of PD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642281/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642281&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.4103/0028-3886.310102&gt;10.4103/0028-3886.310102&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642281/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":147,"discovery_date":"2021-03-01T11:11:00","title":"Pharmacological interventions targeting nuclear factor-kappa B signaling in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neural Regen Res. 2021 Oct;16(10):2023-2025. doi: 10.4103/1673-5374.308088.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642388/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642388&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.4103/1673-5374.308088&gt;10.4103/1673-5374.308088&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642388/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":146,"discovery_date":"2021-03-01T11:11:00","title":"Astrocytic and Oligodendrocytic P2X7 Receptors Determine Neuronal Functions in the CNS","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Mol Neurosci. 2021 Feb 9;14:641570. doi: 10.3389/fnmol.2021.641570. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;P2X7 receptors are members of the ATP-gated cationic channel family with a preferential localization at the microglial cells, the resident macrophages of the brain. However, these receptors are also present at neuroglia (astrocytes, oligodendrocytes) although at a considerably lower density. They mediate necrosis/apoptosis by the release of pro-inflammatory cytokines/chemokines, reactive oxygen species (ROS) as well as the excitotoxic (glio)transmitters glutamate and ATP. Besides mediating cell damage i.e., superimposed upon chronic neurodegenerative processes in Alzheimer&#x27;s Disease, Parkinson&#x27;s Disease, multiple sclerosis, and amyotrophic lateral sclerosis, they may also participate in neuroglial signaling to neurons under conditions of high ATP concentrations during any other form of neuroinflammation/neurodegeneration. It is a pertinent open question whether P2X7Rs are localized on neurons, or whether only neuroglia/microglia possess this receptor-type causing indirect effects by releasing the above-mentioned signaling molecules. We suggest as based on molecular biology and functional evidence that neurons are devoid of P2X7Rs although the existence of neuronal P2X7Rs cannot be excluded with absolute certainty.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642994/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642994&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7906075/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7906075&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fnmol.2021.641570&gt;10.3389/fnmol.2021.641570&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642994/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":145,"discovery_date":"2021-03-01T11:11:00","title":"Engine Failure in Axo-Myelinic Signaling: A Potential Key Player in the Pathogenesis of Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Cell Neurosci. 2021 Feb 10;15:610295. doi: 10.3389/fncel.2021.610295. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a complex and chronic disease of the central nervous system (CNS), characterized by both degenerative and inflammatory processes leading to axonal damage, demyelination, and neuronal loss. In the last decade, the traditional &lt;i&gt;outside-in&lt;/i&gt; standpoint on MS pathogenesis, which identifies a primary autoimmune inflammatory etiology, has been challenged by a complementary &lt;i&gt;inside-out&lt;/i&gt; theory. By focusing on the degenerative processes of MS, the axo-myelinic system may reveal new insights into the disease triggering mechanisms. Oxidative stress (OS) has been widely described as one of the means driving tissue injury in neurodegenerative disorders, including MS. Axonal mitochondria constitute the main energy source for electrically active axons and neurons and are largely vulnerable to oxidative injury. Consequently, axonal mitochondrial dysfunction might impair efficient axo-glial communication, which could, in turn, affect axonal integrity and the maintenance of axonal, neuronal, and synaptic signaling. In this review article, we argue that OS-derived mitochondrial impairment may underline the dysfunctional relationship between axons and their supportive glia cells, specifically oligodendrocytes and that this mechanism is implicated in the development of a primary cytodegeneration and a secondary pro-inflammatory response (&lt;i&gt;inside-out&lt;/i&gt;), which in turn, together with a variably primed host&#x27;s immune system, may lead to the onset of MS and its different subtypes.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642995/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642995&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7902503/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7902503&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fncel.2021.610295&gt;10.3389/fncel.2021.610295&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642995/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":144,"discovery_date":"2021-03-01T11:11:00","title":"A Neurodisparity Index of Nationwide Access to Neurological Health Care in Northern Ireland","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 12;12:608070. doi: 10.3389/fneur.2021.608070. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Nationwide disparities in managing neurological patients have rarely been reported. We compared neurological health care between the population who reside in a Health and Social Care Trust with a tertiary neuroscience center and those living in the four non-tertiary center Trusts in Northern Ireland. Using the tertiary center Trust population as reference, neurodisparity indices (NDIs) defined as the number of treated patients resident in each Trust per 100,000 residents compared to the same ratio in the tertiary center Trust for a fixed time period. NDIs were calculated for four neurological pathways-intravenous thrombolysis (iv-tPA) and mechanical thrombectomy (MT) for acute ischemic stroke (AIS), disease modifying treatment (DMT) in multiple sclerosis (MS) and admissions to a tertiary neurology ward. Neurological management was recorded in 3,026 patients. Patients resident in the tertiary center Trust were more likely to receive AIS treatments (iv-tPA and MT) and access to the neurology ward (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) than patients residing in other Trusts. DMT use for patients with MS was higher in two non-tertiary center Trusts than in the tertiary center Trust. There was a geographical gradient for MT for AIS patients and ward admissions. Averaged NDIs for non-tertiary center Trusts were: 0.48 (95%CI 0.32-0.71) for patient admissions to the tertiary neurology ward, 0.50 (95%CI 0.38-0.66) for MT in AIS patients, 0.78 (95%CI 0.67-0.92) for iv-tPA in AIS patients, and 1.11 (95%CI 0.99-1.26) for DMT use in MS patients. There are important neurodisparities in Northern Ireland, particularly for MT and tertiary ward admissions. Neurologists and health service planners should be aware that geography and time-dependent management of neurological patients worsen neurodisparities.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643193/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643193&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7907594/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7907594&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.608070&gt;10.3389/fneur.2021.608070&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643193/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":143,"discovery_date":"2021-03-01T11:11:00","title":"An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI)","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 11;12:637895. doi: 10.3389/fneur.2021.637895. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; Cognitive impairment is a common feature of multiple sclerosis (MS). A semi-structured interview, including informant input, can characterize the experience of individuals living with MS and cognitive involvement. &lt;b&gt;Objective:&lt;/b&gt; We administered the Cognitive Assessment Interview (CAI), a patient- and informant-based semi-structured interview, to characterize the experience of cognitive impairments in those living with MS. &lt;b&gt;Methods:&lt;/b&gt; Trained raters administered the CAI to a sample of MS participants and their informants enrolled for a trial of cognitive remediation. Cognitive impairments on the CAI were characterized and compared to those captured by neuropsychological and self-report measures. &lt;b&gt;Results:&lt;/b&gt; A total of &lt;i&gt;n&lt;/i&gt; = 109 MS participants (mean age = 50.3 ± 12.2) and their available informants (&lt;i&gt;n&lt;/i&gt; = 71) were interviewed. Participants reported experiencing processing speed (90/106, 85%), working memory (87/109, 80%), and learning and memory (79/109, 72%) problems most commonly. CAI-based ratings were moderately correlated with a self-report measure (Multiple Sclerosis Neuropsychological Screening Questionnaire, &lt;i&gt;r&lt;/i&gt; &lt;sub&gt;s&lt;/sub&gt; = 0.52, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) and only mildly correlated with objective neuropsychological measures specific to executive functions (&lt;i&gt;r&lt;/i&gt; &lt;sub&gt;&lt;i&gt;s&lt;/i&gt;&lt;/sub&gt; = 0.21, &lt;i&gt;p&lt;/i&gt; = 0.029). For those with informant interviews, ratings were overall consistent, suggesting that the CAI is valid even in cases in which an informant is unavailable and the interview is conducted with the patient alone (as is often the case in clinical and research settings). &lt;b&gt;Conclusions:&lt;/b&gt; The CAI provides a semi-structured interview to characterize the experience of cognitive impairment in MS, with findings representing real-world functioning, adding valuable information to both self-report measures and neuropsychological assessment.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643211/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643211&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7905222/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7905222&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.637895&gt;10.3389/fneur.2021.637895&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643211/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":142,"discovery_date":"2021-03-01T11:11:00","title":"Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 12;12:645298. doi: 10.3389/fneur.2021.645298. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Borrelia-specific antibodies in serum did not contribute to the diagnosis of Borrelia arthritis or Borrelia-associated dermatitis in a young woman with ongoing treatment with rituximab due to multiple sclerosis. The diagnosis was confirmed by the detection of Borrelia-DNA in a skin punch biopsy. The patient history did not reveal any tick exposure. She had suffered for several months from fluctuating pain and swelling of the right knee as well as skin involvement with redness and oedema around the ankle of the same leg. Monoarthritis was confirmed by a rheumatologist. Knee puncture was performed but the synovial fluid was only sufficient for microscopic examination of crystals. Neither monosodium urate crystals nor calcium pyrophosphate crystals were found. Borrelia serology in blood revealed borderline levels of immunoglobulin (Ig)M and IgG, respectively. Treatment with doxycycline resulted in resolution of the joint and skin manifestations within a month. This case highlights that Borrelia-specific antibody levels cannot be reliably interpreted in patients who have received B-cell depleting therapy. Under these circumstances, detection of the bacterial genome in different body fluids, such as in the skin, can be a useful complement to the diagnosis of Lyme disease. In this young female, the diagnosis would certainly have been further delayed without the detection of Borrelia-DNA in the skin.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643217/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643217&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7907593/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7907593&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.645298&gt;10.3389/fneur.2021.645298&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643217/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":141,"discovery_date":"2021-03-01T11:11:00","title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Feb 17;14:1756286420987031. doi: 10.1177/1756286420987031. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643441/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643441&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894590/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7894590&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1756286420987031&gt;10.1177/1756286420987031&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643441/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":140,"discovery_date":"2021-03-01T11:11:00","title":"Health Promoting Self-care Behaviors in Patients With Multiple Sclerosis in the Southeast of Iran: Developing a Model for Practice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Basic Clin Neurosci. 2020 Sep-Oct;11(5):687-699. doi: 10.32598/bcn.11.5.1670.1. Epub 2020 Sep 1.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Promoting self-care practice, as a critical strategy for enhancing the quality of life in patients with Multiple Sclerosis (MS) is a challenging issue. This study aimed to propose a model of health-promoting self-care behaviors in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this cross-sectional study, 200 patients with MS, who had referred to the Hospital for Special Diseases in Kerman City, Iran, were chosen. The main data collection instruments were the multiple sclerosis knowledge questionnaire, the Rosenberg self-esteem scale, multiple sclerosis self-efficacy scale, questionnaire of perceived barriers and benefits of self-care behaviors, social support, the health promotion lifestyle profile II, and resilience and sense of coherence scale. Data analysis was conducted in SPSS V. 22 and AMOS18 software. The Structural Equation Modeling (SEM) was also used for further analysis of data.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The model explained 82% of variance in Health-Promoting self-care Behavior (HPB). The results of the final model obtained from the SEM showed that self-efficacy (β=0.53, SE=0.04, P= 0.007), self-esteem (β=0.39, SE=0.04, P=0.005), social support (β=0.36, SE=0.04, P=0.009), sense of coherence (β=0.34, SE=0.07, P=0.006), resilience (β=0.33, SE=0.07, P=0.018), and perceived benefits (β=0.25, SE=0.05, P=0.009) had a positive and significant relationship with HPB.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The self-care empowerment model in patients with MS presented in this study can be used as a framework for designing health promotion interventions to improve the quality of life of patients with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643561/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643561&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878060/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7878060&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.32598/bcn.11.5.1670.1&gt;10.32598/bcn.11.5.1670.1&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643561/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":139,"discovery_date":"2021-03-01T11:11:00","title":"Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - The Danish MS Hospitals Rehabilitation Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 17;7(1):2055217321989384. doi: 10.1177/2055217321989384. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Evidence of the effects of inpatient multidisciplinary rehabilitation (MDR) on physical function in patients with multiple sclerosis (MS) is limited, particularly whether clinically relevant improvements can be achieved. The aim of this study, therefore, was to investigate the effects of personalised inpatient MDR on the physical function of MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Embedded in the Danish MS Hospitals Rehabilitation Study, a pragmatic study was performed in MS patients undergoing four weeks of inpatient MDR specifically targeting physical function. Outcomes were assessed at baseline (n = 142), at discharge (n = 137) and at six months follow-up (n = 126) using the six-minute walk test (6MWT), six-spot step test (SSST), five times sit to stand test (5STS), nine-hole peg test (NHPT), dynamic gait index (DGI) and 12-item MS walking scale (MSWS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: From Baseline-to-Discharge, significant and clinically relevant improvements were found in all measures of walking capacity (6MWT, SSST, 5STS, DGI and MSWS; p &amp;lt; 0.05) along with significant (but not clinically relevant) improvements in upper extremity function (NHPT; p &amp;lt; 0.05). Whilst comparable improvements were observed within subgroups of MS phenotype (relapsing-remitting [RR] vs. secondary + primary progressive [SP + PP]), disease severity (moderate [EDSS&lt;sub&gt;2.5-5.5&lt;/sub&gt;] vs. severe [EDSS&lt;sub&gt;6.0-7.5&lt;/sub&gt;]) and age (young/middle-aged [Age&lt;sub&gt;24-59&lt;/sub&gt;] vs. old [Age&lt;sub&gt;60-65&lt;/sub&gt;]), an attenuated adaptation was nevertheless observed for 6MWT in the most affected and vulnerable subgroups (i.e. SP + PP, EDSS&lt;sub&gt;6.0-7.5&lt;/sub&gt; and Age&lt;sub&gt;60-65&lt;/sub&gt;). The significant improvements in walking capacity and upper extremity function persisted at six months follow-up but did not exceed anymore the thresholds regarded as clinically relevant.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The results provide novel evidence that personalised inpatient MDR targeting physical function in MS patients elicits significant and clinically relevant improvements in physical function.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643662/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643662&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894699/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7894699&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321989384&gt;10.1177/2055217321989384&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643662/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":138,"discovery_date":"2021-03-01T11:11:00","title":"Remote administration of the symbol digit modalities test to individuals with multiple sclerosis is reliable: A short report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 14;7(1):2055217321994853. doi: 10.1177/2055217321994853. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The Symbol Digit Modalities Test (SDMT) is the gold standard for cognitive screening in multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Due to the recent COVID-19 pandemic and the increased need for virtual clinical visits, we examined the reliability of remote administration of the SDMT vs. standard in-person administration to individuals with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Pearson&#x27;s correlation analysis was performed between SDMT scores on the in-person and remote administrations.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: For n = 132 participants, remote and in-person SDMT scores were strongly correlated (r = .80, &lt;i&gt;p&lt;/i&gt; = .000).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Remote administration of the SDMT is a reliable cognitive screening approach in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643663/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643663&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7890734/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7890734&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321994853&gt;10.1177/2055217321994853&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643663/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":137,"discovery_date":"2021-03-01T11:11:00","title":"Research progress of effect of Rhei Radix et Rhizoma and its anthraquinone in treatment of autoimmune diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Zhongguo Zhong Yao Za Zhi. 2021 Jan;46(1):15-23. doi: 10.19540/j.cnki.cjcmm.20201012.601.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Rhei Radix et Rhizoma was first recorded in Shennong Ben Cao Jing, with a wide range of pharmacological activities. Autoimmune disease is a kind of disease that damages the tissue structure and function of immune cells and their components due to the impairment of immune tolerance function, including atherosclerosis, multiple sclerosis, gout, rheumatoid arthritis, autoimmune thyroiditis, ulcerative colitis, type 1 diabetes and IgA nephropathy. In recent years, clinical and experimental studies show that Rhei Radix et Rhizoma has potential therapeutic effects on autoimmune diseases. Under the guidance of the theory of traditional Chinese medicine, this paper reviews therapeutic and intervening effects of Rhei Radix et Rhizoma and its main active ingredient anthraquinone on autoimmune diseases. It also puts forward new study directions in view of the existing problems in studies of rhubarb and its anthraquinone, with the aim to provide reference for clinical treatment and scientific studies of effect of Rhei Radix et Rhizomaon autoimmune diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33645046/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33645046&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.19540/j.cnki.cjcmm.20201012.601&gt;10.19540/j.cnki.cjcmm.20201012.601&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33645046/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":136,"discovery_date":"2021-03-01T11:11:00","title":"Acute myelopathies associated to SARS-CoV-2 infection: viral or immune-mediated damage?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Travel Med Infect Dis. 2021 Feb 25:102000. doi: 10.1016/j.tmaid.2021.102000. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33640477/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33640477&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.tmaid.2021.102000&gt;10.1016/j.tmaid.2021.102000&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33640477/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":135,"discovery_date":"2021-03-01T11:11:00","title":"Gamma Knife radiosurgery for the treatment of trigeminal neuralgia in patients with multiple sclerosis: A single-center retrospective study and literature review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;World Neurosurg. 2021 Feb 25:S1878-8750(21)00267-9. doi: 10.1016/j.wneu.2021.02.074. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Trigeminal neuralgia (TN) in patients with multiple sclerosis (MS) is a challenging condition to manage that is treated with Gamma Knife radiosurgery (GKRS). The aim of this report is to assess the safety, efficacy, and durability of GKRS for the treatment of TN in patients with MS. Our findings are compared with those of the existing literature and discussed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We retrospectively reviewed all patients at our institution who underwent GKRS for the treatment of TN secondary to MS and had one or more years of follow-up. Pre-operative and post-operative pain intensities and facial numbness were evaluated with the Barrow Neurological Institute (BNI) scores. Durability of successful pain relief was statistically evaluated with Kaplan-Meier analysis. The prognostic role of perioperative factors was investigated and analyzed using Cox proportional hazards regression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: There were 29 patients with MS-TN who underwent GKRS at our institution. Two patients underwent bilateral treatment. Four patients underwent repeat GKRS for pain recurrence. The median period of follow-up assessment was 33 months. Rates of reasonable pain reduction at 1, 3, and 5 years were 70%, 57%, and 57% respectively. All patients who underwent repeat GKRS had durable pain reduction. No prognostic factor for successful pain reduction was found.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our study shows that GKRS for the treatment of TN secondary to MS is a safe and effective procedure in controlling pain in the short term, but often fails to provide long-term pain control. GKRS can be safely repeated to prolong the time of pain reduction.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33640527/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33640527&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.wneu.2021.02.074&gt;10.1016/j.wneu.2021.02.074&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33640527/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":134,"discovery_date":"2021-03-01T11:11:00","title":"Comparative treatment effectiveness of oral fingolimod and conventional injectable disease modifying agents in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Pharmacotherapy. 2021 Feb 28. doi: 10.1002/phar.2517. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Fingolimod was the first approved oral Disease Modifying Agent (DMA) to reduce relapses in Multiple Sclerosis (MS). Previous observational studies assessed the effectiveness of DMAs only through relapse and did not consider the treatment switch.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare the effectiveness of oral fingolimod and conventional injectable DMAs using the composite endpoint of relapse or treatment switch in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: This retrospective longitudinal study utilized the IBM MarketScan Commercial Claims and Encounters Database from 2010-2012. Adults (≥18 years) with MS diagnosis (ICD-9-CM:340) and newly initiated with a DMA were included. Cox Proportional Hazards (PH) regression model weighted for stabilized Inverse Probability Treatment Weights (IPTW) with robust sandwich estimator was used to evaluate the composite endpoint (time to relapse/treatment switch) between oral fingolimod and injectable DMA users during the one-year follow-up after the treatment initiation. Additional analyses were performed on patients who were adherent (proportion of days covered [PDC]≥0.8) to DMAs during the first three months.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The incident study cohort consisted of 1,997 MS patients who initiated oral fingolimod (15.6%) or injectable (84.4%) DMAs. The proportion of patients who had a composite endpoint (relapse/DMA treatment switch) in oral fingolimod and injectable DMA users was found to be 16.72% and 27.16%, respectively. The Cox PH regression model with stabilized IPTW revealed that fingolimod is equally effective as injectable DMAs in reducing the risk of experiencing the composite endpoint of relapse or DMA switch (adjusted Hazards Ratio [aHR]: 0.67, 95% CI: 0.43-1.03). Additional analysis among patients who were adherent also found no significant difference in the composite endpoint (aHR: 0.70, 95% CI 0.49-1.15) between oral fingolimod and injectable DMA users.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Oral fingolimod has similar effectiveness as injectable DMAs in reducing the risk of experiencing the composite endpoint (relapse or treatment switch). In addition, when assessed independently, oral fingolimod showed no difference in reducing the time to relapse or DMA treatment switch compared to injectable DMA users.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33641232/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33641232&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/phar.2517&gt;10.1002/phar.2517&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33641232/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":133,"discovery_date":"2021-03-01T11:11:00","title":"Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Feb 25. doi: 10.1515/revneuro-2020-0140. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is the most well-known autoimmune disorder of the central nervous system, and constitutes a major cause of disability, especially in young individuals. A wide array of pharmacological treatments is available, but they have often been proven to be ineffective in ameliorating disease symptomatology or slowing disease progress. As such, non-invasive and non-pharmacological techniques have been gaining more ground. Transcranial magnetic stimulation (TMS) utilizes the electric field generated by a magnetic coil to stimulate neurons and has been applied, usually paired with electroencephalography, to study the underlying pathophysiology of MS, and in repetitive trains, in the form of repetitive transcranial magnetic stimulation (rTMS), to induce long-lasting changes in neuronal circuits. In this review, we present the available literature on the application of TMS and rTMS in the context of MS, with an emphasis on its therapeutic potential on various clinical aspects, while also naming the ongoing trials, whose results are anticipated in the future.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33641274/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33641274&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1515/revneuro-2020-0140&gt;10.1515/revneuro-2020-0140&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33641274/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":132,"discovery_date":"2021-02-28T11:11:00","title":"Mitochondrial Dysfunction and Traffic Jams in Amyotrophic Lateral Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mitochondrion. 2021 Feb 24:S1567-7249(21)00015-5. doi: 10.1016/j.mito.2021.02.008. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neurodegenerative diseases are characterized by progressive neuronal loss anatomically or physiologically and accumulation of protein in the cells. Mitochondria provide energy to these neuronal cells consuming 20% of the body&#x27;s oxygen. Mitochondria are the dynamic membrane-bound cell organelles that function to generate ATP, regulate calcium homeostasis, and produce reactive oxygen species. Because of alterations in the electron transport chain, mutation, and environmental toxins, there is reduced ATP production, calcium dyshomeostasis, and increased oxidative stress, resulting in mitochondrial dysfunction, leading to the pathogenesis of neurodegenerative diseases such as ALS. ALS is described as the loss of upper and lower motor neurons resulting in progressive muscle denervation and loss of voluntary movements. There are multiple shreds of evidence in the literature regarding the mechanism involved in mitochondrial dysfunction and possible therapeutic targets to treat the condition. Moreover, different studies reported the role of different gene mutations and malfunctions in transport system responsible for the accumulation and aggregation of the proteins inside the brain cells. This accumulation and/or aggregation of proteins in the neuronal cells is known as neuronal traffic jam, which also plays the leading role in the progressive neurodegenerative diseases. In this review, we have elucidated the critical insights into mitochondrial dysfunction and neuronal traffic jam; and its role in the initiation and progression of ALS. Moreover, the pharmacological targets and possible conducts to this scenario are also brought together.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33639271/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210228052230&amp;v=2.14.2&quot;&gt;33639271&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.mito.2021.02.008&gt;10.1016/j.mito.2021.02.008&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33639271/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210228052230&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":131,"discovery_date":"2021-02-28T11:11:00","title":"Early neuropsychological markers of cognitive involvement in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol Sci. 2021 Feb 17;423:117349. doi: 10.1016/j.jns.2021.117349. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Cognitive impairment due to multiple sclerosis (MS) is common and often limits occupational functioning, contributes to disability, and reduces quality of life. Early detection of cognitive involvement in MS is critical for treatment planning and intervention, and frequent, regular cognitive monitoring may provide insight into subtle changes in disease progression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare the sensitivity and specificity of clinical, computer-based and experimental measures to early cognitive involvement in MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Cognitive functioning was compared in MS participants early in the disease course to matched healthy controls using conventional, computer-based and functional assessments: the Brief International Cognitive Assessment in MS (BICAMS); the computer-based Cogstate Brief Battery (CBB); the Attention Network Test-Interaction (ANT-I), including intra-individual variability; and the Test of Everyday Cognitive Ability (TECA), a functional measure of instrumental activities of daily living.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: MS participants (n = 25, mean disease duration= 5.82 ± 3.65 years) and demographically matched healthy controls (n = 29) completed the cognitive assessments. The Cogstate measure of choice reaction time (AUC = 0.73, p = .004), intra-individual variability on the ANT-I (AUC = 0.79, p = .001), and TECA (AUC = 0.78, p = .001) scores were the most sensitive and specific markers of cognitive involvement in MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Brief, repeatable, computer-based measures of reaction time and variability detect early MS associated cognitive involvement.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33639421/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210228052230&amp;v=2.14.2&quot;&gt;33639421&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jns.2021.117349&gt;10.1016/j.jns.2021.117349&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33639421/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210228052230&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":130,"discovery_date":"2021-02-28T11:11:00","title":"Fall Prevention Education FOR People WITH Multiple Sclerosis: A Randomized Clinical Trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Int J Qual Health Care. 2021 Feb 26:mzab035. doi: 10.1093/intqhc/mzab035. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Online spaced education (OSE) is a method recognized for promoting long-term knowledge retention, changing behaviors, and improving outcomes for students and healthcare professionals. However, there is little evidence about the impacts on patient education. The aim of this research was to compare knowledge retention using educational brochure and OSE on individuals with multiple sclerosis (MS); to verify the impact of educational methods on fall outcome.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Individuals with MS (n=230) were randomly assigned for two types of patient education - educational brochure (control) and OSE (intervention). During 12 weeks, the intervention group received multiple choice tests on fall prevention. Knowledge retention, behavior change, and fall incidence were assessed before intervention and after three and six months. The participants&#x27; satisfaction with the education method was also evaluated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Knowledge retention was similar between groups and behavior change was observed in both groups. There was a significant reduction in fall rate in the intervention group, from 0.60 to 0.27 at six months (p&amp;lt;0.001). Participants&#x27; satisfaction achieved an average of 8.75, with no differences between groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Individuals demonstrated significant improvement in fall rate outcome in both groups with no significant difference. On regard to test scores and satisfaction, results were similar between groups.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33638988/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227222934&amp;v=2.14.2&quot;&gt;33638988&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1093/intqhc/mzab035&gt;10.1093/intqhc/mzab035&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33638988/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227222934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":129,"discovery_date":"2021-02-27T11:11:00","title":"Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Breathe (Sheff). 2020 Dec;16(4):200203. doi: 10.1183/20734735.0203-2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Systemic inflammatory diseases are a heterogeneous family of autoimmune chronic inflammatory disorders that affect multiple systems within the human body. Connective tissue disease (CTD) is a large group within this family characterised by immune-mediated inflammation of the connective tissue. This group of disorders are often associated with pleural manifestations. CTD-induced pleuritis exhibits a wide variety of symptoms and signs including exudative pleural effusions and chest pain. Accurate estimation of prevalence for CTD-related pleuritis is challenging as small effusions are asymptomatic and remain undetected. Rheumatoid arthritis and systemic lupus erythematosus are frequent CTDs and present with pleural pathology in approximately 5-20% and 17-60% of cases, respectively. By contrast, pleural involvement in systemic sclerosis, eosinophilia-myalgia syndrome, mixed connective tissue disease, ankylosing spondylitis, polymyositis and dermatomyositis syndrome is rare. Clinical management depends on the severity of symptoms; however, most effusions resolve spontaneously. In this review we discuss the pathophysiological mechanisms and the clinical considerations of CTD-induced pleuritis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33447289/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227172937&amp;v=2.14.2&quot;&gt;33447289&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7792825/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227172937&amp;v=2.14.2&quot;&gt;PMC7792825&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1183/20734735.0203-2020&gt;10.1183/20734735.0203-2020&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33447289/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227172937&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":128,"discovery_date":"2021-02-27T11:11:00","title":"Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;BMJ Case Rep. 2021 Feb 26;14(2):e238167. doi: 10.1136/bcr-2020-238167.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;We present a case of 48-year-old woman with relapsing remitting multiple sclerosis (MS), who switched disease modifying therapy from Copaxone to Fingolimod due to her clinical and radiological MS disease progression. Unexpectedly after 2.5 years of stable MS symptoms and liver function tests (LFTs), we noted deranged LFTs during routine testing. Additional investigations showed hepatitis C positivity, genotype 3. It is likely a case of hepatitis C reactivation secondary to prolonged immunosuppressive effects of Fingolimod. Although the increased risk of viral reactivation related to varicella zoster virus is known to occur with Fingolimod treatment, to our knowledge, this is only the second case of hepatitis C disease activity reported with Fingolimod treatment. We would like to raise the awareness of hepatitis C viral reactivation as a possible complication of prolonged immunosuppression with Fingolimod.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637491/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637491&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/bcr-2020-238167&gt;10.1136/bcr-2020-238167&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637491/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":127,"discovery_date":"2021-02-27T11:11:00","title":"Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Actas Urol Esp. 2021 Feb 23:S0210-4806(20)30258-8. doi: 10.1016/j.acuro.2020.11.004. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Renal angiomyolipoma is a frequent manifestation of Tuberous Sclerosis Complex (TSC), for which everolimus therapy has been recently established as a novel non-invasive therapeutic option. As there are limited real life and long-term data, the analysis of our experience provides added value in terms of safety and efficacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIAL AND METHODS: Descriptive analysis of our experience in patients with giant bilateral renal angiomyolipomas, in the context of TSC, treated with 10 mg oral everolimus daily, during a median of 71.5 months. We evaluated the following parameters: response rate and duration, reduction of kidney size and lesions, prevention of complications and presentation of toxicity and its cause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: We confirm the effectiveness of treatment in 4 young patients, with multiple, bilateral angiomyolipomas of a median of 12 (5-19) cm maximum diameter, from June 2013 to date, after continuous reduction in lesion size, a decrease of 30% of the volume in 75% at six months and 50% in half of the subjects at two years, still showing drug response. Absence of complications such as bleeding or glomerular filtration rate decline in the long term, with a favorable safety profile, without interruptions and with mild-moderate, non-cumulative adverse effects, mostly within the first year of treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Everolimus is a safe and effective therapeutic option for renal angiomyolipoma and various manifestations of TSC, which has been reproduced in real life with six years of follow-up.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637375/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637375&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.acuro.2020.11.004&gt;10.1016/j.acuro.2020.11.004&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637375/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":126,"discovery_date":"2021-02-27T11:11:00","title":"Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 26;11(1):4735. doi: 10.1038/s41598-021-84023-0.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Early innate education of hematopoietic progenitors within the bone marrow (BM) stably primes them for either trained immunity or instead immunoregulatory functions. We herein demonstrate that in vivo or in vitro activation within the BM via Toll-like receptor-9 generates a population of plasmacytoid dendritic cell (pDC) precursors (CpG-pre-pDCs) that, unlike pDC precursors isolated from PBS-incubated BM (PBS-pre-pDCs), are endowed with the capacity to halt progression of ongoing experimental autoimmune encephalomyelitis. CpG activation enhances the selective migration of pDC precursors to the inflamed spinal cord, induces their immediate production of TGF-β, and after migration, of enhanced levels of IL-27. CpG-pre-pDC derived TGF-β and IL-27 ensure protection at early and late phases of the disease, respectively. Spinal cords of CpG-pre-pDC-protected recipient mice display enhanced percentages of host-derived pDCs expressing TGF-β as well as an accumulation of IL-10 producing B cells and of CD11c&lt;sup&gt;+&lt;/sup&gt; CD11b&lt;sup&gt;+&lt;/sup&gt; dendritic cells. These results reveal that pDC precursors are conferred stable therapeutic properties by early innate activation within the BM. They further extend to the pDC lineage promising perspectives for cell therapy of autoimmune diseases with innate activated hematopoietic precursor cells.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637789/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637789&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-84023-0&gt;10.1038/s41598-021-84023-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637789/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":125,"discovery_date":"2021-02-27T11:11:00","title":"Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a \"common\" first line treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurol (Paris). 2021 Feb 23:S0035-3787(21)00040-0. doi: 10.1016/j.neurol.2020.11.009. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according to their initial disease activity.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We retrospectively analysed the data of RRMS patients treated with FTY, focusing on 2 groups: 17 highly active patients (HA) defined as follows: ≥2 relapses in the year before treatment initiation and either≥1 Gd-enhancing T1 lesion or a significant increase in T2 lesion load from a baseline MRI; and 37 &quot;not highly active&quot; (NHA). We reviewed treatment efficacy (defined as NEDA-3), reasons for discontinuation and treatment tolerance in both groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Mean follow-up duration was 48.2 months, SD 18.4. Fingolimod efficiently reduced relapses (NHA 90.3% reduction, P&amp;lt;0.001, HA 84.9%, P&amp;lt;0.001), and new Gd enhancing lesions (NHA 85.4% reduction, P=0.019, HA 92.3%, P=0.043). The proportion of patients reaching NEDA-3 status was higher in the NHA group (NHA: 80% at 2 years and 66% at 4 years, HA: 58% at 2 years and 38% at 4 years, P=0.042). Fingolimod was discontinued in 20 cases, mainly because of lack of efficacy (n=15).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: FTY is efficient in reducing relapses and new Gd enhancing lesions in both HA and NHA patients although the probability of achieving NEDA-3 over time is higher in early-treated treatment-naive NHA patients.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637293/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637293&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.neurol.2020.11.009&gt;10.1016/j.neurol.2020.11.009&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637293/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":124,"discovery_date":"2021-02-27T11:11:00","title":"Low Field Magnetic Stimulation Promotes Myelin Repair and Cognitive Recovery in Chronic Cuprizone Mouse Model","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Exp Pharmacol Physiol. 2021 Feb 26. doi: 10.1111/1440-1681.13490. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an inflammatory demyelinating disease featured with neuroinflammation, demyelination, and the loss of oligodendrocytes. Cognitive impairment and depression are common neuropsychiatric symptoms in MS that are poorly managed with the present interventions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: This study aimed to investigate the effects of low field magnetic stimulation (LFMS), a novel non-invasive neuromodulation technology, on cognitive impairment and depressive symptoms associated with MS using a mouse model of demyelination.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: C57BL female mice were fed with a 0.2% cuprizone diet for twelve weeks to induce a chronic demyelinating model followed by four weeks of cuprizone withdrawal with either sham or LFMS treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Improved cognition and depression-like behavior and restored weight gain were observed in mice with LFMS treatment. Immunohistochemical and immunoblotting data showed enhanced myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein expressions (MOG) in the prefrontal cortex of mice with LFMS treatment, supporting that myelin repair was promoted. LFMS also increased the protein expressions of mature oligodendrocyte biomarker glutathione-S-transferase (GST-π).In addition, expression of TGF-β and associated receptors were elevated with LFMS treatment, implicating this pathway in the response.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Results from the present study revealed LFMS to have neuroprotective effects, suggesting that LFMS has potential therapeutic value for treating cognitive impairment and depression related to demyelination disorders.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33638234/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33638234&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/1440-1681.13490&gt;10.1111/1440-1681.13490&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://onlinelibrary.wiley.com/doi/10.1111/1440-1681.13490","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":123,"discovery_date":"2021-02-27T11:11:00","title":"Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102845. doi: 10.1016/j.msard.2021.102845. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) that affects both white and gray matter. Although it has been traditionally considered as a T cell mediated disease, the role of B cell in MS pathology has become a topic of great research interest. Cortical lesions, key feature of the progressive forms of MS, are involved in cognitive impairment and worsening of the patients&#x27; outcome. These lesions present pathognomonic hallmarks, such as: absence of blood-brain barrier (BBB) disruption, limited inflammatory events, reactive microglia, neurodegeneration, demyelination and meningeal inflammation. B cells located in the meninges, either as part of diffuse inflammation or as part of follicle-like structures, are strongly associated with cortical damage. The function of CD20-expressing B cells in MS is further highlighted by the success of specific therapies using anti-CD20 antibodies. The possible roles of B cells in pathology go beyond their ability to produce antibodies, as they also present antigens to T cells, secrete cytokines (both pathogenic and protective) within the CNS to modulate T and myeloid cell functions, and are involved in meningeal inflammation. Here, we will review the contributions of B cells to the pathogenesis of meningeal inflammation and cortical lesions in MS patients as well as in preclinical animal models.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636613/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636613&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102845&gt;10.1016/j.msard.2021.102845&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636613/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":122,"discovery_date":"2021-02-27T11:11:00","title":"Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102830. doi: 10.1016/j.msard.2021.102830. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To survey the pattern and benefits of medical cannabis use (MCU) in a cross section of persons with multiple sclerosis (PWMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: One hundred and fifteen subjects completed a 36-question survey online or on paper which queried aspects of their use of cannabis, including frequency of use, effect on symptoms, and changes in their use of prescription medications, as well asa number of key demographic variables such as age, gender, disease duration and clinical course, etc. All subjects were treated at a multiple sclerosis (MS) clinic in Connecticut and enrolled in the Connecticut Medical Marijuana Program (CTMMP).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Self-reported benefit from cannabis use for two or more symptoms of MS was associated with relapsing remitting MS (RRMS) vs progressive (PMS) (OR 3.043, 95% CI 1.026-9.028, p=0.038) and less benefit for two or more symptoms for those who required a wheelchair vs. those who ambulated without assistance (OR .246, 95% CI .195-.797, p=0.016). General benefit from cannabis use was reported for mood disorders (p&amp;lt;0.001), insomnia (p&amp;lt;0.001), sensory symptoms, including pain (p&amp;lt;0.001), and muscle cramps and spasms (p&amp;lt;0.001). Furthermore, benefit was also significantly associated with symptom severity in the case of insomnia (OR 9.735, 95% CI 2.751-34.445, p&amp;lt;0.001), and cramps and spasms (OR 5.234, 95% CI 1.261-21.729, p=0.014). A significant proportion of respondents had stopped or reduced prescription medications (86% vs. 55%, p&amp;lt;0.001) as a function of finding cannabis more effective than prescription medications. These included opioids, benzodiazepines, muscle relaxers and other pain medications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: MCU among PWMS can lead to the reduction or discontinuation of several categories of prescription medications for symptoms of MS. Persons reporting the most benefit from MCU tended to have a milder form of MS with less disability, in contrast to previous studies. This study confirms the benefit of cannabis in several common MS symptoms, extending these findings to show that benefit can be related to baseline severity of some symptoms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636612/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636612&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102830&gt;10.1016/j.msard.2021.102830&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636612/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":121,"discovery_date":"2021-02-27T11:11:00","title":"Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102837. doi: 10.1016/j.msard.2021.102837. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Background Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) have been recently reevaluated as a biomarker of acquired demyelinating syndromes (ADS) of the central nervous system (CNS). Here, we describe the clinical and neuroimaging features, and the long-term outcome of children with ADS of the CNS associated with MOG-IgG. Methods All patients underwent brain and spinal cord magnetic resonance imaging (MRI), lumbar puncture for cerebrospinal fluid (CSF) analysis and MOG-IgG and aquaporin-4 IgG (AQP4-IgG) testing. Results Forty-eight pediatric patients were recruited. MOG-IgG were detected in 11/48 (25%) patients with the following clinical presentations: encephalomyelitis (EM), 8/11 (73%); optic neuritis (ON), 2/11 (18%); transverse myelitis (TM), 1/11 (9%). Patients negative for MOG-IgG were diagnosed with Multiple Sclerosis (MS) (n=15), EM (n=7), ON (n=7), neuromyelitis optica spectrum disorders (NMOSD) (n=5), TM (n=2) and encephalitis (n=1). MOG-IgG positive patients were younger at disease onset and they more frequently experienced encephalopathy and epileptic seizures compared with negative patients. EM and inflammatory lesions involving optic nerves on MRI imaging were more frequent in MOG-IgG positive patients. None of the patients with MOG-IgG became persistently seronegative during the follow-up, although a decrease in MOG-IgG titer was observed. Patients with MOG-IgG showed a good response to therapy and only two patients presented relapses during follow-up. Conclusion This study supports the distinction of MOG autoimmune oligodendrocytopathy as a unique disease entity, with clinical features different from those of MS and AQP4-IgG-positive NMOSD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636614/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636614&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102837&gt;10.1016/j.msard.2021.102837&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636614/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":120,"discovery_date":"2021-02-27T11:11:00","title":"Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cell Chem Biol. 2021 Feb 16:S2451-9456(21)00051-9. doi: 10.1016/j.chembiol.2021.01.025. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Small molecules that promote the formation of new myelinating oligodendrocytes from oligodendrocyte progenitor cells (OPCs) are potential therapeutics for demyelinating diseases. We recently established inhibition of specific cholesterol biosynthesis enzymes and resulting accumulation of 8,9-unsaturated sterols as a unifying mechanism through which many such molecules act. To identify more potent sterol enhancers of oligodendrocyte formation, we synthesized a collection of 8,9-unsaturated sterol derivatives and found that 24,25-epoxylanosterol potently promoted oligodendrocyte formation. In OPCs, 24,25-epoxylanosterol was metabolized to 24,25-epoxycholesterol via the epoxycholesterol shunt pathway. Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation. Notably, exogenously supplied 24,25-epoxycholesterol promoted oligodendrocyte formation despite lacking an 8,9-unsaturation. This work highlights epoxycholesterol shunt usage, controlled by inhibitors of LSS, as a target to promote oligodendrocyte formation. Additionally, sterols beyond the 8,9-unsaturated sterols, including 24,25-epoxycholesterol, drive oligodendrocyte formation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636107/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636107&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.chembiol.2021.01.025&gt;10.1016/j.chembiol.2021.01.025&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636107/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":119,"discovery_date":"2021-02-27T11:11:00","title":"Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 21;50:102851. doi: 10.1016/j.msard.2021.102851. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636615/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636615&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102851&gt;10.1016/j.msard.2021.102851&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636615/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":118,"discovery_date":"2021-02-27T11:11:00","title":"Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 20;50:102850. doi: 10.1016/j.msard.2021.102850. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: Depression, anxiety, stress, and physical disabilities are a common complaint in people with multiple sclerosis (MS), and monitoring of these symptoms are based on self-report questionnaires. The objective of this study was to determine psychometric properties of the Croatian version of the Depression, Anxiety, and Stress Scale-21 (DASS-21) and Multiple Sclerosis Impact Scale-29 (MSIS-29) in people with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: We included data on 163 people with MS registered in the Association of multiple sclerosis societies of Croatia (AMSSC). Patients&#x27; demographic information, education level, and disease-related variables were ascertained. DASS-21 was applied for assessing depression, anxiety, and stress, while MSIS-29 scale was used for assessment of the physical and psychological impact of MS disease. Psychometric properties were examined by estimating the validity and reliability of the DASS-21 and MSIS-29 scale. Predictive validity of DASS-21 subscales and relevant demographic and disease-related variables was examined by the hierarchical regression model.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The Croatian version of the three DASS-21 subscales and two MSIS-29 subscales had excellent internal consistencies (Cronbach&#x27;s alpha coefficients 0.88-0.93) and good convergent validity, as expressed by inter-correlations between DASS-21 and MSIS-29 subscales. Hierarchical regression analysis using MSIS-29 subscales as criterion variables showed consistent evidence for the predictive validity of depression, anxiety, and stress on psychological impact, and predictive validity of age, EDSS, and anxiety on physical impact.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: The Croatian versions of DASS-21 and MSIS-29 are reliable and valid scales in people with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636617/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636617&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102850&gt;10.1016/j.msard.2021.102850&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636617/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":117,"discovery_date":"2021-02-27T11:11:00","title":"Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 28;50:102801. doi: 10.1016/j.msard.2021.102801. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains unclear. Therefore, we explored whether these modifiable lifestyle factors were associated with 10-year clinical disability progression in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this prospective study, a cohort of 88 patients with relapsing-remitting MS completed a randomized controlled study on ω-3 fatty acids between 2004 and 2008. During 24 months, serum 25-hydroxyvitamin D (25(OH)D), serum cotinine (nicotine metabolite), and BMI were repeatedly measured. In 2017, a follow-up study was conducted among 80 of the participants, including disability assessment by the Expanded Disability Status Scale (EDSS). Linear regression was used to explore associations between the lifestyle factors and the EDSS change over 10 years.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Higher seasonally adjusted 25(OH)D levels were associated with lower 10-year EDSS progression (change in EDSS per 1 SD increase in 25(OH)D in a model adjusted for sex, age and baseline EDSS: -0.45 point, 95% CI: -0.75 to -0.16, p=0.003). Further adjustments for potential confounders related to lifestyle and disease status gave similar results. The association was mainly driven by low 25(OH)D levels during spring, as well as seasonally adjusted levels below 80 nmol/L. No clear association was found for BMI and cotinine.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Lower 25(OH)D levels, but apparently not tobacco use or higher BMI, were significantly associated with worse long-term disability progression in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636616/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636616&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102801&gt;10.1016/j.msard.2021.102801&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636616/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":116,"discovery_date":"2021-02-26T11:11:00","title":"Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The research is focused on sensitive biomarkers in multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA (no evident disease activity), including brain volumetry, in a cohort of MS patients treated with disease-modifying treatment (DMT).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Levels of pNfL (Single Molecule Array (SIMOA) technology) were examined in 95 RRMS (relapsing-remitting multiple sclerosis) patients and analyzed in relationship to NEDA-3 status and NEDA-BVL (brain volume loss; NEDA-3 extended by brain volumetry) during the last 12 months. The statistical model was developed using logistic regression analysis, including the independent variables: demographic, clinical, and magnetic resonance imaging (MRI) data. Dependent variables were NEDA-3 and NEDA-BVL status.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The mean age of the study participants (&lt;i&gt;n&lt;/i&gt; = 95, 62% females) was 37.85 years (standard deviation (SD) = 9.62) and the median disability score was 3.5 (2.5-4.1). Receiver operating characteristics (ROC) analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 92% and 78%, respectively, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) and NEDA-BVL status (the sensitivity and specificity were 80% and 65%, respectively, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-BVL status, including brain MRI-volumetry in patients with RRMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635154/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635154&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521998039&gt;10.1177/1352458521998039&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635154/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":115,"discovery_date":"2021-02-26T11:11:00","title":"Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Feb 26. doi: 10.1007/s10072-021-05086-5. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Fingolimod is currently approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of pediatric patients with relapsing-remitting multiple sclerosis (RRMS). However, transient asymptomatic bradycardia with treatment initiation has been reported in a small population of predisposed patients, which may be a result of short-term activation and internalization/desensitization of the G-protein-gated potassium channel IKACh on the atrial myocyte membrane. Asymptomatic bradycardia, with or without atrioventricular block, is generally self-limiting and has been reported within the first 6 h of administration of the first oral dose of fingolimod. Therefore, patients initiating fingolimod treatment are monitored for this initial period to identify any changes in their electrocardiogram and heart rate that may require further treatment. Here, we report a case of a 17-year-old female with RRMS who received her first fingolimod dose and showed asymptomatic bradycardia that resolved without treatment.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635428/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635428&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10072-021-05086-5&gt;10.1007/s10072-021-05086-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635428/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":114,"discovery_date":"2021-02-26T11:11:00","title":"Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458521994259. doi: 10.1177/1352458521994259. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory demyelinating disorder of the central nervous system (CNS). Aquaporin-4 (AQP4) antibodies in the serum are highly specific for the diagnosis of NMOSD, but the sensitivity remains under 90% allowing for diagnosis of AQP4 IgG seronegative disease. It remains of crucial importance to identify seronegative NMOSD myelitis as early as the first attack to initiate long-term treatment that will reduce future relapses and disability and to avoid potentially harmful treatments such as those of multiple sclerosis (MS). Over the years, many spinal imaging features have been reported to favour the diagnosis of NMOSD, but only longitudinally extensive transverse myelitis (LETM) was specific enough to make the diagnostic criteria in the AQP4 IgG seronegative cases. Bright spotty lesions (BSLs), which are defined as hyperintense lesions on axial T2-weighted images and sometimes associated with T1 low signal, are now reported to have a higher specificity and sensitivity compared to LETM in predicting a diagnosis of NMOSD against other causes of myelitis. In the review, we aim to highlight the position of BSLs in diagnosing NMOSD as well as its possible role as a prognostic factor for the clinical outcome.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635151/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635151&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521994259&gt;10.1177/1352458521994259&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635151/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":113,"discovery_date":"2021-02-26T11:11:00","title":"Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autophagy. 2021 Feb 8:1-382. doi: 10.1080/15548627.2020.1797280. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for &lt;i&gt;bona fide&lt;/i&gt; autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33634751/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33634751&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/15548627.2020.1797280&gt;10.1080/15548627.2020.1797280&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33634751/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":112,"discovery_date":"2021-02-26T11:11:00","title":"Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To evaluate whether ibudilast 100 mg/day alters serum and cerebrospinal fluid (CSF) levels of NfL in progressive MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In a protocol-defined exploratory analysis from a 2-year, phase 2 clinical trial of ibudilast in progressive MS (NCT01982942), serum samples were collected from 239 subjects and a subset contributed CSF and assayed using single-molecule assay (SIMOA) immunoassay. A mixed model for repeated measurements yielded log(NfL) as the response variable.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The geometric mean baseline serum NfL was 31.9 and 28.8 pg/mL in placebo and ibudilast groups, respectively. The geometric mean baseline CSF NfL was 1150.8 and 1290.3 pg/mL in placebo and ibudilast groups, respectively. Serum and CSF NfL correlations were &lt;i&gt;r&lt;/i&gt; = 0.52 and &lt;i&gt;r&lt;/i&gt; = 0.78 at weeks 48 and 96, respectively. Over 96 weeks, there was no between-group difference in NfL in either serum (&lt;i&gt;p&lt;/i&gt; = 0.76) or CSF (&lt;i&gt;p&lt;/i&gt; = 0.46). After controlling for factors that may affect NfL, no effect of ibudilast on NfL in either serum or CSF was observed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Ibudilast treatment was not associated with a change in either serum or CSF NfL.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635141/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635141&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520986956&gt;10.1177/1352458520986956&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635141/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":111,"discovery_date":"2021-02-26T11:11:00","title":"Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Metab Brain Dis. 2021 Feb 26. doi: 10.1007/s11011-021-00691-x. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a progressive neurodegenerative disease with clinical signs of neuroinflammation and the central nervous system&#x27;s demyelination. Numerous studies have identified the role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) overexpression and the low level of peroxisome proliferator-activated receptor-gamma (PPAR-γ) in MS pathogenesis. Guggulsterone (GST), an active component derived from &#x27;Commiphora Mukul,&#x27; has been used to treat various diseases. Traditional uses indicate that GST is a suitable agent for anti-inflammatory action. Therefore, we assessed the therapeutic potential of GST (30 and 60 mg/kg) in ethidium bromide (EB) induced demyelination in experimental rats and investigated the molecular mechanism by modulating the JAK/STAT and PPAR-γ receptor signaling. Wistar rats were randomly divided into six groups (n = 6). EB (0.1%/10 μl) was injected selectively in the intracerebropeduncle (ICP) region for seven days to cause MS-like manifestations. The present study reveals that long-term administration of GST for 28 days has a neuroprotective effect by improving behavioral deficits (spatial cognition memory, grip, and motor coordination) associated with lower STAT-3 levels. While elevating PPAR-γ and myelin basic protein levels in rat brains are consistent with the functioning of both signaling pathways. Also, GST modulates the neurotransmitter level by increasing Ach, dopamine, serotonin and by reducing glutamate. Moreover, GST ameliorates inflammatory cytokines (TNF, IL-1β), and oxidative stress markers (AchE, SOD, catalase, MDA, GSH, nitrite). In addition, GST prevented apoptosis, as demonstrated by the reduction of caspase-3 and Bax. Simultaneously, Bcl-2 elevation and the restoration of gross morphology alterations are also recovered by long-term GST treatment. Therefore, it can be concluded that GST may be a potential alternative drug candidate for MS-related motor neuron dysfunctions.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635478/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635478&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11011-021-00691-x&gt;10.1007/s11011-021-00691-x&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635478/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":110,"discovery_date":"2021-02-26T11:11:00","title":"C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autophagy. 2021 Feb 26:1-17. doi: 10.1080/15548627.2021.1872189. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two clinically distinct classes of neurodegenerative disorders. Yet, they share a range of genetic, cellular, and molecular features. Hexanucleotide repeat expansions (HREs) in the &lt;i&gt;C9orf72&lt;/i&gt; gene and the accumulation of toxic protein aggregates in the nervous systems of the affected individuals are among such common features. Though the mechanisms by which HREs cause toxicity is not clear, the toxic gain of function due to transcribed HRE RNA or dipeptide repeat proteins (DPRs) produced by repeat-associated non-AUG translation together with a reduction in C9orf72 expression are proposed as the contributing factors for disease pathogenesis in ALS and FTD. In addition, several recent studies point toward alterations in protein homeostasis as one of the root causes of the disease pathogenesis. In this review, we discuss the effects of the C9orf72 HRE in the autophagy-lysosome pathway based on various recent findings. We suggest that dysfunction of the autophagy-lysosome pathway synergizes with toxicity from C9orf72 repeat RNA and DPRs to drive disease pathogenesis.&lt;b&gt;Abbreviation:&lt;/b&gt; ALP: autophagy-lysosome pathway; ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ASO: antisense oligonucleotide; C9orf72: C9orf72-SMCR8 complex subunit; DENN: differentially expressed in normal and neoplastic cells; DPR: dipeptide repeat protein; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; ER: endoplasmic reticulum; FTD: frontotemporal dementia; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; HRE: hexanucleotide repeat expansion; iPSC: induced pluripotent stem cell; ISR: integrated stress response; M6PR: mannose-6-phosphate receptor, cation dependent; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MN: motor neuron; MTORC1: mechanistic target of rapamycin kinase complex 1; ND: neurodegenerative disorder; RAN: repeat-associated non-ATG; RB1CC1/FIP200: RB1 inducible coiled-coil 1; SLC66A1/PQLC2: solute carrier family 66 member 1; SMCR8: SMCR8-C9orf72 complex subunit; SQSTM1/p62: sequestosome 1; STX17: syntaxin 17; TARDBP/TDP-43: TAR DNA binding protein; TBK1: TANK binding kinase 1; TFEB: transcription factor EB; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system; WDR41: WD repeat domain 41.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632058/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632058&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/15548627.2021.1872189&gt;10.1080/15548627.2021.1872189&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632058/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":109,"discovery_date":"2021-02-26T11:11:00","title":"Overview of stem cells therapy in amyotrophic lateral sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Res. 2021 Feb 25:1-17. doi: 10.1080/01616412.2021.1893564. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. &lt;b&gt;Methods &amp;amp; Results:&lt;/b&gt; Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. &lt;b&gt;Conclusion:&lt;/b&gt; The determination of whether stem cells offer a viable treatment strategy for ALS rests on well-designed and appropriately powered future clinical trials. Randomized, double-blinded, and sham-controlled studies would be valuable.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632084/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632084&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/01616412.2021.1893564&gt;10.1080/01616412.2021.1893564&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632084/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":108,"discovery_date":"2021-02-26T11:11:00","title":"Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on \"Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function\"","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Fluids Barriers CNS. 2021 Feb 25;18(1):9. doi: 10.1186/s12987-021-00244-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Pilz et al. (Fluids Barriers CNS 17:7; 2020) investigated how CSF CXCL13 concentrations are influenced by CXCL13 serum concentrations and blood-CSF barrier (BCSFB) function, comparing the impact of serum CXCL13 levels and Q&lt;sub&gt;albumin&lt;/sub&gt; (CSF albumin/serum albumin) on CSF CXCL13 among patients with CNS inflammation categorized as CXCL13 negative, low, medium, or high. Among all CXCL13 groups, their results showed no correlation between CSF CXCL13 concentrations and serum CXCL13 or Q&lt;sub&gt;albumin&lt;/sub&gt;. The authors argue that, in contrast to other proteins, CXCL13 passage across the BCSFB does not occur, regardless of BCSFB function, and is instead solely influenced by intrathecal production. In contrast to the authors&#x27; findings, in our studies including both non-inflammatory neurological disorders (NIND; n = 62) and multiple sclerosis (MS) patients we observed a significant correlation between serum CXCL13 concentrations and CSF CXCL13 concentrations. We review several observations which may underlie these contrasting results, including (1) the impact of serum CXCL13 concentrations on CSF CXCL13 in patients with lower intrathecal CXCL13 production and thus lower CXCL13 concentrations (i.e. NIND and MS), (2) the proposed diffusion dynamics of the small molecule CXCL13 across the BCSFB, and (3) differing definitions of negative versus elevated CSF CXCL13 concentrations determined by an assay&#x27;s relative sensitivity. In conclusion, we argue that for patients with moderately elevated CSF CXCL13 concentrations, serum CXCL13 concentrations influence CSF CXCL13 levels, and thus the appropriate corrections including incorporation of CSF/serum ratios and Q&lt;sub&gt;albumin&lt;/sub&gt; values should be utilized.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632258/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632258&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1186/s12987-021-00244-5&gt;10.1186/s12987-021-00244-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632258/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":107,"discovery_date":"2021-02-26T11:11:00","title":"Optic neuropathy by ethambutol in a patient with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Arch Soc Esp Oftalmol. 2021 Feb 22:S0365-6691(21)00019-8. doi: 10.1016/j.oftal.2020.12.009. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;We present the clinical case of a patient who developed a toxic optic neuropathy due to ethambutol in the context of a tuberculosis reactivation and who also had a personal history of multiple sclerosis. The objective is to highlight the importance of making a good differential diagnosis of this adverse effect and of knowing its main clinical, campimetric and tomographic manifestations and characteristics. Furthermore, since the reversibility of damage is still discussed in the literature, early diagnosis is essential. For this purpose, it is important to inform the patient of the possible symptoms and to carry out an ophthalmological examination and colour tests before starting treatment to assess whether there is progression.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632567/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632567&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.oftal.2020.12.009&gt;10.1016/j.oftal.2020.12.009&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632567/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":106,"discovery_date":"2021-02-26T11:11:00","title":"Symptom management of patients with multiple sclerosis in primary care: focus on overlooked symptoms","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Br J Gen Pract. 2021 Feb 25;71(704):139-141. doi: 10.3399/bjgp21X715193. Print 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632695/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632695&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3399/bjgp21X715193&gt;10.3399/bjgp21X715193&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632695/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":105,"discovery_date":"2021-02-26T11:11:00","title":"Cognitive Impairment Impacts Exercise Effects on Cognition in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Jan 28;11:619500. doi: 10.3389/fneur.2020.619500. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Purpose:&lt;/b&gt; Exercise training reveals high potential to beneficially impact cognitive performance in persons with multiple sclerosis (pwMS). Research indicates that high-intensity interval training (HIIT) has potentially higher effects on physical fitness and cognition compared to moderate continuous exercise. This study (i) compares the effects of a 3-week HIIT and moderate continuous exercise training on cognitive performance and cardiorespiratory fitness of pwMS in an overall analysis and (ii) investigates potential effects based on baseline cognitive status in a subgroup analysis. &lt;b&gt;Methods:&lt;/b&gt; Seventy-five pwMS were randomly assigned to an intervention (HIIT: 5 × 1.5-min intervals at 95-100% HR&lt;sub&gt;max&lt;/sub&gt;, 3 ×/week) or active control group (CG: 24 min continuous exercise at 65% HR&lt;sub&gt;max&lt;/sub&gt;, 3 ×/week). Cognitive performance was assessed pre- and post-intervention with the Brief International Cognitive Assessment for MS (BICAMS). (I) To examine potential within (time) and interaction (time × group) effects in the overall analysis, separate analyses of covariance (ANCOVA) were conducted. (II) For the subgroup analysis, participants were divided into two groups [intact cognition or impaired cognition (&amp;gt;1.5 standard deviation (SD) compared to healthy, age-matched norm data in at least one of the three tests of the BICAMS]. Potential impacts of cognitive status and intervention were investigated with multivariate analyses of variance (MANOVA). &lt;b&gt;Results:&lt;/b&gt; Overall analysis revealed significant time effects for processing speed, verbal learning, rel. VO2peak, and rel. power output. A time&lt;sup&gt;*&lt;/sup&gt;group interaction effect was observed for rel. power output. Subgroup analysis indicated a significant main effect for cognition (impaired cognition vs. intact cognition). Subsequent &lt;i&gt;post-hoc&lt;/i&gt; analysis showed significant larger effects on verbal learning in pwMS with impaired cognition. &lt;b&gt;Conclusion:&lt;/b&gt; Current results need to be confirmed in a powered randomized controlled trial with cognitive performance as primary endpoint and eligibility based on cognitive performance that is assessed prior to study inclusion.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633658/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633658&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7902024/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7902024&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2020.619500&gt;10.3389/fneur.2020.619500&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633658/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":104,"discovery_date":"2021-02-26T11:11:00","title":"Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 9;12:618370. doi: 10.3389/fneur.2021.618370. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Sexual dysfunction (SD) in people with multiple sclerosis (pwMS) has a detrimental impact on individual health-related quality of life (HRQoL). It is not clear whether SD in multiple sclerosis (MS) is an independent symptom or merely a byproduct of other symptoms such as depression or anxiety. This cross-sectional study of 93 pwMS determines risk factors for SD in MS based on prevalence, HRQoL, and associated disease outcomes. Diagnosis of SD was determined based on the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19) and correlated with physical disability (measured by Expanded Disability Status scale, EDSS), depression and anxiety [Hospital Anxiety and Depression Scale (HADS)], and HRQoL [Multiple Sclerosis Quality of Life-54 (MSQoL-54)]. Multivariate regression models were performed to determine independent risk factors for SD in pwMS. Almost half of the participants in this study (46%) reported SD. HRQoL was significantly poorer in patients with MS suffering from SD (median [IQR] MSQoL-54 scores: physical subscale 52 [41-68] vs. 81 [69-89], &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001; mental subscale 50 [38-82] vs. 86 [70-89], &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001). In the multivariate model, EDSS was the only independent risk factor for SD (OR 18.1 for EDSS ≥4 [95% CI 3.3-31.4, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001]), while depression and anxiety were not. We conclude that the risk for SD is growing with increasing EDSS and is independent of depression or anxiety. Screening for SD becomes particularly relevant in patients with growing disability.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633671/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633671&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7900565/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7900565&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.618370&gt;10.3389/fneur.2021.618370&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633671/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":103,"discovery_date":"2021-02-26T11:11:00","title":"Coping strategies: Seeking personalized care in relapsing-remitting multiple sclerosis. A patient reported measure-coping responses inventory","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 11;7(1):2055217320987588. doi: 10.1177/2055217320987588. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Coping is defined as a set of cognitive and behavioral efforts made to master stressful specific demands. Adaptation to chronic diseases, such as Multiple Sclerosis (MS), depends on the effectiveness of coping. &lt;b&gt;Objective:&lt;/b&gt; To assess the psychometric properties of the Coping Responses Inventory (CRI-A) in persons with MS (PwMS), verifying the transferability of the measure, already validated in the Argentine general population, and to describe the types of coping strategies available for PwMS. &lt;b&gt;Methods:&lt;/b&gt; 90 PwMS were included. &lt;b&gt;Outcome measures:&lt;/b&gt; CRI-A Inventory, Expanded Disability Status Scale (EDSS), Beck Depression Inventory, Fatigue Severity Scale and MS International Quality of Life questionnaire. &lt;b&gt;Results:&lt;/b&gt; Descriptive data is as follows: mean age (years): 40.97 ± 12.85; years of education: 13.46 ± 3.93; EDSS: 2.48 ± 1.79; disease evolution (years): 10.76 ± 9.72; depression: 13.92 ± 10.45; fatigue 3.77 ± 1.72. The psychometric properties of the CRI-A Inventory observed in the Argentine general population are present in the MS sample as well, with adequate validity and reliability. The respondents most frequently utilized a problem-focused coping style. &lt;b&gt;Conclusions:&lt;/b&gt; Results showed the CRI-A has good transferability properties from the Argentine general population to the MS population.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633866/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633866&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7887687/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7887687&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217320987588&gt;10.1177/2055217320987588&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633866/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":102,"discovery_date":"2021-02-26T11:11:00","title":"Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Psychosom Res. 2021 Feb 16;144:110402. doi: 10.1016/j.jpsychores.2021.110402. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare and characterize major depressive disorder (MDD) subtypes (i.e., pure atypical, pure melancholic and mixed atypical-melancholic) and depression symptoms in persons with multiple sclerosis (PwMS) with persons without MS (Pw/oMS) fulfilling the DSM-5 criteria for a past 12-month MDD.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: MDD in PwMS (n = 92) from the Swiss Multiple Sclerosis Registry was compared with Pw/oMS (n = 277) from a Swiss community-based study. Epidemiological MDD diagnoses were based on the Mini-SPIKE (shortened form of the Structured Psychopathological Interview and Rating of the Social Consequences for Epidemiology). Logistic and multinomial regression analyses (adjusted for sex, age, civil status, depression and severity) were computed for comparisons and characterization. Latent class analysis (LCA) was conducted to empirically identify depression subtypes in PwMS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: PwMS had a higher risk for the mixed atypical-melancholic MDD subtype (OR = 2.22, 95% CI = 1.03-4.80) compared to Pw/oMS. MDD in PwMS was specifically characterized by a higher risk of the two somatic atypical depression symptoms &#x27;weight gain&#x27; (OR = 6.91, 95% CI = 2.20-21.70) and &#x27;leaden paralysis&#x27; (OR = 3.03, 95% CI = 1.35-6.82) and the symptom &#x27;irritable/angry&#x27; (OR = 3.18, 95% CI = 1.08-9.39).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: MDD in PwMS was characterized by a higher risk for specific somatic atypical depression symptoms and the mixed atypical-melancholic MDD subtype. The pure atypical MDD subtype, however, did not differentiate between PwMS and Pw/oMS. Given the high phenomenological overlap with MS symptoms, the mixed atypical-melancholic MDD subtype represents a particular diagnostic challenge.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631437/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631437&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jpsychores.2021.110402&gt;10.1016/j.jpsychores.2021.110402&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631437/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":101,"discovery_date":"2021-02-26T11:11:00","title":"Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Neurol Neurosurg. 2021 Feb 15;203:106563. doi: 10.1016/j.clineuro.2021.106563. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Iran is one of the countries with a high prevalence of multiple sclerosis (MS) and COVID-19.MS patients receiving the immunomodulatory or immunosuppressive therapy have a higher risk of infection. Due to the significance of determining the risk factors for getting COVID-19 among MS patients, the present study was designed to assess the risk of infection following the pulse steroid therapy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: This cross-sectional study included all MS patients that received corticosteroids in Tehran from December 2019 to August 2020 during the COVID-19 pandemic spread. The subjects&#x27; clinical records including their sex, age, the type of MS, the type of medication, the number of days using corticosteroids, the status of prednisolone intake, and the number of days receiving prednisolone after the corticosteroid therapy were obtained. Moreover, main outcomes such as COVID-19 infection and the occurrence of death were recorded by patient&#x27;s visits and follow-up phone calls. COVID-19 infection was confirmed by physicians according to the clinical performance of RT-PCR, chest CT scan, and antibody tests.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Totally, 133 MS cases participated in the study, and the pulse therapy was completed for 104 (78.2%) patients up to 5-7 days. 89 (66.9%) cases used the prednisolone tablet following the pulse therapy. Overall, the infection by Covid-19 was observed in 8 (6%) cases, among whom 5 (71.4%) cases received the pulse therapy for 5-7 days and 4 (57.1%) cases had a history of taking the prednisolone tablet. The age of less than 40 years (OR = 1.03; 95% CI (0.23-4.51)), male sex (OR = 0.35; 95% CI (0.03-3.34)), and the RRMS type (OR = 2.87; 95% CI (0.52-15.72)) had no effect on the risk of Covid-19 infection. In addition, there was not statistically significant difference between subjects with the short-term pulse therapy duration (3-4 days) (OR 0.68 (0.12-3.74) and those with the long-term pulse therapy duration (5-7 days). Similarly, no statistically significant difference was observed between subjects taking prednisolone (OR = 1.62 (0.34-7.61) and those not taking prednisolone. Furthermore, there was no significant association between different medication groups and the risk of Covid-19 infection (p &amp;lt; 0.05). No death occurred due to Covid-19 infection among the subjects.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: COVID-19 infection was more common among female and younger patients as well as patients with a longer duration of the pulse therapy and prednisolone intake. There was no significant association between the pulse steroid therapy in MS patients and the risk of infection by COVID-19 in the Iranian population.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631509/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631509&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.clineuro.2021.106563&gt;10.1016/j.clineuro.2021.106563&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631509/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":100,"discovery_date":"2021-02-26T11:11:00","title":"Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neuroepidemiology. 2021 Feb 25:1-10. doi: 10.1159/000513647. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: COVID-19 can be accompanied by acute neurological complications of both central and peripheral nervous systems (CNS and PNS). In this study, we estimate the frequency of such complications among hospital inpatients with COVID-19 in Assiut and Aswan university hospitals.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: We screened all patients with suspected COVID-19 admitted from 1 June to 10 August 2020 to the university hospitals of Assiut and Aswan in Upper Egypt. Clinical and laboratory tests, CT/MRI of the chest and brain, and neurophysiology study were performed for each patient if indicated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 439 patients had confirmed/probable COVID-19; neurological manifestations occurred in 222. Of these, 117 had acute neurological disease and the remainder had nonspecific neuropsychiatric symptoms such as headache, vertigo, and depression. The CNS was affected in 75 patients: 55 had stroke and the others had convulsions (5), encephalitis (6), hypoxic encephalopathy (4), cord myelopathy (2), relapse of multiple sclerosis (2), and meningoencephalitis (1). The PNS was affected in 42 patients: the majority had anosmia and ageusia (31) and the others had Guillain-Barré syndrome (4), peripheral neuropathy (3), myasthenia gravis (MG, 2), or myositis (2). Fever, respiratory symptoms, and headache were the most common general symptoms. Hypertension, diabetes mellitus, and ischemic heart disease were the most common comorbidities in patients with CNS affection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: In COVID-19, both the CNS and PNS are affected. Stroke was the most common complication for CNS, and anosmia and/or ageusia were common for PNS diseases. However, there were 6 cases of encephalitis, 2 cases of spinal cord myelopathy, 2 cases of MG, and 2 cases of myositis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631765/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631765&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1159/000513647&gt;10.1159/000513647&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631765/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":99,"discovery_date":"2021-02-26T11:11:00","title":"Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter : Effect of Several Administrations of Gadoterate Meglumine in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Neuroradiol. 2021 Feb 25. doi: 10.1007/s00062-021-00995-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Several studies reported gadolinium deposition in the dentate nuclei (DN) and the globus pallidus (GP) that was associated to linear GBCA administrations rather than macrocyclic. It is therefore imperative to evaluate and assess the safety of cumulative administration of gadoterate meglumine (macrocyclic). Thus, T1-weighted images (T1WI) of multiple sclerosis (MS) patients longitudinally followed for 4 years were retrospectively analyzed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this study 44 patients, 10 with clinically isolated syndrome (CIS), 24 relapsing-remitting MS (RRMS) and 10 primary-progressive MS (PPMS) were examined every 6 months (first four scans) and then with a 1-year interval (last two scans). Image processing consisted in reorienting unenhanced T1WI to standard space, followed by B1 inhomogeneity correction. A patient-specific template was then generated to normalize T1WI signal intensity (SI) and segment the DN and subcortical GM structures. All structures were then transformed to each patient space in order to measure the SI in each region. The cerebellar peduncles (CP) and semi-oval (SO) white matter were then manually delineated and used as reference to calculate SI ratios in the DN and subcortical GM structures. A linear mixed-effect model was finally applied to longitudinally analyze SI variations.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The SI measurements performed in all structures showed no significant increases with the cumulative GBCA administration.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: This study showed no significant SI increases within the DN and subcortical GM structures of longitudinally followed MS patients even with the cumulative administration of the macrocyclic GBCA gadoterate meglumine.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33630120/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225202934&amp;v=2.14.2&quot;&gt;33630120&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00062-021-00995-6&gt;10.1007/s00062-021-00995-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33630120/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225202934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":98,"discovery_date":"2021-02-25T11:11:00","title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629615/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629615&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521991433&gt;10.1177/1352458521991433&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629615/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":97,"discovery_date":"2021-02-25T11:11:00","title":"Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Food Funct. 2021 Feb 25. doi: 10.1039/d0fo03203d. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Preliminary evidence shows the potential role of probiotics in ameliorating multiple sclerosis (MS); however, the effects of probiotics on MS remain unclear. Therefore, the aim of this study was to evaluate the efficacy of probiotics on multiple sclerosis by systematically reviewing the preclinical trials (animal trials) and performing meta-analysis of randomized controlled trials. PubMed, Web of Science, Cochrane central of randomized clinical trials, EMBASE, Clinical Trials, and a search engine Google Scholar were systematically searched and manually screened updated to November 2020, resulting in eligible 3 randomized controlled trials (RCTs) and 22 preclinical studies. Meta-analysis of RCTs enrolling 173 patients with MS receiving probiotics revealed significant beneficial effects of probiotic supplementation on mental health (expanded disability status scale scores: standardized mean difference [SMD] = -1.22; I2 = 92%; 95% CI, -2.40 to -0.03, P = 0.04; Beck depression inventory total scores: SMD = -1.58; I2 = 94%; 95% CI, -3.03 to -0.12; P = 0.03; general health questionnaire scores: SMD = -0.71; I2 = 0%; 95% CI, -1.02 to -0.40; P &amp;lt; 0.00001; depression anxiety and stress scale scores: SMD = -0.72; I2 = 0%; 95% CI, -1.12 to -0.33; P = 0.0003), with very low certainty of evidence. In addition, probiotic intake markedly improved insulin resistance and inflammatory and oxidative stress markers. Preclinical studies have shown that probiotic consumption reduces the incidence and severity of MS, delays MS progression (15 studies), and improves motor impairment (3 studies) with favorable alterations of immune and inflammatory markers (20 studies) and intestinal microbiome compositions (4 studies) in MS. These results indicated that probiotics may have beneficial effects on the prevention and treatment of multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629669/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629669&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1039/d0fo03203d&gt;10.1039/d0fo03203d&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629669/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":96,"discovery_date":"2021-02-25T11:11:00","title":"Effects of mindfulness-and acceptance-based interventions on quality of life, coping, cognition, and mindfulness of people with multiple sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Psychol Health Med. 2021 Feb 25:1-18. doi: 10.1080/13548506.2021.1894345. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;This systematic review and meta-analysis of randomized controlled trials (RCTs) examined effects of mindfulness- and acceptance-based interventions (MABIs) on quality of life (QoL), coping, cognition, and mindfulness among people with multiple sclerosis (MS). Four electronic databases were searched to 3 July 2020. Data was combined in a random-effects meta-analysis model. Eighteen RCTs met the eligibility criteria. Meta-analyses at the immediate posttest found: moderate effects of MABIs on QoL, coping, and attention; and a large effect on memory. A large effect of MABIs on QoL was found at follow-up. There was no significant effect of MABIs on mindfulness. Relatively fewer studies in outcomes other than QoL were found, and the overall risk of bias across the included 18 RCTs was unclear. Future high-quality studies with follow-up evaluations are needed to support effects of MABIs on QoL, coping, cognition, and mindfulness in people with MS and examine intervention features that increase and maintain effects.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629885/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629885&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/13548506.2021.1894345&gt;10.1080/13548506.2021.1894345&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629885/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":95,"discovery_date":"2021-02-25T11:11:00","title":"RXRα Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Oxid Med Cell Longev. 2021 Feb 10;2021:8253742. doi: 10.1155/2021/8253742. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Nerve regeneration after spinal cord injury is regulated by many factors. Studies have found that the expression of retinoid X receptor &lt;i&gt;α&lt;/i&gt; (RXR&lt;i&gt;α&lt;/i&gt;) does not change significantly after spinal cord injury but that the distribution of RXR&lt;i&gt;α&lt;/i&gt; in cells changes significantly. In undamaged tissues, RXR&lt;i&gt;α&lt;/i&gt; is distributed in motor neurons and the cytoplasm of glial cells. RXR&lt;i&gt;α&lt;/i&gt; migrates to the nucleus of surviving neurons after injury, indicating that RXR&lt;i&gt;α&lt;/i&gt; is involved in the regulation of gene expression after spinal cord injury. p66shc is an important protein that regulates cell senescence and oxidative stress. It can induce the apoptosis and necrosis of many cell types, promoting body aging. The absence of p66shc enhances the resistance of cells to reactive oxygen species (ROS) and thus prolongs life. It has been found that p66shc deletion can promote hippocampal neurogenesis and play a neuroprotective role in mice with multiple sclerosis. To verify the function of RXR&lt;i&gt;α&lt;/i&gt; after spinal cord injury, we established a rat T9 spinal cord transection model. After RXR&lt;i&gt;α&lt;/i&gt; agonist or antagonist administration, we found that RXR&lt;i&gt;α&lt;/i&gt; agonists inhibited nerve regeneration after spinal cord injury, while RXR&lt;i&gt;α&lt;/i&gt; antagonists promoted the regeneration of injured neurites and the recovery of motor function in rats. The results showed that RXR&lt;i&gt;α&lt;/i&gt; played an impeding role in repair after spinal cord injury. Immunofluorescence staining showed that p66shc expression was upregulated in neurons after spinal cord injury (&lt;i&gt;in vivo&lt;/i&gt; and &lt;i&gt;in vitro&lt;/i&gt;) and colocalized with RXR&lt;i&gt;α&lt;/i&gt;. RXR&lt;i&gt;α&lt;/i&gt; overexpression in cultured neurons promoted the expression of p66shc, while RXR&lt;i&gt;α&lt;/i&gt; interference inhibited the expression of p66shc. Using a luciferase assay, we found that RXR&lt;i&gt;α&lt;/i&gt; could bind to the promoter region of p66shc and regulate the expression of p66shc, thereby regulating nerve regeneration after spinal cord injury. The above results showed that RXR&lt;i&gt;α&lt;/i&gt; inhibited nerve regeneration after spinal cord injury by promoting p66shc expression, and interference with RXR&lt;i&gt;α&lt;/i&gt; or p66shc promoted functional recovery after spinal cord injury.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628383/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628383&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7889345/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7889345&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/8253742&gt;10.1155/2021/8253742&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://www.hindawi.com/journals/omcl/2021/8253742/","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":94,"discovery_date":"2021-02-25T11:11:00","title":"Beneficial Metabolic Effects of TREM2 in Obesity are Uncoupled from its Expression on Macrophages","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Diabetes. 2021 Feb 24:db200572. doi: 10.2337/db20-0572. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Obesity-induced white adipose tissue (WAT) hypertrophy is associated with elevated adipose tissue macrophage (ATM) content. Overexpression of the triggering receptor expressed on myeloid cells 2 (TREM2) reportedly increases adiposity, worsening health. Paradoxically, using insulin resistance, elevated fat mass and hypercholesterolemia as hallmarks of unhealthy obesity, a recent report demonstrated ATM-expressed TREM2 promoted health. Here, we identified that in mice TREM2 deficiency aggravated diet-induced insulin resistance and hepatic steatosis independently of fat and cholesterol levels. Metabolomics linked TREM2 deficiency with elevated obesity-instigated serum ceramides that correlated with impaired insulin sensitivity. Remarkably, while inhibiting ceramide synthesis exerted no influences on TREM2-dependent ATM remodeling, inflammation or lipid load, it restored insulin tolerance, reversing adipose hypertrophy and secondary hepatic steatosis of TREM2-deficient animals. Bone marrow transplantation experiments revealed unremarkable influences of immune cell-expressed TREM2 on health instead demonstrating that WAT-intrinsic mechanisms impinging on sphingolipid metabolism dominate in TREM2&#x27;s systemic protective effects on metabolic health.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627323/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627323&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2337/db20-0572&gt;10.2337/db20-0572&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627323/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":93,"discovery_date":"2021-02-25T11:11:00","title":"Amyloidoma mimicking multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Pract Neurol. 2021 Feb 24:practneurol-2020-002855. doi: 10.1136/practneurol-2020-002855. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627491/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627491&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/practneurol-2020-002855&gt;10.1136/practneurol-2020-002855&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627491/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":92,"discovery_date":"2021-02-25T11:11:00","title":"The tumor therapy landscape of synthetic lethality","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Commun. 2021 Feb 24;12(1):1275. doi: 10.1038/s41467-021-21544-2.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627666/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627666&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41467-021-21544-2&gt;10.1038/s41467-021-21544-2&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627666/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":91,"discovery_date":"2021-02-25T11:11:00","title":"1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Pharmacol Sin. 2021 Feb 24. doi: 10.1038/s41401-021-00613-8. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;NOD-like receptor (NLR) family pyrin domain-containing-3 (NLRP3) inflammasome is implicated in inflammation-associated diseases such as multiple sclerosis, Parkinson&#x27;s disease, and stroke. Targeting the NLRP3 inflammasome is beneficial to these diseases, but few NLRP3 inflammasome-selective inhibitors are identified to date. Essential oils (EOs) are liquid mixtures of volatile and low molecular-weight organic compounds extracted from aromatic plants, which show various pharmacological activities, including antibacterial, antifungal, antiviral, antioxidant, and anti-inflammatory properties. In this study we screened active ingredients from essential oils, and identified 1,2,4-trimethoxybenzene (1,2,4-TTB) as a selective NLRP3 inflammasome inhibitor. We showed that 1,2,4-TTB (1 mM) markedly suppressed nigericin- or ATP-induced NLRP3 inflammasome activation, thus decreased caspase-1 activation and IL-1β secretion in immortalized murine bone marrow-derived macrophages (iBMDMs) and in primary mouse microglia. Moreover, 1,2,4-TTB specifically inhibited the activation of NLRP3 inflammasome without affecting absent in melanoma 2 (AIM2) inflammasome activation. We further demonstrated that 1,2,4-TTB inhibited oligomerization of the apoptosis-associated speck-like protein containing a CARD (ASC) and protein-protein interaction between NLRP3 and ASC, thus blocking NLRP3 inflammasome assembly in iBMDMs and in primary mouse macrophages. In mice with experimental autoimmune encephalomyelitis (EAE), administration of 1,2,4-TTB (200 mg · kg&lt;sup&gt;-1&lt;/sup&gt; · d&lt;sup&gt;-1&lt;/sup&gt;, i.g. for 17 days) significantly ameliorated EAE progression and demyelination. In conclusion, our results demonstrate that 1,2,4-TTB is an NLRP3 inflammasome inhibitor and attenuates the clinical symptom and inflammation of EAE, suggesting that 1,2,4-TTB is a potential candidate compound for treating NLRP3 inflammasome-driven diseases, such as multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627802/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627802&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41401-021-00613-8&gt;10.1038/s41401-021-00613-8&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627802/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":90,"discovery_date":"2021-02-25T11:11:00","title":"Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Jan 22;14:1756286420975227. doi: 10.1177/1756286420975227. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Peginterferon beta-1a administered every 2 weeks &lt;i&gt;via&lt;/i&gt; subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated injection site reactions (ISRs) can lead to treatment discontinuation. Prior studies with interferon beta-1a reported a lower frequency of ISRs with intramuscular (IM) administration than with SC administration. IM administration of peginterferon beta-1a may therefore represent a useful alternative treatment option.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A phase I, open-label, two-period crossover study randomized healthy volunteers to receive a single dose of peginterferon beta-1a 125 mcg administered IM followed by a single 125 mcg dose administered SC after a 28-day washout or vice versa. Blood samples were collected up to 504 h post dose to determine pharmacokinetic (PK) and pharmacodynamic (PD) profiles. The primary endpoint was assessment of bioequivalence based on maximum serum concentration (C&lt;sub&gt;max&lt;/sub&gt;) and area under the curve from time zero extrapolated to infinity (AUC&lt;sub&gt;inf&lt;/sub&gt;). Other PK parameters, as well as PD (serum neopterin) and safety profiles, were also evaluated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The study enrolled 136 participants. Bioequivalence of IM and SC peginterferon beta-1a was established for both C&lt;sub&gt;max&lt;/sub&gt; ([least squares (LS)] mean IM/SC ratio: 1.083 [90% confidence interval (CI), 0.975-1.203]) and AUC&lt;sub&gt;inf&lt;/sub&gt; (LS mean IM/SC ratio: 1.089 [90% CI, 1.020-1.162]). Other PK and PD parameters were similar between administration routes, although moderate to high inter-subject variability was observed for IM and SC. Safety profiles were generally balanced between IM and SC administration. ISRs occurred at a lower frequency with IM [14.4% (95% CI, 8.89-21.56%)] than with SC [32.1% (95% CI, 24.29-40.70%)] administration (&lt;i&gt;p&lt;/i&gt; = 0.0005).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: These results demonstrate bioequivalence between peginterferon beta-1a IM and SC and support the consideration of IM injection of peginterferon beta-1a as a viable treatment option in patients with RRMS and RMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628334/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628334&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7883310/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7883310&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1756286420975227&gt;10.1177/1756286420975227&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628334/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":89,"discovery_date":"2021-02-25T11:11:00","title":"Reelin Depletion Protects Against Atherosclerosis by Decreasing Vascular Adhesion of Leukocytes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Arterioscler Thromb Vasc Biol. 2021 Feb 25:ATVBAHA121316000. doi: 10.1161/ATVBAHA.121.316000. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Reelin and its receptor Apoer2 (apolipoprotein E receptor 2) play a prominent role in endothelial cell dysfunction by promoting leukocyte-endothelial cell adhesion, an important component of the inflammatory process underlying atherosclerosis. We, therefore, hypothesized that pharmacological depletion of circulating reelin represents a novel therapeutic strategy to impede the progression of atherosclerosis. Approach and Results: In vitro studies demonstrated that human plasma induced monocyte adhesion to endothelial cells, while reelin-depleted plasma had no effect on monocyte adhesion. Signaling analysis revealed that reelin activated Dab2, PI3K, Akt, and NF-κB (nuclear factor κB) cascade to promote the expression of adhesion markers (E-selectin, ICAM-1 [intercellular adhesion molecule 1], and VCAM-1 [vascular cell adhesion molecule 1]). Intravital microscopy confirmed decreased leukocyte-endothelial adhesion in mice treated with reelin antisense oligonucleotide. In vascular smooth muscle cells, reelin induced Stat3 phosphorylation to promote cell proliferation, which is another hallmark of atherosclerotic plaque progression. To investigate if reelin pharmaceutical depletion protects against atherosclerosis, low-density lipoprotein receptor-deficient (&lt;i&gt;Ldlr&lt;/i&gt;&lt;sup&gt;-/-&lt;/sup&gt;) mice fed with high-cholesterol diet were treated with either reelin antisense oligonucleotide or neutralizing antibody (CR-50) to systemically deplete circulating reelin. In both treatments, atherosclerotic plaque progression was markedly attenuated. These in vivo results suggest that reelin depletion decreases vascular adhesion and inhibits the recruitment of monocytes and consequently prevents plaque progression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: These findings suggest that reelin inhibition may provide a novel therapeutic approach to counteract leukocyte or monocyte adhesion as well as extravasation and inhibit the progression of atherosclerosis. This strategy may also be relevant for other diseases that involve leukocyte or monocyte extravasation as a central pathological mechanism, such as multiple sclerosis or arthritis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626909/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33626909&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1161/ATVBAHA.121.316000&gt;10.1161/ATVBAHA.121.316000&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626909/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":88,"discovery_date":"2021-02-25T11:11:00","title":"Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;NPJ Digit Med. 2021 Feb 24;4(1):36. doi: 10.1038/s41746-021-00401-y.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;As the burden of neurodegenerative diseases increases, time-limited clinic encounters do not allow quantification of complex neurological functions. Patient-collected digital biomarkers may remedy this, if they provide reliable information. However, psychometric properties of digital tools remain largely un-assessed. We developed a smartphone adaptation of the cognitive test, the Symbol-Digit Modalities Test (SDMT) by randomizing the test&#x27;s symbol-number codes and testing sequences. The smartphone SDMT showed comparable psychometric properties in 154 multiple sclerosis (MS) patients and 39 healthy volunteers (HV). E.g., smartphone SDMT achieved slightly higher correlations with cognitive subscores of neurological examinations and with brain injury measured by MRI (R&lt;sup&gt;2&lt;/sup&gt; = 0.75, Rho = 0.83, p &amp;lt; 0.0001) than traditional SDMT. Mathematical adjustment for motoric disability of the dominant hand, measured by another smartphone test, compensates for the disadvantage of touch-based test. Averaging granular home measurements of the digital biomarker also increases accuracy of identifying true neurological decline.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627777/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627777&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41746-021-00401-y&gt;10.1038/s41746-021-00401-y&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627777/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":87,"discovery_date":"2021-02-25T11:11:00","title":"The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Feb 5;2021:6611897. doi: 10.1155/2021/6611897. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple studies have reported that cannabis administration in multiple sclerosis patients is associated with decreased symptom severity. This study was conducted to evaluate the prevalence of cannabis abuse in multiple sclerosis cases and to evaluate the effect of cannabis on serum cytokines in such cases. &lt;i&gt;Patients and Methods&lt;/i&gt;. A total of 150 multiple sclerosis cases along with 150 healthy controls were included during the study period. All cases were subjected to history taking, neurological examination, and routine investigations. Cases were asked about cannabis intake which was confirmed by a urine test. Serum cytokines including IL-1, IL-2, IL-4, IL-10, IL-12, IL-17, IL-22, IFN-&lt;i&gt;γ&lt;/i&gt;, IFN-&lt;i&gt;β&lt;/i&gt;1, and TNF-&lt;i&gt;α&lt;/i&gt; were ordered for all cases and controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Twenty-eight cases were cannabis abusers (MS/cannabis group, 18.67%). The remaining 122 cases represented the MS group. There was no significant difference between the three groups regarding age, disease duration, or MS type. Male gender was more predominant in the MS/cannabis group, and the number of relapses was significantly lower in the same group. Fifteen cases (53.6%) reported that their symptoms were improved by cannabis. Proinflammatory cytokines were significantly elevated in the MS group compared to the MS/cannabis and control groups. Additionally, anti-inflammatory cytokines had significantly lower values in the MS group compared to the MS/cannabis and control groups. Most clinical symptoms were significantly improved in the MS/cannabis group compared to the MS group apart from sexual dysfunction, bladder symptoms, and visual disturbances. Mild side effects of cannabis were also reported.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Cannabis may have a positive impact on the cytokine and clinical profiles in cases with multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628507/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628507&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7884151/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7884151&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6611897&gt;10.1155/2021/6611897&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628507/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":86,"discovery_date":"2021-02-25T11:11:00","title":"Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Feb 15;2021:6667006. doi: 10.1155/2021/6667006. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;More than half of all patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) are women of childbearing age. Raising a family is an important life goal for women in our region of the world. However, fears and misconceptions about the clinical course of relapsing-remitting MS (RRMS) and the effects of disease-modifying drugs (DMDs) on the foetus have led many women to reduce their expectations of raising a family, sometimes even to the point of avoiding pregnancy altogether. The increase in the number of DMDs available to manage RRMS and recent studies on their effects in pregnancy have broadened management options for these women. Interferon beta now has an indication in Europe for use during pregnancy (according to clinical need) and can be used during breastfeeding. Glatiramer acetate is a further possible option for women with lower levels of RRMS disease activity who are, or about to become, pregnant; natalizumab may be used up to 30 weeks in patients with higher levels of disease activity. Where possible, physicians need to support and encourage women to pursue their dream of a fulfilling family life, supported where necessary by active interventions for RRMS that are increasingly evidence based.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628508/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628508&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7899766/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7899766&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6667006&gt;10.1155/2021/6667006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628508/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":85,"discovery_date":"2021-02-25T11:11:00","title":"Systemic Sclerosis: Current State and Survival After Lung Transplantation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cureus. 2021 Jan 20;13(1):e12797. doi: 10.7759/cureus.12797.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Systemic sclerosis (SSc) is an autoimmune disorder characterized by the involvement of skin and internal organs. With the introduction of angiotensin-converting enzyme inhibitors (ACEIs), scleroderma renal crisis (SRC) is no longer considered a leading cause of death in affected patients. In fact, pulmonary manifestations [interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH)] are currently the major cause of death in patients with SSc. Historically, many centers have been reluctant to offer lung transplantation to patients with SSc due to multiple extrapulmonary manifestations and the assumption of poor post-transplant survival. The purpose of this review is to highlight the recent advances in the evaluation and management of patients with pulmonary manifestations of SSc. We also engage in a systematic literature review to assess all the available data on the survival of patients with SSc after lung transplantation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628666/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628666&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7893677/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7893677&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.7759/cureus.12797&gt;10.7759/cureus.12797&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628666/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":84,"discovery_date":"2021-02-25T11:11:00","title":"Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102840. doi: 10.1016/j.msard.2021.102840. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Neurofilament heavy (NfH) is a promising biomarker for neuro-axonal damage in Multiple Sclerosis (MS). We compared the performance of high-sensitivity serum-NfH immunoassays, with as aim to investigate the value of serum-NfH as biomarker for MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We measured serum-NfH in 76 MS patients with Simoa (one commercial, one in-house) or Luminex assays. Serum-NfH measured by the immunoassay with greatest sensitivity was related to clinical and radiological outcomes with age and sex-adjusted linear regression analysis, and to biological outcomes cerebrospinal fluid (CSF)-NfH, serum neurofilament light (NfL) and CSF-NfL with Spearman&#x27;s correlation analysis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: With the commercial Simoa assay, we obtained 100% serum-NfH detectability (in-house Simoa: 70%, Luminex: 61%), with lowest coefficient of variation (CV) between duplicates of 11%CV (in-house Simoa: 22%CV, Luminex: 30%CV). Serum-NfH quantified with the commercial Simoa assay was associated with disease duration (standardized beta (sβ) = 0.28, p = 0.034), T2 lesion volume (sβ = 0.23, p = 0.041), and tended to associate with black hole count (sβ = 0.21, p = 0.084) but not with Expanded Disease Disability Score (EDSS) or normalized brain volume (all: p&amp;gt;0.10). Furthermore, serum-NfH showed correlations with CSF-NfH (rho = 0.27, p = 0.018) and serum-NfL (rho=0.44, p &amp;lt; 0.001), but not with CSF-NfL.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Serum-NfH can be quantified with high-sensitivity technology. Cross-sectionally, we observed some weak correlations of serum-NfH with MS disease burden parameters, suggesting there might be some utility for serum-NfH as biomarker for MS disease burden.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626430/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626430&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102840&gt;10.1016/j.msard.2021.102840&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626430/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":83,"discovery_date":"2021-02-25T11:11:00","title":"The CYP2R1 Enzyme: Structure, Function, Enzymatic Properties and Genetic Polymorphism","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Pharm Pharm Sci. 2021;24:94-112. doi: 10.18433/jpps31305.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Since the discovery of its role in vitamin D metabolism, significant progress has been made in the understanding of gene organisation, protein structure, catalytic function, and genetic polymorphism of cytochrome P450 2R1 (CYP2R1). Located on chromosome 11p15.2, CYP2R1 possesses five exons, unlike most other CYP isoforms that carry nine exons. CYP2R1 crystal structure displays a fold pattern typical of a CYP protein, with 12 a-helices as its structural core, and b-sheets mostly arranged on one side, and the heme buried in the interior part of the protein. Overall, CYP2R1 structure adopts a closed conformation with the B&#x27; helix serving as a gate covering the substrate access channel, with the substrate vitamin D3 occupying a position with the side chain pointing toward the heme group. In liver, CYP2R1 25-hydroxylates vitamin D and serves as an important determinant of 25(OH)D level in the tissue and in circulation. While substrate profile has been well studied, inhibitor specificity for CYP2R1 requires further investigation. Both exonic and non-exonic single nucleotide polymorphisms (SNPs) have been reported in CYP2R1, including the CYP2R1*2 carrying Leu99Pro exchange, and a number of non-exonic SNPs with variable functional consequences in gene regulation. A non-exonic SNP, rs10741657, has its causal relationship with diseases established, including that of rickets, ovarian cancer, and multiple sclerosis. The role of other CYP2R1 SNPs in vitamin D deficiency and their causal link to other traits however remain uncertain currently and more studies are warranted to help identify possible physiological mechanisms underlying those complex traits.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626316/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626316&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.18433/jpps31305&gt;10.18433/jpps31305&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626316/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":82,"discovery_date":"2021-02-25T11:11:00","title":"The role of language ability in verbal fluency of individuals with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102846. doi: 10.1016/j.msard.2021.102846. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: While cognitive deficits in memory and processing speed have been well-documented in individuals with multiple sclerosis (MS), language is largely considered to be intact. Verbal fluency deficits observed in MS are often attributed to impaired processing speed and executive functions rather than language ability. The current study evaluates the contribution of various cognitive factors to verbal fluency including language ability, oral-motor speed, processing speed, and executive functions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We analyzed pre-existing data from seventy-four (74) individuals with MS who completed a battery of neuropsychological tests designed to assess individual ability for various cognitive factors. We conducted linear multiple regression analyses with letter and category verbal fluency as outcome variables and performance on other cognitive domains (e.g., processing speed, executive functioning) as predictors.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Both vocabulary and processing speed predicted letter fluency while only vocabulary predicted category fluency. These findings suggest that the observed verbal fluency deficits in MS may reflect both impaired language ability and processing speed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: We propose that further research on language ability in MS is needed to determine if comprehensive neuropsychological test batteries for persons with MS should include tests of language ability to fully understand the cognitive profile of any given patient. Given the importance of language ability, it may be necessary to conduct a more thorough assessment of language in individuals with MS who experience a deficit in this domain.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626431/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626431&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102846&gt;10.1016/j.msard.2021.102846&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626431/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":81,"discovery_date":"2021-02-25T11:11:00","title":"Idiopathic Intracranial Hypertension and Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102829. doi: 10.1016/j.msard.2021.102829. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Unexplained elevated intracranial pressure occasionally develops in individuals with Multiple Sclerosis (MS). Visual symptoms and signs are common to both conditions. An awareness of this association is particularly relevant due to the increased incidence of headache in MS and the frequent overlap of symptoms and signs in both conditions.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626432/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626432&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102829&gt;10.1016/j.msard.2021.102829&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626432/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":80,"discovery_date":"2021-02-25T11:11:00","title":"A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different Disability Levels","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;IEEE Trans Biomed Eng. 2021 Feb 24;PP. doi: 10.1109/TBME.2021.3061998. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Mobility assessment is critical in the clinical management of people with Multiple Sclerosis (pwMS). Instrumented gait analysis provides a plethora of metrics for quantifying concurrent factors contributing to gait deterioration. However, a gait model discriminating underlying features contributing to this deterioration is lacking in pwMS. This study aimed at developing and validating such a model.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: The gait of 24 healthy controls and 114 pwMS with mild, moderate, or severe disability was measured with inertial sensors on the shanks and lower trunk while walking for 6 minutes along a hospital corridor. Twenty out of thirty-six initially explored metrics computed from the sensor data met the quality criteria for exploratory factor analysis. This analysis provided the sought model, which underwent a confirmatory factor analysis before being used to characterize gait impairment across the three disability groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: A gait model consisting of five domains (rhythm/variability, pace, asymmetry, and forward and lateral dynamic balance) was revealed by the factor analysis, which was able to highlight gait abnormalities across the disability groups: significant alterations in rhythm/variability-, asymmetry-, and pace-based features were present in the mild group, but these were more profound in the moderate and severe groups. Deterioration in dynamic balance-based features was only noted in pwMS with a moderate and severe disability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: A conceptual model of gait for disease-specific mobility assessment in pwMS was successfully developed and tested.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;SIGNIFICANCE: The new model, built with metrics that represent gait impairment in pwMS, highlighted clinically relevant changes across different disability levels, including those with no clinically observable walking disability. This shows the clear potential as a monitoring biomarker in pwMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625975/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33625975&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1109/TBME.2021.3061998&gt;10.1109/TBME.2021.3061998&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625975/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":79,"discovery_date":"2021-02-25T11:11:00","title":"Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Neurol Scand. 2021 Feb 24. doi: 10.1111/ane.13400. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To identify serum proteins associated with MS and affected by interferon beta treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Plasma samples from 29 untreated relapsing-remitting MS patients and 15 healthy controls were investigated with a multiplexed panel containing 92 proteins related to inflammation. Follow-up samples were available from 13 patients at 1 and 3 months after initiation of treatment with interferon beta-1a.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Ten proteins were differentially expressed in MS patients. Five of these were altered by treatment with IFN-β 1a: uPA, CX3CL1, CCL2, TRAIL and IL18.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN-beta-1a treatment. Conflicting results have been reported on how interferon beta affects IL-18.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626181/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33626181&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/ane.13400&gt;10.1111/ane.13400&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626181/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":78,"discovery_date":"2021-02-25T11:11:00","title":"Leveraging electronic health records data to predict multiple sclerosis disease activity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 24. doi: 10.1002/acn3.51324. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: No relapse risk prediction tool is currently available to guide treatment selection for multiple sclerosis (MS). Leveraging electronic health record (EHR) data readily available at the point of care, we developed a clinical tool for predicting MS relapse risk.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Using data from a clinic-based research registry and linked EHR system between 2006 and 2016, we developed models predicting relapse events from the registry in a training set (n = 1435) and tested the model performance in an independent validation set of MS patients (n = 186). This iterative process identified prior 1-year relapse history as a key predictor of future relapse but ascertaining relapse history through the labor-intensive chart review is impractical. We pursued two-stage algorithm development: (1) L&lt;sub&gt;1&lt;/sub&gt; -regularized logistic regression (LASSO) to phenotype past 1-year relapse status from contemporaneous EHR data, (2) LASSO to predict future 1-year relapse risk using imputed prior 1-year relapse status and other algorithm-selected features.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The final model, comprising age, disease duration, and imputed prior 1-year relapse history, achieved a predictive AUC and F score of 0.707 and 0.307, respectively. The performance was significantly better than the baseline model (age, sex, race/ethnicity, and disease duration) and noninferior to a model containing actual prior 1-year relapse history. The predicted risk probability declined with disease duration and age.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Our novel machine-learning algorithm predicts 1-year MS relapse with accuracy comparable to other clinical prediction tools and has applicability at the point of care. This EHR-based two-stage approach of outcome prediction may have application to neurological disease beyond MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33626237&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/acn3.51324&gt;10.1002/acn3.51324&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":77,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625275/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625275&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521996699&gt;10.1177/1352458521996699&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625275/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":76,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in MS research are just powerful statistics - Yes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520981309. doi: 10.1177/1352458520981309. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625280/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625280&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520981309&gt;10.1177/1352458520981309&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625280/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":75,"discovery_date":"2021-02-24T11:11:00","title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Manag Care Spec Pharm. 2021 Feb 24:1-11. doi: 10.18553/jmcp.2021.20413. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;BACKGROUND:&lt;/b&gt; Ocrelizumab (OCR) is the only disease-modifying therapy (DMT) for both relapsing and primary progressive forms of multiple sclerosis (MS). OCR is given by intravenous (IV) infusion twice a year, which may improve adherence to the dosing schedule relative to other MS DMTs that require more frequent administration. Real-world evidence on the persistence and adherence of patients with MS to OCR compared with other DMTs is limited. &lt;b&gt;OBJECTIVE:&lt;/b&gt; To examine the persistence and adherence to OCR compared with other DMTs for MS in the United States. &lt;b&gt;METHODS:&lt;/b&gt; This analysis was conducted in the PharMetrics Plus commercial claims database and included patients with MS who initiated a new DMT between April 2017 and September 2018. Patients were required to have health plan enrollment for ≥ 1 year before and after DMT initiation (a subgroup analysis was performed for those with ≥ 18 months&#x27; continuous enrollment after DMT initiation). Persistence was defined as not switching to another DMT and having no gap in coverage of the initiated DMT for ≥ 60 days during the postinitiation period. The proportion of days covered (PDC) was calculated as the total days covered by the DMT during the postinitiation period divided by the length of the time period (12 or 18 months); PDC ≥ 0.8 was considered adherent. Multivariable Poisson regression models compared discontinuation (nonpersistence) and nonadherence between OCR users and users of other DMTs grouped by administration route. &lt;b&gt;RESULTS:&lt;/b&gt; A total of 4,587 patients (OCR, 1,319; injectable, 1,051; oral, 1,876; other IV, 341) were included. The OCR group had the lowest proportion of patients discontinuing at 12 months (8% vs. 28%, 32%, and 43% for other IV, oral, and injectable, respectively) and the highest mean PDC (93% vs. 76%, 74%, and 69%, respectively). Compared with patients initiating OCR, adjusted relative risks (RR) of 12-month discontinuation were 3.3 (95% CI = 2.3-4.6), 3.8 (95% CI = 3.0-4.9), and 5.5 (95% CI = 4.1-7.5) for patients initiating other IV, oral, and injectable DMTs, respectively. Similarly, patients initiating other IV, oral, and injectable DMTs had RRs of 4.9 (95% CI = 3.6-6.8), 5.1 (95% CI = 3.9-6.6), and 6.8 (95% CI = 5.0-9.3) for 12-month nonadherence compared with OCR. A subgroup of 2,913 patients with 18 months of continuous enrollment had similar trends, with 17% in the OCR group discontinuing compared with 40%, 41%, and 55% in the other IV, oral, and injectable groups, respectively. Trends over 18 months were consistent with the 12-month analysis in adjusted models. &lt;b&gt;CONCLUSIONS:&lt;/b&gt; Patients initiating OCR had superior persistence and adherence at 12 and 18 months of follow-up compared with patients initiating other MS DMTs. Long-term persistence and adherence should be monitored as OCR experience accrues in a real-world setting. &lt;b&gt;DISCLOSURES:&lt;/b&gt; This study was funded by Genentech (South San Francisco, CA), a member of the Roche Group. Engmann, Sheinson, Bawa, and Ng are employees of Genentech and shareholders of F. Hoffman-La Roche (Basel, Switzerland).&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624535/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33624535&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.18553/jmcp.2021.20413&gt;10.18553/jmcp.2021.20413&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624535/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":74,"discovery_date":"2021-02-24T11:11:00","title":"A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Phytother Res. 2021 Feb 24. doi: 10.1002/ptr.7050. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a demyelinating disease affecting the central nervous system, with no curative medicine available. The use of herbal drugs and dietary supplements is increasing among people with MS (PwMS), raising a need for knowledge about potential interactions between conventional MS medicine and herbal drugs/dietary supplements. This systematic review provides information about the safety of simultaneous use of conventional MS-drugs and herbal drugs frequently used by PwMS. The study included 14 selected disease-modifying treatments and drugs frequently used for symptom-alleviation. A total of 129 published papers found via PubMed and Web of Science were reviewed according to defined inclusion- and exclusion criteria. Findings suggested that daily recommended doses of Panax ginseng and Ginkgo biloba should not be exceeded, and herbal preparations differing from standardized products should be avoided, especially when combined with anticoagulants or substrates of certain cytochrome P450 isoforms. Further studies are required regarding ginseng&#x27;s ability to increase aspirin bioavailability. Combinations between chronic cannabis use and selective serotonin reuptake inhibitors or non-steroidal antiinflammatory drugs should be carefully monitored, whereas no significant evidence for drug-interactions between conventional MS-drugs and ginger, cranberry, vitamin D, fatty acids, turmeric, probiotics or glucosamine was found.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624893/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33624893&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/ptr.7050&gt;10.1002/ptr.7050&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624893/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":73,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in MS research are just powerful statistics - No","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520978648. doi: 10.1177/1352458520978648. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625302/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625302&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520978648&gt;10.1177/1352458520978648&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625302/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":72,"discovery_date":"2021-02-24T11:11:00","title":"Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cell Mol Neurobiol. 2021 Feb 24. doi: 10.1007/s10571-021-01059-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions. We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND). Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases). Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein). We did not observe EO6 in controls. All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions. We did not detect co-localization between EO6 and antibodies. Neither did we between EO6 and TUNEL or APP. 94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM. IgM, but not IgG, co-localized with APP. EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS). We did not observe association between antibodies and cellular or axonal damage in ND patients. MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls. The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions. We observed a main role of B lymphocytes in the development of MS lesions. Antibodies contribute to the oligodendrocyte and axonal damage in MS. Oxidative stress was associated with axonal damage in ALS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625628/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625628&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10571-021-01059-6&gt;10.1007/s10571-021-01059-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625628/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":71,"discovery_date":"2021-02-24T11:11:00","title":"Single-cell immune repertoire and transcriptome sequencing reveals that clonally expanded and transcriptionally distinct lymphocytes populate the aged central nervous system in mice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Proc Biol Sci. 2021 Feb 24;288(1945):20202793. doi: 10.1098/rspb.2020.2793. Epub 2021 Feb 24.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neuroinflammation plays a crucial role during ageing and various neurological conditions, including Alzheimer&#x27;s disease, multiple sclerosis and infection. Technical limitations, however, have prevented an integrative analysis of how lymphocyte immune receptor repertoires and their accompanying transcriptional states change with age in the central nervous system. Here, we leveraged single-cell sequencing to simultaneously profile B cell receptor and T cell receptor repertoires and accompanying gene expression profiles in young and old mouse brains. We observed the presence of clonally expanded B and T cells in the central nervous system of aged male mice. Furthermore, many of these B cells were of the IgM and IgD isotypes, and had low levels of somatic hypermutation. Integrating gene expression information additionally revealed distinct transcriptional profiles of these clonally expanded lymphocytes. Our findings implicate that clonally related T and B cells in the CNS of elderly mice may contribute to neuroinflammation accompanying homeostatic ageing.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622131&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1098/rspb.2020.2793&gt;10.1098/rspb.2020.2793&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":70,"discovery_date":"2021-02-24T11:11:00","title":"Effects of diminished positive mood and depressed mood upon verbal learning and memory among people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Clin Exp Neuropsychol. 2021 Feb 23:1-12. doi: 10.1080/13803395.2020.1853066. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Objective&lt;/b&gt;: Cognitive impairment affects as many as 65% of people with multiple sclerosis (PWMS), and memory impairment confers greater severity of disability and functional impairment. Depression is also common among PWMS, and lifetime prevalence rates are as high as 50%. Research has yet to clearly define the relationship between memory dysfunction and depression among PWMS, and may reflect incomplete assessment of depressive symptoms. The present study examined different aspects of depressive symptoms including anhedonia (i.e., diminished positive mood) and their relationships with verbal learning and memory among PWMS.&lt;b&gt;Method&lt;/b&gt;: Participants were 48 healthy individuals and 96 PWMS. They were primarily Caucasian (90.3%) and female (75.0%). Participants completed the California Verbal Learning Test-2 (CVLT-2) to assess verbal learning and memory and the Chicago Multiscale Depression inventory to assess depressed mood (CMDI-Mood) and diminished positive mood (CMDI-DPM).&lt;b&gt;Results&lt;/b&gt;: Linear regression revealed that the main effect of CMDI-DPM and the interaction of CMDI-DPM and CMDI-Mood significantly explained variance across learning, recall, and recognition CVLT-2 indices. Follow-up analyses indicated that CMDI-DPM was only significant in the absence of high CMDI-Mood scores. CMDI-Mood explained variance in only CVLT-2 Trial B.&lt;b&gt;Conclusions&lt;/b&gt;: Depressed mood had little direct effect upon memory performance in PWMS. In the absence of severe depressed mood, higher levels of positive mood corresponded to better memory performance. However, the impact of diminished positive mood was rendered null among those endorsing high levels of depressed mood. These data may imply that anhedonia corresponds with poorer memory function among PWMS, and suggests that investigators and clinicians should assess multiple mood dimensions among PWMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622171/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622171&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/13803395.2020.1853066&gt;10.1080/13803395.2020.1853066&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622171/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":69,"discovery_date":"2021-02-24T11:11:00","title":"Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(3):e964. doi: 10.1212/NXI.0000000000000964. Print 2021 May.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We enrolled 61 patients with primary or secondary PMS in a randomized double-blind, parallel-group, phase II trial on oral EGCG (up to 1,200 mg daily) or placebo for 36 months with an optional open-label EGCG treatment extension (OE) of 12-month duration. The primary end point was the rate of brain atrophy, quantified as brain parenchymal fraction (BPF). The secondary end points were radiologic and clinical disease parameters and safety assessments.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In our cohort, 30 patients were randomized to EGCG treatment and 31 to placebo. Thirty-eight patients (19 from each group) completed the study. The primary endpoint was not met, as in 36 months the rate of decrease in BPF was 0.0092 ± 0.0152 in the treatment group and -0.0078 ± 0.0159 in placebo-treated patients. None of the secondary MRI and clinical end points revealed group differences. Adverse events of EGCG were mostly mild and occurred with a similar incidence in the placebo group. One patient in the EGCG group had to stop treatment due to elevated aminotransferases (&amp;gt;3.5 times above normal limit).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: In a phase II trial including patients with multiple sclerosis (MS) with progressive disease course, we were unable to demonstrate a treatment effect of EGCG on the primary and secondary radiologic and clinical disease parameters while confirming on overall beneficial safety profile.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLINICALTRIALGOV IDENTIFIER: NCT00799890.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This phase II trial provides Class II evidence that for patients with PMS, EGCG was safe, well tolerated, and did not significantly reduce the rate of brain atrophy.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622766/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622766&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1212/NXI.0000000000000964&gt;10.1212/NXI.0000000000000964&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622766/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":68,"discovery_date":"2021-02-24T11:11:00","title":"Correlation of Dietary Intake and Helicobacter pylori Infection with Multiple Sclerosis, a Case-Control Study in Rafsanjan, Iran, 2017-18","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Qatar Med J. 2021 Feb 5;2020(3):45. doi: 10.5339/qmj.2020.45. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Some environmental factors, such as &lt;i&gt;Helicobacter pylori&lt;/i&gt; infection (HPI), are likely to be considered a protective factor in MS. Dietary intake may provide exposure to or have protective effects for MS. The present study aimed to determine the relationship between serum anti-H. pylori IgG antibody (HPIA) level and dietary intake in patients with MS referred to the MS Clinic in Rafsanjan city, Iran.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: The present case-control study was conducted on 97 patients with MS and 95 controls. The two groups had no significant difference in age and gender (&lt;i&gt;p&lt;/i&gt; &amp;gt; 0.05). HPIA was checked, and the food frequency questionnaire was completed in both groups to measure nutritional intake. All data were analyzed by the SPSS 20 software using independent t-test, Chi-Square, Mann-Whitney U test, and correlation.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The median serum HPIA level was significantly lower in MS cases than in controls. Furthermore, the median consumption of glutamic acid, arginine, serine, aspartic acid, alanine, proline, and caffeine was significantly lower in MS cases than in controls. A significant positive correlation was found between the levels of linoleic acid, lactose, Ca, molybdenum, galactose, leucine, and valine, and the level of HPIA in controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Our study results demonstrated that some dietary nutrients had correlations with MS and HPI. Therefore, professionals from multiple disciplines must find which foods contain these dietary nutrients in future studies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623753/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623753&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878158/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7878158&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.5339/qmj.2020.45&gt;10.5339/qmj.2020.45&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623753/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":67,"discovery_date":"2021-02-24T11:11:00","title":"Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neural Transm (Vienna). 2021 Feb 23. doi: 10.1007/s00702-021-02306-2. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson&#x27;s disease symptoms and viral infections. Considering amantadine&#x27;s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington&#x27;s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine&#x27;s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http://www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624170/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33624170&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00702-021-02306-2&gt;10.1007/s00702-021-02306-2&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624170/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":66,"discovery_date":"2021-02-24T11:11:00","title":"Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Sci Sleep. 2021 Feb 16;13:201-207. doi: 10.2147/NSS.S256676. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The prevalence of sleep disorders in individuals with multiple sclerosis (MS) is 3-5 times higher compared to the general population. Insomnia Disorder, defined as difficulty falling asleep, maintaining sleep or waking up too early, can lead to significant fatigue, the most common and disabling symptom of MS. In addition, fatigue and insomnia in patients with MS also can overlap with and exacerbate other psychological and physical symptoms. Cognitive behavioral therapy for insomnia (CBT-I) has been shown as an effective treatment for chronic insomnia and burgeoning research has demonstrated the effectiveness of this treatment for insomnia in individuals with a variety of comorbid medical conditions including MS. The purpose of the current review will explore the literature surrounding the prevalence and impact of sleep disorders and fatigue in MS. Additionally, this review will address practical ways to help individuals with MS manage fatigue as well as how to modify typical standard behavioral treatments for insomnia to take into account special considerations for individuals with MS based on the level of disability and other comorbid issues that impact sleep.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623461/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623461&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7896778/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7896778&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2147/NSS.S256676&gt;10.2147/NSS.S256676&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623461/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":65,"discovery_date":"2021-02-24T11:11:00","title":"Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 23;11(1):4358. doi: 10.1038/s41598-021-83991-7.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The improvement of life quality and medical advances has resulted in increased life expectancy. Despite this, health status commonly worsens in the last years of life. Frailty is an intermediate and reversible state that often precedes dependency and therefore, its identification may be essential to prevent dependency. However, there is no consensus on the best tools to identify frailty. In this sense, diverse molecules have been proposed as potential biomarkers. Some investigations pointed to an increased chronic inflammation or inflammaging with frailty, while others did not report such differences. In this work, we evaluated the circulating concentration of the inflammaging markers in adults and older adults (aged over 70 years) by ELISA and Luminex techniques. The Barthel Index was applied for the evaluation of dependency and Timed up-and-go, Gait Speed, Short Physical Performance Battery, Tilburg Frailty Indicator and Gerontopole Frailty Screening Tool were used for the identification of frailty. CRP, TNF-α, IL-6 and albumin concentrations were measured, and we found that elevated inflammation is present in older adults, while no differences with frailty and dependency were reported. Our results were consistent for all the evaluated frailty scales, highlighting the need to reconsider increased inflammation as a biomarker of frailty.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623057/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623057&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-83991-7&gt;10.1038/s41598-021-83991-7&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623057/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":64,"discovery_date":"2021-02-24T11:11:00","title":"Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 8;7(1):2055217321992394. doi: 10.1177/2055217321992394. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities Test (SDMT).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time point. For the primary outcome of analysis, SDMT was used.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2% of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV explained 39.4% of the variance of SDMT change.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623706/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623706&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7876764/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7876764&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321992394&gt;10.1177/2055217321992394&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":63,"discovery_date":"2021-02-24T11:11:00","title":"Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Hum Brain Mapp. 2021 Feb 24. doi: 10.1002/hbm.25375. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is evidence that multiple sclerosis (MS) pathology leads to distinct patterns of volume loss over time (VLOT) in different central nervous system (CNS) structures. We aimed to use such patterns to identify patient subgroups. MS patients of all classical disease phenotypes underwent annual clinical, blood, and MRI examinations over 6 years. Spinal, striatal, pallidal, thalamic, cortical, white matter, and T2-weighted lesion volumes as well as serum neurofilament light chain (sNfL) were quantified. CNS VLOT patterns were identified using principal component analysis and patients were classified using hierarchical cluster analysis. 225 MS patients were classified into four distinct Groups A, B, C, and D including 14, 59, 141, and 11 patients, respectively). These groups did not differ in baseline demographics, disease duration, disease phenotype distribution, and lesion-load expansion. Interestingly, Group A showed pronounced spinothalamic VLOT, Group B marked pallidal VLOT, Group C small between-structure VLOT differences, and Group D myelocortical volume increase and pronounced white matter VLOT. Neurologic deficits were more severe and progressed faster in Group A that also had higher mean sNfL levels than all other groups. Group B experienced more frequent relapses than Group C. In conclusion, there are distinct patterns of VLOT across the CNS in MS patients, which do not overlap with clinical MS subtypes and are independent of disease duration and lesion-load but are partially associated to sNfL levels, relapse rates, and clinical worsening. Our findings support the need for a more biologic classification of MS subtypes including volumetric and body-fluid markers.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624390/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33624390&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/hbm.25375&gt;10.1002/hbm.25375&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624390/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":62,"discovery_date":"2021-02-24T11:11:00","title":"miRNA-467b inhibits Th17 differentiation by targeting eIF4E in experimental autoimmune encephalomyelitis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mol Immunol. 2021 Feb 20;133:23-33. doi: 10.1016/j.molimm.2021.02.008. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are neuroinflammatory autoimmune diseases characterized by the axonal loss, demyelination, and neurodegeneration of the central nervous system. Overactivation of CD4&lt;sup&gt;+&lt;/sup&gt; T cells, especially the migration of the Th1 and Th17 subsets into the central nervous system (CNS), leads to the secretion of inflammatory mediators and destruction of the contact between neurons and activated macrophages, which can then result in a series of neurocognitive and motor deficits. In this study, we intended to explore the role of miRNA-467b in regulating Th cell development in EAE. We found that the level of miRNA-467b was decreased and eukaryotic initiation factor 4 F (eIF4E) was increased in lymph nodes and the CNS at EAE peak. eIF4E was confirmed as the direct target of miRNA467b. Overexpression of miRNA-467b could suppress a percentage of CD4&lt;sup&gt;+&lt;/sup&gt; IL-17&lt;sup&gt;+&lt;/sup&gt; cells in EAE CD4 + T cells in vitro. In addition, we also identified miRNA-467b, which could suppress Th17 cell differentiation by targeting eIF4E in vitro. Furthermore, injecting miRNA-467b mimics into the caudal vein of EAE mice contributed to less inflammation in the peripheral lymphoid organs and CNS and alleviated disease severity. Taken together, our findings imply that miRNA-467b inhibits the differentiation and function of Th17 cells by targeting eIF4E, thereby alleviating EAE.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621940/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224012934&amp;v=2.14.2&quot;&gt;33621940&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.molimm.2021.02.008&gt;10.1016/j.molimm.2021.02.008&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621940/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224012934&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":61,"discovery_date":"2021-02-24T11:11:00","title":"Is maximal muscle strength and fatigability of three lower limb muscle groups associated with walking capacity and fatigability in multiple sclerosis? An exploratory study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102841. doi: 10.1016/j.msard.2021.102841. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Both muscle fatigability and walking fatigability are prevalent in persons with MS (pwMS), but their associations remains unclear. The aim of this study was to examine the association of muscle strength and fatigability from both isometric and concentric protocols of three different muscle groups, and their association to walking capacity and walking fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Twenty-seven pwMS and 13 Healthy Controls (HC) were included in this exploratory study. All participants performed a six-minute walking test (6MWT), where the distance walked index (DWI) was calculated to measure walking fatigability with a cut-off score of -10%. In three different muscle groups (knee extensors (KE), knee flexors (KF), ankle dorsiflexors (DF)), isometric and concentric muscle fatigability protocols (FI&lt;sub&gt;isometric&lt;/sub&gt; or FI&lt;sub&gt;concentric&lt;/sub&gt;) were used to quantify maximal voluntary contraction (MVC) and muscle fatigability. Pearson or Spearman correlation coefficients and linear regression models were calculated to establish the association between muscle strength/fatigability and walking capacity/fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Higher MVCs values for all muscle groups were found in HC compared to pwMS (mainly those having walking fatigability) (p &amp;lt; 0.05). FI&lt;sub&gt;isometric&lt;/sub&gt; of DF was lower in pwMS having walking fatigability compared to no walking fatigability. MVC of KE, KF and DF had a low to moderate association with walking capacity (range r = 0.52-0.56; p &amp;lt; 0.05) and walking fatigability in pwMS (range r-r&lt;sub&gt;s&lt;/sub&gt;: 0.39-0.50; p&amp;lt;0.05). FI&lt;sub&gt;concentric&lt;/sub&gt; of KF and DF, but not of KE, were associated with walking fatigability (r = 0.39 and r&lt;sub&gt;s&lt;/sub&gt; = 0.47, respectively; p &amp;lt; 0.05). In contrast, FI&lt;sub&gt;isometric&lt;/sub&gt; for all muscle groups were not related to walking capacity or walking fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: MVC of KE, KF and DF are associated with walking capacity and walking fatigability, while concentric (but not isometric) muscle fatigability of KF and DF are associated with walking fatigability.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621946/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224012934&amp;v=2.14.2&quot;&gt;33621946&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102841&gt;10.1016/j.msard.2021.102841&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621946/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224012934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":60,"discovery_date":"2021-02-24T11:11:00","title":"Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Radiology. 2021 Feb 23:203071. doi: 10.1148/radiol.2021203071. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Susceptibility-weighted imaging (SWI) evolved from simple two-dimensional T2*-weighted sequences to three-dimensional sequences with improved spatial resolution and enhanced susceptibility contrast. SWI is an MRI sequence sensitive to compounds that distort the local magnetic field (eg, calcium and iron), in which the phase information can differentiate. But the term &lt;i&gt;SWI&lt;/i&gt; is colloquially used to denote high-spatial-resolution susceptibility-enhanced sequences across different MRI vendors and sequences even when phase information is not used. The imaging appearance of SWI and related sequences strongly depends on the acquisition technique. Initially, SWI and related sequences were mostly used to improve the depiction of findings already known from standard two-dimensional T2*-weighted neuroimaging: more microbleeds in patients who are aging or with dementia or mild brain trauma; increased conspicuity of superficial siderosis in Alzheimer disease and amyloid angiopathy; and iron deposition in neurodegenerative diseases or abnormal vascular structures, such as capillary telangiectasia. But SWI also helps to identify findings not visible on standard T2*-weighted images: the nigrosome 1 in Parkinson disease and dementia with Lewy bodies, the central vein and peripheral rim signs in multiple sclerosis, the peripheral rim sign in abscesses, arterial signal loss related to thrombus, asymmetrically prominent cortical veins in stroke, and intratumoral susceptibility signals in brain neoplasms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620291/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620291&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1148/radiol.2021203071&gt;10.1148/radiol.2021203071&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620291/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":59,"discovery_date":"2021-02-24T11:11:00","title":"The impact of neurological disability and sensory loss on mindfulness practice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 23:1-9. doi: 10.1080/09638288.2021.1887946. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: Mindfulness-based approaches are increasingly recommended in the management of medical conditions associated with sensory loss and absence, such as Spinal Cord Injury (SCI), Multiple Sclerosis (MS) and Functional Neurological Disorder (FND). Yet the implications of undertaking practices such as body scanning when living with sensory loss have not been considered. This study aimed to explore the impact of sensory loss on the practice and experience of mindfulness in qualified mindfulness teachers with SCI/FND/MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Eight mindfulness teachers (5 females, 3 males) with SCI/FND/MS, sensory loss and wheelchair use were recruited from mindfulness teacher databases. In-depth, semi-structured interviews were undertaken, lasting between 50 and 93 min. Interviews were transcribed verbatim and analysed using Interpretative Phenomenological Analysis. Idiographic analyses for descriptive, linguistic and conceptual themes were completed before cross-case analyses.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Analyses resulted in two superordinate themes: (1) Adopting your Body; and (2) Sensation without Loss. These themes reflected the challenge of overcoming initial resistance to areas of the body with sensory disruption, building a relationship with the whole body, such that sensory awareness could be visualised and experienced without proprioception.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Mindfulness offers a unique approach to accepting and working with the body after paralysis or sensory loss. Fundamental to the use of mindfulness with such populations, is the prioritisation of inclusive sensory language and exploring sensory absence as well as sensory presence. The cognitive and emotional outcomes of body scanning may be uniquely elevated in populations with neurophysiological disorders, highlighting the benefits of mindfulness for adaptive and protective self-management.IMPLICATIONS FOR REHABILITATIONMindfulness-based practices which focus on the body and sensation are accessible to people with neurological limitations.Mindfulness techniques can be extended through the use of visualisation strategies to encourage (non-proprioceptive) awareness of paralysed limbs or areas of the body with sensory loss.The language used in mindfulness-based interventions may need adapted by practitioners so that it remains inclusive for people with sensory loss as well as sensory presence.Additional care needs to be taken when using body scans during mindfulness as they have the potential to exacerbate psychological distress in people with reduced sensory awareness.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621135/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621135&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/09638288.2021.1887946&gt;10.1080/09638288.2021.1887946&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621135/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":58,"discovery_date":"2021-02-24T11:11:00","title":"Efficacy classification of modern therapies in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Comp Eff Res. 2021 Feb 23. doi: 10.2217/cer-2020-0267. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. &lt;b&gt;Materials &amp;amp; methods:&lt;/b&gt; Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. &lt;b&gt;Results:&lt;/b&gt; For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. &lt;b&gt;Conclusion:&lt;/b&gt; Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620251/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620251&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2217/cer-2020-0267&gt;10.2217/cer-2020-0267&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620251/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":57,"discovery_date":"2021-02-24T11:11:00","title":"The effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Int Urol Nephrol. 2021 Feb 23. doi: 10.1007/s11255-021-02804-y. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that involves different neurological areas. In addition to lower urinary tract symptoms (LUTS), sexual dysfunction (SD), and psychopathological effects, MS sometimes seriously impairs the quality of life (QoL). We hypothesize that the pelvic floor exercise program (PFEP) could improve bladder, sexual function, depression, and QoL in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Patients diagnosed with MS completed the Incontinence Questionnaire Short Form (ICIQ-SF), the Beck Depression Inventory (BDI), the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire, and either the Female Sexual Function Index (FSFI) or the Sexual Health Inventory for Men (SHIM). Maximum bladder volumes (MBV) and post-voiding residual (PVR) volumes were measured using ultrasonography. The patients who regularly completed the PFEP for 12 weeks were asked to fill out the questionnaires again, and their MBV and PVR were remeasured.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Seventy-two patients with relapsing-remitting multiple sclerosis (RRMS) were included in the study. Forty-two (58.3%) RRMS patients reached the end of the study. The patients&#x27; post-PFEP average MBV statistically increased (p = 0.01). In contrast, no statistically significant difference was found in the PVR (p = 0.2). After exercise, the FSFI values in women increased (p = 0.02), and ICIQ-SF and BDI values in all the RRMS patients statistically decreased (p = 0.004, p = 0.01, respectively), but there was no improvement in the MSQoL-54 score (p &amp;gt; 0.05).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: PFEP, which causes a reduction in LUTS by enhancing the MBV of RRMS patients, can be seen as an investment in the future in terms of reducing depression in MS patients and preventing or delaying SD in women.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620664/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620664&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11255-021-02804-y&gt;10.1007/s11255-021-02804-y&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620664/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":56,"discovery_date":"2021-02-24T11:11:00","title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;IMPORTANCE: Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination with axonal transection. MS affects an estimated 900 000 people in the US. MS typically presents in young adults (mean age of onset, 20-30 years) and can lead to physical disability, cognitive impairment, and decreased quality of life. This review summarizes current evidence regarding diagnosis and treatment of MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBSERVATIONS: MS typically presents in young adults aged 20 to 30 years with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes such as internuclear ophthalmoplegia developing over several days. The prevalence of MS worldwide ranges from 5 to 300 per 100 000 people and increases at higher latitudes. Overall life expectancy is less than in the general population (75.9 vs 83.4 years), and MS more commonly affects women (female to male sex distribution of nearly 3:1). Diagnosis is made based on a combination of signs and symptoms, radiographic findings (eg, magnetic resonance imaging [MRI] T2 lesions), and laboratory findings (eg, cerebrospinal fluid-specific oligoclonal bands), which are components of the 2017 McDonald Criteria. Nine classes of disease-modifying therapies (DMTs), with varying mechanisms of action and routes of administration, are available for relapsing-remitting MS, defined as relapses at onset with stable neurologic disability between episodes, and secondary progressive MS with activity, defined as steadily increasing neurologic disability following a relapsing course with evidence of ongoing inflammatory activity. These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab, is approved for primary progressive MS. These DMTs reduce clinical relapses and MRI lesions (new T2 lesions, gadolinium-enhancing lesions). Efficacy rates of current DMTs, defined by reduction in annualized relapse rates compared with placebo or active comparators, range from 29%-68%. Adverse effects include infections, bradycardia, heart blocks, macular edema, infusion reactions, injection-site reactions, and secondary autoimmune adverse effects, such as autoimmune thyroid disease.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS AND RELEVANCE: MS is characterized by physical disability, cognitive impairment, and other symptoms that affect quality of life. Treatment with DMT can reduce the annual relapse rate by 29% to 68% compared with placebo or active comparator.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620411/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620411&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1001/jama.2020.26858&gt;10.1001/jama.2020.26858&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620411/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":55,"discovery_date":"2021-02-24T11:11:00","title":"The Efficacy of Ketogenic Therapies in the Clinical Management of People with Neurodegenerative Disease: A Systematic Review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Adv Nutr. 2021 Feb 23:nmaa180. doi: 10.1093/advances/nmaa180. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Ketone bodies have potential disease-modifying activity that represent a novel therapeutic approach for neurodegenerative diseases (NDD). The aim of this systematic review was to summarize and evaluate the evidence for the application of ketogenic therapies (dietary or exogenous ketogenic agents) for NDD and provide recommendations for future research. Eight databases were electronically searched for articles reporting on controlled trials (≥4 wk duration) that induced ketosis or elevated serum ketone concentrations in people with NDD. Of 4498 records identified, 17 articles met the inclusion criteria with a total of 979 participants including studies on mild cognitive impairment (MCI; n = 6), multiple sclerosis (n = 4), Alzheimer&#x27;s disease (n = 5), Parkinson&#x27;s disease (n = 1), and MCI secondary to Parkinson&#x27;s disease (n = 1). Of 17 studies, 7 were randomized double-blind placebo-controlled trials. Most studies used dietary interventions (n = 9), followed by medium-chain triglycerides (n = 7) and a fasting protocol (n = 1). Generally, trials were 6 wk in duration and assessed cognition as the primary outcome. Studies were heterogeneous in type and severity of NDD, interventions used, and outcomes assessed. Overall, 3/17 studies carried a low risk of bias. Based on available evidence, exogenous ketogenic agents may be more feasible than dietary interventions in NDD from a compliance and adherence perspective; more research is required to confirm this. Recommendations for future research include improving exogenous formulations to reduce adverse effects, exploring interindividual factors affecting response-to-treatment, and establishing a &quot;minimum required dose&quot; for clinically meaningful improvements in disease-specific symptoms, such as cognition or motor function.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621313/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621313&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1093/advances/nmaa180&gt;10.1093/advances/nmaa180&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621313/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":54,"discovery_date":"2021-02-24T11:11:00","title":"Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 23. doi: 10.1002/acn3.51310. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N = 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions occurred in 12.4% of patients. None were severe, life-threatening or led to treatment discontinuation. Shorter infusion time did not change the safety profile of OCR. Clinicaltrials.gov (NCT0237856).&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621404/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621404&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/acn3.51310&gt;10.1002/acn3.51310&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621404/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":53,"discovery_date":"2021-02-23T11:11:00","title":"Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurol (Paris). 2021 Feb 19:S0035-3787(21)00032-1. doi: 10.1016/j.neurol.2020.11.003. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618890&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.neurol.2020.11.003&gt;10.1016/j.neurol.2020.11.003&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":52,"discovery_date":"2021-02-23T11:11:00","title":"Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Metab. 2021 Feb;3(2):211-227. doi: 10.1038/s42255-021-00341-7. Epub 2021 Feb 18.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Proregenerative responses are required for the restoration of nervous-system functionality in demyelinating diseases such as multiple sclerosis (MS). Yet, the limiting factors responsible for poor CNS repair are only partially understood. Here, we test the impact of a Western diet (WD) on phagocyte function in a mouse model of demyelinating injury that requires microglial innate immune function for a regenerative response to occur. We find that WD feeding triggers an ageing-related, dysfunctional metabolic response that is associated with impaired myelin-debris clearance in microglia, thereby impairing lesion recovery after demyelination. Mechanistically, we detect enhanced transforming growth factor beta (TGFβ) signalling, which suppresses the activation of the liver X receptor (LXR)-regulated genes involved in cholesterol efflux, thereby inhibiting phagocytic clearance of myelin and cholesterol. Blocking TGFβ or promoting triggering receptor expressed on myeloid cells 2 (TREM2) activity restores microglia responsiveness and myelin-debris clearance after demyelinating injury. Thus, we have identified a druggable microglial immune checkpoint mechanism regulating the microglial response to injury that promotes remyelination.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33619376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33619376&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s42255-021-00341-7&gt;10.1038/s42255-021-00341-7&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33619376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":51,"discovery_date":"2021-02-23T11:11:00","title":"Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Elife. 2021 Feb 22;10:e57417. doi: 10.7554/eLife.57417.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Cells exist within complex milieus of communicating factors, such as cytokines, that combine to generate context-specific responses, yet nearly all knowledge about the function of each cytokine and the signaling propagated downstream of their recognition is based on the response to individual cytokines. Here, we found that regulatory T cells (Tregs) integrate concurrent signaling initiated by IL-2 and IL-4 to generate a response divergent from the sum of the two pathways in isolation. IL-4 stimulation of STAT6 phosphorylation was blocked by IL-2, while IL-2 and IL-4 synergized to enhance STAT5 phosphorylation, IL-10 production, and the selective proliferation of IL-10-producing Tregs, leading to increased inhibition of conventional T cell activation and the reversal of asthma and multiple sclerosis in mice. These data define a mechanism of combinatorial cytokine signaling and lay the foundation upon which to better understand the origins of cytokine pleiotropy while informing improved the clinical use of cytokines.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617447&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.7554/eLife.57417&gt;10.7554/eLife.57417&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":50,"discovery_date":"2021-02-23T11:11:00","title":"Quantifying upper limb tremor in people with multiple sclerosis using Fast Fourier Transform based analysis of wrist accelerometer signals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Rehabil Assist Technol Eng. 2021 Feb 3;8:2055668320966955. doi: 10.1177/2055668320966955. eCollection 2021 Jan-Dec.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Tremor is a disabling symptom of Multiple Sclerosis (MS). The development of objective methods of tremor characterisation to assess intervention efficacy and disease progression is therefore important. The possibility of using a Fast Fourier Transform (FFT) method for tremor detection was explored.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Acceleration from a wrist-worn device was analysed using FFTs to identify and characterise tremor magnitude and frequency. Processing parameters were explored to provide insight into the optimal algorithm. Participants wore a wrist tri-axial accelerometer during 9 tasks. The FAHN clinical assessment of tremor was used as the reference standard.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Five people with MS and tremor (57.6 ± 15.3 years, 3 F/2M) and ten disease-free controls (42.4 ± 10.9 years, 5 M/5F) took part. Using specific algorithm settings tremor identification was possible (peak frequency 3-15Hz; magnitude greater than 0.06 g; 2 s windows with 50% overlap; using 2 of 3 axes of acceleration), giving sensitivity 0.974 and specificity 0.971 (38 tremor occurrences out of 108 tasks, 1 false positive, 2 false negatives). Tremor had frequency 3.5-13.0 Hz and amplitude 0.07-2.60g.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Upper limb tremor in people with MS can be detected using a FFT approach based on acceleration recorded at the wrist, demonstrating the possibility of using this minimally encumbering technique within clinical practice.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614109&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7869147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7869147&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055668320966955&gt;10.1177/2055668320966955&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":49,"discovery_date":"2021-02-23T11:11:00","title":"Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Immunometabolism. 2021;3(1):e210006. doi: 10.20900/immunometab20210006. Epub 2021 Jan 22.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Targeting glycolysis in T helper 17 (Th17) cells presents an attractive opportunity to treat Th17 cell-mediated autoimmune diseases such as multiple sclerosis (MS). Pyruvate kinase isoform 2 (PKM2) is a glycolytic enzyme expressed in T cells infiltrating the central nervous system in a mouse model of MS, suggesting PKM2 modulation could provide a new avenue for MS therapeutics. In a recent article in &lt;i&gt;Science Signaling&lt;/i&gt;, Seki et al. show that pharmacological modulation of PKM2 alters but does not ameliorate disease in a mouse model of MS. These results warrant further consideration of PKM2 modulators to treat Th17 cell-mediated autoimmunity.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614166&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894650/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7894650&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.20900/immunometab20210006&gt;10.20900/immunometab20210006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":48,"discovery_date":"2021-02-23T11:11:00","title":"Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102831. doi: 10.1016/j.msard.2021.102831. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Spasticity is a common problematic symptom in Multiple Sclerosis with over one third of patients failing first line therapies. Intrathecal baclofen is a safe and efficacious option for treatment resistant spasticity. Anecdotally patients report improved concentration/cognitive performance when switching to intrathecal baclofen (ITB) from systemic medications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIM: To explore whether subjects who proceed with ITB pump implantation for spasticity management and reduce oral anti-spasticity agents will have improved cognitive function.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Subjects were admitted for trial of ITB via lumbar puncture and subsequent pump implantation. Spasticity and cognitive measures before ITB trial and 3 months post implant were recorded. Paired t-test or Wilcoxon Signed Ranks test was used for within subject change and effect sizes (Cohen&#x27;s d&lt;sub&gt;z&lt;/sub&gt;) were calculated. Subgroup analysis of those on ≥2, or ≤ 1 spasticity medications at baseline was performed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 27 subjects with MS completed per protocol. Mean age 46 years [26 - 56], disease duration 15 years [6 - 26], RRMS = 3, SPMS = 17 and PPMS=7. The majority were on multiple spasticity medications. Spasticity scores significantly improved post pump implant. Mean ITB dose at 3 months was 143 mcg / day and 19 discontinued all other treatments for spasticity. There was no deterioration on any cognitive or mood measure. An improvement of moderate effect size was found in Backwards Digit Span (d=0.41, p=0.059) and HADS - anxiety (d=0.37, p=0.097). Fatigue Severity Scale score decreased substantially (d=0.81, p=0.005). Small improvements in Symbol Digit Modalities Test score (d=0.24) and Sustained Attention to Response Task response time (d=0.23) were non-significant. Performance on other measures did not change. Effect sizes were larger in subgroup on ≥2 oral spasticity medications at baseline, compared to the group on ≤1 medication (SDMT, d=0.42 vs d=0.07; Backwards digit span 0.45 vs 0.28; HADS-anxiety 0.39 vs 0.32; HADS-depression d=0.32 vs 0.05 and FSS, d= 1.14 vs 0.42).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: In a pilot study exploring the impact of ITB on cognition, spasticity scores improved universally and beneficial effects on some measures of fatigue, anxiety, auditory attention and verbal working memory were found. Improvement of speed of processing in those withdrawing higher doses of oral medication was also demonstrated suggesting that switching to ITB has added cognitive and psychological benefits for people with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618123&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102831&gt;10.1016/j.msard.2021.102831&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":47,"discovery_date":"2021-02-23T11:11:00","title":"Feasibility and efficacy of a physical activity intervention for managing restless legs syndrome in multiple sclerosis: Results of a pilot randomized controlled trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102836. doi: 10.1016/j.msard.2021.102836. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: This pilot randomized controlled trial examined the feasibility and efficacy of a physical activity behavior change intervention for improving restless legs syndrome (RLS) severity and secondary sleep outcomes among a sample of adults with multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Participants with MS(N=15) were randomly assigned into intervention(n=8) or waitlist control(n=7) conditions. The physical activity intervention was delivered over a 16-week period and outcomes were assessed at baseline and immediately following the 16-week period in both conditions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: There was a significant, positive effect of the intervention on overall RLS severity (p=.01;η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.43), severity during the night(p=.03,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.35), severity during the day while resting(p=.01,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.44), and severity during the day while active(p&amp;lt;.01,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.61), and non-significant improvements in RLS severity while falling asleep (p=.33,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.09). There were significant positive effects on sleep satisfaction(p&amp;lt;.01,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.49) and non-significant improvements in self-reported global sleep quality(p=.35,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.08). There was a significant intervention effect on self-reported time in bed(p=.03,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.37) and total sleep time(p=.03,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.36), and non-significant improvements in self-reported sleep latency (p=.08,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.25), sleep efficiency(p=.27,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.11), and daytime sleepiness (p=.52,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.04;p=.35,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.08;p=.51,η&lt;sub&gt;ρ&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.04). There was no significant effect of the intervention on device-measured sleep quality.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: We provide preliminary evidence for the feasibility and efficacy of a physical activity intervention for reducing RLS severity and potentially improving self-reported sleep outcomes in adults with MS. CLINICALTRIALS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;GOV IDENTIFICATION NUMBER: NCT04061681.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618120/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618120&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102836&gt;10.1016/j.msard.2021.102836&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618120/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":46,"discovery_date":"2021-02-23T11:11:00","title":"Design considerations for a multiple sclerosis fatigue mobile app MS Energize: A pragmatic iterative approach using usability testing and resonance checks","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Internet Interv. 2021 Feb 2;24:100371. doi: 10.1016/j.invent.2021.100371. eCollection 2021 Apr.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic neurological condition affecting around 2.2 million people worldwide. The illness includes a range of symptoms, with fatigue considered to be one of the most disabling. This paper describes how a pragmatic and iterative approach, supported by usability and resonance testing, was used to build a minimum viable product of MS Energize-or MS Energise in UK English regions. MS Energise is a mobile application focused on self-management of fatigue for people with MS. The iterative approach included various stages of testing, during which user feedback including comments about interface, navigation and content, was sought to inform incremental app development and continual improvement. Usability testing was conducted with 11 people with longstanding multiple sclerosis in New Zealand and the United Kingdom, and focused on particular sections of the app as well as the accessibility of the app to users with MS. Two participants contributed to further resonance testing post-release to ensure the app was perceived as relevant and useful to the user. The usability testing and resonance testing phases suggested that user experience of MS Energise was mostly positive. Participants provided a number of suggestions for improvements to aspects of content and design; some of which we implemented during our app development process. Findings will also contribute to future planning and design iteration to enhance the user experience. The next step is further improvement of MS Energise prior to a trial of its clinical and cost effectiveness.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614414&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7878181&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.invent.2021.100371&gt;10.1016/j.invent.2021.100371&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":45,"discovery_date":"2021-02-23T11:11:00","title":"Multiple Koenen Tumors, a Rare Entity: Combination Treatment with 1% Topical Sirolimus Electrofulguration and Excision","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Skin Appendage Disord. 2021 Jan;7(1):66-70. doi: 10.1159/000511743. Epub 2020 Dec 16.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Koenen tumors are benign, cutaneous manifestations of tuberous sclerosis. These are disfiguring, painful, and challenging to treat as they frequently recur. We report a case of long-standing, multiple Koenen tumors affecting all twenty nails in an elderly female who was successfully treated with a combination of topical sirolimus 1%, surgical excision, and electrofulguration.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CASE REPORT: A 57-year-old lady presented with multiple, asymptomatic periungual, and subungual tumors affecting all twenty nails since 27 years. Cutaneous examination revealed confetti macules, ash-leaf macule, and shagreen patch over trunk. Nail biopsy was compatible with Koenen&#x27;s tumor. Computerized tomography of brain showed diffuse patchy sclerosis. The tumors were treated with topical sirolimus 1% ointment for 10 months with excellent regression. Electro-fulguration for both great toenails and surgical excision of right thumbnail periungual fibroma was done. 1% sirolimus was advised after the surgical treatment. There were no adverse effects or recurrence of tumors over a 2-year follow-up.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;DISCUSSION: Topical sirolimus 1% was effective in tumor regression and preventing new tumor formation. Larger tumors that interfered in daily chores were treated with excision and electrofulguration. Thus, a combination treatment for this rare presentation of tuberous sclerosis provided optimum results.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614724&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7879313/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7879313&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1159/000511743&gt;10.1159/000511743&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":44,"discovery_date":"2021-02-23T11:11:00","title":"Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare professionals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 22:1-11. doi: 10.1080/09638288.2021.1887378. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Urinary symptoms are highly prevalent among people with MS. This study aimed to explore the experiences of people with MS and HCPs in managing urinary symptoms and explore their views on using TTNS to treat urinary symptoms.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: Audio-recorded semi-structured, interviews were employed with people with MS and HCPs. All transcribed interviews were exported to NVivo software (Version 12) and analyzed using a reflexive approach to thematic analysis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Four main themes were identified; The wide-ranging negative impacts of urinary symptoms (&quot;It&#x27;s limited everything else&quot;), Gaps in urinary services (&quot;Is there somebody like that, sort of specialized in that area?&quot;), Management strategies (&quot;I don&#x27;t go too far from the toilet in case I need to use one&quot;), and optimism about TTNS (&quot;Are you giving Me Hope?&quot;).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Urinary symptoms are common and very troublesome for people with MS. Despite their prevalence, many people with MS continue to suffer in silence. People with MS require skilled multidisciplinary services guided by clinical care pathways to improve service provision and to address urinary symptoms. HCP&#x27;s and people with MS are open to the use of TTNS for urinary symptoms and have clear preferences for location and duration of intervention delivery. Implications for rehabilitation Urinary symptoms are very common and troublesome for people with multiple sclerosis, yet many continue to suffer in silence. People with multiple sclerosis lack knowledge about treatment options for urinary symptoms. There is an on-going need for healthcare provider education on guidelines for screening and managing urinary symptoms in people with MS and the role of specialist urinary service providers. HCP&#x27;s and people with MS are open to the use of TTNS for urinary symptoms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617371&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/09638288.2021.1887378&gt;10.1080/09638288.2021.1887378&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":43,"discovery_date":"2021-02-23T11:11:00","title":"Physician Compensation in the United States - Through the Lens of the MS Neurologist","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 17;50:102847. doi: 10.1016/j.msard.2021.102847. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE OF REVIEW: To explore the elements that are typically considered when determining physician compensation in the United States and to examine if the compensation of neurologists with expertise in multiple sclerosis (MS) care is commensurate with that for other neurological specialists and medical specialists that also employ complex therapies, e.g., oncology.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RECENT FINDINGS: The complexity in the diagnosis and management of MS requires increasing specialization. Additionally, changing models for the delivery of MS care has resulted in the MS neurologist generating significant contribution margins. In fact, the revenue to compensation ratio for the MS neurologist may be significantly higher than that of any other discipline in neuroscience service lines. However, while the contribution margin is often a key justification of compensation of interventional and intensive care practitioners in neuroscience service lines, it is generally not considered in the MS neurologist&#x27;s compensation. Compensation models for MS neurologists typically depend heavily on the absolute number of relative value units associated with evaluation and management (E&amp;amp;M) codes making other fields of neurology financially more attractive to trainees.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;SUMMARY: In considering the shortage of MS specialists, the demands of their discipline, and the revenue to compensation ratios, the MS neurologist is significantly undercompensated relative to other neurological specialists and to physicians in other disciplines. Compensating the MS neurologist appropriately and supporting the necessary infrastructure for MS care will likely attract more trainees to this discipline and help reverse the current scarcity of MS neurologists in the United States.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618121/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618121&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102847&gt;10.1016/j.msard.2021.102847&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618121/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":42,"discovery_date":"2021-02-23T11:11:00","title":"Role of extracellular vesicles in neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Prog Neurobiol. 2021 Feb 19:102022. doi: 10.1016/j.pneurobio.2021.102022. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Extracellular vesicles (EVs) are heterogeneous cell-derived membranous structures that arise from the endosome system or directly detach from the plasma membrane. In recent years, many advances have been made in the understanding of the clinical definition and pathogenesis of neurodegenerative diseases, but translation into effective treatments is hampered by several factors. Current research indicates that EVs are involved in the pathology of diseases such as Alzheimer&#x27;s disease (AD), Parkinson&#x27;s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington&#x27;s disease (HD). Besides, EVs are also involved in the process of myelin formation, and can also cross the blood-brain barrier to reach the sites of CNS injury. It is suggested that EVs have great potential as a novel therapy for the treatment of neurodegenerative diseases. Here, we reviewed the advances in understanding the role of EVs in neurodegenerative diseases and addressed the critical function of EVs in the CNS. We have also outlined the physiological mechanisms of EVs in myelin regeneration and highlighted the therapeutic potential of EVs in neurodegenerative diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617919&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.pneurobio.2021.102022&gt;10.1016/j.pneurobio.2021.102022&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":41,"discovery_date":"2021-02-23T11:11:00","title":"Emerging Therapeutic Applications for Fumarates","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Trends Pharmacol Sci. 2021 Feb 19:S0165-6147(21)00007-9. doi: 10.1016/j.tips.2021.01.004. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Fumarates are successfully used for the treatment of psoriasis and multiple sclerosis. Their antioxidative, immunomodulatory, and neuroprotective properties make fumarates attractive therapeutic candidates for other pathologies. The exact working mechanisms of fumarates are, however, not fully understood. Further elucidation of the mechanisms is required if these drugs are to be successfully repurposed for other diseases. Towards this, administration route, dosage, and treatment timing, frequency, and duration are important parameters to consider and optimize with clinical paradigms in mind. Here, we summarize the rapidly expanding literature on the pharmacokinetics and pharmacodynamics of fumarates, including a discussion on two recently FDA-approved fumarates Vumerity&lt;sup&gt;TM&lt;/sup&gt; and Bafiertam&lt;sup&gt;TM&lt;/sup&gt;. We review emerging applications of fumarates, focusing on neurological and cardiovascular diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618840&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.tips.2021.01.004&gt;10.1016/j.tips.2021.01.004&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":40,"discovery_date":"2021-02-23T11:11:00","title":"The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurosci Behav Physiol. 2021 Feb 18:1-8. doi: 10.1007/s11055-021-01050-0. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The new coronavirus SARS-CoV-2 and the disease it causes COVID-19 involves not only respiratory system damage, but can also lead to disorders of the central and peripheral nervous system, as well as the muscular system. This article presents published data and our own observations on the course of neurological disorders in COVID-19 patients. There is a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations. Severe neurological disorders are mostly seen in severe cases of COVID-19 and include acute cerebrovascular accidents (aCVA), acute necrotizing encephalopathy, and Guillain-Barré syndrome. Factors potentially complicating the course of COVID-19 and increasing the development of neurological complications include arterial hypertension, diabetes mellitus, and chronic cardiac and respiratory system diseases. Questions of the possible effects of human coronaviruses on the course of chronic progressive neurological diseases are addressed using multiple sclerosis (MS) as an example. We discuss the management of patients with aCVA and MS depending on the risk of developing coronavirus infection.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33619413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33619413&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7889305/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7889305&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11055-021-01050-0&gt;10.1007/s11055-021-01050-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33619413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":39,"discovery_date":"2021-02-23T11:11:00","title":"Activated microglia drive demyelination via CSF1R signaling","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Glia. 2021 Feb 23. doi: 10.1002/glia.23980. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Microgliosis is a prominent pathological feature in many neurological diseases including multiple sclerosis (MS), a progressive auto-immune demyelinating disorder. The precise role of microglia, parenchymal central nervous system (CNS) macrophages, during demyelination, and the relative contributions of peripheral macrophages are incompletely understood. Classical markers used to identify microglia do not reliably discriminate between microglia and peripheral macrophages, confounding analyses. Here, we use a genetic fate mapping strategy to identify microglia as predominant responders and key effectors of demyelination in the cuprizone (CUP) model. Colony-stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF) - a secreted cytokine that regulates microglia development and survival-is upregulated in demyelinated white matter lesions. Depletion of microglia with the CSF1R inhibitor PLX3397 greatly abrogates the demyelination, loss of oligodendrocytes, and reactive astrocytosis that results from CUP treatment. Electron microscopy (EM) and serial block face imaging show myelin sheaths remain intact in CUP treated mice depleted of microglia. However, these CUP-damaged myelin sheaths are lost and robustly phagocytosed upon-repopulation of microglia. Direct injection of CSF1 into CNS white matter induces focal microgliosis and demyelination indicating active CSF1 signaling can promote demyelination. Finally, mice defective in adopting a toxic astrocyte phenotype that is driven by microglia nevertheless demyelinate normally upon CUP treatment implicating microglia rather than astrocytes as the primary drivers of CUP-mediated demyelination. Together, these studies indicate activated microglia are required for and can drive demyelination directly and implicate CSF1 signaling in these events.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33620118&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/glia.23980&gt;10.1002/glia.23980&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":38,"discovery_date":"2021-02-23T11:11:00","title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 11;50:102842. doi: 10.1016/j.msard.2021.102842. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Natalizumab (NTZ) treatment of multiple sclerosis (MS) has been associated with increased risk of progressive multifocal leukoencephalopathy (PML). The aim of the present study was to evaluate the impact of PML risk assessment on PML incidence in NTZ treated MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: By using information from the population-based Swedish MS registry a retrospective cohort was established of patients treated with NTZ between 2006-2018. The effect on PML incidence before and after utilizing a risk management plan, including JC virus (JCV) serology, was analyzed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In December 2018, 804 PML cases associated with NTZ therapy of MS had been reported globally, including 9 cases from Sweden. The estimated PML incidence 2018 in Sweden and globally was 0.7 (0.3-1.4) and 4.15 (3.9-4.4) per 1,000 person years, respectively. In Sweden, JCV serology was introduced 2012 for PML risk assessment and the cumulative risk of PML was significantly lower 2012-2018 compared to the period 2006-2011 (p=0.042). The mean NTZ exposure time was 60.1 months (SD 37.2) in the first period (2006-2011) and 32.6 months (SD 22.0) in the second period (2012-2018). The number of patients treated with NTZ decreased, and the number of patients at increased risk of PML was 1.9 % at the end of the study period.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Since 2006 the incidence of PML associated with NTZ treatment of MS has decreased in Sweden. Our findings suggest that this reduction is due to an effective adoptation and adherence to the established risk management plan that implies switching patients at increased PML risk from NTZ to other highly efficacious therapies. A less pronounced decline in PML incidence has recently been observed in France, but not globally.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610957/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33610957&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102842&gt;10.1016/j.msard.2021.102842&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610957/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":37,"discovery_date":"2021-02-23T11:11:00","title":"Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neuroinflammation. 2021 Feb 20;18(1):52. doi: 10.1186/s12974-021-02102-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis. It is released by endothelial cells, but also expressed by neurons and glial cells in the central nervous system (CNS). Interestingly, this enzyme also contributes to pathological processes in the CNS such as neuroinflammation by activating microglia and increasing blood-brain barrier permeability. Nevertheless, its role in the control of adaptive and innate immune response remains poorly understood.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: tPA effects on myeloid and lymphoid cell response were studied in vivo in the mouse model of multiple sclerosis experimental autoimmune encephalomyelitis and in vitro in splenocytes.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: tPA&lt;sup&gt;-/-&lt;/sup&gt; animals exhibited less severe experimental autoimmune encephalomyelitis than their wild-type counterparts. This was accompanied by a reduction in both lymphoid and myeloid cell populations in the spinal cord parenchyma. In parallel, tPA increased T cell activation and proliferation, as well as cytokine production by a protease-dependent mechanism and via plasmin generation. In addition, tPA directly raised the expression of MHC-II and the co-stimulatory molecules CD80 and CD86 at the surface of dendritic cells and macrophages by a direct action dependent of the activation of epidermal growth factor receptor.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our study provides new insights into the mechanisms responsible for the harmful functions of tPA in multiple sclerosis and its animal models: tPA promotes the proliferation and activation of both lymphoid and myeloid populations by distinct, though complementary, mechanisms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610187/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33610187&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1186/s12974-021-02102-5&gt;10.1186/s12974-021-02102-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610187/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":36,"discovery_date":"2021-02-23T11:11:00","title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10460-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFα) treatment and central nervous system (CNS) events. We described eight patients presenting with demyelinating CNS events while on treatment with anti-TNFα for autoimmune diseases and followed up for a medium period of 4 years. Four patients presented with isolated demyelinating events, three patients fulfilled the criteria for multiple sclerosis (MS), and one patient showed worsening of pre-existing MS after anti-TNF therapy initiation. All patients except one, showed a good medium-term prognosis. Our observation supports an association between anti-TNFα treatment and demyelinating events and suggests that a prompt discontinuation of the drug may lead to a favorable demyelinating disease outcome.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611609/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611609&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10460-6&gt;10.1007/s00415-021-10460-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611609/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":35,"discovery_date":"2021-02-23T11:11:00","title":"Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 21. doi: 10.1007/s00415-021-10436-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) and functional neurological disorder (FND) are both diagnostically challenging conditions which can present with similar symptoms. We systematically reviewed the literature to identify patients with MS who were misdiagnosed with FND, patients with FND who were misdiagnosed with MS, and reports of patients with both conditions. In addition to FND, we included studies of patients with other functional and psychiatric disorders where these caused symptoms leading to investigation for or a diagnosis of MS, which in a different context would likely have been labeled as FND. Our review suggests that MS is one of the most common causes of misdiagnosis of FND and vice versa. We discuss the clinical errors that appear to result in misdiagnoses, such as over-reliance on psychiatric comorbidity when making a diagnosis of FND or over-reliance on neuroimaging for the diagnosis of MS, and practical ways to avoid them. Comorbidity between these two conditions is also likely common, has been poorly studied, and adds complexity to diagnosis and treatment in patients with both MS and FND. Misdiagnosis and comorbidity in a landscape of emerging evidence-based treatments for both MS and FND are issues not only of clinical importance to the care of these patients, but also to treatment trials, especially of MS, where FND could be a hidden confounder.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611631/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611631&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10436-6&gt;10.1007/s00415-021-10436-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611631/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":34,"discovery_date":"2021-02-23T11:11:00","title":"COVID-19 in multiple sclerosis patients treated with dimethyl fumarate","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10446-4. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611610/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611610&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10446-4&gt;10.1007/s00415-021-10446-4&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611610/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":33,"discovery_date":"2021-02-23T11:11:00","title":"Efficacy of Gamma Knife radiosurgery in the management of multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurosurg Rev. 2021 Feb 20. doi: 10.1007/s10143-021-01507-3. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Trigeminal neuralgia (TN) is the most frequent craniofacial pain condition, which commonly affects patients suffering from multiple sclerosis (MS). Stereotactic radiosurgery, especially Gamma Knife radiosurgery (GKRS), represents a safe and effective treatment for TN, and it has been adopted also for MS-TN, with a lower success rate. Therefore, we aimed to analyze the outcome of GKRS for MS-TN. PubMed, Web of Science, and Google Scholar and the reference list of relevant articles were searched for GKRS in MS-TN. Two investigators independently identified the articles, assessed the study quality, and extracted the data. Endpoints of interest were initial pain responders, successful treatments at the end of follow-up, and factors influencing the outcome. Data analyses were performed using R software. Twelve articles involving 646 patients met our inclusion criteria. Pooled proportion of patients who experienced an initial response to GKRS treatment was 83% (CI 74-90%). The cumulative proportion of successful treatments at the end of follow-up was 47% (CI 33-60%). No variables were found to have a significant contribution to heterogeneity regarding the initial response outcome. The only variable significantly explaining the heterogeneity found in the proportion of successful treatments was the length of the follow-up, with a negative b coefficient (- 0.0051, p value = 0.0047). Regarding the efficacy of GKRS in MS-TN, the initial pain response rate was 83%, which dramatically decreases to 47% during follow-up. GKRS still represents a valuable option for MS-TN; however, its long-term efficacy should be always considered.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611721/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611721&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10143-021-01507-3&gt;10.1007/s10143-021-01507-3&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611721/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":32,"discovery_date":"2021-02-23T11:11:00","title":"Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Biol Trace Elem Res. 2021 Feb 21. doi: 10.1007/s12011-021-02621-5. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The aim of this meta-analysis was to investigate whether the blood concentrations of patients with multiple sclerosis (MS) are associated with those of the healthy control group in terms of trace elements including zinc (Zn), iron (Fe), manganese (Mn), magnesium (Mg), selenium (Se), and copper (Cu). A comprehensive search was performed in online databases including PubMed, Scopus, Embase, and Web of Science for studies, which have addressed trace elements in MS up to July 23, 2020. The chi-square test and I&lt;sup&gt;2&lt;/sup&gt; statistic were utilized to evaluate inter-study heterogeneity across the included studies. Weighted mean differences (WMDs) and corresponding 95% CI were considered as a pooled effect size (ES). Twenty-seven articles (or 32 studies) with a total sample comprised of 2895 participants (MS patients (n = 1567) and controls (n = 1328)) were included. Pooled results using random-effects model indicated that the levels of Zn (WMD = - 7.83 mcg/dl, 95% CI = - 12.78 to - 2.87, Z = 3.09, P = 0.002), and Fe (WMD = - 13.66 mcg/dl, 95% CI = - 23.13 to - 4.19, Z = 2.83, P = 0.005) were significantly lower in MS patients than in controls. However, it was found that levels of Mn (WMD = 0.03 mcg/dl, 95% CI = 0.01 to 0.04, Z = 2.89, P = 0.004) were significantly higher in MS patients. Yet, no significant differences were observed in the levels of Mg, Se, and Cu between both groups. This meta-analysis revealed that the circulating levels of Zn and Fe were significantly lower in MS patients and that Mn level was significantly higher than those in the control group. However, it was found that there was no significant difference between MS patients and controls with regard to levels of Mg, Se, and Cu.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611740/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611740&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s12011-021-02621-5&gt;10.1007/s12011-021-02621-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611740/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":31,"discovery_date":"2021-02-23T11:11:00","title":"Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Feb 19:10.1212/WNL.0000000000011630. doi: 10.1212/WNL.0000000000011630. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Genetic variants in the vicinity of &lt;i&gt;TNFRSF1A&lt;/i&gt;, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS N = 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (N&lt;sub&gt;cases&lt;/sub&gt;/&lt;sub&gt;controls&lt;/sub&gt; = 37,688/981,372) and age at PD onset (N = 28,568) using GWAS data from the International Parkinson&#x27;s Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis and multiple sclerosis risk (N = 38,589-45,975).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: TNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio/OR per 10% lower circulating CRP = 0.99; 95% CI: 0.91-1.08) or age at onset (0.13 years later onset; 95% CI: -0.66 to 0.92). In contrast, genetically-indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR = 0.75; 95% CI: 0.65-0.86) and ulcerative colitis (OR = 0.84; 95% CI: 0.74-0.97) and increased multiple sclerosis risk (OR = 1.57; 95% CI: 1.36-1.81). Findings were consistent across models using different genetic instruments and MR estimators.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608417/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608417&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1212/WNL.0000000000011630&gt;10.1212/WNL.0000000000011630&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608417/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":30,"discovery_date":"2021-02-23T11:11:00","title":"Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102775. doi: 10.1016/j.autrev.2021.102775. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Immune cells play essential roles in metabolic homeostasis and thus, undergo analogous changes in normal physiology (e.g., puberty and pregnancy) and in various metabolic and immune diseases. An essential component of this close relationship between the two is sex differences. Many autoimmune diseases, such as systemic lupus erythematous and multiple sclerosis, feature strikingly increased prevalence in females, whereas in contrast, infectious diseases, such as Ebola and Middle East Respiratory Syndrome, affect more men than women. Therefore, there are fundamental aspects of metabolic homeostasis and immune functions that are regulated differently in males and females. This can be observed in sex hormone-immune interaction where androgens, such as testosterone, have shown immunosuppressive effects whilst estrogen is on the opposite side of the spectrum with immunoenhancing facilitation of mechanisms. In addition, the two sexes exhibit significant differences in metabolic regulation, with estrous cycles in females known to induce variability in traits and more pronounced metabolic disease phenotype exhibited by males. It is likely that these differences underlie both the development of metabolic and autoimmune diseases and the response to current treatment options. Sexual dimorphism in immunometabolism has emerged to become an area of intense research, aiming to uncover sex-biased effector molecules in the various metabolic tissues and immune cell types, identify sex-biased cell-type-specific functions of common effector molecules, and understand whether the sex differences in metabolic and immune functions influence each other during autoimmune pathogenesis. In this review, we will summarize recent findings that address these critical questions of sexual dimorphism in immunometabolism as well as their translational implications for the clinical management of autoimmune diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609790/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609790&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.autrev.2021.102775&gt;10.1016/j.autrev.2021.102775&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609790/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":29,"discovery_date":"2021-02-23T11:11:00","title":"Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10466-0. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609155/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609155&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10466-0&gt;10.1007/s00415-021-10466-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609155/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":28,"discovery_date":"2021-02-23T11:11:00","title":"Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Feb 20. doi: 10.1111/ene.14782. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: to evaluate the effect of menopause on disability accumulation in women followed from their clinically isolated syndrome (CIS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We examined the longitudinal changes in EDSS from CIS until the last follow-up in women belonging to the Barcelona CIS prospective cohort, followed through their menopausal transition. The analysis is based on 13,718 EDSS measurements with an average of 28 EDSS per patient. Differences in EDSS trajectories between menopausal and non-menopausal women, controlling for age and disease duration were evaluated. We performed two sensitivity analyses, in women with confirmed MS and in those experiencing and early menopause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: from 764 eligible women, 496 (65%) responded to the questionnaire and 74 (14.9%) reached menopause over follow-up. We did not find a significant inflection point in EDSS trajectories around menopause (slope change -0.009 (95%CI -0.066; 0.046). The annual increase in EDSS over the complete course of the disease was significantly higher in menopausal women (0.049 IC 95% 0.026 - 0.074) versus non-menopausal (0.019 IC 95% 0.008 - 0.031, interaction p-value 0.025). This difference was lost once controlling for age and disease duration (EDSS annual increase of 0.059 95% CI 0.025- 0.094 vs 0.038 IC 95% 0.021 - 0.057 respectively, interaction p-value 0.321). No inflection point was detected when the analysis was restricted to women with confirmed MS or with earlier menopause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: menopause is not associated with an increased risk of disability in a CIS population, considering EDSS trajectories throughout the course of the disease, together with age and disease duration.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609298/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609298&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/ene.14782&gt;10.1111/ene.14782&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609298/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":27,"discovery_date":"2021-02-23T11:11:00","title":"Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136/ejhpharm-2019-002048. Epub 2019 Oct 16.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment. Patients were classified into five categories: minimum probability (&amp;lt;0.1/1000); low (0.1/1000); medium-low (0.2-0.6/1000); medium-high (0.8-3/1000); high probability (3-10/1000).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 34 patients were included. The probability of PML in the last cycle was: 55.9% minimum, 8.8% low, 11.8% medium-low, 3% medium-high, and 20.5% high. 12 patients continue with active treatment with natalizumab. No cases of PML have been confirmed. Adverse effects were detected in 50% of patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Quantifying risk factors allows us to estimate the probability of PML appearance, thus assessing the maintenance or suspension of natalizumab.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608441/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608441&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/ejhpharm-2019-002048&gt;10.1136/ejhpharm-2019-002048&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608441/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":26,"discovery_date":"2021-02-23T11:11:00","title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurochem. 2021 Feb 20. doi: 10.1111/jnc.15327. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is growing evidence that excessive microglial phagocytosis of neurons and synapses contributes to multiple brain pathologies. RNA-seq and genome wide association (GWAS) studies have linked multiple phagocytic genes to neurodegenerative diseases, and knock-out of phagocytic genes has been found to protect against neurodegeneration in animal models, suggesting that excessive microglial phagocytosis contributes to neurodegeneration. Here, we review recent evidence that microglial phagocytosis of live neurons and synapses causes neurodegeneration in animal models of Alzheimer&#x27;s disease and other tauopathies, Parkinson&#x27;s disease, frontotemporal dementias, multiple sclerosis, retinal degeneration, and neurodegeneration induced by ischaemia, infection or ageing. We also review factors regulating microglial phagocytosis of neurons, including: nucleotides, frackalkine, phosphatidylserine, calreticulin, UDP, CD47, sialylation, complement, galectin-3, Apolipoprotein E, phagocytic receptors, Siglec receptors, cytokines, microglial epigenetics and expression profile. Some of these factors may be potential treatment targets to prevent neurodegeneration mediated by excessive microglial phagocytosis of live neurons and synapses.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608912/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608912&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/jnc.15327&gt;10.1111/jnc.15327&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608912/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":25,"discovery_date":"2021-02-23T11:11:00","title":"B lymphocytes, the gastrointestinal tract and autoimmunity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102777. doi: 10.1016/j.autrev.2021.102777. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Under homeostatic conditions, bidirectional interactions between the gastrointestinal and the immune system allow production of both inflammatory and anti-inflammatory responses designed to prevent undesirable inflammation and to respond efficiently to potential insults. This balanced regulation can be disrupted in disorders that affect tissues remote to the gastrointestinal tract, as seen in autoimmune diseases. Recent reports have described a variety of B lymphocyte-mediated functions that likely contribute to gastrointestinal homeostasis to a greater extent than previously thought. Studies have shown that early B cell development takes place within the intestine, and that self-reactive B cells are rendered tolerant using mechanisms known to occur in the bone marrow, indicating that the gastrointestinal tract contributes to maintaining immune tolerance to self. Relatedly, continuous bacterial stimulation is essential for maintaining regulatory B cell functions and for mediating mucosal homeostasis. In studies of neuro-inflammation, intestinal IgA+ B cells, which constitute a prominent source of lymphocytes in the organism, can migrate to inflamed tissues and exert regulatory functions that attenuate inflammation in the central nervous system, indicating that, in addition to its local effects in the intestin, gut microbiota-B cell crosstalk can exert long-range beneficial effects. At the translational level, metabolites produced by gut microbiota can act as B cell-intrinsic epigenetic modulators, reducing inflammation in the skin and kidneys of mice suffering from experimental lupus. Given the significant impact of B cell-intestinal microbiota interactions, there is a momentum for improving our understanding of these pathways in autoinflammatory diseases and for designing novel therapeutic strategies for systemic autoimmune diseases where B cells play key roles.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609796/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609796&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.autrev.2021.102777&gt;10.1016/j.autrev.2021.102777&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609796/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":24,"discovery_date":"2021-02-23T11:11:00","title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 3;50:102807. doi: 10.1016/j.msard.2021.102807. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Studies on the prevalence of neuromyelitis optica spectrum disorder (NMOSD) are still scarce. The aim of the current study was to determine the prevalence rate of NMOSD in Belo Horizonte, southeast Brazil, where the prevalence rate of multiple sclerosis (MS) has already been established.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: For this observational study, eligible patients had to meet the 2015 International Panel for Neuromyelitis Optica Diagnosis, be seen at the study center between January 2000 and February 2019 and live in Belo Horizonte. The prevalence rate of NMOSD was estimated based on the number of MS and NMOSD patients seen at same Center during the same period, and the previously established prevalence of MS in Belo Horizonte.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: During the study period, there were 69 patients with NMOSD, 60 (87.0%) of whom were females, and 44 (63.8%) non-whites. The median age at disease onset was 36.7 (4-72) years, the mean EDSS score 4.78±2.36, and the mean ARR 0.57±0.43. Anti-aquaporin-4 immunoglobulin testing was available for 61 (88.4%) patients, of whom 41 (67.2%) had a positive result. During the same period, 280 MS patients were seen. Considering the local known prevalence rate of MS of 18.1/100,000 inhabitants, the estimated NMOSD prevalence rate in Belo Horizonte was 4.52/100,000 (95% CI 3.72-5.43) inhabitants.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The prevalence rate of NMOSD in Belo Horizonte is high as compared with those found in most of the studies reported to date.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609926/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609926&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102807&gt;10.1016/j.msard.2021.102807&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609926/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":23,"discovery_date":"2021-02-23T11:11:00","title":"Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102834. doi: 10.1016/j.msard.2021.102834. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1β. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1β levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609923/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609923&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102834&gt;10.1016/j.msard.2021.102834&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609923/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":22,"discovery_date":"2021-02-23T11:11:00","title":"Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 13;49:102754. doi: 10.1016/j.msard.2021.102754. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs that inhibit immune cell trafficking, such as natalizumab (NTZ) and fingolimod (FTY), remains to be determined, as do the possible effects of these drugs on both the infection and the related disease.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIMS: To describe self-reported COVID-19 symptoms and disease severity in PwMS on NTZ or FTY who received serology confirmation of SARS-CoV-2 infection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: From 27th April to 3rd May 2020, telephone interviews were conducted with 140 PwMS under treatment with NTZ or FTY in order to collect structured data on multiple sclerosis (MS) and COVID-19. The patients, all followed at our center, were classified as symptomatic, paucisymptomatic or asymptomatic on the basis of their self-reported clinical characteristics. COVID-19 severity was rated on a 7-point ordinal scale. In addition, in the period 4th May to 3rd June 2020 SARS-CoV-2 serology testing, using the Roche SARS-CoV-2 IgG assay (Elecsys&lt;sup&gt;Ⓡ&lt;/sup&gt;), was performed in 104/140 (74.2%) of the interviewed PwMS (50 treated with NTZ and 54 with FTY).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 14/104 (13.4%) PwMS on NTZ or FTY had anti-SARS-CoV-2 antibodies: 8 met the criteria for asymptomatic, 3 for paucisymptomatic and 3 for symptomatic COVID-19 (COVID-19 severity score lower than 3). None of them required hospitalization or showed severe COVID-19 complications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Despite the relatively high SARS CoV-2 seroprevalence found in this sample of PwMS, all the positive cases showed either no or only mild COVID-19 symptoms. These reassuring findings indicate a lack of COVID-19 complications in PwMS on DMTs and support the hypothesis that it is safe to maintain ongoing treatment with these drugs in the current setting.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609958/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609958&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102754&gt;10.1016/j.msard.2021.102754&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609958/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":21,"discovery_date":"2021-02-23T11:11:00","title":"Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Stem Cell Res. 2021 Feb 12;52:102246. doi: 10.1016/j.scr.2021.102246. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons, causing gradual paralysis, and resulting in death 3-5 years from diagnosis. ALS causative mutations have been identified in multiple genes, including Fused in sarcoma (FUS), and recently characterized Annexin A11 (ANXA11). We have derived induced pluripotent stem cell (iPSC) lines from six ALS patient lymphoblastoid cell lines, three with mutations in FUS (Q519E, R521H, R522G), and three with mutations in ANXA11 (G38R, D40G, R235Q). These lines have been characterized and provide a novel resource for investigation into ALS pathology.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610019/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33610019&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.scr.2021.102246&gt;10.1016/j.scr.2021.102246&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610019/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":20,"discovery_date":"2021-02-23T11:11:00","title":"Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102838. doi: 10.1016/j.msard.2021.102838. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is not much awareness of varicella zoster virus (VZV) associated central nervous system (CNS) infections under treatment with natalizumab. Here we describe two natalizumab treated MS patients who developed acute retinal necrosis combined with CNS vasculitis caused by VZV. In natalizumab treated patients, visual symptoms atypical of optic neuritis should be promptly evaluated by an ophthalmologist. Currently, a total of 12 cases of natalizumab-associated VZV CNS or retinal infections are reported in literature. Our two cases and overview of currently available data provide information on prognosis and treatment decisions of this rare but devastating complication.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609925/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609925&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102838&gt;10.1016/j.msard.2021.102838&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609925/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":19,"discovery_date":"2021-02-23T11:11:00","title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Dec 28;49:102724. doi: 10.1016/j.msard.2020.102724. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The Expanded Disability Status Scale (EDSS) measures disease progression in Multiple Sclerosis (MS). EDSS changes are assumed to be due to worsening MS-related disability. Strict interpretation of this premise may include some normal findings as abnormal, inflating the disability score. Further, determining the cause of neurologic symptoms can be difficult in an older population with comorbid illness and polypharmacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To examine the association between EDSS, age, comorbidities and polypharmacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: 106 people, 55 years and older, with and without MS were administered the EDSS and a validated comorbidity questionnaire. Polypharmacy was also assessed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Median EDSS scores were 6.0 in people with MS and 3.0 in people without MS. No participant in our cohort had an EDSS of 0. Higher EDSS scores were associated with older age and more polypharmacy. Pyramidal and cerebellar functional systems accounted for the largest percentage of unique variance between groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Older individuals with and without MS demonstrated significant disability on the EDSS. These findings indicate that EDSS scores may be partially due to factors other than MS. Our understanding of disease course and disability may benefit from the development of normative EDSS scores to correct for these factors.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609959/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609959&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2020.102724&gt;10.1016/j.msard.2020.102724&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609959/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":18,"discovery_date":"2021-02-23T11:11:00","title":"Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 5;49:102738. doi: 10.1016/j.msard.2021.102738. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Axonal injury is the primary source of irreversible neurological decline in persons with multiple sclerosis (pwMS). Identifying and quantifying myelin and axonal loss in lesional and perilesional tissue in vivo is fundamental for a better understanding of multiple sclerosis (MS) outcomes and patient impairment. Using advanced magnetic resonance imaging (MRI) methods, consisting of selective inversion recovery quantitative magnetization transfer imaging (SIR-qMT) and multi-compartment diffusion MRI with the spherical mean technique (SMT), we conducted a cross-sectional pilot study to assess myelin and axonal damage in the normal appearing white matter (NAWM) surrounding chronic black holes (cBHs) and how this pathology correlates with disability in vivo. We hypothesized that lesional axonal transection propagates tissue injury in the surrounding NAWM and that the degree of this injury is related to patient disability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Eighteen pwMS underwent a 3.0 Tesla conventional clinical MRI, inclusive of T1 and T2 weighted protocols, as well as SIR-qMT and SMT. Regions of interests (ROIs) were manually delineated in cBHs, NAWM neighboring cBHs (perilesional NAWM), distant ipsilateral NAWM and contra-lateral distant NAWM. SIR-qMT-derived macromolecular-to-free pool size ratio (PSR) and SMT-derived apparent axonal volume fraction (V&lt;sub&gt;ax&lt;/sub&gt;) were extracted to infer on myelin and axonal content, respectively. Group differences were assessed using mixed-effects regression models and correlation analyses were obtained by bootstrapping 95% confidence interval.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In comparison to perilesional NAWM, both PSR and V&lt;sub&gt;ax&lt;/sub&gt; values were reduced in cBHs (p &amp;lt; 0.0001) and increased in distant contra-lateral NAWM ROIs (p &amp;lt; 0.001 for PSR and p &amp;lt; 0.0001 for V&lt;sub&gt;ax&lt;/sub&gt;) but not ipsilateral NAWM (p = 0.176 for PSR and p = 0.549 for V&lt;sub&gt;ax&lt;/sub&gt;). V&lt;sub&gt;ax&lt;/sub&gt; values measured in cBHs correlated with those in perilesional NAWM (Pearson rho = 0.63, p &amp;lt; 0.001). No statistically relevant associations were seen between PSR/V&lt;sub&gt;ax&lt;/sub&gt; values and clinical and/or MRI metrics of the disease with the exception of cBH PSR values, which correlated with the Expanded Disability Status Scale (Pearson rho = -0.63, p = 0.03).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our results show that myelin and axonal content, detected by PSR and V&lt;sub&gt;ax&lt;/sub&gt;, are reduced in perilesional NAWM, as a function of the degree of focal cBH axonal injury. This finding is indicative of an ongoing anterograde/retrograde degeneration and suggests that treatment prevention of cBH development is a key factor for preserving NAWM integrity in surrounding tissue. It also suggests that measuring changes in perilesional areas over time may be a useful measure of outcome for proof-of-concept clinical trials on neuroprotection and repair. PSR and V&lt;sub&gt;ax&lt;/sub&gt; largely failed to capture associations with clinical and MRI characteristics, likely as a result of the small sample size and cross-sectional design, however, longitudinal assessment of a larger cohort may unravel the impact of this pathology on disease progression.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609957/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609957&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102738&gt;10.1016/j.msard.2021.102738&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609957/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":17,"discovery_date":"2021-02-23T11:11:00","title":"Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Feb 12;30:102587. doi: 10.1016/j.nicl.2021.102587. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;In multiple sclerosis (MS), monoaminergic systems are altered as a result of both inflammation-dependent reduced synthesis and direct structural damage. Aberrant monoaminergic neurotransmission is increasingly considered a major contributor to fatigue pathophysiology. In this study, we aimed to compare the integrity of the monoaminergic white matter fibre tracts projecting from brainstem nuclei in a group of patients with MS (n = 68) and healthy controls (n = 34), and to investigate its association with fatigue. Fibre tracts integrity was assessed with the novel fixel-based analysis that simultaneously estimates axonal density, by means of &#x27;fibre density&#x27;, and white matter atrophy, by means of fibre &#x27;cross section&#x27;. We focused on ventral tegmental area, locus coeruleus, and raphe nuclei as the main source of dopaminergic, noradrenergic, and serotoninergic fibres within the brainstem, respectively. Fourteen tracts of interest projecting from these brainstem nuclei were reconstructed using diffusion tractography, and compared by means of the product of fibre-density and cross-section (FDC). Finally, correlations of monoaminergic axonal damage with the modified fatigue impact scale scores were evaluated in MS. Fixel-based analysis revealed significant axonal damage - as measured by FDC reduction - within selective monoaminergic fibre-tracts projecting from brainstem nuclei in MS patients, in comparison to healthy controls; particularly within the dopaminergic-mesolimbic pathway, the noradrenergic-projections to prefrontal cortex, and serotoninergic-projections to cerebellum. Moreover, we observed significant correlations between severity of cognitive fatigue and axonal damage within the mesocorticolimbic tracts projecting from ventral tegmental area, as well as within the locus coeruleus projections to prefrontal cortex, suggesting a potential contribution of dopaminergic and noradrenergic pathways to central fatigue in MS. Our findings support the hypothesis that axonal damage along monoaminergic pathways contributes to the reduction/dysfunction of monoamines in MS and add new information on the mechanisms by which monoaminergic systems contribute to MS pathogenesis and fatigue. This supports the need for further research into monoamines as therapeutic targets aiming to combat and alleviate fatigue in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610097/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33610097&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.nicl.2021.102587&gt;10.1016/j.nicl.2021.102587&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610097/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":16,"discovery_date":"2021-02-20T00:00:00.000Z","title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - PubMed","summary":"Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do not directly promote remyelination in the damaged central nervous system (CNS). Targeting CXCR7 (ACKR3) has been postulated as a potential therapeutic approach in demyelinating diseases, leading to both immunomodulation by reducing leukocyte infiltrates and promyelination by enhancing myelin repair. ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist. The effect of ACT-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) and the cuprizone-induced demyelination mouse models. In addition, ACT-1004-1239 was assessed in a rat oligodendrocyte precursor cell (OPC) differentiation assay in vitro. In the MOG-induced EAE model, ACT-1004-1239 treatment (10-100 mg/kg, twice daily, orally) showed a significant dose-dependent reduction in disease clinical scores, resulting in increased survival. At the highest dose tested (100 mg/kg, twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltrates into the CNS and plasma neurofilament light chain concentration. Treatment with ACT-1004-1239 dose-dependently increased plasma CXCL12 concentration, which correlated with a reduction of the cumulative disease score. Furthermore, in the cuprizone model, ACT-1004-1239 treatment significantly increased the number of mature myelinating oligodendrocytes and enhanced myelination in vivo. In vitro, ACT-1004-1239 promoted the maturation of OPCs into myelinating oligodendrocytes. These results provide evidence that ACT-1004-1239 both reduces neuroinflammation and enhances myelin repair substantiating the rationale to explore its therapeutic potential in a clinical setting.","link":"https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202002465R","published_date":"2021-02-20T00:00:00.000Z","source":"FASEB","relevant":1,"table_constraints":null},{"article_id":15,"discovery_date":"2021-02-23T11:11:00","title":"First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 19. doi: 10.1007/s00415-021-10469-x. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Peripapillary retinal nerve fiber layer thickness correlates with radiological and clinical parameters in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: The aim of this study is to investigate the use of the first measured pRNFL thickness as a predictor of disease course in patients with RRMS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: One hundred and thirty seven RRMS patients were enrolled in the study within the first 5 years of illness. Patients were followed for 34.1 months and the EDSS was used to assess disability status to determine whether the first measured pRNFL thickness, using proportional hazards models, predicts the risk of disability worsening.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The mean disease duration was 26.1 months. Disability worsening was detected in 36 patients. In tertile-based groups formed according to pRNFL thickness, the group with the lowest pRNFL thickness had a 2.8-fold increase in the risk of disability worsening compared to the group with the highest. The risk was higher in the first 2 years of the study (HR = 3.48; p = 0.008).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The first measured pRNFL thickness in RRMS patients can predict the risk of disability worsening, and the risk of disability worsening in the early period was higher in the group with the lowest pRNFL value.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606071/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606071&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10469-x&gt;10.1007/s00415-021-10469-x&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606071/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":14,"discovery_date":"2021-02-23T11:11:00","title":"Healthcare access experiences of persons with MS explored through the Candidacy Framework","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Health Soc Care Community. 2021 Feb 19. doi: 10.1111/hsc.13320. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Canada has one of the highest rates of multiple sclerosis (MS) in the world, affecting 1 in every 385 individuals. This neurodegenerative condition is unpredictable and variable in symptom profile and disease course making it difficult to manage. Canadians with MS are high users of healthcare services; however, they report multiple unmet needs, high disease burden, and low satisfaction with healthcare. Access to healthcare is vital to health maintenance and may explain these poor experiences. Access is often measured using utilisation as a proxy, which may fail to capture the complexities of access experiences that this population faces. The Candidacy Framework offers an alternative to utilisation measures, by examining the process of accessing care, while considering the impact of social patterning and health system environments on this process. The aim of the current study is to align the experiences of persons with MS in accessing healthcare services with the stages of the Candidacy Framework. Forty-eight individuals with MS living across Ontario were recruited to participate in one of five focus groups or ten individual interviews. Analysis included a first inductive phase, using constant comparative methods, followed by a deductive phase, using content analysis. The Candidacy Framework was not able to capture all experiences shared by persons with MS, including patient-centred care, past experiences and outcome expectation, and care outcomes. We propose these concepts be included as refinements to the current Framework, providing a more thorough explanation of the experiences of persons with MS in accessing care to manage their condition.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606904/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606904&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/hsc.13320&gt;10.1111/hsc.13320&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606904/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":13,"discovery_date":"2021-02-23T11:11:00","title":"Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Med Hypotheses. 2021 Feb 10;149:110530. doi: 10.1016/j.mehy.2021.110530. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Hidradenitis Suppurativa (HS) is a chronic, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. The pathophysiology of the disease remains elusive, with newer therapies targeting various aspects of the dysregulated immune system. This presents a useful opportunity to look at the cytokine profile in HS and other inflammatory conditions that share similar patterns with the aim of teasing out less considered explanations for HS pathogenesis. It has been observed that IL-17 appears to be the most common denominator linking HS with other immune mediated diseases like Crohn, ulcerative colitis, multiple sclerosis and psoriasis. Given that IL-17 plays an important role in antifungal immunity, evidenced by the cytokine pattern in fungal disease and the bulk of data citing their potential involvement in Crohn, ulcerative colitis, multiple sclerosis and psoriasis; it is fair to suggest the need to explore the role that fungi play in the setting of HS going forward. The aryl hydrocarbon receptor (ahr) is a ubiquitous and largely conserved entity that is gaining interest in inflammatory conditions such as psoriasis and atopic dermatitis. It is well known to modulate autoimmune states. Its activation by both exogenous and endogenous agents result in secretion of IL-17 by Th17 cells. One of such agents is the tryptophan metabolite 6-formylindolo [3,2-b] carbazole (FICZ)-which can be produced by microorganisms such as fungi. It will be interesting to explore its usefulness in HS pathogenesis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607406/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607406&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.mehy.2021.110530&gt;10.1016/j.mehy.2021.110530&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607406/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":12,"discovery_date":"2021-02-23T11:11:00","title":"Depression and multiple sclerosis: A bidirectional Mendelian randomisation study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Depression is common in multiple sclerosis (MS); however, the underlying mechanism for the relationship remains unknown. In this study, we examined a putative causal relationship between depression and MS using a bidirectional Mendelian randomisation (MR) framework. Using the latest genome-wide association study data available, 168 non-major histocompatibility complex (MHC) independent variants associated with MS and 96 independent genetic variants associated with depression susceptibility were used. Maximum likelihood, weighted median, inverse variance weighted method and MR-Egger regression analyses were performed. There was no significant risk for the development of MS in persons carrying variants associated with depression or for risk of depression in individuals who are genetically susceptible to MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605804/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605804&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521996601&gt;10.1177/1352458521996601&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605804/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":11,"discovery_date":"2021-02-23T11:11:00","title":"The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Obesity is associated with increased risk of multiple sclerosis (MS); however, the underlying mechanisms remain unclear.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To determine the extent to which decreased vitamin D bioavailability and altered levels of adiponectin and leptin mediate the association between obesity and MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We performed Mendelian randomization (MR) analyses to estimate the effects on MS of body mass index (BMI), 25-hydroxyvitamin D (25OHD), adiponectin, and leptin levels in a cohort of 14,802 MS cases and 26,703 controls. We then estimated the proportion of the effect of obesity on MS explained by these potential mediators.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Genetic predisposition to higher BMI was associated with increased MS risk (odds ratio (OR) = 1.33 per standard deviation (SD), 95% confidence interval (CI) = 1.09-1.63), while higher 25OHD levels reduced odds of MS (OR = 0.72 per SD, 95% CI = 0.60-0.87). In contrast, we observed no effect of adiponectin or leptin. In MR mediation analysis, 5.2% of the association between BMI and MS was attributed to obesity lowering 25OHD levels (95% CI = 0.3%-31.0%).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: This study found that a minority of the increased risk of MS conferred by obesity is mediated by lowered vitamin D levels, while leptin and adiponectin had no effect. Consequently, vitamin D supplementation would only modestly reverse the effect of obesity on MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605807/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605807&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521995484&gt;10.1177/1352458521995484&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605807/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":10,"discovery_date":"2021-02-23T11:11:00","title":"N-Acetyl-Lysyltyrosylcysteine Amide, a Novel Systems Pharmacology Agent, Reduces Bronchopulmonary Dysplasia in Hyperoxic Neonatal Rat Pups","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Free Radic Biol Med. 2021 Feb 16:S0891-5849(21)00079-4. doi: 10.1016/j.freeradbiomed.2021.02.006. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Bronchopulmonary dysplasia (BPD) is caused primarily by oxidative stress and inflammation. To induce BPD, neonatal rat pups were raised in hyperoxic (&amp;gt;90% O&lt;sub&gt;2&lt;/sub&gt;) environments from day one (P1) until day ten (P10) and treated with N-acetyl-lysyltyrosylcysteine amide (KYC). In vivo studies showed that KYC improved lung complexity, reduced myeloperoxidase (MPO) positive (+) myeloid cell counts, MPO protein, chlorotyrosine formation, increased endothelial cell CD31 expression, decreased 8-OH-dG and Cox-1/Cox-2, HMGB1, RAGE, TLR4, increased weight gain and improved survival in hyperoxic pups. EPR studies confirmed that MPO reaction mixtures oxidized KYC to a KYC thiyl radical. Adding recombinant HMGB1 to the MPO reaction mixture containing KYC resulted in KYC thiylation of HMGB1. In rat lung microvascular endothelial cell (RLMVEC) cultures, KYC thiylation of RLMVEC proteins was increased the most in RLMVEC cultures treated with MPO+H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;, followed by H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;, and then KYC alone. KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs. MPO-dependent and independent KYC-thiylation of Keap1 were both increased in RLMVEC cultures. Treating hyperoxic pups with KYC increased KYC thiylation and S-glutathionylation of Keap1, and Nrf2 activation. These data suggest that KYC is a novel system pharmacological agent that exploits MPO to inhibit toxic oxidant production and is oxidized into a thiyl radical that inactivates HMGB1, activates Nrf2, and increases antioxidant enzyme expression to improve lung complexity and reduce BPD in hyperoxic rat pups.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607217/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607217&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.freeradbiomed.2021.02.006&gt;10.1016/j.freeradbiomed.2021.02.006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607217/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":9,"discovery_date":"2021-02-23T11:11:00","title":"CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 18;11(1):4132. doi: 10.1038/s41598-021-83591-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;To identify markers in the CSF of multiple sclerosis (MS) subtypes, we used a two-step proteomic approach: (i) Discovery proteomics compared 169 pooled CSF from MS subtypes and inflammatory/degenerative CNS diseases (NMO spectrum and Alzheimer disease) and healthy controls. (ii) Next, 299 proteins selected by comprehensive statistics were quantified in 170 individual CSF samples. (iii) Genes of the identified proteins were also screened among transcripts in 73 MS brain lesions compared to 25 control brains. F-test based feature selection resulted in 8 proteins differentiating the MS subtypes, and secondary progressive (SP)MS was the most different also from controls. Genes of 7 out these 8 proteins were present in MS brain lesions: GOLM was significantly differentially expressed in active, chronic active, inactive and remyelinating lesions, FRZB in active and chronic active lesions, and SELENBP1 in inactive lesions. Volcano maps of normalized proteins in the different disease groups also indicated the highest amount of altered proteins in SPMS. Apolipoprotein C-I, apolipoprotein A-II, augurin, receptor-type tyrosine-protein phosphatase gamma, and trypsin-1 were upregulated in the CSF of MS subtypes compared to controls. This CSF profile and associated brain lesion spectrum highlight non-inflammatory mechanisms in differentiating CNS diseases and MS subtypes and the uniqueness of SPMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603109/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603109&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-83591-5&gt;10.1038/s41598-021-83591-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603109/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":8,"discovery_date":"2021-02-23T11:11:00","title":"Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Neurosci. 2021 Feb 18. doi: 10.1038/s41593-021-00801-z. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neurodegeneration occurring in multiple sclerosis (MS) contributes to the progression of disability. It is therefore important to identify and neutralize the mechanisms that promote neurodegeneration in MS. Here, we report that oxidized phosphatidylcholines (OxPCs) found in MS lesions, previously identified as end-product markers of oxidative stress, are potent drivers of neurodegeneration. Cultured neurons and oligodendrocytes were killed by OxPCs, and this was ameliorated by microglia. After OxPC injection, mouse spinal cords developed focal demyelinating lesions with prominent axonal loss. The depletion of microglia that accumulated in OxPC lesions exacerbated neurodegeneration. Single-cell RNA sequencing of lesioned spinal cords identified unique subsets of TREM2&lt;sup&gt;high&lt;/sup&gt; mouse microglia responding to OxPC deposition. TREM2 was detected in human MS lesions, and TREM2&lt;sup&gt;-/-&lt;/sup&gt; mice exhibited worsened OxPC lesions. These results identify OxPCs as potent neurotoxins and suggest that enhancing microglia-mediated OxPC clearance via TREM2 could help prevent neurodegeneration in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603230/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603230&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41593-021-00801-z&gt;10.1038/s41593-021-00801-z&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603230/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":7,"discovery_date":"2021-02-23T11:11:00","title":"Binocular Vision in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Optom (Auckl). 2021 Feb 12;13:39-49. doi: 10.2147/OPTO.S286862. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Oculomotor disorders have been reported in multiple sclerosis (MS) in up to 80% of cases. There have been studies evaluating binocular vision in several neurological diseases, but not in MS. Considering that a high percentage of eye-movement anomalies have been reported, the aim of this study was to analyze binocular vision in these subjects.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A total of 59 participants with MS - 21 with monocular optic neuritis, eleven with binocular optic neuritis, and 27 without optic neuritis - and 26 age-matched controls were enrolled. Binocular vision was analyzed using near point of convergence (NPC), positive and negative fusional vergence for far and near distance, measurement of heterophoria at both distances with cover and modified Thorington tests, and random-dot stereoscopy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The percentage of subjects with abnormal NPC values was highest in the MS group, followed by the MSONm (MS with optic neuritis in one eye), MSONb (MS with optic neuritis in both eyes), and control groups. MS patients showed an esophoric trend at near distance. Positive fusional vergence showed no significant differences between control and MS groups, but higher variability in recovery was found in MS groups. Negative fusional vergence at near distance showed significant differences between the control group and the two MS groups, with optic neuritis for both break-point and recovery values. A high percentage of patients with MS had alterations on stereopsis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Alterations in binocular vision were present in MS, with divergence at near distance and stereopsis the most affected parameters. Likewise, MS patients with optic neuritis showed worse binocular vision.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603529/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603529&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7886387/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7886387&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2147/OPTO.S286862&gt;10.2147/OPTO.S286862&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603529/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":6,"discovery_date":"2021-02-23T11:11:00","title":"The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimers Disease Patients: A Network Pharmacology Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Aging Neurosci. 2021 Feb 2;13:609679. doi: 10.3389/fnagi.2021.609679. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; The sphingosine-1-phosphate receptor (S1PR) modulator fingolimod (FTY720), which is commonly used as an immunomodulator in multiple sclerosis treatment, has recently been found to reduce pathological changes in the brain tissue of Alzheimer&#x27;s disease (AD) animal models, but this has yet to be verified in human brain tissue. In this study, network pharmacology methods were applied to determine the potential pharmacological mechanisms of fingolimod in the frontal cortex of AD patients. &lt;b&gt;Methods:&lt;/b&gt; The pharmacological macromolecular targets of fingolimod and fingolimod phosphate were downloaded from SwissTarget and DrugBank. Systematic intersection analysis of the expression profiles of brain frontal cortex tissues (423 AD tissues and 266 control tissues) was performed to obtain AD-associated fingolimod targets (F-ADGs). Immune cell infiltration analysis and a primary mouse cortical culture RNA-seq drug screen database were used to identify immune-related F-ADGs and cortex-related F-ADGs. Then, the expression values of F-ADGs were correlated with the disease severity score (MMSE score) of AD patients to identify severity-related F-ADGs. We also analyzed miRNA expression microarray data in the frontal cortex of AD patients associated with disease severity to obtain severity-related F-ADG-miRNAs. &lt;b&gt;Results:&lt;/b&gt; A total of 188 F-ADGs were detected in the frontal cortices of AD patients and were enriched in biological processes such as synaptic signaling, inflammatory response, and response to oxygen-containing compounds. Eleven immune-related F-ADGs (like FPR1, BLNK.) and 17 cortex-related F-ADGs (like ALDH1L1, DUSP1.) were detected. Other F-ADGs, such as S1PR1 and GABBR2, although not classified into the above two categories, were still predicted by bioinformatics methods to play an important role in the development of AD. Two F-ADGs (GNAQ and MMP14) and 28 miRNAs (like miR- 323a-3p, miR-181a-5p.) were found to be associated with AD severity (MMSE 0-27 group). Fifteen F-ADGs (like ALDH1L1, FPR1, and IL6.) and 46 miRNAs (like miR-212-5p, miR-93-5p.) were found to be associated with mild or moderate dementia AD patients&#x27; severity (MMSE11-22 subgroup). &lt;b&gt;Conclusions:&lt;/b&gt; Fingolimod may affect the brain frontal cortex function of AD patients in many different ways, such as affecting immune cell infiltration, nerve cell, or glial cell function, and synaptic function. miRNAs may also be involved. ALDH1L1, FPR1, S1PR1, and GABBR2 may be core drug targets.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603656/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603656&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7884771/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7884771&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fnagi.2021.609679&gt;10.3389/fnagi.2021.609679&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603656/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":5,"discovery_date":"2021-02-23T11:11:00","title":"Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Can J Infect Dis Med Microbiol. 2021 Jan 31;2021:6616763. doi: 10.1155/2021/6616763. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (&lt;i&gt;p&lt;/i&gt;=560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (&lt;i&gt;p&lt;/i&gt; ≤ 0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603936/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603936&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7870309/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7870309&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6616763&gt;10.1155/2021/6616763&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603936/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":4,"discovery_date":"2021-02-23T11:11:00","title":"Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Case Rep Neurol Med. 2021 Jan 28;2021:5952724. doi: 10.1155/2021/5952724. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Spinal neurosarcoidosis is a rare disease that can manifest as myelopathy, radiculopathy, or cauda equine syndrome. Spinal epidural lipomatosis is also a rare condition resulting from overgrowth of epidural fat tissue causing compressive myelopathy. To our knowledge, there are no reports linking epidural lipomatosis and spinal neurosarcoidosis. &lt;i&gt;Case Report&lt;/i&gt;. We describe a case of progressive myelitis in the presence of concomitant spinal neurosarcoidosis and epidural lipomatosis which was a challenging diagnosis with complete response to treatment after addressing both diseases. Both etiologies are inflammatory in nature and share similar expression of inflammatory factors such as TNF-&lt;i&gt;α&lt;/i&gt; and IL-1&lt;i&gt;β&lt;/i&gt;.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The common inflammatory process involved in these two diseases might explain a pathophysiological interconnection between both diseases that may underlie their concomitant development in our patient. If these two diseases are interconnected, in their pathophysiological mechanism remains a hypothesis that will need further investigation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33604089/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33604089&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7869444/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7869444&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/5952724&gt;10.1155/2021/5952724&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33604089/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":3,"discovery_date":"2021-02-23T11:11:00","title":"Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurosci Nurs. 2021 Feb 17. doi: 10.1097/JNN.0000000000000578. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The challenges in dealing with multiple sclerosis (MS) have increased considerably in recent years. In addition to neurologists, MS nurse specialists are key to the management of MS patients, but there is a lack of evidence regarding their quality of counseling. METHODS: The data collection took place between October 2018 and March 2019 in the outpatient clinic of a university hospital. The quality of counseling was assessed using the APN-BQ, an instrument that contains 19 items that can be assigned to 4 dimensions. Participants were asked to rate their satisfaction on a scale from 0 to 3. General satisfaction was assessed on a scale from 0 to 100. RESULTS: The participants (n = 110) rated the quality of counseling and their general satisfaction high. The mean (SD) of the structure quality dimension was 2.64 (0.44), and satisfaction with length and frequency of consultations (2.53 [0.63]) scored better than outcome quality (1.99 [0.62]) and process quality (2.13 [0.60]). CONCLUSION: Overall, there was a high rate of satisfaction with the quality of counseling. In addition to the length and frequency of consultations, MS patients particularly appreciated the availability and expertise of MS nurse specialists.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605649/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605649&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1097/JNN.0000000000000578&gt;10.1097/JNN.0000000000000578&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605649/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":2,"discovery_date":"2021-02-23T11:11:00","title":"Is Migraine Associated to Brain Anatomical Alterations? New Data and Coordinate-Based Meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Feb 19. doi: 10.1007/s10548-021-00824-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;A growing number of studies investigate brain anatomy in migraine using voxel- (VBM) and surface-based morphometry (SBM), as well as diffusion tensor imaging (DTI). The purpose of this article is to identify consistent patterns of anatomical alterations associated with migraine. First, 19 migraineurs without aura and 19 healthy participants were included in a brain imaging study. T1-weighted MRIs and DTI sequences were acquired and analyzed using VBM, SBM and tract-based spatial statistics. No significant alterations of gray matter (GM) volume, cortical thickness, cortical gyrification, sulcus depth and white-matter tract integrity could be observed. However, migraineurs displayed decreased white matter (WM) volume in the left superior longitudinal fasciculus. Second, a systematic review of the literature employing VBM, SBM and DTI was conducted to investigate brain anatomy in migraine. Meta-analysis was performed using Seed-based d Mapping via permutation of subject images (SDM-PSI) on GM volume, WM volume and cortical thickness data. Alterations of GM volume, WM volume, cortical thickness or white-matter tract integrity were reported in 72%, 50%, 56% and 33% of published studies respectively. Spatial distribution and direction of the disclosed effects were highly inconsistent across studies. The SDM-PSI analysis revealed neither significant decrease nor significant increase of GM volume, WM volume or cortical thickness in migraine. Overall there is to this day no strong evidence of specific brain anatomical alterations reliably associated to migraine. Possible explanations of this conflicting literature are discussed. Trial registration number: NCT02791997, registrated February 6th, 2015.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606142/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606142&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10548-021-00824-6&gt;10.1007/s10548-021-00824-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606142/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":1,"discovery_date":"2021-02-23T11:11:00","title":"COVID-19, HHV6 and MOG antibody: A perfect storm","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 12;353:577521. doi: 10.1016/j.jneuroim.2021.577521. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607505/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607505&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jneuroim.2021.577521&gt;10.1016/j.jneuroim.2021.577521&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607505/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null}]